- Smilow Cancer Hospital at Greenwich77 Lafayette PlaceGreenwich, CT 06830
- Smilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
William K. Oh, MD
Biography
William K. Oh, MD, is a genitourinary oncologist with decades of experience specializing in prostate cancer. He integrates molecular and genetic testing into routine cancer care, ensuring that patients receive the most personalized treatment plans possible. Throughout his career he has focused on decreasing barriers to the delivery of care for prostate cancer nationally.
Dr. Oh is the director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital, where he leads efforts to develop cohesive programs that combine basic and translational science with clinical trials. He also oversees the Precision Medicine Tumor Board, which is pivotal in guiding treatment decisions based on genetic and molecular data. Additionally, he serves as the service line medical director of Smilow Cancer Hospital at Greenwich Hospital, where he continues to develop integrated oncology care teams and expand the impact of multidisciplinary cancer care for patients in the region.
Dr. Oh completed his undergraduate degree at Yale University, received his medical degree from New York University School of Medicine, and did his internship and residency at Brigham and Women’s Hospital before his clinical fellowship in medical oncology at Dana-Farber Cancer Institute.
Dr. Oh currently serves as chair of the American Cancer Society's National Prostate Cancer Roundtable, whose mission is to improve prostate cancer outcomes and survivorship through increasing awareness and equitable access to prevention, screening, and treatment. Also, he is the chair of the Medical Advisory Council for the Chemotherapy Foundation, which is committed to discovering novel therapies for cancer.
“I love taking care of patients because it brings me tremendous personal satisfaction to both help them and learn from them,” Dr. Oh says. “I also love the precision medicine part of my job, but in the end, my patient care responsibilities always bring me back to what it’s all about and why we’re all here and I enjoy getting to know my patients and their generosity of spirit and courage. I take a lot of lessons from that.”
Titles
- Director, Precision Medicine, Yale Cancer Center and Smilow Cancer Hospital
- Service Line Medical Director, Smilow Cancer Hospital at Greenwich Hospital
Education & Training
- MDNew York University School of Medicine
- BSYale University, Molecular Biophysics and Biochemistry
Additional Information
- Ebrahimi H, Allen J, Biru Y, Garg R, Hodgdon C, Oh WK, Steensma D, Pal SK, Mulvey T. Practical Guide to Clinical Trial Accessibility: Making Trial Participation a Standard of Care. Am Soc Clin Oncol Educ Book 2025, 45: e100052. PMID: 40388680, DOI: 10.1200/EDBK-25-100052.
- Ganta T, Anker JF, Miller E, Joshi H, Tsao CK, Oh WK. Characterization of Exceptional Responses in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Cabozantinib and Immune Checkpoint Inhibitors. Clin Genitourin Cancer 2025, 23: 102336. PMID: 40222171, DOI: 10.1016/j.clgc.2025.102336.
- Carlsson SV, Barata PC, Bryce AH, George DJ, Gillessen S, Loeb S, Montgomery B, Morris D, Riaz IB, Palapattu G, Schoen MW, Washington Iii SL, Cornell B, Levine R, Aggarwal P, McGowan T, Cotter M, Thompson B, Devgan G, Russell D, Kuperman G, Lenero E, Iwata K, Miyahira AK, Soule HR, Carithers G, Oh WK, Agarwal N. Prostate Cancer Foundation White Paper on Combination Therapy for Metastatic Hormone-Sensitive Prostate Cancer. JCO Oncol Pract 2025, OP2500050. PMID: 40315399, DOI: 10.1200/OP-25-00050.
- Yu R, Qin QJ, Haines GK, Oh WK, Lewis S. Intravesical BCG therapy-induced granulomatous prostatitis in a patient with non-muscle invasive bladder cancer and prostate adenocarcinoma. Urol Case Rep 2025, 60: 103020. PMID: 40230614, DOI: 10.1016/j.eucr.2025.103020.
- Carlsson S, Oh W. How Can Guidelines Give Clearer Guidance on Prostate Cancer Screening? JAMA Oncology 2024, 10: 1497-1498. PMID: 39325462, DOI: 10.1001/jamaoncol.2024.3909.
- Oh W, Agarwal N, Bryce A, Barata P, Bugler C, Carlsson S, Cornell B, Dahut W, George D, Loeb S, Montgomery B, Morris D, Mucci L, Omlin A, Palapattu G, Riaz I, Ryan C, Schoen M, Washington S, Gillessen S. What’s in a Name? Why Words Matter in Advanced Prostate Cancer. European Urology 2024, 87: 101-103. PMID: 39472202, DOI: 10.1016/j.eururo.2024.10.017.
- Lee K, Mai Y, Liu Z, Raja K, Jun T, Ma M, Wang T, Ai L, Calay E, Oh W, Schadt E, Wang X. CriteriaMapper: establishing the automatic identification of clinical trial cohorts from electronic health records by matching normalized eligibility criteria and patient clinical characteristics. Scientific Reports 2024, 14: 25387. PMID: 39455879, PMCID: PMC11511882, DOI: 10.1038/s41598-024-77447-x.
- Gillessen S, Turco F, Davis I, Efstathiou J, Fizazi K, James N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Zilli T, Agarwal N, Antonarakis E, Aparicio A, Armstrong A, Bastos D, Attard G, Axcrona K, Ayadi M, Beltran H, Bjartell A, Blanchard P, Bourlon M, Briganti A, Bulbul M, Buttigliero C, Caffo O, Castellano D, Castro E, Cheng H, Chi K, Clarke C, Clarke N, de Bono J, De Santis M, Duran I, Efstathiou E, Ekeke O, El Nahas T, Emmett L, Fanti S, Fatiregun O, Feng F, Fong P, Fonteyne V, Fossati N, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Hofman M, Hope T, Horvath L, Hussain M, Jereczek-Fossa B, Jones R, Joshua A, Kanesvaran R, Keizman D, Khauli R, Kramer G, Loeb S, Mahal B, Maluf F, Mateo J, Matheson D, Matikainen M, McDermott R, McKay R, Mehra N, Merseburger A, Morgans A, Morris M, Mrabti H, Mukherji D, Murphy D, Murthy V, Mutambirwa S, Nguyen P, Oh W, Ost P, O'Sullivan J, Padhani A, Parker C, Poon D, Pritchard C, Rabah D, Rathkopf D, Reiter R, Renard-Penna R, Ryan C, Saad F, Sade J, Sandhu S, Sartor O, Schaeffer E, Scher H, Sharifi N, Skoneczna I, Soule H, Spratt D, Srinivas S, Sternberg C, Suzuki H, Taplin M, Thellenberg-Karlsson C, Tilki D, Türkeri L, Uemura H, Ürün Y, Vale C, Vapiwala N, Walz J, Yamoah K, Ye D, Yu E, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). European Urology 2024, 87: 157-216. PMID: 39394013, DOI: 10.1016/j.eururo.2024.09.017.
- Chakrani Z, Patel M, Mellgard G, McCroskery S, Saffran N, Taylor N, Liaw B, Galsky M, Oh W, Tsao C, Ganta T, Patel V. The Association of Statin Use With Survival Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Androgen Receptor Targeted Therapies (ART). Clinical Genitourinary Cancer 2024, 22: 102227. PMID: 39437664, DOI: 10.1016/j.clgc.2024.102227.
- Leader A, Rebbeck T, Oh W, Patel A, Winer E, Bailey L, Gomella L, Lumpkins C, Garraway I, Aiello L, Baskin M, Cheng H, Cooney K, Ganzak A, George D, Halabi S, Hathaway F, Healy C, Kim J, Leapman M, Loeb S, Maxwell K, McNair C, Morgan T, Prindeville B, Soule H, Steward W, Suttiratana S, Taplin M, Yamoah K, Fortune T, Bennett K, Blanding-Godbolt J, Gross L, Giri V. Adaptation of the socioecological model to address disparities in engagement of Black men in prostate cancer genetic testing. BMC Public Health 2024, 24: 2533. PMID: 39289635, PMCID: PMC11409532, DOI: 10.1186/s12889-024-20008-8.
- Mellgard G, Saffran N, Chakrani Z, McCroskery S, Taylor N, Patel M, Liaw B, Galsky M, Oh W, Tsao C, Patel V. Performance Status and End-of-Life Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Androgen Receptor Targeted Therapy. American Journal Of Clinical Oncology 2024, 47: 459-464. PMID: 39087466, DOI: 10.1097/coc.0000000000001115.
- Lee K, Liu Z, Mai Y, Jun T, Ma M, Wang T, Ai L, Calay E, Oh W, Stolovitzky G, Schadt E, Wang X. Optimizing Clinical Trial Eligibility Design Using Natural Language Processing Models and Real-World Data: Algorithm Development and Validation. JMIR AI 2024, 3: e50800. PMID: 39073872, PMCID: PMC11319878, DOI: 10.2196/50800.
- Wang L, Izadmehr S, Sfakianos J, Tran M, Beaumont K, Brody R, Cordon-Cardo C, Horowitz A, Sebra R, Oh W, Bhardwaj N, Galsky M, Zhu J. Single-cell transcriptomic-informed deconvolution of bulk data identifies immune checkpoint blockade resistance in urothelial cancer. IScience 2024, 27: 109928. PMID: 38812546, PMCID: PMC11133924, DOI: 10.1016/j.isci.2024.109928.
- Garraway I, Carlsson S, Nyame Y, Vassy J, Chilov M, Fleming M, Frencher S, George D, Kibel A, King S, Kittles R, Mahal B, Pettaway C, Rebbeck T, Rose B, Vince R, Winn R, Yamoah K, Oh W. Prostate Cancer Foundation Screening Guidelines for Black Men in the United States. NEJM Evidence 2024, 3: evidoa2300289. PMID: 38815168, DOI: 10.1056/evidoa2300289.
- Chakrani Z, Mellgard G, Saffran N, McCroskery S, Taylor N, Patel M, Liaw B, Galsky M, Oh W, Tsao C, Patel V. Risk Factors for Early Treatment Discontinuation Due to Toxicity Among Patients With Metastatic Castration-resistant Prostate Cancer Receiving Androgen Receptor–targeted Therapy. American Journal Of Clinical Oncology 2024, 47: 271-278. PMID: 38344754, DOI: 10.1097/coc.0000000000001087.
- Liaw B, Joshi H, Sheng T, Tsao C, Galsky M, Bakst R, Stewart R, Stock R, Oh W. Final study analysis of PRINT: Prostate cancer intensive, non–cross-reactive therapy for CRPC. Journal Of Clinical Oncology 2024, 42: 147-147. DOI: 10.1200/jco.2024.42.4_suppl.147.
- Garraway I, Carlsson S, Nyame Y, Vassey J, Chilov M, Fleming M, Frencher S, George D, Kibel A, King S, Kittles R, Mahal B, Pettaway C, Rebbeck T, Rose B, Vince R, Winn R, Yamoah K, Oh W. Prostate Cancer Foundation (PCF) screening guidelines for prostate cancer in Black men in the United States. Journal Of Clinical Oncology 2024, 42: 264-264. DOI: 10.1200/jco.2024.42.4_suppl.264.
- Williams C, Starks D, Rojas-Espaillat L, Meissner T, Elsey R, Jun T, Solomon B, Feng S, Koenen M, van Oosbree A, Clem A, Lee J, Oh W. Comprehensive molecular profiling and deep clinical annotation of electronic health records in patients with cancer: Implementation of the Avera/Sema4 oncology and analytics protocol (ASAP) in gynecologic oncology (1255). Gynecologic Oncology 2023, 176: s161-s162. DOI: 10.1016/j.ygyno.2023.06.164.
- Lee K, Liu Z, Chandran U, Kalsekar I, Laxmanan B, Higashi M, Jun T, Ma M, Li M, Mai Y, Gilman C, Wang T, Ai L, Aggarwal P, Pan Q, Oh W, Stolovitzky G, Schadt E, Wang X. Detecting Ground Glass Opacity Features in Patients With Lung Cancer: Automated Extraction and Longitudinal Analysis via Deep Learning–Based Natural Language Processing. JMIR AI 2023, 2: e44537. PMID: 38875565, PMCID: PMC11041451, DOI: 10.2196/44537.
- Ganta T, Anker J, Miller E, Tsao K, Oh W. Real world utilization and outcomes of immunotherapy regimens in metastatic castration resistant prostate cancer (mCRPC). Journal Of Clinical Oncology 2023, 41: e17038-e17038. DOI: 10.1200/jco.2023.41.16_suppl.e17038.
- Liu Z, Lee K, Cohn D, Zhang M, Ai L, Li M, Zhang X, Jun T, Higashi M, Pan Q, Oh W, Stolovitzky G, Schadt E, Wang X, Li S. Analysis of real-world data to investigate evolving treatment sequencing patterns in advanced non-small cell lung cancers and their impact on survival. Journal Of Thoracic Disease 2023, 0: 0-0. PMID: 37324065, PMCID: PMC10267939, DOI: 10.21037/jtd-22-1481.
- Gillessen S, Bossi A, Davis I, de Bono J, Fizazi K, James N, Mottet N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Antonarakis E, Aparicio A, Armstrong A, Attard G, Beer T, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow R, Bulbul M, Caffo O, Castellano D, Castro E, Cheng H, Chi K, Chowdhury S, Clarke C, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke O, Evans C, Fanti S, Feng F, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman M, Horvath L, Hussain M, Jereczek-Fossa B, Jones R, Kanesvaran R, Kellokumpu-Lehtinen P, Khauli R, Klotz L, Kramer G, Leibowitz R, Logothetis C, Mahal B, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans A, Morris M, Mrabti H, Mukherji D, Murphy D, Murthy V, Nguyen P, Oh W, Ost P, O'Sullivan J, Padhani A, Pezaro C, Poon D, Pritchard C, Rabah D, Rathkopf D, Reiter R, Rubin M, Ryan C, Saad F, Sade J, Sartor O, Scher H, Sharifi N, Skoneczna I, Soule H, Spratt D, Srinivas S, Sternberg C, Steuber T, Suzuki H, Sydes M, Taplin M, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale C, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu E, Zapatero A, Zilli T, Omlin A. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. European Journal Of Cancer 2023, 185: 178-215. PMID: 37003085, DOI: 10.1016/j.ejca.2023.02.018.
- Mellgard G, Chakrani Z, Mccroskery S, Saffran N, Taylor N, Liaw B, Galsky M, Oh W, Tsao K, Patel V. Survival outcomes and toxicity in older adults with metastatic castration-resistant prostate cancer (mCRPC) treated with androgen receptor targeted (ART) therapies. Journal Of Clinical Oncology 2023, 41: 117-117. DOI: 10.1200/jco.2023.41.6_suppl.117.
- Mellgard G, Mccroskery S, Chakrani Z, Saffran N, Taylor N, Liaw B, Galsky M, Oh W, Tsao K, Patel V. Clinical characteristics and outcomes of trial-ineligible patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving androgen receptor targeted (ART) therapy. Journal Of Clinical Oncology 2023, 41: 118-118. DOI: 10.1200/jco.2023.41.6_suppl.118.
- Chakrani Z, Mellgard G, Mccroskery S, Saffran N, Taylor N, Liaw B, Oh W, Tsao K, Patel V. Risk factors for treatment (tx) toxicity and discontinuation among patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) on androgen receptor targeted therapy (ART). Journal Of Clinical Oncology 2023, 41: 135-135. DOI: 10.1200/jco.2023.41.6_suppl.135.
- Ganta T, Anker J, Miller E, Kannry J, Bhardwaj A, Tsao K, Oh W. Oncologist-driven development of an electronic health record (EHR) clinical data visualization tool for prostate cancer. Journal Of Clinical Oncology 2023, 41: 267-267. DOI: 10.1200/jco.2023.41.6_suppl.267.
- Liaw B, Tsao C, Seng S, Jun T, Gong Y, Galsky M, Oh W. Biomarker Development Trial of Satraplatin in Patients with Metastatic Castration-Resistant Prostate Cancer. The Oncologist 2022, 28: 366-e224. PMID: 36519763, PMCID: PMC10078918, DOI: 10.1093/oncolo/oyac224.
- Gillessen S, Bossi A, Davis I, de Bono J, Fizazi K, James N, Mottet N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Antonarakis E, Aparicio A, Armstrong A, Attard G, Beer T, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow R, Bulbul M, Caffo O, Castellano D, Castro E, Cheng H, N. K, Chowdhury S, Clarke C, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke O, Evans C, Fanti S, Feng F, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman M, Horvath L, Hussain M, Jereczek-Fossa B, Jones R, Kanesvaran R, Kellokumpu-Lehtinen P, Khauli R, Klotz L, Kramer G, Leibowitz R, Logothetis C, Mahal B, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans A, Morris M, Mrabti H, Mukherji D, Murphy D, Murthy V, Nguyen P, Oh W, Ost P, O’Sullivan J, Padhani A, Pezaro C, Poon D, Pritchard C, Rabah D, Rathkopf D, Reiter R, Rubin M, Ryan C, Saad F, Sade J, Sartor O, Scher H, Sharifi N, Skoneczna I, Soule H, Spratt D, Srinivas S, Sternberg C, Steuber T, Suzuki H, Sydes M, Taplin M, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale C, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu E, Zapatero A, Zilli T, Omlin A. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. European Urology 2022, 83: 267-293. PMID: 36494221, PMCID: PMC7614721, DOI: 10.1016/j.eururo.2022.11.002.
- Al-Kateb H, Jun T, Hayes J, Rossi M, Hantash F, Oh W, Onel K. Prevalence of Pathogenic Germline Mutations in Solid Tumor Predisposition Genes Detected By Tumor-Normal Whole Exome Sequencing Analysis Among Adults with Hematologic Malignancies. Blood 2022, 140: 7852-7853. DOI: 10.1182/blood-2022-159618.
- Lee K, Paek H, Ai L, Liu Z, Jin L, Li M, Jun T, Higashi M, Onel K, Oh W, Pan Q, Stolovitzky G, Schadt E, Wang X. Treatment Profile of CAR-T Cell Therapy Induced Cytokine Release Syndrome and Neurotoxicity: Insights from Real-World Evidence. Blood 2022, 140: 12750-12752. DOI: 10.1182/blood-2022-166716.
- Higashi M, Kruszka P, Francis M, Parsons K, Oh W, Onel K. Pediatric Age at Hematopoietic Stem Cell Transplant: Associations with Non-Malignant Genetic Disease and Race. Blood 2022, 140: 7973-7974. DOI: 10.1182/blood-2022-170315.
- Calvo M, Caruthers S, Tripodi J, Houldsworth J, Fink M, Newman S, Chen R, Zhang W, Liu L, Shi Y, Jun T, Onel K, Oh W, Edelmann L, Schadt E, Rossi M, Hantash F, Al-Kateb H. 61. Clinical whole exome/whole transcriptome analysis detects clinically relevant structural alterations in Multiple Myeloma. Cancer Genetics 2022, 268: 20. DOI: 10.1016/j.cancergen.2022.10.064.
- Griffin J, Tsao C, Patel V, Liaw B, Guin S, Joshi H, Rossi M, Hantash F, Zhou X, Tewari A, Galsky M, Oh W, Chen R, Jun T. Clinical actionability and utilization of next-generation sequencing for prostate cancer in a changing treatment landscape. Frontiers In Urology 2022, 2: 997396. DOI: 10.3389/fruro.2022.997396.
- Jin L, Govindaraj S, Liu Z, Ai L, Higashi M, Jun T, Lee K, Raja K, Zhang X, Li M, Calay E, Savic R, Ghosh K, Kasarskis A, Pan Q, Oh W, Stolovitzky G, Schadt E, Wang X. Seasonal variations of hospitalizations for chronic rhinosinusitis by different endotypes. ISEE Conference Abstracts 2022, 2022 DOI: 10.1289/isee.2022.p-1062.
- Mellgard G, Chakrani Z, McCroskery S, Saffran N, Taylor N, Liaw B, Galsky M, Oh W, Tsao C, Patel V. 1274P Performance status (PS) and end-of-life (EOL) care in patients (pts) with metastatic prostate cancer (mPC) treated with androgen receptor targeted (ART) therapy. Annals Of Oncology 2022, 33: s1129. DOI: 10.1016/j.annonc.2022.07.1407.
- Guin S, Liaw B, Jun T, Ayers K, Patel B, O’Connell T, Deitz M, Klein M, Mullaney T, Prentice T, Newman S, Fink M, Zhou X, Schadt E, Chen R, Oh W. Management of de novo metastatic hormone-sensitive prostate cancer: A comprehensive report of a single-center experience. PLOS ONE 2022, 17: e0264800. PMID: 35984843, PMCID: PMC9390935, DOI: 10.1371/journal.pone.0264800.
- Qin Q, Jun T, Wang B, Patel V, Mellgard G, Zhong X, Gogerly-Moragoda M, Parikh A, Leiter A, Gallagher E, Alerasool P, Garcia P, Joshi H, MBBS, Galsky M, Oh W, Tsao C. Clinical factors associated with outcome in solid tumor patients treated with immune-checkpoint inhibitors: a single institution retrospective analysis. Discover Oncology 2022, 13: 73. PMID: 35960456, PMCID: PMC9374856, DOI: 10.1007/s12672-022-00538-6.
- Mellgard G, Patel V, Zhong X, Joshi H, Qin Q, Wang B, Parikh A, Jun T, Alerasool P, Garcia P, Gogerly-Moragoda M, Leiter A, Gallagher E, Oh W, Galsky M, Tsao C. Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors. Journal Of Cancer Research And Clinical Oncology 2022, 149: 2833-2841. PMID: 35788726, PMCID: PMC10739778, DOI: 10.1007/s00432-022-04159-y.
- Jun T, Oh W. Does Circulating Tumor DNA Measure Up to Prostate-Specific Antigen? JAMA Oncology 2022, 8: 972-974. PMID: 35551363, DOI: 10.1001/jamaoncol.2022.0511.
- Guin S, Jun T, Patel V, Ayers K, Deitz M, Cai Y, Zhou X, Tsao C, Oh W, Chen R, Liaw B. Extraction of Treatment Information From Electronic Health Records and Evaluation of Testosterone Recovery in Patients With Prostate Cancer. JCO Clinical Cancer Informatics 2022, 6: e2200010. PMID: 35696627, PMCID: PMC9225507, DOI: 10.1200/cci.22.00010.
- Kier M, Li Z, Casasanta N, Patel R, Agarwal P, Zimmerman B, Yang Y, Fink M, Zhou X, Newman S, Chen R, Schadt E, Oh W, Tiersten A. Socioeconomic disparities in supportive therapy use and tolerance of aromatase inhibitors in patients with early-stage, hormone-positive breast cancer. Journal Of Clinical Oncology 2022, 40: 523-523. DOI: 10.1200/jco.2022.40.16_suppl.523.
- Karagoz K, Ayers K, Patel B, Wells J, Newman S, Oh W, Zhou X, Chen R, Guin S. Analysis of genomic alterations and treatment landscape in patients with advanced tumors using real-world data for precision oncology. Journal Of Clinical Oncology 2022, 40: 6584-6584. DOI: 10.1200/jco.2022.40.16_suppl.6584.
- Williams C, Karagoz K, Elsey R, Meißner T, Higashi M, Schadt E, Jun T, Wang X, Chen R, Zhou X, Guin S, Lee J, Oh W. QOPI Clinical Informatics: A digital platform to enable real-time quality reporting, clinical decision support, and rapid learning. Journal Of Clinical Oncology 2022, 40: e13545-e13545. DOI: 10.1200/jco.2022.40.16_suppl.e13545.
- Lee K, Cohn D, Liu Z, Ai L, Paek H, Jin L, Raja K, Li M, Zhang X, Jun T, Higashi M, Oh W, Calay E, Savic R, Ghosh K, Kasarskis A, Mullaney T, Pan Q, Schadt E, Wang X. Phenotypic and endotypic features of COPD associated with lung cancer development. Journal Of Clinical Oncology 2022, 40: e13563-e13563. DOI: 10.1200/jco.2022.40.16_suppl.e13563.
- Williams C, Guin S, Elsey R, Meißner T, Xu B, Sun Y, Amallraja A, Jun T, Schadt E, Chen R, Zhou X, Higashi M, Lee J, Oh W. Landscape of tumor genetic testing and targeted therapies over an eight-year span in a rural population. Journal Of Clinical Oncology 2022, 40: e15036-e15036. DOI: 10.1200/jco.2022.40.16_suppl.e15036.
- Patel K, Oh W, Jun T, Naidu S, Nathwani N, Hansen G, Hubert A, Mukhi H, Chhadwa S, Zabala V, Gill S, Branchcomb R, Mehta D, Nixon S, Kodali A, Zimmerman M. Clinical utility of widespread germline testing of cancer patients in a diverse community cancer clinic. Journal Of Clinical Oncology 2022, 40: e18537-e18537. DOI: 10.1200/jco.2022.40.16_suppl.e18537.
- Patel K, Jun T, Chhadwa S, Zabala V, Gill S, Branchcomb R, Naidu S, Nathwani N, Hansen G, Hubbert A, Mukhi H, Mehta D, Nixon S, Kodali A, Zimmerman M, Hantash F, Oh W. Social determinants of health in a prospective study of whole-exome sequencing in advanced cancer patients from underserved communities. Journal Of Clinical Oncology 2022, 40: e18539-e18539. DOI: 10.1200/jco.2022.40.16_suppl.e18539.
- Jun T, Oh W, Schadt E, Higashi M. Health outcomes modelling of RNA-based versus DNA-based detection of driver gene rearrangements in non-small cell lung cancer. Journal Of Clinical Oncology 2022, 40: e18837-e18837. DOI: 10.1200/jco.2022.40.16_suppl.e18837.
- Williams C, Starks D, Elsey R, Meissner T, Solomon B, Albano M, Hantash F, Schadt E, Rojas-Espaillat L, Lee J, Oh W. Implementation of the Avera/Sema4 oncology and analytics protocol (ASAP). Journal Of Clinical Oncology 2022, 40: tps6605-tps6605. DOI: 10.1200/jco.2022.40.16_suppl.tps6605.
- Ai L, Higashi M, Lee K, Liu Z, Jin L, Raja K, Mai Y, Jun T, Oh W, Beckmann A, Schadt E, Schadt Z, Wallsten R, Calay E, Kasarskis A, Pan Q, Schadt E, Wang X. AB0227 TREATMENT SEQUENCING PATTERNS AND COMPARATIVE EFFICACY IN PATIENTS WITH RHEUMATOID ARTHRITIS FROM A REAL-WORLD SETTING. Annals Of The Rheumatic Diseases 2022, 81: 1241. DOI: 10.1136/annrheumdis-2022-eular.4655.
- Lee K, Liu Z, Ma M, Chandran U, Kalsekar I, Laxmanan B, Li M, Mai Y, Gilman C, Wang T, Zhang M, Ai L, Aggarwal P, Pan Q, Oh W, Schadt E, Wang X. Automated Extraction and Longitudinal Analysis of Ground Glass OpacityFeatures in Lung Cancer Patients Powered by Natural Language Processing. 2022, a5077-a5077. DOI: 10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a5077.
- Shah N, Patel V, Zhong X, Pina L, Hawley J, Lin E, Gartrell B, Febles V, Wise D, Qin Q, Mellgard G, Joshi H, Nauseef J, Green D, Vlachostergios P, Kwon D, Huang F, Liaw B, Tagawa S, Kantoff P, Morris M, Oh W. The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer. JNCI Cancer Spectrum 2022, 6: pkac035. PMID: 35657341, PMCID: PMC9165550, DOI: 10.1093/jncics/pkac035.
- Griffin J, Jun T, Guin S, Liaw B, Patel V, Tsao C, Rossi M, Chen R, Zhou X, Hantash F, Oh W. MP27-10 CLINICAL UTILITY OF NEXT-GENERATION SEQUENCING FOR PROSTATE CANCER IN THE CONTEXT OF A CHANGING TREATMENT LANDSCAPE. Journal Of Urology 2022, 207: e453. DOI: 10.1097/ju.0000000000002570.10.
- Rettig M, Beltran H, Oh W. Factors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer. Clinical Advances In Hematology And Oncology 2022, 20 Suppl 9: 1-20. PMID: 35579577.
- Oh W. Clinical observations regarding the use of androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer. Clinical Advances In Hematology And Oncology 2022, 20 Suppl 9: 13-16. PMID: 35579580.
- Oh W, Rettig M. Factors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer: Q&A. Clinical Advances In Hematology And Oncology 2022, 20 Suppl 9: 16-17. PMID: 35579581.
- Jun T, Hahn N, Sonpavde G, Albany C, MacVicar G, Hauke R, Fleming M, Gourdin T, Jana B, Oh W, Taik P, Wang H, Varadarajan A, Uzilov A, Galsky M. Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma. The Oncologist 2022, 27: 432-e452. PMID: 35438782, PMCID: PMC9177111, DOI: 10.1093/oncolo/oyab075.
- Gillessen S, Armstrong A, Attard G, Beer T, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow R, Bulbul M, Caffo O, Chi K, Clarke C, Clarke N, Davis I, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke O, Evans C, Fanti S, Feng F, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman M, Hussain M, James N, Jones R, Kanesvaran R, Khauli R, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans A, Morris M, Mottet N, Mrabti H, Murphy D, Murthy V, Oh W, Ost P, O'Sullivan J, Padhani A, Parker C, Poon D, Pritchard C, Rabah D, Rathkopf D, Reiter R, Rubin M, Ryan C, Saad F, Sade J, Sartor O, Scher H, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg C, Suzuki H, Sweeney C, Sydes M, Taplin M, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology 2022, 82: 115-141. PMID: 35450732, DOI: 10.1016/j.eururo.2022.04.002.
- Turco F, Armstrong A, Attard G, Beer T, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow R, Bulbul M, Caffo O, Chi K, Clarke C, Clarke N, Davis I, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Evans C, Fanti S, Feng F, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman M, Hussain M, James N, Jones R, Kanesvaran R, Khauli R, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans A, Morris M, Mottet N, Mrabti H, Murphy D, Murthy V, Oh W, Ekeke O, Ost P, O'Sullivan J, Padhani A, Parker C, Poon D, Pritchard C, Rabah D, Rathkopf D, Reiter R, Rubin M, Ryan C, Saad F, Sade J, Sartor O, Scher H, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg C, Suzuki H, Sweeney C, Sydes M, Taplin M, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Gillessen S, Omlin A. Corrigendum to “What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021” [Eur Urol 82(1):6–11]. European Urology 2022, 82: e18-e19. PMID: 35440417, PMCID: PMC9012951, DOI: 10.1016/j.eururo.2022.04.004.
- Mack P, Klein M, Ayers K, Zhou X, Guin S, Fink M, Rossi M, AI-Kateb H, O’Connell T, Hantash F, Oh W, Newman S, Schadt E, Chen R, Hirsch F. Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma. The Oncologist 2022, 27: 476-486. PMID: 35298662, PMCID: PMC9177106, DOI: 10.1093/oncolo/oyac035.
- Yu H, Tuminello S, Alpert N, van Gerwen M, Yoo S, Mulholland D, Aaronson S, Donovan M, Oh W, Gong Y, Wang L, Zhu J, Taioli E. Global DNA methylation of WTC prostate cancer tissues show signature differences compared to non-exposed cases. Carcinogenesis 2022, 43: 528-537. PMID: 35239955, PMCID: PMC9234756, DOI: 10.1093/carcin/bgac025.
- Li S, Jun T, Tyler J, Schadt E, Kao Y, Wang Z, Konig M, Bettegowda C, Vogelstein J, Papadopoulos N, Parsons R, Chen R, Schadt E, Li L, Oh W. Inpatient Administration of Alpha-1-Adrenergic Receptor Blocking Agents Reduces Mortality in Male COVID-19 Patients. Frontiers In Medicine 2022, 9: 849222. PMID: 35295598, PMCID: PMC8919772, DOI: 10.3389/fmed.2022.849222.
- Welén K, Rosendal E, Freyhult E, Oh W, Gisslén M, Ahlm C, Connolly A, Överby A, Josefsson A. Reply to Carlos G. Wambier and Gerard J. Nau’s Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients Still No Positive Effect of Enzalutamide for Hospitalized COVID-19 Patients. European Urology 2022, 81: e143-e144. PMID: 35248411, PMCID: PMC8864103, DOI: 10.1016/j.eururo.2022.02.016.
- Griffin J, Jun T, Liaw B, Guin S, Tsao C, Patel V, Rossi M, Zhou X, Hantash F, Chen R, Oh W. Clinical utility of next-generation sequencing for prostate cancer in the context of a changing treatment landscape. Journal Of Clinical Oncology 2022, 40: 112-112. DOI: 10.1200/jco.2022.40.6_suppl.112.
- Turco F, Armstrong A, Attard G, Beer T, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow R, Bulbul M, Caffo O, Chi K, Clarke C, Clarke N, Davis I, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Evans C, Fanti S, Feng F, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman M, Hussain M, James N, Jones R, Kanesvaran R, Khauli R, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans A, Morris M, Mottet N, Mrabti H, Murphy D, Murthy V, Oh W, Ekeke Onyeanunam N, Ost P, O'Sullivan J, Padhani A, Parker C, Poon D, Pritchard C, Rabah D, Rathkopf D, Reiter R, Rubin M, Ryan C, Saad F, Pablo Sade J, Sartor O, Scher H, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg C, Suzuki H, Sweeney C, Sydes M, Taplin M, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Gillessen S, Omlin A. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology 2022, 82: 6-11. PMID: 35393158, PMCID: PMC8849852, DOI: 10.1016/j.eururo.2022.02.010.
- Patel R, Li Z, Zimmerman B, Fink M, Wells J, Zhou X, Ayers K, Redfern A, Newman S, Schadt E, Oh W, Chen R, Tiersten A. Impact of body mass index on the efficacy of aromatase inhibitors in patients with metastatic breast cancer. Breast Cancer Research And Treatment 2022, 192: 313-319. PMID: 35006484, DOI: 10.1007/s10549-021-06504-0.
- Mirza H, Garcia J, Bell C, Jones K, Flynn V, Pepe J, Oh W. Fluid Intake in the First Week of Life and the Duration of Hemodynamically Significant Patent Ductus Arteriosus in Extremely Preterm Infants. American Journal Of Perinatology 2021, 40: 1345-1350. PMID: 34384119, DOI: 10.1055/a-1585-6093.
- Evolving Patterns of Metastasis in Renal Cell Carcinoma: Do We Need to Perform Routine Bone Imaging?Lin J, Zhang Y, Hou W, Qin Q, Galsky M, Oh W, Tsao C. Evolving Patterns of Metastasis in Renal Cell Carcinoma: Do We Need to Perform Routine Bone Imaging? Journal Of Kidney Cancer And VHL 2021, 8: 13-19. PMID: 34722126, PMCID: PMC8523177, DOI: 10.15586/jkcvhl.v8i4.202.
- Cirulli G, Martini A, Gandaglia G, Fossati N, Necchi A, Raggi D, Stabile A, Cucchiara V, Leni R, Robesti D, Pellegrino F, Nocera L, Scuderi S, Karakiewicz P, Galsky M, Oh W, Sfakianos J, Parikh A, Tsao C, Montorsi F, Briganti A. SC206 The obesity paradox in metastatic castration resistant prostate cancer. European Urology Open Science 2021, 32: s101. DOI: 10.1016/s2666-1683(21)00897-1.
- Izadmehr S, Lundon D, Mohamed N, Katims A, Patel V, Eilender B, Mehrazin R, Badani K, Sfakianos J, Tsao C, Wiklund P, Oh W, Cordon-Cardo C, Tewari A, Galsky M, Kyprianou N. The Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic. Frontiers In Oncology 2021, 11: 734963. PMID: 34646777, PMCID: PMC8504458, DOI: 10.3389/fonc.2021.734963.
- Mirza H, Garcia J, Bell C, Jones K, Flynn V, Pepe J, Oh W. Fluid Intake in the First Week of Life and the Duration of Hemodynamically Significant Patent Ductus Arteriosus in Extremely Preterm Infants. American Journal Of Perinatology 2021 DOI: 10.1055/s-0041-1735623.
- Martini A, Cirulli G, Gandaglia G, Fossati N, Necchi A, Stabile A, Cucchiara V, Mazzone E, Karakiewicz P, Sfakianos J, Galsky M, Oh W, Gallagher E, Montorsi F, Briganti A. PD05-01 THE OBESITY PARADOX IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER. Journal Of Urology 2021, 206: e55-e55. DOI: 10.1097/ju.0000000000001969.01.
- Martini A, Cirulli G, Parikh A, Sfakianos J, Galsky M, Oh W, Tsao C, Gandaglia G, Fossati N, Stabile A, Necchi A, Cucchiara V, Pellegrino F, Scuderi S, Karakiewicz P, Montorsi F, Briganti A. MP24-09 BALANCING EFFICACY AND TOXICITY OF DOCETAXEL IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER. RESULTS FROM A POOLED ANALYSIS OF THREE PROSPECTIVE RANDOMIZED TRIALS. Journal Of Urology 2021, 206: e415-e415. DOI: 10.1097/ju.0000000000002015.09.
- Mack P, Klein M, Ayers K, Uzilov A, Zhou X, Corrigan D, Dietz M, Fink M, Guin S, Kip N, Rossi M, Oh W, Hantash F, Newman S, Schadt E, Chen R, Hirsch F. 1271P Molecular driver mutations in never-smokers with lung adenocarcinoma. Annals Of Oncology 2021, 32: s993. DOI: 10.1016/j.annonc.2021.08.1873.
- Riddle M, Cefalu W, Evans P, Gerstein H, Nauck M, Oh W, Rothberg A, le Roux C, Rubino F, Schauer P, Taylor R, Twenefour D. Consensus report: definition and interpretation of remission in type 2 diabetes. Diabetologia 2021, 64: 2359-2366. PMID: 34458934, DOI: 10.1007/s00125-021-05542-z.
- Riddle M, Cefalu W, Evans P, Gerstein H, Nauck M, Oh W, Rothberg A, le Roux C, Rubino F, Schauer P, Taylor R, Twenefour D. Consensus report: Definition and interpretation of remission in type 2 diabetes. Diabetic Medicine 2021, 39: e14669. PMID: 34460965, DOI: 10.1111/dme.14669.
- Riddle M, Cefalu W, Evans P, Gerstein H, Nauck M, Oh W, Rothberg A, le Roux C, Rubino F, Schauer P, Taylor R, Twenefour D. Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. The Journal Of Clinical Endocrinology & Metabolism 2021, 107: 1-9. PMID: 34459898, PMCID: PMC8825709, DOI: 10.1210/clinem/dgab585.
- Riddle M, Cefalu W, Evans P, Gerstein H, Nauck M, Oh W, Rothberg A, le Roux C, Rubino F, Schauer P, Taylor R, Twenefour D. Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. Diabetes Care 2021, 44: 2438-2444. PMID: 34462270, PMCID: PMC8929179, DOI: 10.2337/dci21-0034.
- Koshkin V, Patel V, Ali A, Bilen M, Ravindranathan D, Park J, Kellezi O, Cieslik M, Shaya J, Cabal A, Brown L, Labriola M, Graham L, Pritchard C, Tripathi A, Nusrat S, Barata P, Jang A, Chen S, Garje R, Acharya L, Hwang C, Pilling A, Oh W, Jun T, Natesan D, Nguyen C, Kilari D, Pierro M, Thapa B, Cackowski F, Mack A, Heath E, Marshall C, Tagawa S, Halabi S, Schweizer M, Armstrong A, Dorff T, Alva A, McKay R. PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. Prostate Cancer And Prostatic Diseases 2021, 25: 388-396. PMID: 34363009, PMCID: PMC9385488, DOI: 10.1038/s41391-021-00433-1.
- Singh D, Patel V, Oh W, Aguirre-Ghiso J. Prostate Cancer Dormancy and Reactivation in Bone Marrow. Journal Of Clinical Medicine 2021, 10: 2648. PMID: 34208521, PMCID: PMC8234151, DOI: 10.3390/jcm10122648.
- Cirulli G, Martini A, Sfakianos J, Gandaglia G, Fossati N, Stabile A, Cucchiara V, Mazzone E, Necchi A, Karakiewicz P, Briganti A, Montorsi F, Oh W, Gallagher E, Galsky M. P0855 The obesity paradox in metastatic castration resistant prostate cancer. European Urology 2021, 79: s1195-s1196. DOI: 10.1016/s0302-2838(21)01229-x.
- Cirulli G, Martini A, Pellegrino F, Scuderi S, Parikh A, Oh W, Sfakianos J, Karakiewicz P, Galsky M, Tsao C, Cucchiara V, Stabile A, Gandaglia G, Fossati N, Necchi A, Montorsi F, Briganti A. P0860 Balancing efficacy and toxicity of docetaxel in patients with metastatic castration-resistant prostate cancer. Results from a pooled analysis of three prospective randomized trials. European Urology 2021, 79: s1203-s1204. DOI: 10.1016/s0302-2838(21)01234-3.
- A Rapid Guidance Process for the Development of an Anticoagulation Protocol in the COVID-19 PandemicTremblay D, Dunn A, Oh W. A Rapid Guidance Process for the Development of an Anticoagulation Protocol in the COVID-19 Pandemic. Quality Management In Health Care 2021, 30: 276-279. PMID: 34048378, PMCID: PMC8462300, DOI: 10.1097/qmh.0000000000000324.
- Liaw B, Zhong X, Tsao C, Bakst R, Stewart R, Stock R, Galsky M, Oh W. Prostate cancer intensive, non-cross reactive therapy (PRINT) for CRPC: Interim analysis of efficacy endpoints. Journal Of Clinical Oncology 2021, 39: e17027-e17027. DOI: 10.1200/jco.2021.39.15_suppl.e17027.
- Liaw B, Guin S, Jun T, Ayers K, Patel B, O'Connell T, Dietz M, Klein M, Prentice T, Newman S, Fink M, Zhou X, Schadt E, Chen R, Oh W. Comparative efficacy of docetaxel versus novel hormonal agent in de novo metastatic hormone-sensitive prostate cancer: Real-world data curated by deidentified chart abstraction. Journal Of Clinical Oncology 2021, 39: e17047-e17047. DOI: 10.1200/jco.2021.39.15_suppl.e17047.
- Ayers K, Mullaney T, Zhou X, Liu J, Lee K, Ma M, Jones S, Li L, Redfern A, Jappe W, Liu Z, Goldsweig H, Yadav K, Hahner N, Dietz M, Zimmerman M, Prentice T, Newman S, Veluswamy R, Wisnivesky J, Hirsch F, Oh W, Li S, Schadt E, Chen R. Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers. The Oncologist 2021, 26: e1226-e1239. PMID: 33829580, PMCID: PMC8265370, DOI: 10.1002/onco.13780.
- Bikkasani K, Qin Q, Zhong X, Lin J, Galsky M, Oh W, Tsao C. Characterizing Prostate-Specific Antigen Levels at Death in Patients with Metastatic Castration-Resistant Prostate Cancer: Are We Underutilizing Imaging? Clinical Genitourinary Cancer 2021, 19: e346-e351. PMID: 34011488, DOI: 10.1016/j.clgc.2021.04.003.
- Wang L, Sfakianos J, Beaumont K, Akturk G, Horowitz A, Sebra R, Farkas A, Gnjatic S, Hake A, Izadmehr S, Wiklund P, Oh W, Szabo P, Wind-Rotolo M, Unsal-Kacmaz K, Yao X, Schadt E, Sharma P, Bhardwaj N, Zhu J, Galsky M. Myeloid Cell–associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing. Clinical Cancer Research 2021, 27: 4287-4300. PMID: 33837006, PMCID: PMC8338756, DOI: 10.1158/1078-0432.ccr-20-4574.
- Patel V, Zhong X, Shah N, Pina Martina L, Hawley J, Lin E, Gartrell B, Adorno Febles V, Wise D, Qin Q, Mellgard G, Nauseef J, Green D, Vlachostergios P, Kwon D, Huang F, Liaw B, Tagawa S, Morris M, Oh W. The role of androgen deprivation therapy on the clinical course of COVID-19 infection in men with prostate cancer. Journal Of Clinical Oncology 2021, 39: 41-41. DOI: 10.1200/jco.2021.39.6_suppl.41.
- Martini A, Parikh A, Sfakianos J, Montorsi F, Galsky M, Oh W, Tsao C. Predicting toxicity-related docetaxel discontinuation and overall survival in metastatic castration-resistant prostate cancer: a pooled analysis of open phase 3 clinical trial data. Prostate Cancer And Prostatic Diseases 2021, 24: 743-749. PMID: 33531652, DOI: 10.1038/s41391-021-00326-3.
- Parikh A, Zhong X, Mellgard G, Qin Q, Patel V, Wang B, Alerasool P, Garcia P, Leiter A, Gallagher E, Clinton S, Mortazavi A, Monk P, Folefac E, Yin M, Yang Y, Galsky M, Oh W, Tsao C. Risk Factors for Emergency Room and Hospital Care Among Patients With Solid Tumors on Immune Checkpoint Inhibitor Therapy. American Journal Of Clinical Oncology 2021, 44: 114-120. PMID: 33417323, PMCID: PMC7902456, DOI: 10.1097/coc.0000000000000793.
- Mateo J, McKay R, Abida W, Aggarwal R, Alumkal J, Alva A, Feng F, Gao X, Graff J, Hussain M, Karzai F, Montgomery B, Oh W, Patel V, Rathkopf D, Rettig M, Schultz N, Smith M, Solit D, Sternberg C, Van Allen E, VanderWeele D, Vinson J, Soule H, Chinnaiyan A, Small E, Simons J, Dahut W, Miyahira A, Beltran H. Accelerating precision medicine in metastatic prostate cancer. Nature Cancer 2020, 1: 1041-1053. PMID: 34258585, PMCID: PMC8274325, DOI: 10.1038/s43018-020-00141-0.
- Wang Z, Zheutlin A, Kao Y, Ayers K, Gross S, Kovatch P, Nirenberg S, Charney A, Nadkarni G, De Freitas J, O’Reilly P, Just A, Horowitz C, Martin G, Branch A, Glicksberg B, Charney D, Reich D, Oh W, Schadt E, Chen R, Li L. Hospitalised COVID-19 patients of the Mount Sinai Health System: a retrospective observational study using the electronic medical records. BMJ Open 2020, 10: e040441. PMID: 33109676, PMCID: PMC7592304, DOI: 10.1136/bmjopen-2020-040441.
- Martini A, Parikh A, Gandaglia G, Fossati N, Fallara G, Barletta F, Scuderi S, Robesti D, Cannoletta D, Leni R, Cucchiara V, Bravi C, Mazzone E, Rosiello G, Basile G, Nocera L, Necchi A, Moschini M, Sfakianos J, Galsky M, Oh W, Tsao C, Montorsi F, Briganti A. SC241 Predicting toxicity-related Docetaxel discontinuation and survival in metastatic castration-resistant prostate cancer using open phase 3 trial data. European Urology Open Science 2020, 20: s141-s142. DOI: 10.1016/s2666-1683(20)35563-4.
- Cignoli D, Martini A, Sfakianos J, Gandaglia G, Fossati N, Salonia A, Barletta F, Scuderi S, Robesti D, Bravi C, Mazzone E, Rosiello G, Fallara G, Nocera L, Cirulli G, Stabile A, Briganti A, Montorsi F, Oh W, Gallagher E, Galsky M. SC56 The inverse correlation between obesity and mortality in patients with metastatic castration resistant prostate cancer: Results from the control arms of ASCENT2, MAINSAL and VENICE trials. European Urology Open Science 2020, 20: s55-s56. DOI: 10.1016/s2666-1683(20)35378-7.
- Marco B, Martini A, Pfail J, Gandaglia G, Fossati N, Scuderi S, Fallara G, Barletta F, Robesti D, Rizzo A, Basile G, Bravi C, Rosiello G, Nocera L, Stabile A, Gallina A, Salonia A, Montorsi F, Briganti A, Galsky M, Oh W. SC242 Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial. European Urology Open Science 2020, 20: s142. DOI: 10.1016/s2666-1683(20)35564-6.
- Schmid S, Omlin A, Higano C, Sweeney C, Chanza N, Mehra N, Kuppen M, Beltran H, Condeduca V, de Almeida D, Maluf F, Oh W, Tsao C, Sartor O, Ledet E, Di Lorenzo G, Yip S, N. K, Bianchini D, De Giorgi U, Hansen A, Beer T, Pernelle L, Morales-Barrera R, Tucci M, Castro E, Karalis K, Bergman A, Le M, Zürrer-Härdi U, Pezaro C, Suzuki H, Zivi A, Klingbiel D, Schär S, Gillessen S. Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. JAMA Network Open 2020, 3: e2021692. PMID: 33112397, PMCID: PMC7593810, DOI: 10.1001/jamanetworkopen.2020.21692.
- Lowrance W, Breau R, Chou R, Chapin B, Crispino T, Dreicer R, Jarrard D, Kibel A, Morgan T, Morgans A, Oh W, Resnick M, Zietman A, Cookson M. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II. Journal Of Urology 2020, 205: 22-29. PMID: 32960678, DOI: 10.1097/ju.0000000000001376.
- Lowrance W, Breau R, Chou R, Chapin B, Crispino T, Dreicer R, Jarrard D, Kibel A, Morgan T, Morgans A, Oh W, Resnick M, Zietman A, Cookson M. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I. Journal Of Urology 2020, 205: 14-21. PMID: 32960679, DOI: 10.1097/ju.0000000000001375.
- Patel V, Oh W, Galsky M. Treatment of muscle‐invasive and advanced bladder cancer in 2020. CA A Cancer Journal For Clinicians 2020, 70: 404-423. PMID: 32767764, DOI: 10.3322/caac.21631.
- Abramson D, Fallon J, Biran N, Francis J, Jaben K, Oh W. Lacrimal sac adenocarcinoma managed with androgen deprivation. American Journal Of Ophthalmology Case Reports 2020, 19: 100607. PMID: 32760849, PMCID: PMC7393461, DOI: 10.1016/j.ajoc.2020.100607.
- Patel V, Zhong X, Liaw B, Tremblay D, Tsao C, Galsky M, Oh W. Does androgen deprivation therapy protect against severe complications from COVID-19? Annals Of Oncology 2020, 31: 1419-1420. PMID: 32653425, PMCID: PMC7347319, DOI: 10.1016/j.annonc.2020.06.023.
- Tremblay D, van Gerwen M, Alsen M, Thibaud S, Kessler A, Venugopal S, Makki I, Qin Q, Dharmapuri S, Jun T, Bhalla S, Berwick S, Feld J, Mascarenhas J, Troy K, Cromwell C, Dunn A, Oh W, Naymagon L. Impact of anticoagulation prior to COVID-19 infection: a propensity score–matched cohort study. Blood 2020, 136: 144-147. PMID: 32462179, PMCID: PMC7332896, DOI: 10.1182/blood.2020006941.
- Patel V, Qin Q, Wang B, Gogerly-Moragoda M, Mellgard G, Zhong X, Parikh A, Leiter A, Gallagher E, Oh W, Galsky M, Tsao C. Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors. Journal Of Clinical Oncology 2020, 38: e15068-e15068. DOI: 10.1200/jco.2020.38.15_suppl.e15068.
- Jun T, Ganta T, Qin Q, Patel V, Wang B, Mellgard G, Gogerly-Moragoda M, Leiter A, Gallagher E, Oh W, Galsky M, Tsao C. Smoking status and immunotherapy outcomes in smoking-associated cancers. Journal Of Clinical Oncology 2020, 38: e15097-e15097. DOI: 10.1200/jco.2020.38.15_suppl.e15097.
- Ganta T, Jun T, Qin Q, Patel V, Wang B, Mellgard G, Gogerly-Moragoda M, Leiter A, Gallagher E, Oh W, Galsky M, Tsao C. Clinical efficacy of immunotherapy for the treatment of solid tumors in patients with chronic kidney disease. Journal Of Clinical Oncology 2020, 38: e15109-e15109. DOI: 10.1200/jco.2020.38.15_suppl.e15109.
- Parikh A, Mellgard G, Qin Q, Patel V, Wang B, Zhong X, Leiter A, Gallagher E, Galsky M, Oh W, Clinton S, Mortazavi A, Monk P, Folefac E, Yin M, Yang Y, Tsao C. Risk factors for emergency room and hospital care for patients with advanced solid tumors on immune checkpoint inhibitor therapy. Journal Of Clinical Oncology 2020, 38: e15142-e15142. DOI: 10.1200/jco.2020.38.15_suppl.e15142.
- Lin J, Patel V, Qin Q, Wang B, Mellgard G, Gogerly-Moragoda M, Leiter A, Gallagher E, Zhong X, Oh W, Galsky M, Tsao C. What happens at radiographic disease progression in patients with metastatic cancer receiving immune checkpoint inhibitors? A single institution analysis. Journal Of Clinical Oncology 2020, 38: e15157-e15157. DOI: 10.1200/jco.2020.38.15_suppl.e15157.
- Qin Q, Patel V, Wang B, Mellgard G, Gogerly-Moragoda M, Zhong X, Parikh A, Leiter A, Gallagher E, Galsky M, Oh W, Tsao C. Type, timing, and patient characteristics associated with immune-related adverse event development in patients with advanced solid tumors treated with immune checkpoint inhibitors. Journal Of Clinical Oncology 2020, 38: e15160-e15160. DOI: 10.1200/jco.2020.38.15_suppl.e15160.
- Lin J, Zhong X, Galsky M, Oh W, Tsao C. Predictors of successful randomized phase III studies in the treatment metastatic renal cell carcinoma: A meta-analysis. Journal Of Clinical Oncology 2020, 38: e17105-e17105. DOI: 10.1200/jco.2020.38.15_suppl.e17105.
- Liaw B, Tsao C, Galsky M, Bakst R, Stewart R, Stock R, Oh W. PRINT: Prostate cancer intensive, non-cross reactive therapy for CRPC—Early observations of efficacy. Journal Of Clinical Oncology 2020, 38: e17575-e17575. DOI: 10.1200/jco.2020.38.15_suppl.e17575.
- Ayers K, Liu Z, Ma M, Lee K, Newman S, Li L, Zhou X, Mullaney T, Redfern A, Jappe W, Zimmerman M, Prentice T, Oh W, Schadt E, Li D, Chen R. Using real-world data to investigate time-dependent blood count response to PD-1 and PD-L1 inhibitors and its impact on survival in advanced non-small cell lung cancers. Journal Of Clinical Oncology 2020, 38: e21514-e21514. DOI: 10.1200/jco.2020.38.15_suppl.e21514.
- Schweizer M, Ha G, Gulati R, Brown L, McKay R, Dorff T, Hoge A, Reichel J, Vats P, Kilari D, Patel V, Oh W, Chinnaiyan A, Pritchard C, Armstrong A, Montgomery R, Alva A. CDK12-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade. JCO Precision Oncology 2020, 4: 382-392. PMID: 32671317, PMCID: PMC7363399, DOI: 10.1200/po.19.00383.
- Martini A, Pfail J, Montorsi F, Galsky M, Oh W. Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial. Prostate Cancer And Prostatic Diseases 2020, 23: 638-645. PMID: 32313142, DOI: 10.1038/s41391-020-0231-5.
- Martini* A, Sfakianos J, Gandaglia G, Fossati N, Barletta F, Scuderi S, Robesti D, Fallara G, Salonia A, Briganti A, Montorsi F, Oh W, Gallagher E, Galsky M. PD16-05 THE INVERSE CORRELATION BETWEEN OBESITY AND MORTALITY IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER: RESULTS FROM THE CONTROL ARMS OF ASCENT2, MAINSAL AND VENICE TRIALS. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000859.05.
- Martini A, Pfail* J, Fossati N, Gandaglia G, Fallara G, Barletta F, Scuderi S, Robesti D, Salonia A, Briganti A, Montorsi F, Galsky M, Oh W. PD16-06 SURROGATE ENDPOINTS FOR OVERALL SURVIVAL FOR PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER IN THE CHAARTED TRIAL. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000859.06.
- Martini* A, Parikh A, Sfakianos J, Fossati N, Gandaglia G, Scuderi S, Cannoletta D, Fallara G, Mazzone E, Stabile A, Barletta F, Robesti D, Bravi C, Briganti A, Montorsi F, Oh W, Galsky M, Tsao C. PD16-07 PREDICTING TOXICITY-RELATED DOCETAXEL DISCONTINUATION AND SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER USING OPEN PHASE 3 TRIAL DATA. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000859.07.
- Oh W. COVID-19 infection in cancer patients: early observations and unanswered questions. Annals Of Oncology 2020, 31: 838-839. PMID: 32243894, PMCID: PMC7270512, DOI: 10.1016/j.annonc.2020.03.297.
- Liu M, Oxnard G, Klein E, Swanton C, Seiden M, Consortium C, investigators C, Liu M, Oxnard G, Klein E, Smith D, Richards D, Yeatman T, Cohn A, Lapham R, Clement J, Parker A, Tummala M, McIntyre K, Sekeres M, Bryce A, Siegel R, Wang X, Cosgrove D, Abu-Rustum N, Trent J, Thiel D, Becerra C, Agrawal M, Garbo L, Giguere J, Michels R, Harris R, Richey S, McCarthy T, Waterhouse D, Couch F, Wilks S, Krie A, Balaraman R, Restrepo A, Meshad M, Rieger-Christ K, Sullivan T, Lee C, Greenwald D, Oh W, Tsao C, Fleshner N, Kennecke H, Khalil M, Spigel D, Manhas A, Ulrich B, Kovoor P, Stokoe C, Courtright J, Yimer H, Larson T, Swanton C, Seiden M, investigators S, Cummings S, GRAIL I, Absalan F, Alexander G, Allen B, Amini H, Aravanis A, Bagaria S, Bazargan L, Beausang J, Berman J, Betts C, Blocker A, Bredno J, Calef R, Cann G, Carter J, Chang C, Chawla H, Chen X, Chien T, Civello D, Davydov K, Demas V, Desai M, Dong Z, Fayzullina S, Fields A, Filippova D, Freese P, Fung E, Gnerre S, Gross S, Halks-Miller M, Hall M, Hartman A, Hou C, Hubbell E, Hunkapiller N, Jagadeesh K, Jamshidi A, Jiang R, Jung B, Kim T, Klausner R, Kurtzman K, Lee M, Lin W, Lipson J, Liu H, Liu Q, Lopatin M, Maddala T, Maher M, Melton C, Mich A, Nautiyal S, Newman J, Newman J, Nicula V, Nicolaou C, Nikolic O, Pan W, Patel S, Prins S, Rava R, Ronaghi N, Sakarya O, Satya R, Schellenberger J, Scott E, Sehnert A, Shaknovich R, Shanmugam A, Shashidhar K, Shen L, Shenoy A, Shojaee S, Singh P, Steffen K, Tang S, Toung J, Valouev A, Venn O, Williams R, Wu T, Xu H, Yakym C, Yang X, Yecies J, Yip A, Youngren J, Yue J, Zhang J, Zhang L, Zhang L, Zhang N, Advisors, Curtis C, Berry D. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Annals Of Oncology 2020, 31: 745-759. PMID: 33506766, PMCID: PMC8274402, DOI: 10.1016/j.annonc.2020.02.011.
- Schweizer M, Gulati R, Brown L, McKay R, Dorff T, Kilari D, Vats P, Patel V, Oh W, Armstrong A, Montgomery R, Alva A. CDK12 -mutated prostate cancer (PC): Clinical outcomes to standard therapies and immune checkpoint blockade. Journal Of Clinical Oncology 2020, 38: 191-191. DOI: 10.1200/jco.2020.38.6_suppl.191.
- Lin J, Caress A, Ahmed F, Taylor N, Gong Y, Oh W. Elevated circulating CCL2 in prostate cancer patients. Journal Of Clinical Oncology 2020, 38: 201-201. DOI: 10.1200/jco.2020.38.6_suppl.201.
- PRINT: Prostate cancer intensive, non-cross reactive therapy for CRP—Early observations of efficacy.Liaw B, Tsao C, Galsky M, Bakst R, Stewart R, Stock R, Oh W. PRINT: Prostate cancer intensive, non-cross reactive therapy for CRP—Early observations of efficacy. Journal Of Clinical Oncology 2020, 38: 89-89. DOI: 10.1200/jco.2020.38.6_suppl.89.
- Parikh A, Martini A, Sfakianos J, Galsky M, Oh W, Tsao C. Predicting toxicity-related docetaxel discontinuation and survival in metastatic castration-resistant prostate cancer (mCRPC) using open phase III trial data. Journal Of Clinical Oncology 2020, 38: 75-75. DOI: 10.1200/jco.2020.38.6_suppl.75.
- Patel V, Qin Q, Mellgard G, Parikh A, Wang B, Alerasool P, Garcia P, Jaladanki S, Leiter A, Carroll E, Brooks D, Shimol J, Eisenberg E, Gallagher E, Galsky M, Oh W, Tsao C. Characterizing patterns of disease progression in patients with genitourinary cancers treated with immune checkpoint inhibitors. Journal Of Clinical Oncology 2020, 38: 482-482. DOI: 10.1200/jco.2020.38.6_suppl.482.
- Qin Q, Patel V, Mellgard G, Parikh A, Wang B, Alerasool P, Garcia P, Jaladanki S, Leiter A, Carroll E, Brooks D, Shimol J, Eisenberg E, Gallagher E, Galsky M, Oh W, Tsao C. Type, timing, and risk factors associated with immune-related adverse event development in patients with advanced genitourinary cancers treated with immune checkpoint inhibitor. Journal Of Clinical Oncology 2020, 38: 480-480. DOI: 10.1200/jco.2020.38.6_suppl.480.
- Gillessen S, Attard G, Beer T, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow R, Chi K, Clarke N, Davis I, de Bono J, Drake C, Duran I, Eeles R, Efstathiou E, Evans C, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Heinrich D, Higano C, Hofman M, Hussain M, James N, Kanesvaran R, Kantoff P, Khauli R, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans A, Morris M, Mottet N, Mrabti H, Murphy D, Murthy V, Oh W, Ost P, O'Sullivan J, Padhani A, Parker C, Poon D, Pritchard C, Reiter R, Roach M, Rubin M, Ryan C, Saad F, Sade J, Sartor O, Scher H, Shore N, Small E, Smith M, Soule H, Sternberg C, Steuber T, Suzuki H, Sweeney C, Sydes M, Taplin M, Tombal B, Türkeri L, van Oort I, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. European Urology 2020, 77: 508-547. PMID: 32001144, DOI: 10.1016/j.eururo.2020.01.012.
- Fei K, Lin J, Supoyo S, Franco R, Abramson S, Hoke G, Oh W, Stock R, Bickell N. Impact of Age and Life-expectancy on Treatment Receipt in High-risk Prostate Cancer. Journal Of Advances In Medicine And Medical Research 2019, 1-9. DOI: 10.9734/jammr/2019/v30i1130248.
- Mehrazin R, Oh W. Prostate Cancer. 2019, 23-31. DOI: 10.1002/9781119189596.ch2.
- Gong Y, Wang L, Yu H, Alpert N, Cohen M, Prophete C, Horton L, Sisco M, Park S, Lee H, Zelikoff J, Chen L, Hashim D, Suarez-Farinas M, Donovan M, Aaronson S, Galsky M, Zhu J, Taioli E, Oh W. Prostate Cancer in World Trade Center Responders Demonstrates Evidence of an Inflammatory Cascade. Molecular Cancer Research 2019, 17: 1605-1612. PMID: 31221798, PMCID: PMC6684261, DOI: 10.1158/1541-7786.mcr-19-0115.
- Wang L, Gong Y, Saci A, Szabo P, Martini A, Necchi A, Siefker-Radtke A, Pal S, Plimack E, Sfakianos J, Bhardwaj N, Horowitz A, Farkas A, Mulholland D, Fischer B, Oh W, Sharma P, Zhu J, Galsky M. Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer. European Urology 2019, 76: 599-603. PMID: 31272788, PMCID: PMC6801024, DOI: 10.1016/j.eururo.2019.06.025.
- Niglio S, Jia R, Ji J, Ruder S, Patel V, Martini A, Sfakianos J, Marqueen K, Waingankar N, Mehrazin R, Wiklund P, Oh W, Mazumdar M, Ferket B, Galsky M. Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. European Urology 2019, 76: 782-789. PMID: 31200951, DOI: 10.1016/j.eururo.2019.05.037.
- Patel V, Oh W. The evolving landscape of immunotherapy in advanced prostate cancer. Immunotherapy 2019, 11: 903-912. PMID: 31161846, DOI: 10.2217/imt-2019-0019.
- McCafferty J, Grover K, Li L, Li Z, Fink M, Goldsweig H, Ma M, Zhou X, Mullaney T, Redfern A, Jappe W, Zimmerman M, Prentice T, Pan Q, Oh W, Schadt E, Li D, Chen R. A systematic analysis of off-label drug use in real-world data (RWD) across more than 145,000 cancer patients. Journal Of Clinical Oncology 2019, 37: e18031-e18031. DOI: 10.1200/jco.2019.37.15_suppl.e18031.
- Liu Z, Ma M, Grover K, Li L, Goldsweig H, Yadav K, Zhou X, Mullaney T, Redfern A, Jappe W, Zimmerman M, Prentice T, Pan Q, Oh W, Schadt E, Li D, Chen R. Investigating racial differences in treatment responses through analysis of real-world data (RWD). Journal Of Clinical Oncology 2019, 37: e18141-e18141. DOI: 10.1200/jco.2019.37.15_suppl.e18141.
- Ma M, Zhou X, Goldsweig H, Hahner N, Han D, Dietz M, Jones S, Mullaney T, Redfern A, Jappe W, Liu Z, Yadav K, Zimmerman M, Prentice T, Pan Q, Hirsch F, Oh W, Schadt E, Li D, Chen R. Analysis of real-world data (RWD) on treatment (tx) sequencing in patients with advanced non-small cell lung cancer (aNSCLC). Journal Of Clinical Oncology 2019, 37: e20642-e20642. DOI: 10.1200/jco.2019.37.15_suppl.e20642.
- Chong* J, Muhleman M, Say R, Kostakoglu L, Ahmed J, Tewari A, Stock R, Oh W. MP13-01 PET/CT WITH 18 F-FLUCICLOVINE TO PREDICT RECURRENCE IN POST-TREATMENT PROSTATE CANCER AND ITS ROLE IN ALTERING TREATMENT PLANS. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000555214.12968.a4.
- Chong J, Muhleman M, Say R, Kostakoglu L, Ahmed J, Tewari A, Stock R, Oh W. Positron emission tomography with 18F-fluciclovine to predict recurrence in post-treatment recurrent prostate cancer and its role in altering treatment plans. Journal Of Clinical Oncology 2019, 37: 214-214. DOI: 10.1200/jco.2019.37.7_suppl.214.
- Qin Q, Bikkasani K, Oh W, Liaw B, Galsky M, Tsao C. Patients with an extremely high prostate-specific antigen at prostate cancer diagnosis: A single institution analysis. Journal Of Clinical Oncology 2019, 37: 309-309. DOI: 10.1200/jco.2019.37.7_suppl.309.
- Liaw B, Tsao C, Galsky M, Bakst R, Stewart R, Stock R, Oh W. PRINT: Prostate cancer intensive, non-cross reactive therapy for CRPC—Early observations of feasibility and efficacy. Journal Of Clinical Oncology 2019, 37: 310-310. DOI: 10.1200/jco.2019.37.7_suppl.310.
- Patel V, Oh W, Galsky M, Liaw B, Tsao C. Effect of concurrent beta-blocker (BB) use in patients receiving immune checkpoint inhibitors for metastatic urothelial (mUC) and renal cell carcinomas (mRCC). Journal Of Clinical Oncology 2019, 37: 467-467. DOI: 10.1200/jco.2019.37.7_suppl.467.
- Lin J, Oh W, Liaw B, Galsky M, Tsao C. Evolving patterns of metastatic renal cell carcinoma: A meta-analysis. Journal Of Clinical Oncology 2019, 37: 563-563. DOI: 10.1200/jco.2019.37.7_suppl.563.
- Taplin M, Hussain A, Shah S, Shore N, Agrawal M, Clark W, Edenfield W, Nordquist L, Sartor O, Butrynski J, Chatta G, Fleming M, Oh W, Bradley B, Piel J, Nash D, Colak G, Li J, Lebedinsky C, Antonarakis E. ProSTAR: A phase Ib/II study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer (mCRPC). Journal Of Clinical Oncology 2019, 37: tps335-tps335. DOI: 10.1200/jco.2019.37.7_suppl.tps335.
- Bikkasani K, Qin Q, Lin J, Galsky M, Liaw B, Oh W, Tsao C. Characterization of PSA at death in patients with metastatic castration-resistant prostate cancer. Journal Of Clinical Oncology 2019, 37: 184-184. DOI: 10.1200/jco.2019.37.7_suppl.184.
- Ahmed J, Muhleman M, Chong J, Tewari A, Oh W, Kostakoglu L, Stock R. Application of 18-F Fluciclovine PET/CT in Guiding Salvage Radiation Therapy for Recurrent Prostate Cancer. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: e95-e96. DOI: 10.1016/j.ijrobp.2018.07.371.
- Phelps D, Watterberg K, Nolen T, Cole C, Cotten C, Oh W, Poindexter B, Zaterka-Baxter K, Das A, Lacy C, Scorsone A, Walsh M, Bell E, Kennedy K, Schibler K, Sokol G, Laughon M, Lakshminrusimha S, Truog W, Garg M, Carlo W, Laptook A, Van Meurs K, Carlton D, Graf A, DeMauro S, Brion L, Shankaran S, Orge F, Olson R, Mintz-Hittner H, Yang M, Haider K, Wallace D, Chung M, Hug D, Tsui I, Cogen M, Donahue J, Gaynon M, Hutchinson A, Bremer D, Quinn G, He Y, Lucas W, Winter T, Kicklighter S, Kumar K, Chess P, Colaizy T, Hibbs A, Ambalavanan N, Harmon H, McGowan E, Higgins R. Effects of Myo-inositol on Type 1 Retinopathy of Prematurity Among Preterm Infants <28 Weeks' Gestational Age: A Randomized Clinical Trial. JAMA 2018, 320: 1649-1658. PMID: 30357297, DOI: 10.1001/jama.2018.14996.
- Omidele O, Schiff H, Oh W, Tewari A. Multimodal therapy in the treatment of metastatic prostate cancer: A case report. Urology Case Reports 2018, 21: 92-94. PMID: 30258788, PMCID: PMC6154777, DOI: 10.1016/j.eucr.2018.09.010.
- Friedlander P, Wood K, Wassmann K, Christenfeld A, Bhardwaj N, Oh W. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab. Journal For ImmunoTherapy Of Cancer 2018, 6: 90. PMID: 30227886, PMCID: PMC6145108, DOI: 10.1186/s40425-018-0408-9.
- Oh W, Cheng W, Miao R, Vekeman F, Gauthier-Loiselle M, Duh M, Drea E, Szatrowski T. Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting. Urologic Oncology Seminars And Original Investigations 2018, 36: 500.e1-500.e9. PMID: 30201382, DOI: 10.1016/j.urolonc.2018.08.002.
- Wang L, Saci A, Szabo P, Chasalow S, Castillo-Martin M, Domingo-Domenech J, Siefker-Radtke A, Sharma P, Sfakianos J, Gong Y, Dominguez-Andres A, Oh W, Mulholland D, Azrilevich A, Hu L, Cordon-Cardo C, Salmon H, Bhardwaj N, Zhu J, Galsky M. EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nature Communications 2018, 9: 3503. PMID: 30158554, PMCID: PMC6115401, DOI: 10.1038/s41467-018-05992-x.
- Patel V, Liaw B, Oh W. The role of ketoconazole in current prostate cancer care. Nature Reviews Urology 2018, 15: 643-651. PMID: 30154429, DOI: 10.1038/s41585-018-0077-y.
- Lowrance W, Murad M, Oh W, Jarrard D, Resnick M, Cookson M. Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018. Journal Of Urology 2018, 200: 1264-1272. PMID: 30086276, DOI: 10.1016/j.juro.2018.07.090.
- Resende Salgado L, Rhome R, Oh W, Stone N, Stock R. Prostate-specific antigen doubling time is a significant predictor of overall and disease-free survival in patients with prostate adenocarcinoma treated with brachytherapy. Brachytherapy 2018, 17: 874-881. PMID: 30061057, DOI: 10.1016/j.brachy.2018.07.008.
- Lee E, Collazo-Lorduy A, Castillo-Martin M, Gong Y, Wang L, Oh W, Galsky M, Cordon-Cardo C, Zhu J. Identification of microR-106b as a prognostic biomarker of p53-like bladder cancers by ActMiR. Oncogene 2018, 37: 5858-5872. PMID: 29970902, PMCID: PMC6212417, DOI: 10.1038/s41388-018-0367-0.
- Hashim D, Boffetta P, Galsky M, Oh W, Lucchini R, Crane M, Luft B, Moline J, Udasin I, Harrison D, Taioli E. Prostate cancer characteristics in the World Trade Center cohort, 2002–2013. European Journal Of Cancer Prevention 2018, 27: 347-354. PMID: 27898584, PMCID: PMC5443704, DOI: 10.1097/cej.0000000000000315.
- Chong J, Oh W, Liaw B. Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date. OncoTargets And Therapy 2018, 11: 2141-2147. PMID: 29695920, PMCID: PMC5905496, DOI: 10.2147/ott.s147168.
- McClinch K, Avelar R, Callejas D, Izadmehr S, Wiredja D, Perl A, Sangodkar J, Kastrinsky D, Schlatzer D, Cooper M, Kiselar J, Stachnik A, Yao S, Hoon D, McQuaid D, Zaware N, Gong Y, Brautigan D, Plymate S, Sprenger C, Oh W, Levine A, Kirschenbaum A, Sfakianos J, Sears R, DiFeo A, Ioannou Y, Ohlmeyer M, Narla G, Galsky M. Small molecule activators of protein phosphatase 2A for the treatment of castration-resistant prostate cancer. Cancer Research 2018, 78: canres.0123.2017. PMID: 29358171, PMCID: PMC5899650, DOI: 10.1158/0008-5472.can-17-0123.
- Levin R, Given R, Nemeth P, Bosch B, Chapas-Reed J, Oh W. Multicenter extension and switch study evaluating the safety of long-term treatment with abiraterone acetate fine particle formulation (AAFP) in patients with metastatic castration-resistant prostate cancer (mCRPC): The STAAR-E study. Journal Of Clinical Oncology 2018, 36: 181-181. DOI: 10.1200/jco.2018.36.6_suppl.181.
- Liaw B, Oh W. Prostate Cancer. 2018, 344-362. DOI: 10.1002/9781118592168.ch26.
- Tsao C, Oh W. First-Line Treatment of Hormone-Sensitive Metastatic Prostate Cancer: Is There a Single Standard of Care? Journal Of Clinical Oncology 2018, 36: jco.2017.77.431. PMID: 29432079, DOI: 10.1200/jco.2017.77.4315.
- Azad A, Chang P, Devuni D, Bichoupan K, Kesar V, Branch A, Oh W, Galsky M, Ahmad J, Odin J. Real World Experience of Drug Induced Liver Injury in Patients Undergoing Chemotherapy. Journal Of Clinical Gastroenterology And Hepatology 2018, 2 PMID: 30637414, PMCID: PMC6327955, DOI: 10.21767/2575-7733.1000047.
- Galsky M, Wang H, Hahn N, Twardowski P, Pal S, Albany C, Fleming M, Starodub A, Hauke R, Yu M, Zhao Q, Sonpavde G, Donovan M, Patel V, Sfakianos J, Domingo-Domenech J, Oh W, Akers N, Losic B, Gnjatic S, Schadt E, Chen R, Kim-Schulze S, Bhardwaj N, Uzilov A. Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. European Urology 2017, 73: 751-759. PMID: 29248319, DOI: 10.1016/j.eururo.2017.12.001.
- Bickell N, Lin J, Abramson S, Hoke G, Oh W, Hall S, Stock R, Fei K, McAlearney A. Racial Disparities in Clinically Significant Prostate Cancer Treatment: The Potential Health Information Technology Offers. JCO Oncology Practice 2017, 14: jop.2017.025957. PMID: 29194001, PMCID: PMC5765902, DOI: 10.1200/jop.2017.025957.
- Lieberman-Cribbin W, Galsky M, Casey M, Liu B, Oh W, Flores R, Taioli E. Hospital Centralization Impacts High-Risk Lung and Bladder Cancer Surgical Patients. Cancer Investigation 2017, 35: 652-661. PMID: 29243986, DOI: 10.1080/07357907.2017.1406495.
- Galsky M, Shahin M, Jia R, Shaffer D, Gimpel-Tetra K, Tsao C, Baker C, Leiter A, Holland J, Sablinski T, Mehrazin R, Sfakianos J, Acon P, Oh W. Telemedicine-Enabled Clinical Trial of Metformin in Patients With Prostate Cancer. JCO Clinical Cancer Informatics 2017, 1: 1-10. PMID: 30657386, DOI: 10.1200/cci.17.00044.
- Galsky M, Diefenbach M, Mohamed N, Baker C, Pokhriya S, Rogers J, Atreja A, Hu L, Tsao C, Sfakianos J, Mehrazin R, Waingankar N, Oh W, Mazumdar M, Ferket B. Web-Based Tool to Facilitate Shared Decision Making With Regard to Neoadjuvant Chemotherapy Use in Muscle-Invasive Bladder Cancer. JCO Clinical Cancer Informatics 2017, 1: 1-12. PMID: 30657403, PMCID: PMC6874030, DOI: 10.1200/cci.17.00116.
- Drudge-Coates L, Oh W, Tombal B, Delacruz A, Tomlinson B, Ripley A, Mastris K, O'Sullivan J, Shore N. Recognizing Symptom Burden in Advanced Prostate Cancer: A Global Patient and Caregiver Survey. Clinical Genitourinary Cancer 2017, 16: e411-e419. PMID: 29111175, DOI: 10.1016/j.clgc.2017.09.015.
- Galsky M, Diefenbach M, Mohamed N, Baker C, Pokhriya S, Rogers J, Atreja A, Ramireddy K, Hu L, Tsao C, Sfakianos J, Mehrazin R, Hassanzadeh N, Waingankar N, Oh W, Kohli A, Otobo E, Mazumdar M, Ferket B. A Web-Based Tool to Facilitate Shared Decision-Making Regarding Neoadjuvant Chemotherapy Use in Muscle-Invasive Bladder Cancer. Iproceedings 2017, 3: e43. DOI: 10.2196/iproc.8456.
- Friedlander P, Wassmann K, Christenfeld A, Fisher D, Kyi C, Kirkwood J, Bhardwaj N, Oh W. Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab. Journal For ImmunoTherapy Of Cancer 2017, 5: 67. PMID: 28807052, PMCID: PMC5557000, DOI: 10.1186/s40425-017-0272-z.
- Oh W, Miao R, Vekeman F, Sung J, Cheng W, Gauthier-Loiselle M, Dhawan R, Duh M. Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting. Medical Oncology 2017, 34: 160. PMID: 28795333, PMCID: PMC5550521, DOI: 10.1007/s12032-017-1014-2.
- Gillessen S, Attard G, Beer T, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung B, Clarke N, Daugaard G, Davis I, de Bono J, dos Reis R, Drake C, Eeles R, Efstathiou E, Evans C, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano C, James N, Kantoff P, Kellokumpu-Lehtinen P, Khauli R, Kramer G, Logothetis C, Maluf F, Morgans A, Morris M, Mottet N, Murthy V, Oh W, Ost P, Padhani A, Parker C, Pritchard C, Roach M, Rubin M, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg C, Suzuki H, Sweeney C, Sydes M, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. European Urology 2017, 73: 178-211. PMID: 28655541, DOI: 10.1016/j.eururo.2017.06.002.
- Oh W, Miao R, Vekeman F, Sung J, Cheng W, Gauthier-Loiselle M, Dhawan R, Duh M. Real-world Characteristics and Outcomes of Patients With Metastatic Castration-resistant Prostate Cancer Receiving Chemotherapy Versus Androgen Receptor-targeted Therapy After Failure of First-line Androgen Receptor-targeted Therapy in the Community Setting. Clinical Genitourinary Cancer 2017, 16: 50-57. PMID: 28729067, DOI: 10.1016/j.clgc.2017.06.004.
- Pomerantz M, Spisák S, Jia L, Cronin A, Csabai I, Ledet E, Sartor A, Rainville I, O'Connor E, Herbert Z, Szállási Z, Oh W, Kantoff P, Garber J, Schrag D, Kibel A, Freedman M. The association between germline BRCA2 variants and sensitivity to platinum‐based chemotherapy among men with metastatic prostate cancer. Cancer 2017, 123: 3532-3539. PMID: 28608931, PMCID: PMC5802871, DOI: 10.1002/cncr.30808.
- Kyi C, Sabado R, Blazquez A, Posner M, Genden E, Miles B, Khorasani H, Dottino P, Irie H, Port E, Wolf A, Cho H, Parekh S, Mandeli J, Galsky M, Oh W, Gnjatic S, Schadt E, Friedlander P, Bhardwaj N. A phase I study of the safety and immunogenicity of a multipeptide personalized genomic vaccine in the adjuvant treatment of solid cancers. Journal Of Clinical Oncology 2017, 35: tps3114-tps3114. DOI: 10.1200/jco.2017.35.15_suppl.tps3114.
- Oh W, Kandadi H, Sheikh N, Galsky M. Blood-based predictive biomarkers for overall survival (OS) in patients (pts) receiving the immunotherapy sipuleucel-T (sip-T). Journal Of Clinical Oncology 2017, 35: 36-36. DOI: 10.1200/jco.2017.35.7_suppl.36.
- Friedlander P, Wassman K, Kyi C, Oh W, Bhardwaj N. Correlation of consistent blood-based gene expression with change in CTLA4 in two large independent clinical studies of patients with advanced melanoma treated with tremelimumab. Journal Of Clinical Oncology 2017, 35: 6-6. DOI: 10.1200/jco.2017.35.7_suppl.6.
- Oh W, Cheng W, Miao R, Vekeman F, Gauthier-Loiselle M, Duh M, Drea E, Szatrowski T. Real-world outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving second-line (2L) chemotherapy (CT) vs alternative androgen receptor-targeted agents (ARTA) after lack of response to first-line (1L) ARTA in US community oncology practices. Journal Of Clinical Oncology 2017, 35: 214-214. DOI: 10.1200/jco.2017.35.6_suppl.214.
- Galsky M, Shahin M, Olson A, Shaffer D, Gimpel-Tetra K, Tsao C, Baker C, Leiter A, Holland J, Sablinski T, Mehrazin R, Sfakianos J, Acon P, Oh W. Telemedicine-enabled clinical trial of metformin in patients (pts) with biochemically-recurrent prostate cancer (PCa). Journal Of Clinical Oncology 2017, 35: 243-243. DOI: 10.1200/jco.2017.35.6_suppl.243.
- Tsao C, Liaw B, He C, Galsky M, Sfakianos J, Oh W. Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: latest evidence and therapeutic implications. Therapeutic Advances In Medical Oncology 2017, 9: 287-298. PMID: 28491148, PMCID: PMC5405995, DOI: 10.1177/1758834016687261.
- McNeel DG, Bander NH, Beer TM, Drake CG, Fong L, Harrelson S, Kantoff PW, Madan RA, Oh WK, Peace DJ, Petrylak DP, Porterfield H, Sartor O, Shore ND, Slovin SF, Stein MN, Vieweg J, Gulley JL. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. Journal For ImmunoTherapy Of Cancer 2016, 4: 92. PMID: 28031820, PMCID: PMC5170901, DOI: 10.1186/s40425-016-0198-x.
- Roubaud G, Liaw B, Oh W, Mulholland D. Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer. Nature Reviews Clinical Oncology 2016, 14: 269-283. PMID: 27874061, PMCID: PMC5567685, DOI: 10.1038/nrclinonc.2016.181.
- Tsao C, Sfakianos J, Liaw B, Gimpel‐Tetra K, Kemeny M, Bulone L, Shahin M, Oh W, Galsky M. Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer. The Oncologist 2016, 21: 1414-e9. PMID: 27742908, PMCID: PMC5153336, DOI: 10.1634/theoncologist.2016-0026.
- Stock R, Sfakianos J, Oh W, Stone N. Prostate-Specific Antigen Doubling Time Posttreatment Is the Most Significant Predictor of Survival Following the Brachytherapy Management of Localized Prostate Cancer. International Journal Of Radiation Oncology • Biology • Physics 2016, 96: e236. DOI: 10.1016/j.ijrobp.2016.06.1216.
- Gong Y, Wang L, Chippada-Venkata U, Dai X, Oh W, Zhu J. Constructing bayesian networks by integrating gene expression and copy number data identifies NLGN4Y as a novel regulator of prostate cancer progression. Oncotarget 2016, 7: 68688-68707. PMID: 27626693, PMCID: PMC5356583, DOI: 10.18632/oncotarget.11925.
- Wang L, Oh W, Zhu J. Disease-specific classification using deconvoluted whole blood gene expression. Scientific Reports 2016, 6: 32976. PMID: 27596246, PMCID: PMC5011717, DOI: 10.1038/srep32976.
- Casey M, Wisnivesky J, Le V, Sarpel U, Stensland K, Oh W, Galsky M. The Relationship between Centralization of Care and Geographic Barriers to Cystectomy for Bladder Cancer. Bladder Cancer 2016, 2: 319-327. PMID: 27500199, PMCID: PMC4969695, DOI: 10.3233/blc-160058.
- Tsao C, Galsky M, Oh W. Docetaxel for Metastatic Hormone-sensitive Prostate Cancer: Urgent Need to Minimize the Risk of Neutropenic Fever. European Urology 2016, 70: 707-708. PMID: 27417033, DOI: 10.1016/j.eururo.2016.06.041.
- Galsky M, Stensland K, Sfakianos J, Mehrazin R, Diefenbach M, Mohamed N, Tsao C, Boffetta P, Wiklund P, Oh W, Mazumdar M, Ferket B. Comparative Effectiveness of Treatment Strategies for Bladder Cancer With Clinical Evidence of Regional Lymph Node Involvement. Journal Of Clinical Oncology 2016, 34: 2627-2635. PMID: 27269939, PMCID: PMC5012691, DOI: 10.1200/jco.2016.67.5033.
- Oh W, Tombal B, Delacruz A, Tomlinson B, Vella Ripley A, Drudge-Coates L, Mastris K, O'Sullivan J, Shore N. Recognizing symptom burden in advanced prostate cancer: A global patient and caregiver survey. Journal Of Clinical Oncology 2016, 34: 10124-10124. DOI: 10.1200/jco.2016.34.15_suppl.10124.
- Galsky M, Stensland K, Sfakianos J, Mehrazin R, Diefenbach M, Tsao C, Boffetta P, Oh W, Mazumdar M, Ferket B. Comparative effectiveness of treatment strategies for urothelial cancer of the bladder (UCB) with clinical lymph node involvement (cN+). Journal Of Clinical Oncology 2016, 34: 4530-4530. DOI: 10.1200/jco.2016.34.15_suppl.4530.
- McBride R, Patel V, Lorduy A, Castillo-Martin M, Cha E, Berger M, Wang L, Oh W, Zhu J, Cordon-Cardo C, Solit D, Sfakianos J, Galsky M. Prognostic significance of DNA damage repair (DDR) mutations in patients with urothelial carcinoma (UC) and associations with tumor infiltrating lymphocytes (TILs). Journal Of Clinical Oncology 2016, 34: 4538-4538. DOI: 10.1200/jco.2016.34.15_suppl.4538.
- Oh W, Kandadi H, Fan L, Sheikh N, Trager J, Galsky M. Blood-based predictive biomarkers for overall survival (OS) in patients (pts) receiving the immunotherapy sipuleucel-T (sip-T). Journal Of Clinical Oncology 2016, 34: 5026-5026. DOI: 10.1200/jco.2016.34.15_suppl.5026.
- Patel V, McBride R, Lorduy A, Castillo-Martin M, Cha E, Berger M, Wang L, Oh W, Zhu J, Cordon-Cardo C, Solit D, Sfakianos J, Galsky M. Prognostic significance of PIK3CA mutation in patients with muscle-invasive urothelial carcinoma (UC). Journal Of Clinical Oncology 2016, 34: e16002-e16002. DOI: 10.1200/jco.2016.34.15_suppl.e16002.
- Heck M, Thalgott M, Schmid S, Oh W, Gong Y, Wang L, Zhu J, Seitz A, Porst D, Höppner M, Retz M, Gschwend J, Nawroth R. A 2‐Gene Panel Derived From Prostate Cancer‐Enhanced Transcripts in Whole Blood Is Prognostic for Survival and Predicts Treatment Benefit in Metastatic Castration‐Resistant Prostate Cancer. The Prostate 2016, 76: 1160-1168. PMID: 27198487, DOI: 10.1002/pros.23202.
- Collazo-Lorduy A, Castillo-Martin M, Wang L, Patel V, Iyer G, Jordan E, Al-Ahmadie H, Leonard I, Oh W, Zhu J, McBride R, Cordon-Cardo C, Solit D, Sfakianos J, Galsky M. Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition. European Urology 2016, 70: 771-775. PMID: 27178450, PMCID: PMC5489411, DOI: 10.1016/j.eururo.2016.04.037.
- Oh W, Miao R, Duh, Vekeman F, Sung J, Cheng W, Gauthier-Loiselle M, Fortier J, Dhawan R. PCN33 Treatment Sequences, Patient Characteristics, And Overall Survival Of Patients With Post-Docetaxel Metastatic Castration-Resistant Prostate Cancer In The Community Setting. Value In Health 2016, 19: a139. DOI: 10.1016/j.jval.2016.03.1655.
- Shevach J, Marcellino B, Oh W, Tsao C. Enzalutamide in Metastatic Castration Resistant Prostate Cancer. 2016, 157-169. DOI: 10.1007/978-3-319-31341-2_10.
- Leiter A, Doucette J, Krege S, Lin C, Hahn N, Ecke T, Sonpavde G, Bamias A, Oh W, Galsky M. Obesity and Outcomes in Patients with Metastatic Urothelial Carcinoma. Bladder Cancer 2016, 2: 341-349. PMID: 27500201, PMCID: PMC4969712, DOI: 10.3233/blc-160047.
- Kesar V, Devuni D, Azad A, Bichoupan K, Branch A, Oh W, Galsky M, Ahmad J, Odin J. 357 The Clinical Spectrum of Liver Injury in Cancer Patients. Gastroenterology 2016, 150: s1029. DOI: 10.1016/s0016-5085(16)33482-5.
- Kim S, Isola L, Oh W. Severe post-treatment leukopenia associated with the development of encephalopathy following ifosfamide infusion. Anti-Cancer Drugs 2016, 27: 235-238. PMID: 26628483, DOI: 10.1097/cad.0000000000000321.
- Heck M, Thalgott M, Schmid S, Oh W, Gong Y, Wang L, Zhu J, Seitz A, Porst D, Höppner M, Retz M, Gschwend J, Nawroth R. 1072 A 2-gene panel derived from prostate cancer-enhanced transcripts in whole blood is prognostic for survival and predicts treatment benefit in metastatic castration-resistant prostate cancer. European Urology Open Science 2016, 15: e1072. DOI: 10.1016/s1569-9056(16)61073-4.
- Galsky M, Stensland K, Moshier E, Sfakianos J, McBride R, Tsao C, Casey M, Boffetta P, Oh W, Mazumdar M, Wisnivesky J. Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer. Journal Of Clinical Oncology 2016, 34: 825-832. PMID: 26786930, DOI: 10.1200/jco.2015.64.1076.
- Galsky M, Hahn N, Albany C, Fleming M, Starodub A, Twardowski P, Pal S, Hauke R, Sonpavde G, Oh W, Bhardwaj N, Gnjatic S, Kim-Schulze S, Liu Z. Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer. Journal Of Clinical Oncology 2016, 34: 357-357. DOI: 10.1200/jco.2016.34.2_suppl.357.
- Galsky M, Stensland K, Sfakianos J, McBride R, Mehrazin R, Tsao C, Boffetta P, Oh W. Frequency and clinical implications of pathologic complete response (pCR) at cystectomy for muscle-invasive bladder cancer (MIBC) with or without neoadjuvant chemotherapy (NAC). Journal Of Clinical Oncology 2016, 34: 383-383. DOI: 10.1200/jco.2016.34.2_suppl.383.
- Galsky M, Noah H, Starodub A, Hauke R, Twardowski P, Fleming M, Qi J, Sonpavde G, Patel M, Zhu J, Chippada-Venkata U, Albany C, Wang L, Merad M, Oh W, Bhardwaj N, Gnjatic S, Kim-Schulze S. Impact of chemotherapy alone, and chemotherapy plus ipilimumab, on circulating immune cells in patients with metastatic bladder cancer. Journal For ImmunoTherapy Of Cancer 2015, 3: p257. PMCID: PMC4649313, DOI: 10.1186/2051-1426-3-s2-p257.
- Beer T, Vogelzang N, Bartůňková J, Miller K, Oh W, Oudard S, Pandha H, Sartor A, Špíšek R, Toole T, Borgstein N, Gerritsen W. Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer. Journal For ImmunoTherapy Of Cancer 2015, 3: p164. PMCID: PMC4646109, DOI: 10.1186/2051-1426-3-s2-p164.
- Mercer J, Erickson-Owens D, Vohr B, Tucker R, Parker A, Oh W, Padbury J. Effects of Placental Transfusion on Neonatal and 18 Month Outcomes in Preterm Infants: A Randomized Controlled Trial. The Journal Of Pediatrics 2015, 168: 50-55.e1. PMID: 26547399, PMCID: PMC4698069, DOI: 10.1016/j.jpeds.2015.09.068.
- Williams E, Rodriguez-Bravo V, Chippada-Venkata U, De Ia Iglesia-Vicente J, Gong Y, Galsky M, Oh W, Cordon-Cardo C, Domingo-Domenech J. Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells. Journal Of Visualized Experiments 2015 DOI: 10.3791/53182-v.
- Williams E, Rodriguez-Bravo V, Chippada-Venkata U, De Ia Iglesia-Vicente J, Gong Y, Galsky M, Oh W, Cordon-Cardo C, Domingo-Domenech J. Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells. Journal Of Visualized Experiments 2015, 53182. PMID: 26555435, PMCID: PMC4692658, DOI: 10.3791/53182.
- Gartrell B, Small A, Oh W, Galsky M. Renal Cell Carcinoma and Targeted Therapy. 2015, 287-295. DOI: 10.1002/9781118468678.ch29.
- Galsky M, Hahn N, Wong B, Lee K, Argiriadi P, Albany C, Gimpel-Tetra K, Lowe N, Shahin M, Patel V, Tsao C, Oh W. Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma. Cancer Chemotherapy And Pharmacology 2015, 76: 1259-1265. PMID: 26464352, DOI: 10.1007/s00280-015-2884-7.
- Oh W, Miao R, Vekeman F, Sung J, Cheng W, Gauthier-Loiselle M, Fortier J, Dhawan R, Hennessy D, Duh M. 2512 Is there a difference in outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) who receive chemotherapy (CT) vs androgen receptor-targeted therapy (ART) after 1st-line ART in the community setting? European Journal Of Cancer 2015, 51: s478. DOI: 10.1016/s0959-8049(16)31332-6.
- Wang L, Gong Y, Chippada-Venkata U, Heck M, Retz M, Nawroth R, Galsky M, Tsao C, Schadt E, de Bono J, Olmos D, Zhu J, Oh W. A robust blood gene expression-based prognostic model for castration-resistant prostate cancer. BMC Medicine 2015, 13: 201. PMID: 26297150, PMCID: PMC4546313, DOI: 10.1186/s12916-015-0442-0.
- Shevach J, Gallagher E, Kochukoshy T, Gresia V, Brar M, Galsky M, Oh W. Concurrent Diabetes Mellitus may Negatively Influence Clinical Progression and Response to Androgen Deprivation Therapy in Patients with Advanced Prostate Cancer. Frontiers In Oncology 2015, 5: 129. PMID: 26125012, PMCID: PMC4467174, DOI: 10.3389/fonc.2015.00129.
- Gillessen S, Omlin A, Attard G, de Bono J, Efstathiou E, Fizazi K, Halabi S, Nelson P, Sartor O, Smith M, Soule H, Akaza H, Beer T, Beltran H, Chinnaiyan A, Daugaard G, Davis I, De Santis M, Drake C, Eeles R, Fanti S, Gleave M, Heidenreich A, Hussain M, James N, Lecouvet F, Logothetis C, Mastris K, Nilsson S, Oh W, Olmos D, Padhani A, Parker C, Rubin M, Schalken J, Scher H, Sella A, Shore N, Small E, Sternberg C, Suzuki H, Sweeney C, Tannock I, Tombal B. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Annals Of Oncology 2015, 26: 1589-1604. PMID: 26041764, PMCID: PMC4511225, DOI: 10.1093/annonc/mdv257.
- Galsky M, Stensland K, Moshier E, Sfakianos J, McBride R, Tsao C, Casey M, Hall S, Boffetta P, Oh W, Wisnivesky J. Effectiveness of adjuvant chemotherapy (AC) versus observation in patients with ≥ pT3 and/or pN+ bladder cancer (BCa). Journal Of Clinical Oncology 2015, 33: 4517-4517. DOI: 10.1200/jco.2015.33.15_suppl.4517.
- Galsky M, Hahn N, Albany C, Fleming M, Starodub A, Twardowski P, Hauke R, Sonpavde G, Merad M, Gnjatic S, Bhardwaj N, Chippada-Venkata U, Oh W, Kim-Schulze S. Impact of gemcitabine + cisplatin + ipilimumab on circulating immune cells in patients (pts) with metastatic urothelial cancer (mUC). Journal Of Clinical Oncology 2015, 33: 4586-4586. DOI: 10.1200/jco.2015.33.15_suppl.4586.
- Liaw B, Chippada-Venkata U, Gong Y, Wang L, Zhu J, Heck M, Tsao C, Galsky M, Oh W. Influence of prostate cancer disease state and therapeutic selection on peripheral whole-blood RNA signature. Journal Of Clinical Oncology 2015, 33: 5046-5046. DOI: 10.1200/jco.2015.33.15_suppl.5046.
- Oh W, Miao R, Duh M, Vekeman F, Sung J, Cheng W, Hennessy D, Gauthier-Loiselle M, Fortier J, Dhawan R. Clinical features and overall survival (OS) in patients (pts) with post-docetaxel (DTX) metastatic castration-resistant prostate cancer (mCRPC) receiving second-line (2L) therapy in the community setting. Journal Of Clinical Oncology 2015, 33: e16029-e16029. DOI: 10.1200/jco.2015.33.15_suppl.e16029.
- Shevach J, Gallagher E, Kochukoshy T, Gresia V, Brar M, Galsky M, Oh W. Influence of concurrent diabetes mellitus on clinical progression and response to androgen deprivation therapy in patients with advanced prostate cancer. Journal Of Clinical Oncology 2015, 33: e16036-e16036. DOI: 10.1200/jco.2015.33.15_suppl.e16036.
- Vogelzang N, Beer T, Bartunkova J, Kuklík R, Miller K, Oh W, Oudard S, Pandha H, Sartor A, Spisek R, Borgstein N, Gerritsen W. Autologous dendritic cell vaccination (DCVAC/PCa) added to docetaxel chemotherapy in a double-blind, randomized phase III trial (VIABLE) in men with advanced (mCRPC) prostate cancer. Journal Of Clinical Oncology 2015, 33: tps5070-tps5070. DOI: 10.1200/jco.2015.33.15_suppl.tps5070.
- Liaw B, Oh W. Is docetaxel the 'black widow' of mCRPC drugs? Nature Reviews Clinical Oncology 2015, 12: 316-318. PMID: 25917253, DOI: 10.1038/nrclinonc.2015.79.
- Liaw B, Chippada-Venkata U, Gong Y, Wang L, Zhu J, Heck M, Tsao C, Galsky M, Oh W. Influence of prostate cancer disease state and therapeutic selection on peripheral whole-blood RNA signature. Journal Of Clinical Oncology 2015, 33: 166-166. DOI: 10.1200/jco.2015.33.7_suppl.166.
- Galsky M, Stensland K, Moshier E, Sfakianos J, McBride R, Tsao C, Casey M, Hall S, Boffetta P, Oh W, Wisnivesky J. Comparative effectiveness of adjuvant chemotherapy (AC) versus observation in patients with ≥ pT3 and/or pN+ bladder cancer (BCa). Journal Of Clinical Oncology 2015, 33: 292-292. DOI: 10.1200/jco.2015.33.7_suppl.292.
- Leiter A, Doucette J, Krege S, Lin C, Hahn N, Ecke T, Sonpavde G, Bamias A, Oh W, Galsky M. Impact of obesity in patients with metastatic urothelial carcinoma. Journal Of Clinical Oncology 2015, 33: 346-346. DOI: 10.1200/jco.2015.33.7_suppl.346.
- Liaw B, Shevach J, Oh W. Systemic Therapy for the Treatment of Hormone-Sensitive Metastatic Prostate Cancer: from Intermittent Androgen Deprivation Therapy to Chemotherapy. Current Urology Reports 2015, 16: 13. PMID: 25677235, DOI: 10.1007/s11934-015-0486-x.
- Leiter A, Diefenbach M, Doucette J, Oh W, Galsky M. Clinical trial awareness: Changes over time and sociodemographic disparities. Clinical Trials 2015, 12: 215-223. PMID: 25673636, PMCID: PMC4667750, DOI: 10.1177/1740774515571917.
- Galsky M, Stensland K, McBride R, Latif A, Moshier E, Oh W, Wisnivesky J. Geographic Accessibility to Clinical Trials for Advanced Cancer in the United States. JAMA Internal Medicine 2015, 175: 293-295. PMID: 25437434, DOI: 10.1001/jamainternmed.2014.6300.
- Tsao C, Gray K, Nakabayashi M, Evan C, Kantoff P, Huang J, Galsky M, Pomerantz M, Oh W. Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease. Journal Of Urology 2015, 194: 91-97. PMID: 25623747, DOI: 10.1016/j.juro.2015.01.078.
- Casey M, Gross T, Wisnivesky J, Stensland K, Oh W, Galsky M. The Impact of Regionalization of Cystectomy on Racial Disparities in Bladder Cancer Care. Journal Of Urology 2015, 194: 36-41. PMID: 25623748, DOI: 10.1016/j.juro.2015.01.076.
- Gong Y, Chippada‐Venkata U, Galsky M, Huang J, Oh W. Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP‐1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer. The Prostate 2015, 75: 616-627. PMID: 25560638, DOI: 10.1002/pros.22945.
- Petrylak DP, Gandhi JG, Clark WR, Heath E, Lin J, Oh WK, Agus DB, Carthon B, Moran S, Kong N, Suri A, Bargfrede M, Liu G. Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel–prednisone in metastatic castration-resistant prostate cancer. Investigational New Drugs 2015, 33: 397-408. PMID: 25556680, PMCID: PMC4390470, DOI: 10.1007/s10637-014-0199-x.
- Tsao C, Liaw B, Oh W, Galsky M. Muscle invasive bladder cancer: closing the gap between practice and evidence. Minerva Urologica E Nefrologica 2014, 67: 65-73. PMID: 25424386.
- Sonpavde G, Wang C, Galsky M, Oh W, Armstrong A. Cytotoxic chemotherapy in the contemporary management of metastatic castration‐resistant prostate cancer (mCRPC). BJU International 2014, 116: 17-29. PMID: 25046451, DOI: 10.1111/bju.12867.
- Courtney K, Manola J, Elfiky A, Ross R, Oh W, Yap J, Van den Abbeele A, Ryan C, Beer T, Loda M, Priolo C, Kantoff P, Taplin M. A Phase I Study of Everolimus and Docetaxel in Patients With Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer 2014, 13: 113-123. PMID: 25450031, PMCID: PMC4418946, DOI: 10.1016/j.clgc.2014.08.007.
- Leiter A, Sablinski T, Diefenbach M, Foster M, Greenberg A, Holland J, Oh W, Galsky M. Use of Crowdsourcing for Cancer Clinical Trial Development. Journal Of The National Cancer Institute 2014, 106: dju258. PMID: 25217580, DOI: 10.1093/jnci/dju258.
- Stensland K, McBride R, Latif A, Wisnivesky J, Hendricks R, Roper N, Boffetta P, Hall S, Oh W, Galsky M. Adult Cancer Clinical Trials That Fail to Complete: An Epidemic? Journal Of The National Cancer Institute 2014, 106: dju229. PMID: 25190726, DOI: 10.1093/jnci/dju229.
- Agarwal N, Apolo A, Tsao C, Lee K, Godbold J, Soto R, Poole A, Gimpel‐Tetra K, Lowe N, Oh W, Galsky M. Phase Ib/II Trial of Gemcitabine, Cisplatin, and Lenalidomide as First‐Line Therapy in Patients With Metastatic Urothelial Carcinoma. The Oncologist 2014, 19: 915-916. PMID: 25052451, PMCID: PMC4153455, DOI: 10.1634/theoncologist.2014-0153.
- Martin J, Oh W. Evidence-Based Therapeutic Approaches for mCRPC Patients: Rational Sequence of Standard Treatment Options and Design for Future Drug Development. Current Clinical Urology 2014, 321-327. DOI: 10.1007/978-1-4939-1176-9_23.
- Galsky M, Posner M, Holcombe R, Lee K, Misiukiewicz K, Tsao C, Godbold J, Soto R, Gimpel-Tetra K, Lowe N, Oh W. Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors. Cancer Chemotherapy And Pharmacology 2014, 74: 465-471. PMID: 25023489, PMCID: PMC4146643, DOI: 10.1007/s00280-014-2518-5.
- Elfiky A, Pomerantz M, Katz L, Oh W. Genitourinary Cancers. 2014, 118-129. DOI: 10.1093/med/9780199358274.003.0013.
- Gong Y, Chippada-Venkata U, Oh W. Roles of Matrix Metalloproteinases and Their Natural Inhibitors in Prostate Cancer Progression. Cancers 2014, 6: 1298-1327. PMID: 24978435, PMCID: PMC4190542, DOI: 10.3390/cancers6031298.
- Galsky M, Oh W. Mind the gap: Efficacy versus effectiveness and pivotal prostate cancer clinical trial demographics. Cancer 2014, 120: 2944-2945. PMID: 24965362, DOI: 10.1002/cncr.28808.
- Saenger Y, Magidson J, Liaw B, de Moll E, Harcharik S, Fu Y, Wassmann K, Fisher D, Kirkwood J, Oh WK, Friedlander P. Blood mRNA Expression Profiling Predicts Survival in Patients Treated with Tremelimumab. Clinical Cancer Research 2014, 20: 3310-3318. PMID: 24721645, DOI: 10.1158/1078-0432.ccr-13-2906.
- Leiter A, Sablinski T, Diefenbach M, Foster M, Greenberg A, Holland J, Oh W, Galsky M. Use of crowdsourcing for cancer clinical trial development. Journal Of Clinical Oncology 2014, 32: e16019-e16019. DOI: 10.1200/jco.2014.32.15_suppl.e16019.
- Bickell N, Hall S, Stock R, Fei K, Veluswamy R, Franco R, Oh W. Does race affect the quality of treatment for intermediate-risk and high-risk prostate cancer? Journal Of Clinical Oncology 2014, 32: e17678-e17678. DOI: 10.1200/jco.2014.32.15_suppl.e17678.
- The metastatic castration-resistant prostate cancer treatment paradigm: more choices, more questionsYu E, Oh W. The metastatic castration-resistant prostate cancer treatment paradigm: more choices, more questions. Asian Journal Of Andrology 2014, 16: 331-333. PMID: 24759585, PMCID: PMC4023355, DOI: 10.4103/1008-682x.127813.
- Tsao C, Cutting E, Martin J, Oh W. The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer. Therapeutic Advances In Urology 2014, 6: 97-104. PMID: 24883107, PMCID: PMC4003844, DOI: 10.1177/1756287214528557.
- Tsao C, Small A, Hall S, Oh W, Galsky M, Buckstein M, Stock R, Ali G, Morris G. T2 Muscle-Invasive Bladder Cancer. Seminars In Oncology 2014, 41: e11-e18. PMID: 24787300, DOI: 10.1053/j.seminoncol.2014.03.005.
- Sivendran S, Chang R, Pham L, Phelps RG, Harcharik ST, Hall LD, Bernardo SG, Moskalenko MM, Sivendran M, Fu Y, de Moll EH, Pan M, Moon JY, Arora S, Cohain A, DiFeo A, Ferringer TC, Tismenetsky M, Tsui CL, Friedlander PA, Parides MK, Banchereau J, Chaussabel D, Lebwohl MG, Wolchok JD, Bhardwaj N, Burakoff SJ, Oh WK, Palucka K, Merad M, Schadt EE, Saenger YM. Dissection of Immune Gene Networks in Primary Melanoma Tumors Critical for Antitumor Surveillance of Patients with Stage II–III Resectable Disease. Journal Of Investigative Dermatology 2014, 134: 2202-2211. PMID: 24522433, PMCID: PMC4291112, DOI: 10.1038/jid.2014.85.
- Morgan C, Oh W, Naik G, Galsky M, Sonpavde G. Impact of prednisone on toxicities and survival in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of randomized clinical trials. Critical Reviews In Oncology/Hematology 2014, 90: 253-261. PMID: 24500033, DOI: 10.1016/j.critrevonc.2013.12.001.
- Liaw B, Seng S, Galsky M, Tsao C, Febbo P, Oh W. Biomarker development trial of satraplatin in patients with metastatic castrate-resistant prostate cancer. Journal Of Clinical Oncology 2014, 32: 170-170. DOI: 10.1200/jco.2014.32.4_suppl.170.
- Naik G, Morgan C, Galsky M, Oh W, Sonpavde G. Meta-analysis of randomized trials to study the impact of prednisone on toxicities and survival in metastatic castration-resistant prostate cancer. Journal Of Clinical Oncology 2014, 32: 28-28. DOI: 10.1200/jco.2014.32.4_suppl.28.
- Stensland K, McBride R, Wisnivesky J, Latif A, Hendricks R, Roper N, Boffetta P, Hall S, Oh W, Galsky M. Premature termination of genitourinary cancer clinical trials. Journal Of Clinical Oncology 2014, 32: 288-288. DOI: 10.1200/jco.2014.32.4_suppl.288.
- Casey M, Gross T, Stensland K, Oh W, Galsky M. Geographic and racial disparities in the utilization of low-volume cystectomy hospitals for bladder cancer. Journal Of Clinical Oncology 2014, 32: 302-302. DOI: 10.1200/jco.2014.32.4_suppl.302.
- Tsao C, Agarwal N, Apolo A, Lee K, Godbold J, Oh W, Galsky M. Phase Ib/II trial of gemcitabine, cisplatin, plus lenalidomide as first-line therapy for patients with metastatic urothelial carcinoma. Journal Of Clinical Oncology 2014, 32: 321-321. DOI: 10.1200/jco.2014.32.4_suppl.321.
- Oh W, Chippada Venkata U, Wang L, Reese E, Yee T, Kochukoshy T, Tsao C, Galsky M, Zhu J, Gong Y. Validation of a whole-blood RNA prognostic signature in metastatic castration-resistant prostate cancer (mCRPC) patients. Journal Of Clinical Oncology 2014, 32: 36-36. DOI: 10.1200/jco.2014.32.4_suppl.36.
- Galsky M, Latif A, Stensland K, Moshier E, McBride R, Hendricks R, Sonpavde G, Godbold J, Hall S, Oh W, Wisnivesky J. Distribution and geographic accessibility of prostate cancer clinical trials in the United States. Journal Of Clinical Oncology 2014, 32: 59-59. DOI: 10.1200/jco.2014.32.4_suppl.59.
- Tsao C, Galsky M, Oh W. Is Metastatic Prostate Cancer Changing, and How Will We Know It? It's Time for Standard Nomenclature for Nonosseous Metastases in Clinical Trials of Patients with Metastatic Castration Resistant Prostate Cancer. European Urology 2014, 66: 184-185. PMID: 24433812, DOI: 10.1016/j.eururo.2013.12.061.
- Doctor S, Tsao C, Godbold J, Galsky M, Oh W. Is prostate cancer changing?: Evolving patterns of metastatic castration‐resistant prostate cancer. Cancer 2013, 120: 833-839. PMID: 25302607, DOI: 10.1002/cncr.28494.
- Sivendran S, Latif A, McBride R, Stensland K, Wisnivesky J, Haines L, Oh W, Galsky M. Adverse Event Reporting in Cancer Clinical Trial Publications. Journal Of Clinical Oncology 2013, 32: 83-89. PMID: 24323037, DOI: 10.1200/jco.2013.52.2219.
- OH W, McDERMOTT D, PORTA C, LEVY A, ELAIDI R, SCOTTE F, HAWKINS R, CASTELLANO D, BELLMUNT J, RHA S, SUN J, NATHAN P, FEINBERG B, SCOTT J, McDERMOTT R, AHN J, WAGSTAFF J, CHANG Y, OU Y, DONNELLAN P, HUANG C, McCAFFREY J, CHIANG P, CHUANG C, KORVES C, NEARY M, DIAZ J, MEHMUD F, DUH M. Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review. International Journal Of Oncology 2013, 44: 5-16. PMID: 24247547, PMCID: PMC3867384, DOI: 10.3892/ijo.2013.2181.
- Oh W, Venkata U, Wang L, Reese E, Yee T, Kochukoshy T, Tsao C, Galsky M, Zhu J, Gong Y. MC13-0070 Whole blood RNA signature as prognostic and predictive biomarker in genitourinary malignancies. European Journal Of Cancer 2013, 49: s32. DOI: 10.1016/s0959-8049(13)70178-3.
- Gong Y, Scott E, Lu R, Xu Y, Oh W, Yu Q. TIMP-1 Promotes Accumulation of Cancer Associated Fibroblasts and Cancer Progression. PLOS ONE 2013, 8: e77366. PMID: 24143225, PMCID: PMC3797040, DOI: 10.1371/journal.pone.0077366.
- Galsky M, Moshier E, Krege S, Lin C, Hahn N, Ecke T, Sonpavde G, Pond G, Godbold J, Oh W, Bamias A. Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy. Urologic Oncology Seminars And Original Investigations 2013, 32: 48.e1-48.e8. PMID: 24055428, DOI: 10.1016/j.urolonc.2013.07.001.
- Gartrell B, Ying J, Sivendran S, Boucher K, Choueiri T, Sonpavde G, Oh W, Agarwal N, Galsky M. Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. Targeted Oncology 2013, 9: 195-204. PMID: 23852656, PMCID: PMC4744485, DOI: 10.1007/s11523-013-0289-2.
- Galsky M, Oh W. Tumour angiogenesis: an elusive target in castration-resistant prostate cancer. The Lancet Oncology 2013, 14: 681-682. PMID: 23742876, DOI: 10.1016/s1470-2045(13)70239-0.
- Galsky M, Krege S, Lin C, Hahn N, Ecke T, Moshier E, Sonpavde G, Godbold J, Oh W, Bamias A. Relationship between 6‐ and 9‐month progression‐free survival and overall survival in patients with metastatic urothelial cancer treated with first‐line cisplatin‐based chemotherapy. Cancer 2013, 119: 3020-3026. PMID: 23720197, DOI: 10.1002/cncr.28145.
- Galsky M, Moshier E, Krege S, Lin C, Hahn N, Ecke T, Sonpavde G, Godbold J, Oh W, Bamias A. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin‐based chemotherapy. Cancer 2013, 119: 3012-3019. PMID: 23720216, DOI: 10.1002/cncr.28146.
- Galsky M, Xie W, Nakabayashi M, Ross R, Fennessy F, Tempany C, Choueiri T, Khine K, Kantoff P, Taplin M, Oh W. Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer. Prostate Cancer And Prostatic Diseases 2013, 16: 266-270. PMID: 23712318, PMCID: PMC4026061, DOI: 10.1038/pcan.2013.15.
- Sivendran S, Chang R, Harcharik S, Hall L, Bernardo S, Moskalenko M, Phelps R, Sivendran M, Cohain A, DiFeo A, Parides M, Lebwohl M, Friedlander P, Banchereau J, Bhardwaj N, Oh W, Burakoff S, Palucka K, Merad M, Saenger Y. Immune gene expression in primary melanomas to predict lower risk of recurrence and death. Journal Of Clinical Oncology 2013, 31: 3014-3014. DOI: 10.1200/jco.2013.31.15_suppl.3014.
- Doctor S, Tsao C, Godbold J, Galsky M, Oh W. Evolving patterns of metastatic disease in castration-resistant prostate cancer (CRPC) reported in clinical trials from 1990 to 2011. Journal Of Clinical Oncology 2013, 31: 5015-5015. DOI: 10.1200/jco.2013.31.15_suppl.5015.
- Latif A, Stensland K, Hendricks R, Moshier E, Godbold J, Oh W, Galsky M. Cancer clinical trial accessibility in the United States: An analysis of travel distance. Journal Of Clinical Oncology 2013, 31: 6540-6540. DOI: 10.1200/jco.2013.31.15_suppl.6540.
- Stensland K, Latif A, Hendricks R, Roper N, McBride R, Hall S, Oh W, Galsky M. Prevalence and characteristics of prematurely terminated cancer clinical trials. Journal Of Clinical Oncology 2013, 31: 6613-6613. DOI: 10.1200/jco.2013.31.15_suppl.6613.
- Tsao C, Gray K, Nakabayashi M, Evan C, Galsky M, Kantoff P, Oh W, Pomerantz M. Association of Gleason 9-10 prostate cancer with worse outcomes compared to Gleason 8 disease. Journal Of Clinical Oncology 2013, 31: e16032-e16032. DOI: 10.1200/jco.2013.31.15_suppl.e16032.
- Saenger Y, Magidson J, Liaw B, Wassmann K, Barker W, Harcharik S, Fisher D, Oh W, Friedlander P. Blood mRNA signature to predict survival in patients with metastatic melanoma treated with tremelimumab. Journal Of Clinical Oncology 2013, 31: 9080-9080. DOI: 10.1200/jco.2013.31.15_suppl.9080.
- Sivendran S, Agarwal N, Gartrell B, Ying J, Boucher K, Choueiri T, Sonpavde, Oh W, Galsky M. Metabolic complications with the use of mTOR inhibitors for cancer therapy. Cancer Treatment Reviews 2013, 40: 190-196. PMID: 23684373, PMCID: PMC4744486, DOI: 10.1016/j.ctrv.2013.04.005.
- Haines L, Bamias A, Krege S, Lin C, Hahn N, Ecke T, Moshier E, Sonpavde, Godbold J, Oh W, Galsky M. The Impact of Gender on Outcomes in Patients With Metastatic Urothelial Carcinoma. Clinical Genitourinary Cancer 2013, 11: 346-352. PMID: 23673281, DOI: 10.1016/j.clgc.2013.04.010.
- Cookson M, Roth B, Dahm P, Engstrom C, Freedland S, Hussain M, Lin D, Lowrance W, Murad M, Oh W, Penson D, Kibel A. Castration-Resistant Prostate Cancer: AUA Guideline. Journal Of Urology 2013, 190: 429-438. PMID: 23665272, DOI: 10.1016/j.juro.2013.05.005.
- Mistry S, Oh W. New Paradigms in Microtubule-Mediated Endocrine Signaling in Prostate Cancer. Molecular Cancer Therapeutics 2013, 12: 555-566. PMID: 23635655, DOI: 10.1158/1535-7163.mct-12-0871.
- Tsao C, Liaw B, Yee T, Galsky M, Oh W. Metabolic and toxicological considerations of newly approved prostate cancer drugs. Expert Opinion On Drug Metabolism & Toxicology 2013, 9: 835-846. PMID: 23581700, DOI: 10.1517/17425255.2013.789019.
- Pollard M, Moskowitz A, Oh W, Galsky M, Hall S. 128 COST-EFFECTIVE ANALYSIS (CEA) OF THE CURRENT TREATMENT PARADIGM FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC). Journal Of Urology 2013, 189: e51-e52. DOI: 10.1016/j.juro.2013.02.1507.
- Mirza H, Oh W, Laptook, Vohr B, Tucker R, Stonestreet B. Indomethacin Prophylaxis to Prevent Intraventricular Hemorrhage: Association between Incidence and Timing of Drug Administration. The Journal Of Pediatrics 2013, 163: 706-710.e1. PMID: 23522865, PMCID: PMC3939677, DOI: 10.1016/j.jpeds.2013.02.030.
- Sivendran S, Ying J, Gartrell B, Agarwal N, Boucher K, Choueiri T, Sonpavde G, Oh W, Galsky M. Metabolic complications with the use of mTOR inhibitors for cancer therapy: A systematic review and meta-analysis. Journal Of Clinical Oncology 2013, 31: 398-398. DOI: 10.1200/jco.2013.31.6_suppl.398.
- Tsao C, Gray K, Nakabayashi M, Evan C, Galsky M, Kantoff P, Oh W, Pomerantz M. Association of Gleason 9-10 prostate cancer with worse outcomes compared to Gleason 8 disease. Journal Of Clinical Oncology 2013, 31: 157-157. DOI: 10.1200/jco.2013.31.6_suppl.157.
- Gartrell B, Ying J, Sivendran S, Agarwal N, Boucher K, Choueiri T, Sonpavde G, Oh W, Galsky M. Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: A systematic review and meta-analysis. Journal Of Clinical Oncology 2013, 31: 362-362. DOI: 10.1200/jco.2013.31.6_suppl.362.
- Bamias A, Krege S, Lin C, Hahn N, Ecke T, Moshier E, Sonpavde G, Godbold J, Oh W, Koutras A, Pu Y, Galsky M. Cisplatin-based combination chemotherapy in elderly patients with metastatic urothelial cancer. Journal Of Clinical Oncology 2013, 31: 269-269. DOI: 10.1200/jco.2013.31.6_suppl.269.
- Galsky M, Moshier E, Krege S, Lin C, Hahn N, Ecke T, Sonpavde G, Pond G, Godbold J, Oh W, Bamias A. Post-treatment prognostic model for patients (pts) with metastatic urothelial cancer (UC) treated with first-line chemotherapy. Journal Of Clinical Oncology 2013, 31: 256-256. DOI: 10.1200/jco.2013.31.6_suppl.256.
- Galsky M, Krege S, Lin C, Hahn N, Ecke T, Moshier E, Sonpavde G, Godbold J, Oh W, Bamias A. Progression-free survival as an endpoint for clinical trials in first-line metastatic urothelial cancer. Journal Of Clinical Oncology 2013, 31: 251-251. DOI: 10.1200/jco.2013.31.6_suppl.251.
- Galsky M, Xie W, Nakabayashi M, Ross R, Fennessy F, Tempany C, Choueiri T, Khine K, Kantoff P, Taplin M, Oh W. Paradoxical significance of endorectal MRI (erMRI) response to neoadjuvant chemotherapy in patients with high-risk localized prostate cancer (HRLPC). Journal Of Clinical Oncology 2013, 31: 23-23. DOI: 10.1200/jco.2013.31.6_suppl.23.
- Petrylak D, Gandhi J, Clark W, Heath E, Lin J, Oh W, Agus D, Carthon B, Moran S, Kong N, Suri A, Bargfrede M, Liu G. A phase I/II study of safety and efficacy of orteronel (TAK-700), an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC): Updated phase II results. Journal Of Clinical Oncology 2013, 31: 59-59. DOI: 10.1200/jco.2013.31.6_suppl.59.
- Oh W, Doctor S, Godbold J, Galsky M, Tsao C. Evolving patterns of metastatic disease in castration-resistant prostate cancer (CRPC) reported in clinical trials from 1990 to 2011. Journal Of Clinical Oncology 2013, 31: 195-195. DOI: 10.1200/jco.2013.31.6_suppl.195.
- Galsky M, Krege S, Lin C, Hahn N, Ecke T, Moshier E, Sonpavde G, Godbold J, Oh W, Bamias A. Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer. Urologic Oncology Seminars And Original Investigations 2013, 32: 30.e15-30.e21. PMID: 23428534, DOI: 10.1016/j.urolonc.2012.11.001.
- Tsao C, Small A, Kates M, Moshier E, Wisnivesky J, Gartrell B, Sonpavde G, Godbold J, Palese M, Hall S, Oh W, Galsky M. Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis. World Journal Of Urology 2012, 31: 1535-1539. PMID: 23223962, PMCID: PMC4744480, DOI: 10.1007/s00345-012-1001-3.
- Tsao C, Gartrell B, Oh W, Galsky M. Emerging personalized approaches for the management of advanced urothelial carcinoma. Expert Review Of Anticancer Therapy 2012, 12: 1537-1543. PMID: 23253220, PMCID: PMC4744482, DOI: 10.1586/era.12.141.
- Seng S, Tsao C, Oh W. Chemotherapy and Associated Symptoms. 2012, 835-858. DOI: 10.1142/9789814354912_0071.
- Seng S, Liu Z, Chiu S, Proverbs-Singh T, Sonpavde G, Choueiri T, Tsao C, Yu M, Hahn N, Oh W, Galsky M. Risk of Venous Thromboembolism in Patients With Cancer Treated With Cisplatin: A Systematic Review and Meta-Analysis. Journal Of Clinical Oncology 2012, 30: 4416-4426. PMID: 23150697, DOI: 10.1200/jco.2012.42.4358.
- Petrylak D, Gandhi J, Clark W, Heath E, Lin J, Oh W, Agus D, Carthon B, Moran S, Mortimer P, Liu G. P114 Safety and efficacy of orteronel (TAK-700), an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC): Phase 2 results from a phase 1/2 study. European Urology Open Science 2012, 11: 230. DOI: 10.1016/s1569-9056(13)60480-7.
- Proverbs-Singh T, Chiu S, Liu Z, Seng S, Sonpavde G, Choueiri T, Tsao C, Yu M, Hahn N, Oh W, Galsky M. Arterial Thromboembolism in Cancer Patients Treated With Cisplatin: A Systematic Review and Meta-analysis. Journal Of The National Cancer Institute 2012, 104: 1837-1840. PMID: 23093559, DOI: 10.1093/jnci/djs435.
- Tsao C, Oh W. Enzalutamide in metastatic CRPC—old dog, new tricks. Nature Reviews Clinical Oncology 2012, 9: 613-614. PMID: 23044775, DOI: 10.1038/nrclinonc.2012.181.
- Ross R, Galsky M, Scher H, Magidson J, Wassmann K, Lee G, Katz L, Subudhi S, Anand A, Fleisher M, Kantoff P, Oh W. A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. The Lancet Oncology 2012, 13: 1105-1113. PMID: 23059047, DOI: 10.1016/s1470-2045(12)70263-2.
- Lin C, Galsky M, Krege S, Hahn N, Ecke T, Sonpavde G, Oh W, Bamias A. WS14-7 Efficacy of Cisplatin-Based Chemotherapy as First-Line Treatment in Asian Patients with Metastatic Urothelial Carcinoma Results of an Exploratory Subgroup Analysis of a Pool Analysis of Phase II/III Trials. Annals Of Oncology 2012, 23: xi96-xi97. DOI: 10.1016/s0923-7534(20)32244-4.
- Tsao C, Galsky M, Small A, Yee T, Oh W. Targeting the androgen receptor signalling axis in castration‐resistant prostate cancer (CRPC). BJU International 2012, 110: 1580-1588. PMID: 22985411, DOI: 10.1111/j.1464-410x.2012.11445.x.
- Petrylak D, Gandhi J, Clark W, Heath E, Lin J, Oh W, Agus D, Carthon B, Moran S, Liu G. 918P Phase 2 Results from a Phase 1/2 Study of Tak-700 (ORTERONEL), An Oral, Investigational, Nonsteroidal 17,20-Lyase Inhibitor, with Docetaxel and Prednisone (DP) in Metastatic Castration-Resistant Prostate Cancer (MCRPC). Annals Of Oncology 2012, 23: ix302-ix303. DOI: 10.1016/s0923-7534(20)33476-1.
- Nakabayashi M, Werner L, Courtney K, Buckle G, Oh W, Bubley G, Hayes J, Weckstein D, Elfiky A, Sims D, Kantoff P, Taplin M. Phase II trial of RAD001 and bicalutamide for castration‐resistant prostate cancer. BJU International 2012, 110: 1729-1735. PMID: 22928480, DOI: 10.1111/j.1464-410x.2012.11456.x.
- Vinjamoori A, Jagannathan J, Shinagare A, Taplin M, Oh W, Van den Abbeele A, Ramaiya N. Atypical metastases from prostate cancer: 10-year experience at a single institution. American Journal Of Roentgenology 2012, 199: 367-72. PMID: 22826398, DOI: 10.2214/ajr.11.7533.
- Small A, Oh W. Bevacizumab treatment of prostate cancer. Expert Opinion On Biological Therapy 2012, 12: 1241-1249. PMID: 22775507, DOI: 10.1517/14712598.2012.704015.
- Small A, Tsao C, Moshier E, Gartrell B, Wisnivesky J, Godbold J, Smith C, Sonpavde, Oh W, Galsky M. Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy. Cancer 2012, 118: 5947-5954. PMID: 22707387, DOI: 10.1002/cncr.27658.
- Pomerantz M, Elfiky A, Katz L, Oh W. Genitourinary Cancers. 2012, 114-124. DOI: 10.1093/med/9780195366273.003.0013.
- Tsao C, Small A, Moshier E, Gartrell B, Wisnivesky J, Sonpavde, Godbold J, Palese M, Hall S, Oh W, Galsky M. Trends in the Use of Cytoreductive Nephrectomy in the United States. Clinical Genitourinary Cancer 2012, 10: 159-163. PMID: 22651971, PMCID: PMC4744481, DOI: 10.1016/j.clgc.2012.03.008.
- Sivendran S, Liu Z, Portas L, Yu M, Hahn N, Sonpavde, Oh W, Galsky M. Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: A meta-analysis. Cancer Treatment Reviews 2012, 38: 919-925. PMID: 22651902, DOI: 10.1016/j.ctrv.2012.05.001.
- Small A, Tsao C, Moshier E, Gartrell B, Wisnivesky J, Godbold J, Sonpavde G, Palese M, Hall S, Oh W, Galsky M. Trends and variations in utilization of nephron-sparing procedures for stage I kidney cancer in the United States. World Journal Of Urology 2012, 31: 1211-1217. PMID: 22622394, PMCID: PMC4744479, DOI: 10.1007/s00345-012-0873-6.
- Oh W, Kantoff P, Scher H, Magidson J, Wassmann K, Lee G, Katz L, Subudhi S, Anand A, Fleisher M, Galsky M, Ross R. A validated whole-blood RNA transcript-based prognostic model that predicts survival in men with castration-resistant prostate cancer. Journal Of Clinical Oncology 2012, 30: 4516-4516. DOI: 10.1200/jco.2012.30.15_suppl.4516.
- Galsky M, Krege S, Lin C, Hahn N, Ecke T, Moshier E, Sonpavde G, Godbold J, Oh W, Bamias A. Prognostic model for overall survival in patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. Journal Of Clinical Oncology 2012, 30: 4524-4524. DOI: 10.1200/jco.2012.30.15_suppl.4524.
- Tsao C, Small A, Kates M, Gartrell B, Wisnivesky J, Sonpavde G, Palese M, Hall S, Oh W, Galsky M. Trends in the use of cytoreductive nephrectomy for metastatic renal cell carcinoma in the VEGFR tyrosine kinase inhibitor era. Journal Of Clinical Oncology 2012, 30: 4623-4623. DOI: 10.1200/jco.2012.30.15_suppl.4623.
- Petrylak D, Gandhi J, Clark W, Heath E, Lin J, Oh W, Agus D, Kucuk O, Moran S, Wang J, Bargfrede M, Liu G. Phase I results from a phase I/II study of orteronel, an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC). Journal Of Clinical Oncology 2012, 30: 4656-4656. DOI: 10.1200/jco.2012.30.15_suppl.4656.
- Small A, Tsao C, Moshier E, Gartrell B, Wisnivesky J, Godbold J, Smith C, Sonpavde G, Oh W, Galsky M. Prevalence and characteristics of patients with stage IV solid tumors who receive no anticancer therapy. Journal Of Clinical Oncology 2012, 30: 6065-6065. DOI: 10.1200/jco.2012.30.15_suppl.6065.
- Seng S, Liu Z, Chiu S, Proverbs-Singh T, Sonpavde G, Choueiri T, Tsao C, Yu M, Hahn N, Oh W, Galsky M. Risk of venous thromboembolism in cancer patients treated with cisplatin: A systematic review and meta-analysis. Journal Of Clinical Oncology 2012, 30: e21016-e21016. DOI: 10.1200/jco.2012.30.15_suppl.e21016.
- Latif A, Small A, Moshier E, Adelson K, Raptis G, Godbold J, Oh W, Galsky M. Practice patterns in the use of adjuvant therapy for post-menopausal early-stage breast cancer in the pre- and post-Onco type DX era. Journal Of Clinical Oncology 2012, 30: e21032-e21032. DOI: 10.1200/jco.2012.30.15_suppl.e21032.
- Small A, Gong Y, Oh W, Hall S, van Rijn C, Galsky M. The Emerging Role of Circulating Tumor Cell Detection in Genitourinary Cancer. Journal Of Urology 2012, 188: 21-26. PMID: 22578722, DOI: 10.1016/j.juro.2012.02.2558.
- Tsao C, Small A, Galsky M, Oh W. Overcoming castration resistance in prostate cancer. Current Opinion In Urology 2012, 22: 167-174. PMID: 22472508, DOI: 10.1097/mou.0b013e3283523b8b.
- Galsky M, Small A, Tsao C, Oh W. Clinical development of novel therapeutics for castration‐resistant prostate cancer. CA A Cancer Journal For Clinicians 2012, 62: 299-308. PMID: 22535487, DOI: 10.3322/caac.21141.
- Morris B, Tyson J, Stevenson D, Oh W, Phelps D, O'Shea T, McDavid G, Van Meurs K, Vohr B, Grisby C, Yao Q, Kandefer S, Wallace D, Higgins R. Efficacy of phototherapy devices and outcomes among extremely low birth weight infants: multi-center observational study. Journal Of Perinatology 2012, 33: 126-133. PMID: 22499082, PMCID: PMC3570170, DOI: 10.1038/jp.2012.39.
- Small A, Tsao C, Moshier E, Godbold J, Palese M, Hall S, Oh W, Galsky M. 659 RACIAL AND SOCIOECONOMIC DISPARITIES IN THE UTILIZATION OF NEPHRON-SPARING PROCEDURES FOR STAGE I KIDNEY CANCER IN THE UNITED STATES. Journal Of Urology 2012, 187: e269. DOI: 10.1016/j.juro.2012.02.739.
- Lee B, Garcia J, Dreicer R, Tendulkar R, Stephans K, Magi-Galluzzi C, Klein E, Oh W, Stephenson A. 336 ALL HIGH-GRADE PROSTATE CANCERS CREATED EQUALLY? AN ANALYSIS OF CLINICAL FEATURES AND SURVIVAL AMONG PATIENTS WITH BIOPSY GLEASON SCORE 8, 9, AND 10 DISEASE. Journal Of Urology 2012, 187: e137. DOI: 10.1016/j.juro.2012.02.397.
- Small A, Tsao C, Moshier E, Godbold J, Sonpavde G, Oh W, Galsky M. Prevalence and characteristics of patients with metastatic prostate cancer who receive no anticancer therapy. Journal Of Clinical Oncology 2012, 30: 101-101. DOI: 10.1200/jco.2012.30.5_suppl.101.
- Tsao C, Moshier E, Small A, Sonpavde G, Godbold J, Oh W, Galsky M. Cytoreductive nephrectomy in the United States: Patterns of care and patient characteristics. Journal Of Clinical Oncology 2012, 30: 366-366. DOI: 10.1200/jco.2012.30.5_suppl.366.
- Ross R, Galsky M, Febbo P, Barry M, Richie J, Xie W, Fennessy F, Bhatt R, Hayes J, Choueiri T, Tempany C, Kantoff P, Taplin M, Oh W. Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high‐risk localized prostate cancer. Cancer 2012, 118: 4777-4784. PMID: 22282219, PMCID: PMC3791849, DOI: 10.1002/cncr.27416.
- Sun T, Oh W, Jacobus S, Regan M, Pomerantz M, Freedman M, Lee G, Kantoff P. The Impact of Common Genetic Variations in Genes of the Sex Hormone Metabolic Pathways on Steroid Hormone Levels and Prostate Cancer Aggressiveness. Cancer Prevention Research 2011, 4: 2044-2050. PMID: 21900597, PMCID: PMC3773969, DOI: 10.1158/1940-6207.capr-11-0283.
- Tsao C, Moshier E, Seng S, Godbold J, Grossman S, Winston J, Oh W, Galsky M. Impact of the CKD-EPI Equation for Estimating Renal Function on Eligibility for Cisplatin-based Chemotherapy in Patients With Urothelial Cancer. Clinical Genitourinary Cancer 2011, 10: 15-20. PMID: 22130294, DOI: 10.1016/j.clgc.2011.10.004.
- Nakabayashi M, Werner L, Oh W, Regan M, Kantoff P, Taplin M. Secondary Hormonal Therapy in Men With Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer 2011, 9: 95-103. PMID: 21958520, DOI: 10.1016/j.clgc.2011.06.006.
- Galsky M, Camacho L, Chiorean E, Mulkerin D, Hong D, Oh W, Bajorin D. Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors. Annals Of Oncology 2011, 23: 1037-1044. PMID: 21828377, DOI: 10.1093/annonc/mdr358.
- Oh W, Galsky M, Stadler W, Srinivas S, Chu F, Bubley G, Goddard J, Dunbar J, Ross R. Multicenter Phase II Trial of the Heat Shock Protein 90 Inhibitor, Retaspimycin Hydrochloride (IPI-504), in Patients With Castration-resistant Prostate Cancer. Urology 2011, 78: 626-630. PMID: 21762967, PMCID: PMC3166448, DOI: 10.1016/j.urology.2011.04.041.
- Galsky M, Seng S, Camacho L, Chiorean E, Mulkerin D, Hong D, Oh W, Bajorin D. Retrospective Analysis of Satraplatin in Patients with Metastatic Urothelial Cancer Refractory to Standard Platinum-Based Chemotherapy. Clinical Genitourinary Cancer 2011, 9: 27-30. PMID: 21700509, DOI: 10.1016/j.clgc.2011.05.003.
- Yang M, Xie W, Mostaghel E, Nakabayashi M, Werner L, Sun T, Pomerantz M, Freedman M, Ross R, Regan M, Sharifi N, Figg W, Balk S, Brown M, Taplin M, Oh W, Lee G, Kantoff P. SLCO2B1 and SLCO1B3 May Determine Time to Progression for Patients Receiving Androgen Deprivation Therapy for Prostate Cancer. Journal Of Clinical Oncology 2011, 29: 2565-2573. PMID: 21606417, PMCID: PMC3138634, DOI: 10.1200/jco.2010.31.2405.
- Oh W, Galsky M, Barry M, Fennessey F, Richie J, Hayes J, Bhatt R, Taplin M, Febbo P, Ross R. A phase II study of neoadjuvant docetaxel (D) plus bevacizumab (B) in patients (pts) with high-risk localized prostate cancer. Journal Of Clinical Oncology 2011, 29: 4642-4642. DOI: 10.1200/jco.2011.29.15_suppl.4642.
- Galsky M, Chen G, Oh W, Bellmunt J, Roth B, Petrioli R, Dogliotti L, Dreicer R, Sonpavde G. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Journal Of Clinical Oncology 2011, 29: e15027-e15027. DOI: 10.1200/jco.2011.29.15_suppl.e15027.
- Tsao C, Seng S, Grossman S, Oh W, Galsky M. Impact of the chronic kidney disease epidemiology collaboration (CKD-EPI) equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with bladder cancer. Journal Of Clinical Oncology 2011, 29: e15139-e15139. DOI: 10.1200/jco.2011.29.15_suppl.e15139.
- Seng S, Galsky M, Tsao C, Li J, Febbo P, Oh W. Predicting response to platinum chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) using a genomic signature for “BRCAness”: A phase II clinical trial of satraplatin in men with mCRPC who have progressed on docetaxel. Journal Of Clinical Oncology 2011, 29: tps191-tps191. DOI: 10.1200/jco.2011.29.15_suppl.tps191.
- Galsky M, Hahn N, Rosenberg J, Sonpavde G, Hutson T, Oh W, Dreicer R, Vogelzang N, Sternberg C, Bajorin D, Bellmunt J. Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy. Journal Of Clinical Oncology 2011, 29: 2432-2438. PMID: 21555688, DOI: 10.1200/jco.2011.34.8433.
- Galsky M, Chen G, Oh W, Bellmunt J, Roth B, Petrioli R, Dogliotti L, Dreicer R, Sonpavde G. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Annals Of Oncology 2011, 23: 406-410. PMID: 21543626, DOI: 10.1093/annonc/mdr156.
- Pomerantz M, Werner L, Xie W, Regan M, Lee G, Sun T, Evan C, Petrozziello G, Nakabayashi M, Oh W, Kantoff P, Freedman M. Association of Prostate Cancer Risk Loci with Disease Aggressiveness and Prostate Cancer–Specific Mortality. Cancer Prevention Research 2011, 4: 719-728. PMID: 21367958, PMCID: PMC3811002, DOI: 10.1158/1940-6207.capr-10-0292.
- Tsao C, Seng S, Oh W, Galsky M. Endocrine therapy for prostate cancer: review of the latest clinical evidence. Clinical Investigation 2011, 1: 533-541. DOI: 10.4155/cli.11.28.
- Tai S, Sun Y, Squires J, Zhang H, Oh W, Liang C, Huang J. PC3 is a cell line characteristic of prostatic small cell carcinoma. The Prostate 2011, 71: 1668-1679. PMID: 21432867, PMCID: PMC3426349, DOI: 10.1002/pros.21383.
- Misra D, Xie W, Regan M, Ross R, Lee G, Germain D, Kantoff P, Oh W. Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapy. BJU International 2011, 108: 1086-1091. PMID: 21410629, DOI: 10.1111/j.1464-410x.2010.10037.x.
- Sun T, Mary L, Oh W, Freedman M, Pomerantz M, Pienta K, Kantoff P. Inherited Variants in the Chemokine CCL2 Gene and Prostate Cancer Aggressiveness in a Caucasian Cohort. Clinical Cancer Research 2011, 17: 1546-1552. PMID: 21135144, PMCID: PMC3060307, DOI: 10.1158/1078-0432.ccr-10-2015.
- Galsky M, Hahn N, Rosenberg J, Sonpavde G, Oh W, Dreicer R, Vogelzang N, Sternberg C, Bajorin D, Bellmunt J. Defining “cisplatin ineligible” patients with metastatic bladder cancer. Journal Of Clinical Oncology 2011, 29: 238-238. DOI: 10.1200/jco.2011.29.7_suppl.238.
- Sonpavde G, Galsky M, Chen G, Bellmunt J, Roth B, Petrioli R, Hutson T, Dogliotti L, Dreicer R, Oh W. Meta-analysis of randomized trials comparing cisplatin versus carboplatin-based regimens for the first-line therapy of metastatic transitional cell carcinoma of the urothelium (TCCU). Journal Of Clinical Oncology 2011, 29: 247-247. DOI: 10.1200/jco.2011.29.7_suppl.247.
- Galsky M, Hahn N, Rosenberg J, Sonpavde, Hutson T, Oh W, Dreicer R, Vogelzang N, Sternberg C, Bajorin D, Bellmunt J. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. The Lancet Oncology 2011, 12: 211-214. PMID: 21376284, DOI: 10.1016/s1470-2045(10)70275-8.
- Tsao C, Seng S, Oh W, Galsky M. Clinical Development of Cabazitaxel for the Treatment of Castration-Resistant Prostate Cancer. Clinical Medicine Insights Oncology 2011, 5: cmo.s6566. PMID: 21695098, PMCID: PMC3117627, DOI: 10.4137/cmo.s6566.
- Abe M, Xie W, Regan M, King I, Stampfer M, Kantoff P, Oh W, Chan J. Single‐nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer. BJU International 2010, 107: 126-134. PMID: 20477822, PMCID: PMC3010266, DOI: 10.1111/j.1464-410x.2010.09344.x.
- Drzymalski D, Oh W, Werner L, Regan M, Kantoff P, Tuli S. Predictors of survival in patients with prostate cancer and spinal metastasis. Presented at the 2009 Joint Spine Section Meeting. Clinical article. Journal Of Neurosurgery Spine 2010, 13: 789-94. PMID: 21121759, DOI: 10.3171/2010.6.spine10167.
- Oh W, Burakoff S. Cancer Therapy from Bench to Bedside. Annals Of Global Health 2010, 77: 571-572. PMID: 21105120, DOI: 10.1002/msj.20221.
- Tsao C, Oh W. Selective cell death mediated by small conditional RNAs: a novel therapeutic approach to cancer therapy. Asian Journal Of Andrology 2010, 13: 181-2. PMID: 21076441, PMCID: PMC3739191, DOI: 10.1038/aja.2010.148.
- Pomerantz M, Shrestha Y, Flavin R, Regan M, Penney K, Mucci L, Stampfer M, Hunter D, Chanock S, Schafer E, Chan J, Tabernero J, Baselga J, Richardson A, Loda M, Oh W, Kantoff P, Hahn W, Freedman M. Analysis of the 10q11 Cancer Risk Locus Implicates MSMB and NCOA4 in Human Prostate Tumorigenesis. PLOS Genetics 2010, 6: e1001204. PMID: 21085629, PMCID: PMC2978684, DOI: 10.1371/journal.pgen.1001204.
- Anees M, Horak P, El‐Gazzar A, Susani M, Heinze G, Perco P, Loda M, Lis R, Krainer M, Oh W. Recurrence‐free survival in prostate cancer is related to increased stromal TRAIL expression. Cancer 2010, 117: 1172-1182. PMID: 21381010, DOI: 10.1002/cncr.25504.
- Penney K, Pyne S, Schumacher F, Sinnott J, Mucci L, Kraft P, Ma J, Oh W, Kurth T, Kantoff P, Giovannucci E, Stampfer M, Hunter D, Freedman M. Genome-wide Association Study of Prostate Cancer Mortality. Cancer Epidemiology Biomarkers & Prevention 2010, 19: 2869-2876. PMID: 20978177, PMCID: PMC3197738, DOI: 10.1158/1055-9965.epi-10-0601.
- Gansler T, Ganz P, Grant M, Greene F, Johnstone P, Mahoney M, Newman L, Oh W, Thomas C, Thun M, Vickers A, Wender R, Brawley O. Sixty Years of CA: A Cancer Journal for Clinicians. CA A Cancer Journal For Clinicians 2010, 60: 345-350. PMID: 21075954, DOI: 10.3322/caac.20088.
- Sun T, Lee G, Oh W, Pomerantz M, Yang M, Xie W, Freedman M, Kantoff P. Single-Nucleotide Polymorphisms in p53 Pathway and Aggressiveness of Prostate Cancer in a Caucasian Population. Clinical Cancer Research 2010, 16: 5244-5251. PMID: 20855462, PMCID: PMC2970725, DOI: 10.1158/1078-0432.ccr-10-1261.
- Choueiri T, McDermott D, Duh M, Sarda S, Neary M, Oh W. Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: Results from a medical chart review study. Urologic Oncology Seminars And Original Investigations 2010, 30: 848-855. PMID: 20926319, DOI: 10.1016/j.urolonc.2010.07.009.
- Oh W, Vargas R, Jacobus S, Leitzel K, Regan M, Hamer P, Pierce K, Brown‐Shimer S, Carney W, Ali S, Kantoff P, Lipton A. Elevated plasma tissue inhibitor of metalloproteinase‐1 levels predict decreased survival in castration‐resistant prostate cancer patients. Cancer 2010, 117: 517-525. PMID: 20862742, DOI: 10.1002/cncr.25394.
- Galsky M, Dritselis A, Kirkpatrick P, Oh W. Cabazitaxel. Nature Reviews Drug Discovery 2010, 9: 677-678. PMID: 20811375, DOI: 10.1038/nrd3254.
- Choueiri T, Regan M, Rosenberg J, Oh W, Clement J, Amato A, McDermott D, Cho D, Atkins M, Signoretti S. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear‐cell renal cell carcinoma receiving vascular endothelial growth factor‐targeted therapy. BJU International 2010, 106: 772-778. PMID: 20230385, DOI: 10.1111/j.1464-410x.2010.09218.x.
- Brick A, Niu J, Huang J, Oh W. Platinum Agents in Prostate Cancer. 2010, 153-161. DOI: 10.1007/978-1-60327-829-4_14.
- Sun T, Lee G, Werner L, Pomerantz M, Oh W, Kantoff P, Freedman M. Inherited Variations in AR, ESR1, and ESR2 Genes Are Not Associated With Prostate Cancer Aggressiveness or With Efficacy of Androgen Deprivation Therapy. Cancer Epidemiology Biomarkers & Prevention 2010, 19: 1871-1878. PMID: 20615892, PMCID: PMC3755451, DOI: 10.1158/1055-9965.epi-10-0216.
- Seng S, Tsao C, Galsky M, Oh W. Cytotoxic chemotherapy for castration resistant prostate cancer: 2010 and beyond. Drug Discovery Today Therapeutic Strategies 2010, 7: 17-22. DOI: 10.1016/j.ddstr.2011.02.001.
- Harrison M, Hahn N, Pili R, Oh W, Hammers H, Sweeney C, Kim K, Perlman S, Arnott J, Sidor C, Wilding G, Liu G. A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). Investigational New Drugs 2010, 29: 1465-1474. PMID: 20499131, PMCID: PMC3042040, DOI: 10.1007/s10637-010-9455-x.
- Buckle G, Werner L, Oh W, Bubley G, Hayes J, Weckstein D, Elfiky A, Sims D, Kantoff P, Taplin M. Phase II trial of RAD001 (R) and bicalutamide (B) for castration-resistant prostrate cancer (CPRC). Journal Of Clinical Oncology 2010, 28: 4660-4660. DOI: 10.1200/jco.2010.28.15_suppl.4660.
- Elfiky A, Cho D, McDermott D, Rosenberg J, Fortner B, Antràs L, Chen K, Duh M, Jayawant S, Oh W, Atkins M, Choueiri T. Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma. Urologic Oncology Seminars And Original Investigations 2010, 29: 756-763. PMID: 20451414, DOI: 10.1016/j.urolonc.2010.01.008.
- Oh W, McDermott D, Duh, Antràs L, Chen K, Sarda S, Luka A, Whittemore S, Ramamurthy P, Neary M, Choueiri T. PCN50 COSTS OF TREATMENT WITH ANGIOGENESIS INHIBITORS (AIS) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC): RESULTS FROM A MEDICAL CHART REVIEW STUDY. Value In Health 2010, 13: a32. DOI: 10.1016/s1098-3015(10)72139-2.
- Dial E, Duh, Antras L, Rodermund D, Neary M, Choueiri T, Oh W. PUK1 INCIDENCE AND COST OF ADVERSE EVENTS (AES) IN PATIENTS WITH RENAL CELL CARCINOMA (RCC) TREATED WITH ANGIOGENESIS INHIBITORS (AIS). Value In Health 2010, 13: a76. DOI: 10.1016/s1098-3015(10)72356-1.
- Choueiri T, Duh M, Clement J, Brick A, Rogers M, Kwabi C, Shah K, Percy A, Antràs L, Jayawant S, Chen K, Wang S, Luka A, Neary M, McDermott D, Oh W. Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice‐based on medical chart review. BJU International 2010, 105: 1247-1254. PMID: 19863525, DOI: 10.1111/j.1464-410x.2009.08972.x.
- Weinberg A, Alemozaffar M, Soukup J, Kacker R, Choi W, Oh W, Hu J. 587 THE EFFECT OF NEO-ADJUVANT CHEMOTHERAPY ON RADICAL PROSTATECTOMY OUTCOMES IN INTERMEDIATE AND HIGH-RISK PROSTATE CANCER. Journal Of Urology 2010, 183: e230-e231. DOI: 10.1016/j.juro.2010.02.859.
- Bellmunt J, Oh W. Review: Castration-resistant prostate cancer: new science and therapeutic prospects. Therapeutic Advances In Medical Oncology 2010, 2: 189-207. PMID: 21789134, PMCID: PMC3126017, DOI: 10.1177/1758834009359769.
- Oh W, Hu J. Preface. Urologic Clinics Of North America 2010, 37: xiii. PMID: 20152513, DOI: 10.1016/j.ucl.2009.12.001.
- Schutz F, Oh W. Neoadjuvant and Adjuvant Therapies in Prostate Cancer. Urologic Clinics Of North America 2010, 37: 97-104. PMID: 20152523, DOI: 10.1016/j.ucl.2009.11.012.
- Oh W, Ross R, Choueiri T, Kantoff P, Corless C. 8 Cancer of the Genitourinary Tract. 2010, 233-277. DOI: 10.1016/b978-0-323-05905-3.00008-x.
- Oh W, Landrum M, Lamont E, McNeil B, Keating N. Does Oral Antiandrogen Use Before Leuteinizing Hormone-releasing Hormone Therapy in Patients With Metastatic Prostate Cancer Prevent Clinical Consequences of a Testosterone Flare? Urology 2009, 75: 642-647. PMID: 19962733, DOI: 10.1016/j.urology.2009.08.008.
- Taplin M, Regan M, Ko Y, Bubley G, Duggan S, Werner L, Beer T, Ryan C, Mathew P, Tu S, Denmeade S, Oh W, Sartor O, Mantzoros C, Rittmaster R, Kantoff P, Balk S. Phase II Study of Androgen Synthesis Inhibition with Ketoconazole, Hydrocortisone, and Dutasteride in Asymptomatic Castration-Resistant Prostate Cancer. Clinical Cancer Research 2009, 15: 7099-7105. PMID: 19887483, PMCID: PMC3644858, DOI: 10.1158/1078-0432.ccr-09-1722.
- Nakabayashi M, Oh W, Jacobus S, Regan M, Taplin M, Kantoff P, Rosenberg J. Activity of ketoconazole after taxane‐based chemotherapy in castration‐resistant prostate cancer. BJU International 2009, 105: 1392-1396. PMID: 19863532, DOI: 10.1111/j.1464-410x.2009.08971.x.
- Mercer J, Vohr B, Erickson-Owens D, Padbury J, Oh W. Seven-month developmental outcomes of very low birth weight infants enrolled in a randomized controlled trial of delayed versus immediate cord clamping. Journal Of Perinatology 2009, 30: 11-16. PMID: 19847185, PMCID: PMC2799542, DOI: 10.1038/jp.2009.170.
- Heng D, Xie W, Regan M, Warren M, Golshayan A, Sahi C, Eigl B, Ruether J, Cheng T, North S, Venner P, Knox J, N. K, Kollmannsberger C, McDermott D, Oh W, Atkins M, Bukowski R, Rini B, Choueiri T. Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study. Journal Of Clinical Oncology 2009, 27: 5794-5799. PMID: 19826129, DOI: 10.1200/jco.2008.21.4809.
- Aggarwal R, Weinberg V, Small E, Oh W, Rushakoff R, Ryan C. The Mechanism of Action of Estrogen in Castration-Resistant Prostate Cancer: Clues From Hormone Levels. Clinical Genitourinary Cancer 2009, 7: e71-e76. PMID: 19815485, DOI: 10.3816/cgc.2009.n.027.
- Oh W, Magidson J, Bankaitis-Davis D, Siconolfi L, Schurko B, Cantu R, Braitsch S, Wassman K, Kantoff P, Ross R. PP138 A whole blood RNA transcript-based model to predict biopsy Gleason score in newly diagnosed prostate cancer patients. European Journal Of Cancer Supplements 2009, 7: 27. DOI: 10.1016/s1359-6349(09)72197-4.
- Sartor O, Nakabayashi M, Taplin M, Ross R, Kantoff P, Balk S, Oh W. Activity of Dutasteride Plus Ketoconazole in Castration-Refractory Prostate Cancer After Progression on Ketoconazole Alone. Clinical Genitourinary Cancer 2009, 7: e90-e92. PMID: 19815488, DOI: 10.3816/cgc.2009.n.030.
- Jacobsen E, Chen J, Schurko B, Benson C, Oh W. Metastatic seminoma and grade 1 follicular lymphoma presenting concurrently in a supraclavicular lymph node: a case report. Cases Journal 2009, 2: 7273. PMID: 19918516, PMCID: PMC2769346, DOI: 10.4076/1757-1626-2-7273.
- Jia L, Landan G, Pomerantz M, Jaschek R, Herman P, Reich D, Yan C, Khalid O, Kantoff P, Oh W, Manak J, Berman B, Henderson B, Frenkel B, Haiman C, Freedman M, Tanay A, Coetzee G. Functional Enhancers at the Gene-Poor 8q24 Cancer-Linked Locus. PLOS Genetics 2009, 5: e1000597. PMID: 19680443, PMCID: PMC2717370, DOI: 10.1371/journal.pgen.1000597.
- Regan M, O'Donnell E, Kelly W, Halabi S, Berry W, Urakami S, Kikuno N, Oh W. Efficacy of carboplatin–taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials. Annals Of Oncology 2009, 21: 312-318. PMID: 19633053, PMCID: PMC2852201, DOI: 10.1093/annonc/mdp308.
- Duh M, Dial E, Choueiri T, Fournier A, Antras L, Rodermund D, Neary M, Oh W. Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis*. Current Medical Research And Opinion 2009, 25: 2081-2090. PMID: 19586325, DOI: 10.1185/03007990903084800.
- Pomerantz M, Beckwith C, Regan M, Wyman S, Petrovics G, Chen Y, Hawksworth D, Schumacher F, Mucci L, Penney K, Stampfer M, Chan J, Ardlie K, Fritz B, Parkin R, Lin D, Dyke M, Herman P, Lee S, Oh W, Kantoff P, Tewari M, McLeod D, Srivastava S, Freedman M. Evaluation of the 8q24 Prostate Cancer Risk Locus and MYC Expression. Cancer Research 2009, 69: 5568-5574. PMID: 19549893, PMCID: PMC2884104, DOI: 10.1158/0008-5472.can-09-0387.
- Chan J, Oh W, Xie W, Regan M, Stampfer M, King I, Abe M, Kantoff P. Plasma Selenium, Manganese Superoxide Dismutase, and Intermediate- or High-Risk Prostate Cancer. Journal Of Clinical Oncology 2009, 27: 3577-3583. PMID: 19528373, PMCID: PMC2720077, DOI: 10.1200/jco.2008.18.8938.
- Ross R, Bankaitis-Davis D, Siconolfi L, Katz L, Storm K, Magidson J, Wassmann K, Oh W. Sensitivity and specificity of a whole-blood RNA transcript-based diagnostic test for the diagnosis of prostate cancer (CaP) compared with prostate-specific antigen (PSA) alone. Journal Of Clinical Oncology 2009, 27: 5052-5052. DOI: 10.1200/jco.2009.27.15_suppl.5052.
- Oh W, Febbo P, Richie J, Fennessy F, Scibelli G, Hayes J, Choueiri T, Tempany C, Taplin M, Ross R. A phase II study of neoadjuvant chemotherapy with docetaxel and bevacizumab in patients (pts) with high-risk localized prostate cancer: A Prostate Cancer Clinical Trials Consortium trial. Journal Of Clinical Oncology 2009, 27: 5060-5060. DOI: 10.1200/jco.2009.27.15_suppl.5060.
- Dial E, Duh M, Fournier A, Antras L, Rodermund D, Neary M, Oh W. Cost implications of intravenous bevacizumab treatment in patients with renal cell carcinoma (RCC): A retrospective claims database analysis. Journal Of Clinical Oncology 2009, 27: 5112-5112. DOI: 10.1200/jco.2009.27.15_suppl.5112.
- Vinson J, Mathew P, Beer T, Carducci M, Oh W, Small E, Wilding G, Higano C, Hussain M, Scher H. Prostate cancer clinical trials consortium: A multicenter mechanism for the rapid design, development, and implementation of early phase clinical trials. Journal Of Clinical Oncology 2009, 27: e16065-e16065. DOI: 10.1200/jco.2009.27.15_suppl.e16065.
- Choueiri T, Regan M, Oh W, Clement J, Amato A, McDermott D, Cho D, Atkins M, Signoretti S. Prognostic and predictive values of carbonic anhydrase IX (CAIX) and pathologic features in patients with metastatic clear cell renal cell carcinoma receiving targeted therapy. Journal Of Clinical Oncology 2009, 27: e16067-e16067. DOI: 10.1200/jco.2009.27.15_suppl.e16067.
- Michaelson M, Regan M, Oh W, Kaufman D, Olivier K, Michaelson S, Spicer B, Gurski C, Kantoff P, Smith M. Phase II study of sunitinib in men with advanced prostate cancer. Annals Of Oncology 2009, 20: 913-920. PMID: 19403935, PMCID: PMC2674960, DOI: 10.1093/annonc/mdp111.
- Penney K, Salinas C, Pomerantz M, Schumacher F, Beckwith C, Lee G, Oh W, Sartor O, Ostrander E, Kurth T, Ma J, Mucci L, Stanford J, Kantoff P, Hunter D, Stampfer M, Freedman M. Evaluation of 8q24 and 17q Risk Loci and Prostate Cancer Mortality. Clinical Cancer Research 2009, 15: 3223-3230. PMID: 19366828, PMCID: PMC2878092, DOI: 10.1158/1078-0432.ccr-08-2733.
- Priolo C, Oh W, Loda M. Novel therapeutic strategies in prostate cancer: establishing a stratification system for patient selection in targeted trials. IDrugs 2009, 12: 165-8. PMID: 19333896.
- Sher D, Oh W. Reply. Urology 2009, 73: 362. DOI: 10.1016/j.urology.2008.09.016.
- Choueiri T, Xie W, D'Amico A, Ross R, Hu J, Pomerantz M, Regan M, Taplin M, Kantoff P, Sartor O, Oh W. Time to prostate‐specific antigen nadir independently predicts overall survival in patients who have metastatic hormone‐sensitive prostate cancer treated with androgen‐deprivation therapy. Cancer 2009, 115: 981-987. PMID: 19152438, PMCID: PMC2931827, DOI: 10.1002/cncr.24064.
- Morris M, Basch E, Wilding G, Hussain M, Carducci M, Higano C, Kantoff P, Oh W, Small E, George D, Mathew P, Beer T, Slovin S, Ryan C, Logothetis C, Scher H. Department of Defense Prostate Cancer Clinical Trials Consortium: A New Instrument for Prostate Cancer Clinical Research. Clinical Genitourinary Cancer 2009, 7: 51-57. PMID: 19213669, PMCID: PMC3394090, DOI: 10.3816/cgc.2009.n.009.
- Sher D, Mantzoros C, Jacobus S, Regan M, Lee G, Oh W. Absence of Relationship Between Steroid Hormone Levels and Prostate Cancer Tumor Grade. Urology 2008, 73: 356-361. PMID: 19036418, DOI: 10.1016/j.urology.2008.07.068.
- Romanus D, Oh W, Cook F, Weeks J. PCN86 SYMPTOM PREVALENCE IN HORMONE REFRACTORY PROSTATE CANCER (HRPC). Value In Health 2008, 11: a487. DOI: 10.1016/s1098-3015(10)66623-5.
- Rosenberg J, Oh W. What is the current status of second-line chemotherapy for castration-resistant prostate cancer? Nature Reviews Urology 2008, 5: 650-651. PMID: 18936787, DOI: 10.1038/ncpuro1232.
- Mathew P, Thall P, Wen S, Bucana C, Jones D, Horne E, Oh W, Morris M, Lee Y, Logothetis C, Lin S, Fidler I. Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer. British Journal Of Cancer 2008, 99: 1426-1432. PMID: 18841158, PMCID: PMC2579696, DOI: 10.1038/sj.bjc.6604706.
- Simon R, di Sant'Agnese P, Huang L, Xu H, Yao J, Yang Q, Liang S, Liu J, Yu R, Cheng L, Oh W, Palapattu G, Wei J, Huang J. CD44 expression is a feature of prostatic small cell Carcinoma and Distinguishes it from its Mimickers. Human Pathology 2008, 40: 252-258. PMID: 18835619, DOI: 10.1016/j.humpath.2008.07.014.
- Schurko B, Oh W. Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer. Nature Reviews Clinical Oncology 2008, 5: 506-507. PMID: 18648352, DOI: 10.1038/ncponc1201.
- Sher D, Oh W, Jacobus S, Regan M, Lee G, Mantzoros C. Relationship between serum adiponectin and prostate cancer grade. The Prostate 2008, 68: 1592-1598. PMID: 18646046, DOI: 10.1002/pros.20823.
- Clement J, McDermott D, Choueiri T, Brick A, Kwabi C, Shah K, Weiner J, Duh M, Neary M, Oh W. Patients with metastatic renal cell carcinoma (mRCC) receiving sunitinib in “real-world” clinical practice: Baseline characteristics and treatment efficacy. Journal Of Clinical Oncology 2008, 26: 16071-16071. DOI: 10.1200/jco.2008.26.15_suppl.16071.
- Oh W, Leitzel K, Jacobus S, Vargas R, Regan M, Hamer P, Carney W, Ali S, Kantoff P, Lipton A. Elevated plasma TIMP-1 and survival in metastatic castration-resistant prostate cancer patients. Journal Of Clinical Oncology 2008, 26: 11077-11077. DOI: 10.1200/jco.2008.26.15_suppl.11077.
- Duh M, Fournier A, Moyneur E, Dial E, Neary M, Oh W. Dosing and switching patterns for renal cell carcinoma (RCC) patients receiving selected angiogenesis inhibitor therapies. Journal Of Clinical Oncology 2008, 26: 5111-5111. DOI: 10.1200/jco.2008.26.15_suppl.5111.
- Jacobus S, Sher D, Regan M, Chamberland J, Oh W, Mantzoros C. Association between serum adiponectin and prostate cancer risk. Journal Of Clinical Oncology 2008, 26: 5147-5147. DOI: 10.1200/jco.2008.26.15_suppl.5147.
- Harrison M, Hahn N, Pili R, Oh W, Kim K, Wilding G, Sweeney C, Sidor C, Arnott J, Liu G. Phase II study of 2-methoxyestradiol (2ME2) NanoCrystal Dispersion (NCD) in patients with taxane-refractory, metastatic hormone-refractory prostate cancer (HRPC). Journal Of Clinical Oncology 2008, 26: 5173-5173. DOI: 10.1200/jco.2008.26.15_suppl.5173.
- Taplin M, Ko Y, Regan M, Beer T, Carducci M, Mathew P, Bubley G, Oh W, Kantoff P, Balk S. Phase II trial of ketoconazole, hydrocortisone, and dutasteride (KHAD) for castration resistant prostate cancer (CRPC). Journal Of Clinical Oncology 2008, 26: 5068-5068. DOI: 10.1200/jco.2008.26.15_suppl.5068.
- Ross R, Manola J, Oh W, Ryan C, Kim J, Rastarhuyeva I, Yap J, Van Den Abbeele A, Kantoff P, Taplin M. Phase I trial of RAD001 (R) and docetaxel (D) in castration resistant prostate cancer (CRPC) with FDG-PET assessment of RAD001 activity. Journal Of Clinical Oncology 2008, 26: 5069-5069. DOI: 10.1200/jco.2008.26.15_suppl.5069.
- Pomerantz M, Beckwith C, Regan M, Xie W, Herman P, Chan J, Ardlie K, Oh W, Kantoff P, Freedman M. Quantitative gene expression at the 8q24 prostate cancer risk locus. Journal Of Clinical Oncology 2008, 26: 5055-5055. DOI: 10.1200/jco.2008.26.15_suppl.5055.
- Dial E, Fournier A, Moyneur E, Neary M, Duh M, Oh W. Frequency and cost of adverse events in renal cell carcinoma (RCC) patients receiving angiogenesis inhibitor therapies. Journal Of Clinical Oncology 2008, 26: 14609-14609. DOI: 10.1200/jco.2008.26.15_suppl.14609.
- Brick A, McDermott D, Clement J, Kwabi C, Shah K, Weiner J, Duh M, Neary M, Oh W, Choueiri T. Treatment discontinuations, dose reductions, and interruptions for angiogenesis inhibitor therapies in patients with metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2008, 26: 14636-14636. DOI: 10.1200/jco.2008.26.15_suppl.14636.
- Fournier A, Duh, Moyneur É, Dial E, Neary M, Oh W. PUK15 COST IMPLICATIONS OF INTRAVENOUS (IV) BEVACIZUMAB TREATMENT IN PATIENTS WITH RENAL CELL CARCINOMA (RCC). Value In Health 2008, 11: a304-a305. DOI: 10.1016/s1098-3015(10)70960-8.
- Taplin M, Manola J, Oh W, Kantoff P, Bubley G, Smith M, Barb D, Mantzoros C, Gelmann E, Balk S. A phase II study of mifepristone (RU‐486) in castration‐resistant prostate cancer, with a correlative assessment of androgen‐related hormones. BJU International 2008, 101: 1084-1089. PMID: 18399827, DOI: 10.1111/j.1464-410x.2008.07509.x.
- Ross R, Oh W, Xie W, Pomerantz M, Nakabayashi M, Sartor O, Taplin M, Regan M, Kantoff P, Freedman M. Inherited Variation in the Androgen Pathway Is Associated With the Efficacy of Androgen-Deprivation Therapy in Men With Prostate Cancer. Journal Of Clinical Oncology 2008, 26: 842-847. PMID: 18281655, DOI: 10.1200/jco.2007.13.6804.
- Ross R, Xie W, Regan M, Pomerantz M, Nakabayashi M, Daskivich T, Sartor O, Taplin M, Kantoff P, Oh W. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer. Cancer 2008, 112: 1247-1253. PMID: 18293426, DOI: 10.1002/cncr.23304.
- Keating N, O’Malley A, McNaughton‐Collins M, Oh W, Smith M. Use of androgen deprivation therapy for metastatic prostate cancer in older men. BJU International 2008, 101: 1077-1083. PMID: 18190632, PMCID: PMC2900629, DOI: 10.1111/j.1464-410x.2007.07405.x.
- Nakabayashi M, Sartor O, Jacobus S, Regan M, McKearn D, Ross R, Kantoff P, Taplin M, Oh W. Response to docetaxel/carboplatin‐based chemotherapy as first‐ and second‐line therapy in patients with metastatic hormone‐refractory prostate cancer. BJU International 2008, 101: 308-312. PMID: 18184327, DOI: 10.1111/j.1464-410x.2007.07331.x.
- Ross R, Beer T, Jacobus S, Bubley G, Taplin M, Ryan C, Huang J, Oh W. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone‐refractory prostate cancer who are refractory to docetaxel. Cancer 2007, 112: 521-526. PMID: 18085595, DOI: 10.1002/cncr.23195.
- Xie W, Nakabayashi M, Regan M, Oh W. Higher prostate‐specific antigen levels predict improved survival in patients with hormone‐refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase. Cancer 2007, 110: 2709-2715. PMID: 17960608, DOI: 10.1002/cncr.23111.
- Avigan D, Vasir B, George D, Oh W, Atkins M, McDermott D, Kantoff P, Figlin R, Vasconcelles M, Xu Y, Kufe D, Bukowski R. Phase I/II Study of Vaccination With Electrofused Allogeneic Dendritic Cells/Autologous Tumor-derived Cells in Patients With Stage IV Renal Cell Carcinoma. Journal Of Immunotherapy 2007, 30: 749-761. PMID: 17893567, DOI: 10.1097/cji.0b013e3180de4ce8.
- Mathew P, Thall P, Bucana C, Oh W, Morris M, Jones D, Johnson M, Wen S, Pagliaro L, Tannir N, Tu S, Meluch A, Smith L, Cohen L, Kim S, Troncoso P, Fidler I, Logothetis C. Platelet-Derived Growth Factor Receptor Inhibition and Chemotherapy for Castration-Resistant Prostate Cancer with Bone Metastases. Clinical Cancer Research 2007, 13: 5816-5824. PMID: 17908974, DOI: 10.1158/1078-0432.ccr-07-1269.
- Daskivich T, Regan M, Oh W. Distinct Prognostic Role of Prostate-Specific Antigen Doubling Time and Velocity at Emergence of Androgen Independence in Patients Treated with Chemotherapy. Urology 2007, 70: 527-531. PMID: 17905110, DOI: 10.1016/j.urology.2007.04.035.
- Samnotra V, Vassilopoulou-Sellin R, Fojo A, Oh W, LaRocca R, Ernstoff M, Memoli V, Cole B, Quinn D, Simmons P, Tretter C. A phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC). Journal Of Clinical Oncology 2007, 25: 15527-15527. DOI: 10.1200/jco.2007.25.18_suppl.15527.
- Oh W, Leitzel K, Kantoff P, Regan M, Hamer P, Pierce K, Brown-Shimer S, Carney W, Ali S, Lipton A. Elevated plasma TIMP-1 levels predict reduced survival in metastatic hormone-refractory prostate cancer patients. Journal Of Clinical Oncology 2007, 25: 5143-5143. DOI: 10.1200/jco.2007.25.18_suppl.5143.
- Nakabayashi M, Sartor O, Jacobus S, Regan M, McKearn D, Ross R, Kantoff P, Taplin M, Oh W. Response to docetaxel (D)/carboplatin (C)-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer (HRPC). Journal Of Clinical Oncology 2007, 25: 5156-5156. DOI: 10.1200/jco.2007.25.18_suppl.5156.
- Pomerantz M, Manola J, Taplin M, Bubley G, Inman M, Lowell J, Beard C, Kantoff P, Oh W. Phase II Study of Low Dose and High Dose Conjugated Estrogen for Androgen Independent Prostate Cancer. Journal Of Urology 2007, 177: 2146-2150. PMID: 17509304, DOI: 10.1016/j.juro.2007.01.119.
- Oh W. Editorial Comment. Journal Of Urology 2007, 177: 2145. DOI: 10.1016/j.juro.2007.01.265.
- Nakabayashi M, Ling J, Xie W, Regan M, Oh W. Response to Vinorelbine With or Without Estramustine as Second-Line Chemotherapy in Patients with Hormone-Refractory Prostate Cancer. The Cancer Journal 2007, 13: 125-129. PMID: 17476141, DOI: 10.1097/ppo.0b013e3180465940.
- Oh W, Proctor K, Nakabayashi M, Evan C, Tormey L, Daskivich T, Antràs L, Smith M, Neary M, Duh M. The risk of renal impairment in hormone‐refractory prostate cancer patients with bone metastases treated with zoledronic acid. Cancer 2007, 109: 1090-1096. PMID: 17311345, DOI: 10.1002/cncr.22504.
- Oh W, Tay M, Huang J. Is there a role for platinum chemotherapy in the treatment of patients with hormone‐refractory prostate cancer? Cancer 2006, 109: 477-486. PMID: 17186531, DOI: 10.1002/cncr.22439.
- STERNBERG C, KRAINER M, OH W, BRACARDA S, BELLMUNT J, OZEN H, ZLOTTA A, BEER T, OUDARD S, RAUCHENWALD M, SKONECZNA I, BORNER M, FITZPATRICK J. The medical management of prostate cancer: a multidisciplinary team approach. BJU International 2006, 99: 22-27. PMID: 16956362, DOI: 10.1111/j.1464-410x.2006.06477.x.
- Mathew P, Thall P, Wen S, Horne E, Johnson M, Oh W, Morris M, Logothetis C, Fidler I, Bucana C. 79 POSTER Correlative results of in-vivo monitoring of platelet-derived growth factor receptor (PDGFR) activation status in a randomized placebocontrolled trial of docetaxel +/− imatinib in castration-resistant prostate cancer (CRPC) and bone metastases (BM). European Journal Of Cancer Supplements 2006, 4: 28. DOI: 10.1016/s1359-6349(06)70085-4.
- Daskivich T, Regan M, Oh W. Prostate Specific Antigen Doubling Time Calculation: Not as Easy as 1, 2, 4. Journal Of Urology 2006, 176: 1927-1937. PMID: 17070213, DOI: 10.1016/j.juro.2006.07.002.
- Nakabayashi M, Beard C, Kelly S, Carr-Locke D, Oh W. Treatment of a radiation-induced rectal ulcer with hyperbaric oxygen therapy in a man with prostate cancer. Urologic Oncology Seminars And Original Investigations 2006, 24: 503-508. PMID: 17138131, DOI: 10.1016/j.urolonc.2006.02.002.
- Oh W. Preface. Hematology/Oncology Clinics Of North America 2006, 20: xiii-xiv. DOI: 10.1016/j.hoc.2006.07.001.
- Nakabayashi M, Xie W, Regan M, Jackman D, Kantoff P, Oh W. Response to low‐dose ketoconazole and subsequent dose escalation to high‐dose ketoconazole in patients with androgen‐independent prostate cancer. Cancer 2006, 107: 975-981. PMID: 16862573, DOI: 10.1002/cncr.22085.
- Michaelson M, Kaufman D, Kantoff P, Oh W, Smith M. Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer 2006, 107: 530-535. PMID: 16804927, DOI: 10.1002/cncr.22043.
- Hayes J, Oh W, Kantoff P, Manola J, Smith M, Gelmann E, Bubley G, Balk S, Taplin M. Mifepristone (RU-486) in androgen independent prostate cancer. Journal Of Clinical Oncology 2006, 24: 14508-14508. DOI: 10.1200/jco.2006.24.18_suppl.14508.
- Oh W, Manola J, Ross R, Berkowitz A, Ryan C, Eilers K, Beer T. A phase II trial of docetaxel plus carboplatin in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel chemotherapy: Preliminary results. Journal Of Clinical Oncology 2006, 24: 14533-14533. DOI: 10.1200/jco.2006.24.18_suppl.14533.
- Pomerantz M, Manola J, Taplin M, Bubley G, Inman M, Lowell J, Kantoff P, Oh W. Phase II study of low dose (LD) and high dose (HD) premarin in androgen independent prostate cancer (AIPC). Journal Of Clinical Oncology 2006, 24: 4560-4560. DOI: 10.1200/jco.2006.24.18_suppl.4560.
- Mathew P, Thall P, Johnson M, Oh W, Meluch A, Morris M, Troncoso P, Bucana C, Fidler I, Logothetis C. Preliminary results of a randomized placebo-controlled double-blind trial of weekly docetaxel combined with imatinib in men with metastatic androgen-independent prostate cancer (AIPC) and bone metastases (BM). Journal Of Clinical Oncology 2006, 24: 4562-4562. DOI: 10.1200/jco.2006.24.18_suppl.4562.
- Daskivich T, Regan M, Kantoff P, Oh W. Prostate specific antigen doubling time (PSA-DT) and velocity (PSA-V) provide independent prognostic information in androgen independent prostate cancer (AIPC) patients receiving chemotherapy. Journal Of Clinical Oncology 2006, 24: 4616-4616. DOI: 10.1200/jco.2006.24.18_suppl.4616.
- Regan M, Daskivich T, Kantoff P, Oh W. Utility of prostate specific antigen doubling time (PSA-DT) at the start of androgen independent prostate cancer (AIPC) and immediately before chemotherapy in predicting efficacy of taxane chemotherapy. Journal Of Clinical Oncology 2006, 24: 4640-4640. DOI: 10.1200/jco.2006.24.18_suppl.4640.
- Nakabayashi M, Xie W, Regan M, Jackman D, Kantoff P, Oh W. Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer. Journal Of Clinical Oncology 2006, 24: 4646-4646. DOI: 10.1200/jco.2006.24.18_suppl.4646.
- Nakabayashi M, Bartlett R, Oh W. Treatment of Bicalutamide-Induced Gynecomastia With Breast-Reduction Surgery in Prostate Cancer. Journal Of Clinical Oncology 2006, 24: 2958-2959. PMID: 16782932, DOI: 10.1200/jco.2005.03.8505.
- Smith M, Manola J, Kaufman D, Oh W, Bubley G, Kantoff P. Celecoxib Versus Placebo for Men With Prostate Cancer and a Rising Serum Prostate-Specific Antigen After Radical Prostatectomy and/or Radiation Therapy. Journal Of Clinical Oncology 2006, 24: 2723-2728. PMID: 16782912, DOI: 10.1200/jco.2005.03.7804.
- Gilligan T, Oh W, Kantoff P. Carboplatin for Stage I Seminoma. Journal Of Clinical Oncology 2006, 24: 2971-2972. PMID: 16782940, DOI: 10.1200/jco.2005.05.3231.
- Oh W, Hayes J, Evan C, Manola J, George D, Waldron H, Donovan M, Varner J, Orechia J, Katcher B, Lu D, Nevins A, Wright R, Tormey L, Talcott J, Rubin M, Loda M, Sellers W, Richie J, Kantoff P, Weeks J. Development of an Integrated Prostate Cancer Research Information System. Clinical Genitourinary Cancer 2006, 5: 61-66. PMID: 16859581, DOI: 10.3816/cgc.2006.n.019.
- Oh W, Manola J, Babcic V, Harnam N, Kantoff P. Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. Urology 2006, 67: 1235-1240. PMID: 16765185, DOI: 10.1016/j.urology.2006.01.006.
- Daskivich T, Oh W. Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: Insight into mechanisms? Urology 2006, 67: 1084.e15-1084.e17. PMID: 16698377, DOI: 10.1016/j.urology.2005.11.015.
- Daskivich T, Oh W. Recent progress in hormonal therapy for advanced prostate cancer. Current Opinion In Urology 2006, 16: 173-178. PMID: 16679855, DOI: 10.1097/01.mou.0000193392.77469.e2.
- Nakabayashi M, Oh W. Chemotherapy for high‐risk localized prostate cancer. BJU International 2006, 97: 679-683. PMID: 16536752, DOI: 10.1111/j.1464-410x.2006.06092.x.
- Febbo P, Thorner A, Rubin M, Loda M, Kantoff P, Oh W, Golub T, George D. Application of Oligonucleotide Microarrays to Assess the Biological Effects of Neoadjuvant Imatinib Mesylate Treatment for Localized Prostate Cancer. Clinical Cancer Research 2006, 12: 152-158. PMID: 16397037, DOI: 10.1158/1078-0432.ccr-05-1652.
- Rosenberg J, Galsky M, Rohs N, Weinberg V, Oh W, Kelly W, Small E. A retrospective evaluation of second‐line chemotherapy response in hormone‐refractory prostate carcinoma. Cancer 2005, 106: 58-62. PMID: 16329138, DOI: 10.1002/cncr.21559.
- Oh W, Proctor K, Nakabayashi M, Evan C, Tormey L, Breierova L, Smith M, Neary M, Duh. CO4 A COMPARISON OF LOGISTIC REGRESSION AND COX PROPORTIONAL HAZARDS MODELS FOR IDENTIFICATION OF RISK FACTORS FOR RENAL IMPAIRMENT IN HORMONE REFRACTORY PROSTATE CANCER (HRPC) PATIENTS WITH BONE METASTASES (BM) TREATED WITH ZOLEDRONIC ACID (ZA). Value In Health 2005, 8: a16-a17. DOI: 10.1016/s1098-3015(10)67190-2.
- Oh W. Docetaxel in Hormone-Refractory Metastatic Prostate Cancer. Drugs 2005, 65: 2295-2297. DOI: 10.2165/00003495-200565160-00006.
- Oh W. High-Risk Localized Prostate Cancer: Integrating Chemotherapy. The Oncologist 2005, 10: 18-22. PMID: 16272455, DOI: 10.1634/theoncologist.10-90002-18.
- Nakabayashi M, Regan M, Lifsey D, Kantoff P, Taplin M, Sartor O, Oh W. Efficacy of nilutamide as secondary hormonal therapy in androgen‐independent prostate cancer. BJU International 2005, 96: 783-786. PMID: 16153200, DOI: 10.1111/j.1464-410x.2005.05714.x.
- Febbo P, Richie J, George D, Loda M, Manola J, Shankar S, Barnes A, Tempany C, Catalona W, Kantoff P, Oh W. Neoadjuvant Docetaxel before Radical Prostatectomy in Patients with High-Risk Localized Prostate Cancer. Clinical Cancer Research 2005, 11: 5233-5240. PMID: 16033841, DOI: 10.1158/1078-0432.ccr-05-0299.
- Nakabayashi M, Regan M, Lifsey D, Evan C, Kantoff P, Taplin M, Sartor O, Oh W. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer (AIPC). Journal Of Clinical Oncology 2005, 23: 4683-4683. DOI: 10.1200/jco.2005.23.16_suppl.4683.
- Oh W, Manola J, Babcic V, Harnam N, Kantoff P. Response to second-line chemotherapy in patients with hormone refractory prostate cancer (HRPC) receiving two sequences of mitoxantrone (M) and taxanes (T). Journal Of Clinical Oncology 2005, 23: 4616-4616. DOI: 10.1200/jco.2005.23.16_suppl.4616.
- Oh W, George D, Tay M. Response to Docetaxel/Carboplatin in Patients with Hormone-Refractory Prostate Cancer Not Responding to Taxane-Based Chemotherapy. Clinical Genitourinary Cancer 2005, 4: 61-64. PMID: 15992464, DOI: 10.3816/cgc.2005.n.014.
- Michaelson M, Gilligan T, Oh W, Kantoff P, Taplin M, Izquierdo M, Flores L, Smith M. Phase II study of three hour, weekly infusion of trabectedin (ET-743) in men with metastatic, androgen-independent prostate carcinoma (AIPC). Journal Of Clinical Oncology 2005, 23: 4517-4517. DOI: 10.1200/jco.2005.23.16_suppl.4517.
- Galsky M, Small E, Oh W, Chen I, Smith D, Colevas A, Martone L, Curley T, DeLaCruz A, Scher H, Kelly W. Multi-Institutional Randomized Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) With or Without Estramustine Phosphate in Patients With Progressive Castrate Metastatic Prostate Cancer. Journal Of Clinical Oncology 2005, 23: 1439-1446. PMID: 15735119, DOI: 10.1200/jco.2005.09.042.
- Oh W, Hagmann E, Manola J, George D, Gilligan T, Jacobson J, Smith M, Kaufman D, Kantoff P. A Phase I Study of Estramustine, Weekly Docetaxel, and Carboplatin Chemotherapy in Patients with Hormone-Refractory Prostate Cancer. Clinical Cancer Research 2005, 11: 284-289. PMID: 15671557, DOI: 10.1158/1078-0432.284.11.1.
- Tay M, Oh W. Chapter 28 Metastatic Adenocarcinoma of the Prostate. 2005, 505-513. DOI: 10.1016/b978-0-7216-0003-1.50032-0.
- Oh W. AN OVERVIEW OF CHEMOTHERAPY TRIALS IN LOCALIZED AND RECURRENT NONMETASTATIC PROSTATE CANCER. Journal Of Urology 2004, 172: s34-s37. PMID: 15535440, DOI: 10.1097/01.ju.0000141674.92253.fe.
- CARROLL P, CHAN J, D’AMICO A, GELMANN E, IVERSEN P, KLOTZ L, NELSON J, NELSON P, NELSON W, OH W, ROSEN N, RUBIN M, SANDLER H, SELLERS W, SMITH M, XU J, McMANN M, KANTOFF P. FOURTH INTERNATIONAL CONFERENCE ON INNOVATIONS AND CHALLENGES IN PROSTATE CANCER. Journal Of Urology 2004, 172: s3-s5. PMID: 15535434, DOI: 10.1097/01.ju.0000142276.19511.ac.
- Nakabayashi M, Oh W. Neoadjuvant and adjuvant chemotherapy for high-risk localized prostate cancer. Current Treatment Options In Oncology 2004, 5: 349-355. PMID: 15341673, DOI: 10.1007/s11864-004-0025-3.
- Smith M, Manola J, Kaufman D, George D, Oh W, Mueller E, Slovin S, Spiegelman B, Small E, Kantoff P. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate‐specific antigen level after radical prostatectomy and/or radiation therapy. Cancer 2004, 101: 1569-1574. PMID: 15468186, DOI: 10.1002/cncr.20493.
- Kaufman D, Carducci M, Kuzel T, Todd M, Oh W, Smith M, Ye Z, Nicol S, Stadler W. A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urologic Oncology Seminars And Original Investigations 2004, 22: 393-397. PMID: 15464919, DOI: 10.1016/j.urolonc.2004.01.002.
- Oh W, Kantoff P, Weinberg V, Jones G, Rini B, Derynck M, Bok R, Smith M, Bubley G, Rosen R, DiPaola R, Small E. Prospective, Multicenter, Randomized Phase II Trial of the Herbal Supplement, PC-SPES, and Diethylstilbestrol in Patients With Androgen-Independent Prostate Cancer. Journal Of Clinical Oncology 2004, 22: 3705-3712. PMID: 15289492, DOI: 10.1200/jco.2004.10.195.
- Kelly W, Galsky M, Small E, Oh W, Chen I, Smith D, Martone L, Curley T, Delacruz A, Scher H. Multi-institutional trial of the epothilone B analogue BMS-247550 with or without estramustine phosphate (EMP) in patients with progressive castrate-metastatic prostate cancer (PCMPC): Updated results. Journal Of Clinical Oncology 2004, 22: 4509-4509. DOI: 10.1200/jco.2004.22.14_suppl.4509.
- Oh W, Hagmann E, Manola J, George D, Gilligan T, Smith M, Kaufman D, Kantoff P. A phase I study of estramustine, weekly docetaxel and carboplatin (EDC) chemotherapy in patients with hormone refractory prostate cancer (HRPC). Journal Of Clinical Oncology 2004, 22: 4656-4656. DOI: 10.1200/jco.2004.22.14_suppl.4656.
- Tay M, George D, Gilligan T, Kelly S, Appleby L, Taplin M, Febbo P, Kantoff P, Oh W. Docetaxel plus carboplatin (DC) may have significant activity in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel-based chemotherapy. Journal Of Clinical Oncology 2004, 22: 4679-4679. DOI: 10.1200/jco.2004.22.14_suppl.4679.
- George D, Oh W, Gilligan T, Masson E, Souppart C, Wang Y, Ho Y, Lebwohl D, Laurent D, Kantoff P. Phase I study of the novel, oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK): Evaluating the pharmacokinetic effect of a high-fat meal in patients with hormone-refractory prostate cancer (HRPC). Journal Of Clinical Oncology 2004, 22: 4689-4689. DOI: 10.1200/jco.2004.22.14_suppl.4689.
- Kelly W, Galsky M, Small E, Oh W, Chen I, Smith D, Martone L, Curley T, Delacruz A, Scher H. Multi-institutional trial of the epothilone B analogue BMS-247550 with or without estramustine phosphate (EMP) in patients with progressive castrate-metastatic prostate cancer (PCMPC): Updated results. Journal Of Clinical Oncology 2004, 22: 4509-4509. DOI: 10.1200/jco.2004.22.90140.4509.
- Oh W, Hagmann E, Manola J, George D, Gilligan T, Smith M, Kaufman D, Kantoff P. A phase I study of estramustine, weekly docetaxel and carboplatin (EDC) chemotherapy in patients with hormone refractory prostate cancer (HRPC). Journal Of Clinical Oncology 2004, 22: 4656-4656. DOI: 10.1200/jco.2004.22.90140.4656.
- Tay M, George D, Gilligan T, Kelly S, Appleby L, Taplin M, Febbo P, Kantoff P, Oh W. Docetaxel plus carboplatin (DC) may have significant activity in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel-based chemotherapy. Journal Of Clinical Oncology 2004, 22: 4679-4679. DOI: 10.1200/jco.2004.22.90140.4679.
- George D, Oh W, Gilligan T, Masson E, Souppart C, Wang Y, Ho Y, Lebwohl D, Laurent D, Kantoff P. Phase I study of the novel, oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK): Evaluating the pharmacokinetic effect of a high-fat meal in patients with hormone-refractory prostate cancer (HRPC). Journal Of Clinical Oncology 2004, 22: 4689-4689. DOI: 10.1200/jco.2004.22.90140.4689.
- Tay M, Kaufman D, Regan M, Leibowitz S, George D, Febbo P, Manola J, Smith M, Kaplan I, Kantoff P, Oh W. Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate. Annals Of Oncology 2004, 15: 974-978. PMID: 15151957, DOI: 10.1093/annonc/mdh221.
- Abe M, Manola J, Oh W, Parslow D, George D, Austin C, Kantoff P. Plasma Levels of Heat Shock Protein 70 in Patients with Prostate Cancer: A Potential Biomarker for Prostate Cancer. Clinical Genitourinary Cancer 2004, 3: 49-53. PMID: 15279691, DOI: 10.3816/cgc.2004.n.013.
- Liu G, Gandara D, Lara P, Raghavan D, Doroshow J, Twardowski P, Kantoff P, Oh W, Kim K, Wilding G. A Phase II Trial of Flavopiridol (NSC #649890) in Patients with Previously Untreated Metastatic Androgen-Independent Prostate Cancer. Clinical Cancer Research 2004, 10: 924-928. PMID: 14871968, DOI: 10.1158/1078-0432.ccr-03-0050.
- George D, Regan M, Oh W, Tay M, Manola J, Decalo N, Duggan S, Dewolf W, Kantoff P, Bubley G. Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer. Urology 2004, 63: 327-332. PMID: 14972483, DOI: 10.1016/j.urology.2003.09.059.
- Oh W, Halabi S, Kelly W, Werner C, Godley P, Vogelzang N, Small E, B F. A Phase II study of estramustine, docetaxel, and carboplatin with granulocyte–colony‐stimulating factor support in patients with hormone‐refractory prostate carcinoma. Cancer 2003, 98: 2592-2598. PMID: 14669278, DOI: 10.1002/cncr.11829.
- CARROLL P, BENARON D, BLACKLEDGE G, COAKLEY F, D’AMICO A, HIGANO C, IVERSEN P, KATTAN M, NANUS D, NELSON J, OH W, ROACH M, SELLERS W, SMITH M, MCMANN M, KANTOFF P. Third International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment. Journal Of Urology 2003, 170: s3-s5. PMID: 14610403, DOI: 10.1097/01.ju.0000095101.18470.a0.
- Oh W. The Evolving Role of Chemotherapy and Other Systemic Therapies for Managing Localized Prostate Cancer. Journal Of Urology 2003, 170: s28-s34. PMID: 14610407, DOI: 10.1097/01.ju.0000095356.02647.64.
- LEIBOWITZ S, OH W. Overtreatment of a Patient With Presumed Recurrent Prostate Cancer Based on False-Positive Prostate Specific Antigen Results. Journal Of Urology 2003, 170: 1305. PMID: 14501750, DOI: 10.1097/01.ju.0000084670.47887.a5.
- Bhayani S, Ong A, Oh W, Kantoff P, Kavoussi L. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer: a long-term update. Urology 2003, 62: 324-327. PMID: 12893344, DOI: 10.1016/s0090-4295(03)00324-8.
- Oh W, Manola J, Bittmann L, Brufsky A, Kaplan I, Smith M, Kaufman D, Kantoff P. Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up. Urology 2003, 62: 99-104. PMID: 12837431, DOI: 10.1016/s0090-4295(03)00145-6.
- Oh W, Kaplan I, Febbo P, Prisby J, Manola J, Kaufman D, Kantoff P. Neoadjuvant Doxil Chemotherapy Prior to Androgen Ablation Plus Radiotherapy for High-Risk Localized Prostate Cancer: Feasibility and Toxicity. American Journal Of Clinical Oncology 2003, 26: 312. DOI: 10.1097/00000421-200306000-00021.
- Oh W, Kaplan I, Febbo P, Prisby J, Manola J, Kaufman D, Kantoff P. Neoadjuvant Doxil Chemotherapy Prior to Androgen Ablation Plus Radiotherapy for High-Risk Localized Prostate Cancer. American Journal Of Clinical Oncology 2003, 26: 312-316. PMID: 12796607, DOI: 10.1097/01.coc.0000020921.08768.1f.
- Yu E, Oh W. Neoadjuvant therapy for high-risk localized prostate cancer. Current Oncology Reports 2003, 5: 250-257. PMID: 12667424, DOI: 10.1007/s11912-003-0118-3.
- Leibowitz S, Garber J, Fox E, Loda M, Kaufman D, Kantoff P, Oh W. Male Patients with Diagnoses of Both Breast Cancer and Prostate Cancer. The Breast Journal 2003, 9: 208-212. PMID: 12752629, DOI: 10.1046/j.1524-4741.2003.09312.x.
- Oh W. Neoadjuvant therapy before radical prostatectomy in high-risk localized prostate cancer: defining appropriate endpoints. Urologic Oncology Seminars And Original Investigations 2003, 21: 229-234. PMID: 12810211, DOI: 10.1016/s1078-1439(03)00019-x.
- Oh W, Tully P, Kantoff P, Regan M. Physician attitudes toward cytotoxic chemotherapy use in patients with advanced prostate carcinoma. Cancer 2003, 97: 2171-2179. PMID: 12712468, DOI: 10.1002/cncr.11344.
- Lee D, Sartor O, Kosty M, Oh W. Highlights from the Third Annual Meeting of the Society of Urologic Oncology; Bethesda, Maryland, December 13-14, 2002. Clinical Genitourinary Cancer 2003, 1: 203-206. PMID: 15040876, DOI: 10.1016/s1540-0352(11)70002-6.
- Michaelson M, Kaufman D, Oh W. Transitional cell carcinoma of the upper uroepithelial tract. Clinical Advances In Hematology And Oncology 2003, 1: 102-4; discussion 105. PMID: 16224387.
- Oh W. Predicting Outcome in Localized Prostate Cancer: How Far Have We Come? Cancer Investigation 2003, 21: 487-488. PMID: 12901296, DOI: 10.1081/cnv-120018656.
- Oh W, Small E. Complementary and alternative therapies in prostate cancer. Seminars In Oncology 2002, 29: 575-584. PMID: 12516040, DOI: 10.1053/sonc.2002.50007.
- Smith M, Kaufman D, George D, Oh W, Kazanis M, Manola J, Kantoff P. Selective aromatase inhibition for patients with androgen‐independent prostate carcinoma. Cancer 2002, 95: 1864-1868. PMID: 12404279, DOI: 10.1002/cncr.10844.
- OH W. Secondary hormonal therapies in the treatment of prostate cancer. Urology 2002, 60: 87-92. PMID: 12231058, DOI: 10.1016/s0090-4295(02)01581-9.
- Carroll P, Kantoff P, Balk S, Brown M, D’amico A, George D, Grossfeld G, Johnson C, Kelly W, Klotz L, Lee W, Lubeck D, Mcleod D, Oh W, Pollack A, Sartor O, Smith M, Hart C. Overview consensus statement. Urology 2002, 60: 1-6. PMID: 12231036, DOI: 10.1016/s0090-4295(02)01559-5.
- Carlo W, Stark A, Wright L, Tyson J, Papile L, Shankaran S, Donovan E, Oh W, Bauer C, Saha S, Poole W, Stoll B, Network* F. Minimal ventilation to prevent bronchopulmonary dysplasia in extremely-low-birth-weight infants. The Journal Of Pediatrics 2002, 141: 370-375. PMID: 12219057, DOI: 10.1067/mpd.2002.127507.
- Oh W. The Evolving Role of Estrogen Therapy in Prostate Cancer. Clinical Genitourinary Cancer 2002, 1: 81-89. PMID: 15046698, DOI: 10.3816/cgc.2002.n.009.
- D'Amico A, Saegaert T, Chen M, Renshaw A, George D, Oh W, Kantoff P. Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high‐risk prostate cancer. Cancer 2002, 95: 275-280. PMID: 12124826, DOI: 10.1002/cncr.10673.
- Harafuji N, Keys DN, Levine M. Genome-wide identification of tissue-specific enhancers in the Ciona tadpole. Proc Natl Acad Sci U S A 2002, 99: 6802-5. PMID: 12011440, DOI: 10.1073/pnas.052024999.
- OH W, LODA M, KANTOFF P, JANICEK M. PROGRESSIVE SCLEROSIS OF ISOLATED FOOT METASTASIS OF PROSTATE CANCER. Journal Of Urology 2002, 167: 1392. PMID: 11832744, DOI: 10.1016/s0022-5347(05)65312-8.
- OH W, LODA M, KANTOFF P, JANICEK M. PROGRESSIVE SCLEROSIS OF ISOLATED FOOT METASTASIS OF PROSTATE CANCER. Journal Of Urology 2002, 167: 1392. DOI: 10.1097/00005392-200203000-00047.
- Oh W, Small E. PC-SPES and prostate cancer. Urologic Clinics Of North America 2002, 29: 59-66. PMID: 12109356, DOI: 10.1016/s0094-0143(02)00017-4.
- Oh W, George D, Kantoff P. Rapid rise of serum prostate specific antigen levels after discontinuation of the herbal therapy PC‐SPES in patients with advanced prostate carcinoma. Cancer 2002, 94: 686-689. PMID: 11857300, DOI: 10.1002/cncr.10269.
- Oh W, Manola J, George D, Fierman A, Fontaine-Rothe P, Morrissey S, Prisby J, Kaufman D, Shapiro C, Kantoff P, Smith M. A Phase II Trial of Interferon-Alpha and Toremifene in Advanced Renal Cell Cancer Patients. Cancer Investigation 2002, 20: 186-191. PMID: 11901538, DOI: 10.1081/cnv-120001145.
- DAmico A, Saegart T, Chen M, Renshaw A, George D, Oh W, Kantoff P. The impact of anemia on psa outcome following radiation and androgen suppression therapy in patients with high-risk prostate cancer. International Journal Of Radiation Oncology • Biology • Physics 2001, 51: 113. DOI: 10.1016/s0360-3016(01)02031-4.
- Oh W, George D, Kaufman D, Moss K, Smith M, Richie J, Kantoff P. Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: A preliminary report. Seminars In Oncology 2001, 28: 40-44. PMID: 11685727, DOI: 10.1016/s0093-7754(01)90153-8.
- Oh W, George D, Kaufman D, Moss K, Smith M, Richie J, Kantoff P. Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: A preliminary report. Seminars In Oncology 2001, 28: 40-44. DOI: 10.1053/sonc.2001.26899.
- Gilligan T, Oh W. Overall Survival after Prostate‐Specific‐Antigen‐Detected Recurrence Following Conformal Radiation Therapy. The Prostate Journal 2001, 3: 43-44. DOI: 10.1046/j.1525-1411.2001.31007-2.x.
- Gilligan T, Oh W. Bicalutamide Monotherapy Compared with Castration in Patients with Nonmetastatic Locally Advanced Prostate Cancer: 6.3 Years of Follow‐up. The Prostate Journal 2001, 3: 42-43. DOI: 10.1046/j.1525-1411.2001.003001042.x.
- Oh W. Anemia Related to Hormonal Ablation Therapy for Prostate Cancer. The Prostate Journal 2001, 3: 14-17. DOI: 10.1046/j.1525-1411.2001.003001014.x.
- Oh W, George D, Hackmann K, Manola J, Kantoff P. Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer. Urology 2001, 57: 122-126. PMID: 11164156, DOI: 10.1016/s0090-4295(00)00986-9.
- Gilligan T, Oh W. Biochemical Outcome Following External Beam Radiation Therapy With or Without Androgen Suppression Therapy for Clinically Localized Prostate Cancer. The Prostate Journal 2001, 3: 45-46. DOI: 10.1046/j.1525-1411.2001.31007-4.x.
- Kelly W, Curley T, Slovin S, Heller G, McCaffrey J, Bajorin D, Ciolino A, Regan K, Schwartz M, Kantoff P, George D, Oh W, Smith M, Kaufman D, Small E, Schwartz L, Larson S, Tong W, Scher H. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. Journal Of Clinical Oncology 2001, 19: 44-53. PMID: 11134194, DOI: 10.1200/jco.2001.19.1.44.
- Gilligan T, Oh W. Prospective Trial of the Herbal Supplement PC‐SPEC in Patients with Progressive Prostate Cancer. The Prostate Journal 2001, 3: 44-45. DOI: 10.1046/j.1525-1411.2001.31007-3.x.
- Smith M, Kaufman D, Oh W, Guerin K, Seiden M, Makatsoris T, Manola J, Kantoff P. Vinorelbine and estramustine in androgen‐independent metastatic prostate cancer. Cancer 2000, 89: 1824-1828. PMID: 11042579, DOI: 10.1002/1097-0142(20001015)89:8<1824::aid-cncr24>3.0.co;2-r.
- Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman D, Oh W, Demetri G, Figg W, Zhou X, Eng C, Spiegelman B, Kantoff P. Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer. Proceedings Of The National Academy Of Sciences Of The United States Of America 2000, 97: 10990-10995. PMID: 10984506, PMCID: PMC27136, DOI: 10.1073/pnas.180329197.
- George D, Paz‐Ares L, Oh W. Article Reviews. The Prostate Journal 2000, 2: 163-167. DOI: 10.1046/j.1525-1411.2000.23006.x.
- Oh W. Chemotherapy for patients with advanced prostate carcinoma. Cancer 2000, 88: 3015-3021. PMID: 10898346, DOI: 10.1002/1097-0142(20000615)88:12+<3015::aid-cncr18>3.0.co;2-m.
- Kaufman D, Raghavan D, Carducci M, Levine E, Murphy B, Aisner J, Kuzel T, Nicol S, Oh W, Stadler W. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. Journal Of Clinical Oncology 2000, 18: 1921-7. PMID: 10784633, DOI: 10.1200/jco.2000.18.9.1921.
- Eder J, Kantoff P, Roper K, Xu G, Bubley G, Boyden J, Gritz L, Mazzara G, Oh W, Arlen P, Tsang K, Panicali D, Schlom J, Kufe D. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clinical Cancer Research 2000, 6: 1632-8. PMID: 10815880.
- Reid P, Oh W. Article Reviews. The Prostate Journal 2000, 2: 102-105. DOI: 10.1046/j.1525-1411.2000.22008.x.
- Oh W, Manola J, Renshaw A, Brodkin D, Loughlin K, Richie J, Shapiro C, Kantoff P. Smoking and alcohol use may be risk factors for poorer outcome in patients with clear cell renal carcinoma. Urology 2000, 55: 31-35. PMID: 10654890, DOI: 10.1016/s0090-4295(99)00408-2.
- Nelson J, Chen R, Bishoff J, Oh W, Kantoff P, Donehower R, Kavoussi L. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumors. Urology 1999, 54: 1064-1067. PMID: 10604709, DOI: 10.1016/s0090-4295(99)00289-7.
- Bubley G, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg W, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak D, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small E, Smith M, Trump D, Vollmer R, Wilding G. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. Journal Of Clinical Oncology 1999, 17: 3461-7. PMID: 10550143, DOI: 10.1200/jco.1999.17.11.3461.
- Oh W, Kantoff P. Treatment of locally advanced prostate cancer: is chemotherapy the next step? Journal Of Clinical Oncology 1999, 17: 3664-75. PMID: 10550165, DOI: 10.1200/jco.1999.17.11.3664.
- Oh W, Manola J, Richie J, Loughlin K, Kantoff P. A phase II trial of methotrexate, cisplatin, 5‐fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma. Cancer 1999, 86: 1329-1334. PMID: 10506721, DOI: 10.1002/(sici)1097-0142(19991001)86:7<1329::aid-cncr31>3.0.co;2-r.
- Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer.Oh W, Kantoff P. Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer. Seminars In Oncology 1999, 26: 49-54. PMID: 10604270.
- Reid P, Kantoff P, Oh W. Antiandrogens in Prostate Cancer. Investigational New Drugs 1999, 17: 271-284. PMID: 10665479, DOI: 10.1023/a:1006344807086.
- Oh W. Article Reviews. The Prostate Journal 1999, 1: 203-207. DOI: 10.1046/j.1525-1411.1999.14006.x.
- Smith M, Kantoff P, Oh W, Elson G, Manola J, McMullin M, Jacobsen J, Brufsky A, Kaufman D. Phase II Trial of the Antiestrogen Toremifene for Androgen‐Independent Prostate Cancer. The Prostate Journal 1999, 1: 185-189. DOI: 10.1046/j.1525-1411.1999.14003.x.
- Kavoussi L, Nelson J, Chen R, Bishoff J, Donehower R, Oh W, Kantoff P. LAPAROSCOPIC RETROPERITONEAL LYMPH NODE DISSECTION (RPLND) FOR CLINICAL STAGE I NONSEMINOMATOUS GERM CELL TESTICULAR TUMORS (NSGCT). Journal Of Urology 1999, 161: 4.. DOI: 10.1097/00005392-199904010-00018.
- Kelly K, Gaudin P, Slovin S, Curley T, McCaffrey J, Ciolino A, Dalbagni G, Donat S, Scardino P, Scher H, Kantoff P, Smith M, Oh W, Smith D, Small E. PACLITAXEL(T), ESTRAMUSTINE(E) AND CARBOPLATIN(C) IN PATIENTS (Pts) WITH ADVANCED PROSTATE CANCER(PC). Journal Of Urology 1999, 161: 177.. DOI: 10.1097/00005392-199904010-00711.
- Oh W. Article Reviews. The Prostate Journal 1999, 1: 103-108. DOI: 10.1046/j.1525-1411.1999.09916.x.
- Stevenson D, Wright L, Lemons J, Oh W, Korones S, Papile L, Bauer C, Stoll B, Tyson J, Shankaran S, Fanaroff A, Donovan E, Ehrenkranz R, Verter J. Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, January 1993 through December 1994. American Journal Of Obstetrics And Gynecology 1998, 179: 1632-1639. PMID: 9855609, DOI: 10.1016/s0002-9378(98)70037-7.
- OH W, KANTOFF P. MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS. Journal Of Urology 1998, 160: 1220-1229. PMID: 9751323, DOI: 10.1016/s0022-5347(01)62501-1.
- OH W, KANTOFF P. MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER. Journal Of Urology 1998, 160: 1220-1229.. DOI: 10.1097/00005392-199810000-00003.
- Smilow Cancer Hospital at Greenwich77 Lafayette PlaceGreenwich, CT 06830
- Smilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
Biography
William K. Oh, MD, is a genitourinary oncologist with decades of experience specializing in prostate cancer. He integrates molecular and genetic testing into routine cancer care, ensuring that patients receive the most personalized treatment plans possible. Throughout his career he has focused on decreasing barriers to the delivery of care for prostate cancer nationally.
Dr. Oh is the director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital, where he leads efforts to develop cohesive programs that combine basic and translational science with clinical trials. He also oversees the Precision Medicine Tumor Board, which is pivotal in guiding treatment decisions based on genetic and molecular data. Additionally, he serves as the service line medical director of Smilow Cancer Hospital at Greenwich Hospital, where he continues to develop integrated oncology care teams and expand the impact of multidisciplinary cancer care for patients in the region.
Dr. Oh completed his undergraduate degree at Yale University, received his medical degree from New York University School of Medicine, and did his internship and residency at Brigham and Women’s Hospital before his clinical fellowship in medical oncology at Dana-Farber Cancer Institute.
Dr. Oh currently serves as chair of the American Cancer Society's National Prostate Cancer Roundtable, whose mission is to improve prostate cancer outcomes and survivorship through increasing awareness and equitable access to prevention, screening, and treatment. Also, he is the chair of the Medical Advisory Council for the Chemotherapy Foundation, which is committed to discovering novel therapies for cancer.
“I love taking care of patients because it brings me tremendous personal satisfaction to both help them and learn from them,” Dr. Oh says. “I also love the precision medicine part of my job, but in the end, my patient care responsibilities always bring me back to what it’s all about and why we’re all here and I enjoy getting to know my patients and their generosity of spirit and courage. I take a lot of lessons from that.”
Titles
- Director, Precision Medicine, Yale Cancer Center and Smilow Cancer Hospital
- Service Line Medical Director, Smilow Cancer Hospital at Greenwich Hospital
Education & Training
- MDNew York University School of Medicine
- BSYale University, Molecular Biophysics and Biochemistry
Additional Information
- Ebrahimi H, Allen J, Biru Y, Garg R, Hodgdon C, Oh WK, Steensma D, Pal SK, Mulvey T. Practical Guide to Clinical Trial Accessibility: Making Trial Participation a Standard of Care. Am Soc Clin Oncol Educ Book 2025, 45: e100052. PMID: 40388680, DOI: 10.1200/EDBK-25-100052.
- Ganta T, Anker JF, Miller E, Joshi H, Tsao CK, Oh WK. Characterization of Exceptional Responses in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Cabozantinib and Immune Checkpoint Inhibitors. Clin Genitourin Cancer 2025, 23: 102336. PMID: 40222171, DOI: 10.1016/j.clgc.2025.102336.
- Carlsson SV, Barata PC, Bryce AH, George DJ, Gillessen S, Loeb S, Montgomery B, Morris D, Riaz IB, Palapattu G, Schoen MW, Washington Iii SL, Cornell B, Levine R, Aggarwal P, McGowan T, Cotter M, Thompson B, Devgan G, Russell D, Kuperman G, Lenero E, Iwata K, Miyahira AK, Soule HR, Carithers G, Oh WK, Agarwal N. Prostate Cancer Foundation White Paper on Combination Therapy for Metastatic Hormone-Sensitive Prostate Cancer. JCO Oncol Pract 2025, OP2500050. PMID: 40315399, DOI: 10.1200/OP-25-00050.
- Yu R, Qin QJ, Haines GK, Oh WK, Lewis S. Intravesical BCG therapy-induced granulomatous prostatitis in a patient with non-muscle invasive bladder cancer and prostate adenocarcinoma. Urol Case Rep 2025, 60: 103020. PMID: 40230614, DOI: 10.1016/j.eucr.2025.103020.
- Carlsson S, Oh W. How Can Guidelines Give Clearer Guidance on Prostate Cancer Screening? JAMA Oncology 2024, 10: 1497-1498. PMID: 39325462, DOI: 10.1001/jamaoncol.2024.3909.
- Oh W, Agarwal N, Bryce A, Barata P, Bugler C, Carlsson S, Cornell B, Dahut W, George D, Loeb S, Montgomery B, Morris D, Mucci L, Omlin A, Palapattu G, Riaz I, Ryan C, Schoen M, Washington S, Gillessen S. What’s in a Name? Why Words Matter in Advanced Prostate Cancer. European Urology 2024, 87: 101-103. PMID: 39472202, DOI: 10.1016/j.eururo.2024.10.017.
- Lee K, Mai Y, Liu Z, Raja K, Jun T, Ma M, Wang T, Ai L, Calay E, Oh W, Schadt E, Wang X. CriteriaMapper: establishing the automatic identification of clinical trial cohorts from electronic health records by matching normalized eligibility criteria and patient clinical characteristics. Scientific Reports 2024, 14: 25387. PMID: 39455879, PMCID: PMC11511882, DOI: 10.1038/s41598-024-77447-x.
- Gillessen S, Turco F, Davis I, Efstathiou J, Fizazi K, James N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Zilli T, Agarwal N, Antonarakis E, Aparicio A, Armstrong A, Bastos D, Attard G, Axcrona K, Ayadi M, Beltran H, Bjartell A, Blanchard P, Bourlon M, Briganti A, Bulbul M, Buttigliero C, Caffo O, Castellano D, Castro E, Cheng H, Chi K, Clarke C, Clarke N, de Bono J, De Santis M, Duran I, Efstathiou E, Ekeke O, El Nahas T, Emmett L, Fanti S, Fatiregun O, Feng F, Fong P, Fonteyne V, Fossati N, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Hofman M, Hope T, Horvath L, Hussain M, Jereczek-Fossa B, Jones R, Joshua A, Kanesvaran R, Keizman D, Khauli R, Kramer G, Loeb S, Mahal B, Maluf F, Mateo J, Matheson D, Matikainen M, McDermott R, McKay R, Mehra N, Merseburger A, Morgans A, Morris M, Mrabti H, Mukherji D, Murphy D, Murthy V, Mutambirwa S, Nguyen P, Oh W, Ost P, O'Sullivan J, Padhani A, Parker C, Poon D, Pritchard C, Rabah D, Rathkopf D, Reiter R, Renard-Penna R, Ryan C, Saad F, Sade J, Sandhu S, Sartor O, Schaeffer E, Scher H, Sharifi N, Skoneczna I, Soule H, Spratt D, Srinivas S, Sternberg C, Suzuki H, Taplin M, Thellenberg-Karlsson C, Tilki D, Türkeri L, Uemura H, Ürün Y, Vale C, Vapiwala N, Walz J, Yamoah K, Ye D, Yu E, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). European Urology 2024, 87: 157-216. PMID: 39394013, DOI: 10.1016/j.eururo.2024.09.017.
- Chakrani Z, Patel M, Mellgard G, McCroskery S, Saffran N, Taylor N, Liaw B, Galsky M, Oh W, Tsao C, Ganta T, Patel V. The Association of Statin Use With Survival Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Androgen Receptor Targeted Therapies (ART). Clinical Genitourinary Cancer 2024, 22: 102227. PMID: 39437664, DOI: 10.1016/j.clgc.2024.102227.
- Leader A, Rebbeck T, Oh W, Patel A, Winer E, Bailey L, Gomella L, Lumpkins C, Garraway I, Aiello L, Baskin M, Cheng H, Cooney K, Ganzak A, George D, Halabi S, Hathaway F, Healy C, Kim J, Leapman M, Loeb S, Maxwell K, McNair C, Morgan T, Prindeville B, Soule H, Steward W, Suttiratana S, Taplin M, Yamoah K, Fortune T, Bennett K, Blanding-Godbolt J, Gross L, Giri V. Adaptation of the socioecological model to address disparities in engagement of Black men in prostate cancer genetic testing. BMC Public Health 2024, 24: 2533. PMID: 39289635, PMCID: PMC11409532, DOI: 10.1186/s12889-024-20008-8.
- Mellgard G, Saffran N, Chakrani Z, McCroskery S, Taylor N, Patel M, Liaw B, Galsky M, Oh W, Tsao C, Patel V. Performance Status and End-of-Life Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Androgen Receptor Targeted Therapy. American Journal Of Clinical Oncology 2024, 47: 459-464. PMID: 39087466, DOI: 10.1097/coc.0000000000001115.
- Lee K, Liu Z, Mai Y, Jun T, Ma M, Wang T, Ai L, Calay E, Oh W, Stolovitzky G, Schadt E, Wang X. Optimizing Clinical Trial Eligibility Design Using Natural Language Processing Models and Real-World Data: Algorithm Development and Validation. JMIR AI 2024, 3: e50800. PMID: 39073872, PMCID: PMC11319878, DOI: 10.2196/50800.
- Wang L, Izadmehr S, Sfakianos J, Tran M, Beaumont K, Brody R, Cordon-Cardo C, Horowitz A, Sebra R, Oh W, Bhardwaj N, Galsky M, Zhu J. Single-cell transcriptomic-informed deconvolution of bulk data identifies immune checkpoint blockade resistance in urothelial cancer. IScience 2024, 27: 109928. PMID: 38812546, PMCID: PMC11133924, DOI: 10.1016/j.isci.2024.109928.
- Garraway I, Carlsson S, Nyame Y, Vassy J, Chilov M, Fleming M, Frencher S, George D, Kibel A, King S, Kittles R, Mahal B, Pettaway C, Rebbeck T, Rose B, Vince R, Winn R, Yamoah K, Oh W. Prostate Cancer Foundation Screening Guidelines for Black Men in the United States. NEJM Evidence 2024, 3: evidoa2300289. PMID: 38815168, DOI: 10.1056/evidoa2300289.
- Chakrani Z, Mellgard G, Saffran N, McCroskery S, Taylor N, Patel M, Liaw B, Galsky M, Oh W, Tsao C, Patel V. Risk Factors for Early Treatment Discontinuation Due to Toxicity Among Patients With Metastatic Castration-resistant Prostate Cancer Receiving Androgen Receptor–targeted Therapy. American Journal Of Clinical Oncology 2024, 47: 271-278. PMID: 38344754, DOI: 10.1097/coc.0000000000001087.
- Liaw B, Joshi H, Sheng T, Tsao C, Galsky M, Bakst R, Stewart R, Stock R, Oh W. Final study analysis of PRINT: Prostate cancer intensive, non–cross-reactive therapy for CRPC. Journal Of Clinical Oncology 2024, 42: 147-147. DOI: 10.1200/jco.2024.42.4_suppl.147.
- Garraway I, Carlsson S, Nyame Y, Vassey J, Chilov M, Fleming M, Frencher S, George D, Kibel A, King S, Kittles R, Mahal B, Pettaway C, Rebbeck T, Rose B, Vince R, Winn R, Yamoah K, Oh W. Prostate Cancer Foundation (PCF) screening guidelines for prostate cancer in Black men in the United States. Journal Of Clinical Oncology 2024, 42: 264-264. DOI: 10.1200/jco.2024.42.4_suppl.264.
- Williams C, Starks D, Rojas-Espaillat L, Meissner T, Elsey R, Jun T, Solomon B, Feng S, Koenen M, van Oosbree A, Clem A, Lee J, Oh W. Comprehensive molecular profiling and deep clinical annotation of electronic health records in patients with cancer: Implementation of the Avera/Sema4 oncology and analytics protocol (ASAP) in gynecologic oncology (1255). Gynecologic Oncology 2023, 176: s161-s162. DOI: 10.1016/j.ygyno.2023.06.164.
- Lee K, Liu Z, Chandran U, Kalsekar I, Laxmanan B, Higashi M, Jun T, Ma M, Li M, Mai Y, Gilman C, Wang T, Ai L, Aggarwal P, Pan Q, Oh W, Stolovitzky G, Schadt E, Wang X. Detecting Ground Glass Opacity Features in Patients With Lung Cancer: Automated Extraction and Longitudinal Analysis via Deep Learning–Based Natural Language Processing. JMIR AI 2023, 2: e44537. PMID: 38875565, PMCID: PMC11041451, DOI: 10.2196/44537.
- Ganta T, Anker J, Miller E, Tsao K, Oh W. Real world utilization and outcomes of immunotherapy regimens in metastatic castration resistant prostate cancer (mCRPC). Journal Of Clinical Oncology 2023, 41: e17038-e17038. DOI: 10.1200/jco.2023.41.16_suppl.e17038.
- Liu Z, Lee K, Cohn D, Zhang M, Ai L, Li M, Zhang X, Jun T, Higashi M, Pan Q, Oh W, Stolovitzky G, Schadt E, Wang X, Li S. Analysis of real-world data to investigate evolving treatment sequencing patterns in advanced non-small cell lung cancers and their impact on survival. Journal Of Thoracic Disease 2023, 0: 0-0. PMID: 37324065, PMCID: PMC10267939, DOI: 10.21037/jtd-22-1481.
- Gillessen S, Bossi A, Davis I, de Bono J, Fizazi K, James N, Mottet N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Antonarakis E, Aparicio A, Armstrong A, Attard G, Beer T, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow R, Bulbul M, Caffo O, Castellano D, Castro E, Cheng H, Chi K, Chowdhury S, Clarke C, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke O, Evans C, Fanti S, Feng F, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman M, Horvath L, Hussain M, Jereczek-Fossa B, Jones R, Kanesvaran R, Kellokumpu-Lehtinen P, Khauli R, Klotz L, Kramer G, Leibowitz R, Logothetis C, Mahal B, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans A, Morris M, Mrabti H, Mukherji D, Murphy D, Murthy V, Nguyen P, Oh W, Ost P, O'Sullivan J, Padhani A, Pezaro C, Poon D, Pritchard C, Rabah D, Rathkopf D, Reiter R, Rubin M, Ryan C, Saad F, Sade J, Sartor O, Scher H, Sharifi N, Skoneczna I, Soule H, Spratt D, Srinivas S, Sternberg C, Steuber T, Suzuki H, Sydes M, Taplin M, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale C, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu E, Zapatero A, Zilli T, Omlin A. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. European Journal Of Cancer 2023, 185: 178-215. PMID: 37003085, DOI: 10.1016/j.ejca.2023.02.018.
- Mellgard G, Chakrani Z, Mccroskery S, Saffran N, Taylor N, Liaw B, Galsky M, Oh W, Tsao K, Patel V. Survival outcomes and toxicity in older adults with metastatic castration-resistant prostate cancer (mCRPC) treated with androgen receptor targeted (ART) therapies. Journal Of Clinical Oncology 2023, 41: 117-117. DOI: 10.1200/jco.2023.41.6_suppl.117.
- Mellgard G, Mccroskery S, Chakrani Z, Saffran N, Taylor N, Liaw B, Galsky M, Oh W, Tsao K, Patel V. Clinical characteristics and outcomes of trial-ineligible patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving androgen receptor targeted (ART) therapy. Journal Of Clinical Oncology 2023, 41: 118-118. DOI: 10.1200/jco.2023.41.6_suppl.118.
- Chakrani Z, Mellgard G, Mccroskery S, Saffran N, Taylor N, Liaw B, Oh W, Tsao K, Patel V. Risk factors for treatment (tx) toxicity and discontinuation among patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) on androgen receptor targeted therapy (ART). Journal Of Clinical Oncology 2023, 41: 135-135. DOI: 10.1200/jco.2023.41.6_suppl.135.
- Ganta T, Anker J, Miller E, Kannry J, Bhardwaj A, Tsao K, Oh W. Oncologist-driven development of an electronic health record (EHR) clinical data visualization tool for prostate cancer. Journal Of Clinical Oncology 2023, 41: 267-267. DOI: 10.1200/jco.2023.41.6_suppl.267.
- Liaw B, Tsao C, Seng S, Jun T, Gong Y, Galsky M, Oh W. Biomarker Development Trial of Satraplatin in Patients with Metastatic Castration-Resistant Prostate Cancer. The Oncologist 2022, 28: 366-e224. PMID: 36519763, PMCID: PMC10078918, DOI: 10.1093/oncolo/oyac224.
- Gillessen S, Bossi A, Davis I, de Bono J, Fizazi K, James N, Mottet N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Antonarakis E, Aparicio A, Armstrong A, Attard G, Beer T, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow R, Bulbul M, Caffo O, Castellano D, Castro E, Cheng H, N. K, Chowdhury S, Clarke C, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke O, Evans C, Fanti S, Feng F, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman M, Horvath L, Hussain M, Jereczek-Fossa B, Jones R, Kanesvaran R, Kellokumpu-Lehtinen P, Khauli R, Klotz L, Kramer G, Leibowitz R, Logothetis C, Mahal B, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans A, Morris M, Mrabti H, Mukherji D, Murphy D, Murthy V, Nguyen P, Oh W, Ost P, O’Sullivan J, Padhani A, Pezaro C, Poon D, Pritchard C, Rabah D, Rathkopf D, Reiter R, Rubin M, Ryan C, Saad F, Sade J, Sartor O, Scher H, Sharifi N, Skoneczna I, Soule H, Spratt D, Srinivas S, Sternberg C, Steuber T, Suzuki H, Sydes M, Taplin M, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale C, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu E, Zapatero A, Zilli T, Omlin A. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. European Urology 2022, 83: 267-293. PMID: 36494221, PMCID: PMC7614721, DOI: 10.1016/j.eururo.2022.11.002.
- Al-Kateb H, Jun T, Hayes J, Rossi M, Hantash F, Oh W, Onel K. Prevalence of Pathogenic Germline Mutations in Solid Tumor Predisposition Genes Detected By Tumor-Normal Whole Exome Sequencing Analysis Among Adults with Hematologic Malignancies. Blood 2022, 140: 7852-7853. DOI: 10.1182/blood-2022-159618.
- Lee K, Paek H, Ai L, Liu Z, Jin L, Li M, Jun T, Higashi M, Onel K, Oh W, Pan Q, Stolovitzky G, Schadt E, Wang X. Treatment Profile of CAR-T Cell Therapy Induced Cytokine Release Syndrome and Neurotoxicity: Insights from Real-World Evidence. Blood 2022, 140: 12750-12752. DOI: 10.1182/blood-2022-166716.
- Higashi M, Kruszka P, Francis M, Parsons K, Oh W, Onel K. Pediatric Age at Hematopoietic Stem Cell Transplant: Associations with Non-Malignant Genetic Disease and Race. Blood 2022, 140: 7973-7974. DOI: 10.1182/blood-2022-170315.
- Calvo M, Caruthers S, Tripodi J, Houldsworth J, Fink M, Newman S, Chen R, Zhang W, Liu L, Shi Y, Jun T, Onel K, Oh W, Edelmann L, Schadt E, Rossi M, Hantash F, Al-Kateb H. 61. Clinical whole exome/whole transcriptome analysis detects clinically relevant structural alterations in Multiple Myeloma. Cancer Genetics 2022, 268: 20. DOI: 10.1016/j.cancergen.2022.10.064.
- Griffin J, Tsao C, Patel V, Liaw B, Guin S, Joshi H, Rossi M, Hantash F, Zhou X, Tewari A, Galsky M, Oh W, Chen R, Jun T. Clinical actionability and utilization of next-generation sequencing for prostate cancer in a changing treatment landscape. Frontiers In Urology 2022, 2: 997396. DOI: 10.3389/fruro.2022.997396.
- Jin L, Govindaraj S, Liu Z, Ai L, Higashi M, Jun T, Lee K, Raja K, Zhang X, Li M, Calay E, Savic R, Ghosh K, Kasarskis A, Pan Q, Oh W, Stolovitzky G, Schadt E, Wang X. Seasonal variations of hospitalizations for chronic rhinosinusitis by different endotypes. ISEE Conference Abstracts 2022, 2022 DOI: 10.1289/isee.2022.p-1062.
- Mellgard G, Chakrani Z, McCroskery S, Saffran N, Taylor N, Liaw B, Galsky M, Oh W, Tsao C, Patel V. 1274P Performance status (PS) and end-of-life (EOL) care in patients (pts) with metastatic prostate cancer (mPC) treated with androgen receptor targeted (ART) therapy. Annals Of Oncology 2022, 33: s1129. DOI: 10.1016/j.annonc.2022.07.1407.
- Guin S, Liaw B, Jun T, Ayers K, Patel B, O’Connell T, Deitz M, Klein M, Mullaney T, Prentice T, Newman S, Fink M, Zhou X, Schadt E, Chen R, Oh W. Management of de novo metastatic hormone-sensitive prostate cancer: A comprehensive report of a single-center experience. PLOS ONE 2022, 17: e0264800. PMID: 35984843, PMCID: PMC9390935, DOI: 10.1371/journal.pone.0264800.
- Qin Q, Jun T, Wang B, Patel V, Mellgard G, Zhong X, Gogerly-Moragoda M, Parikh A, Leiter A, Gallagher E, Alerasool P, Garcia P, Joshi H, MBBS, Galsky M, Oh W, Tsao C. Clinical factors associated with outcome in solid tumor patients treated with immune-checkpoint inhibitors: a single institution retrospective analysis. Discover Oncology 2022, 13: 73. PMID: 35960456, PMCID: PMC9374856, DOI: 10.1007/s12672-022-00538-6.
- Mellgard G, Patel V, Zhong X, Joshi H, Qin Q, Wang B, Parikh A, Jun T, Alerasool P, Garcia P, Gogerly-Moragoda M, Leiter A, Gallagher E, Oh W, Galsky M, Tsao C. Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors. Journal Of Cancer Research And Clinical Oncology 2022, 149: 2833-2841. PMID: 35788726, PMCID: PMC10739778, DOI: 10.1007/s00432-022-04159-y.
- Jun T, Oh W. Does Circulating Tumor DNA Measure Up to Prostate-Specific Antigen? JAMA Oncology 2022, 8: 972-974. PMID: 35551363, DOI: 10.1001/jamaoncol.2022.0511.
- Guin S, Jun T, Patel V, Ayers K, Deitz M, Cai Y, Zhou X, Tsao C, Oh W, Chen R, Liaw B. Extraction of Treatment Information From Electronic Health Records and Evaluation of Testosterone Recovery in Patients With Prostate Cancer. JCO Clinical Cancer Informatics 2022, 6: e2200010. PMID: 35696627, PMCID: PMC9225507, DOI: 10.1200/cci.22.00010.
- Kier M, Li Z, Casasanta N, Patel R, Agarwal P, Zimmerman B, Yang Y, Fink M, Zhou X, Newman S, Chen R, Schadt E, Oh W, Tiersten A. Socioeconomic disparities in supportive therapy use and tolerance of aromatase inhibitors in patients with early-stage, hormone-positive breast cancer. Journal Of Clinical Oncology 2022, 40: 523-523. DOI: 10.1200/jco.2022.40.16_suppl.523.
- Karagoz K, Ayers K, Patel B, Wells J, Newman S, Oh W, Zhou X, Chen R, Guin S. Analysis of genomic alterations and treatment landscape in patients with advanced tumors using real-world data for precision oncology. Journal Of Clinical Oncology 2022, 40: 6584-6584. DOI: 10.1200/jco.2022.40.16_suppl.6584.
- Williams C, Karagoz K, Elsey R, Meißner T, Higashi M, Schadt E, Jun T, Wang X, Chen R, Zhou X, Guin S, Lee J, Oh W. QOPI Clinical Informatics: A digital platform to enable real-time quality reporting, clinical decision support, and rapid learning. Journal Of Clinical Oncology 2022, 40: e13545-e13545. DOI: 10.1200/jco.2022.40.16_suppl.e13545.
- Lee K, Cohn D, Liu Z, Ai L, Paek H, Jin L, Raja K, Li M, Zhang X, Jun T, Higashi M, Oh W, Calay E, Savic R, Ghosh K, Kasarskis A, Mullaney T, Pan Q, Schadt E, Wang X. Phenotypic and endotypic features of COPD associated with lung cancer development. Journal Of Clinical Oncology 2022, 40: e13563-e13563. DOI: 10.1200/jco.2022.40.16_suppl.e13563.
- Williams C, Guin S, Elsey R, Meißner T, Xu B, Sun Y, Amallraja A, Jun T, Schadt E, Chen R, Zhou X, Higashi M, Lee J, Oh W. Landscape of tumor genetic testing and targeted therapies over an eight-year span in a rural population. Journal Of Clinical Oncology 2022, 40: e15036-e15036. DOI: 10.1200/jco.2022.40.16_suppl.e15036.
- Patel K, Oh W, Jun T, Naidu S, Nathwani N, Hansen G, Hubert A, Mukhi H, Chhadwa S, Zabala V, Gill S, Branchcomb R, Mehta D, Nixon S, Kodali A, Zimmerman M. Clinical utility of widespread germline testing of cancer patients in a diverse community cancer clinic. Journal Of Clinical Oncology 2022, 40: e18537-e18537. DOI: 10.1200/jco.2022.40.16_suppl.e18537.
- Patel K, Jun T, Chhadwa S, Zabala V, Gill S, Branchcomb R, Naidu S, Nathwani N, Hansen G, Hubbert A, Mukhi H, Mehta D, Nixon S, Kodali A, Zimmerman M, Hantash F, Oh W. Social determinants of health in a prospective study of whole-exome sequencing in advanced cancer patients from underserved communities. Journal Of Clinical Oncology 2022, 40: e18539-e18539. DOI: 10.1200/jco.2022.40.16_suppl.e18539.
- Jun T, Oh W, Schadt E, Higashi M. Health outcomes modelling of RNA-based versus DNA-based detection of driver gene rearrangements in non-small cell lung cancer. Journal Of Clinical Oncology 2022, 40: e18837-e18837. DOI: 10.1200/jco.2022.40.16_suppl.e18837.
- Williams C, Starks D, Elsey R, Meissner T, Solomon B, Albano M, Hantash F, Schadt E, Rojas-Espaillat L, Lee J, Oh W. Implementation of the Avera/Sema4 oncology and analytics protocol (ASAP). Journal Of Clinical Oncology 2022, 40: tps6605-tps6605. DOI: 10.1200/jco.2022.40.16_suppl.tps6605.
- Ai L, Higashi M, Lee K, Liu Z, Jin L, Raja K, Mai Y, Jun T, Oh W, Beckmann A, Schadt E, Schadt Z, Wallsten R, Calay E, Kasarskis A, Pan Q, Schadt E, Wang X. AB0227 TREATMENT SEQUENCING PATTERNS AND COMPARATIVE EFFICACY IN PATIENTS WITH RHEUMATOID ARTHRITIS FROM A REAL-WORLD SETTING. Annals Of The Rheumatic Diseases 2022, 81: 1241. DOI: 10.1136/annrheumdis-2022-eular.4655.
- Lee K, Liu Z, Ma M, Chandran U, Kalsekar I, Laxmanan B, Li M, Mai Y, Gilman C, Wang T, Zhang M, Ai L, Aggarwal P, Pan Q, Oh W, Schadt E, Wang X. Automated Extraction and Longitudinal Analysis of Ground Glass OpacityFeatures in Lung Cancer Patients Powered by Natural Language Processing. 2022, a5077-a5077. DOI: 10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a5077.
- Shah N, Patel V, Zhong X, Pina L, Hawley J, Lin E, Gartrell B, Febles V, Wise D, Qin Q, Mellgard G, Joshi H, Nauseef J, Green D, Vlachostergios P, Kwon D, Huang F, Liaw B, Tagawa S, Kantoff P, Morris M, Oh W. The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer. JNCI Cancer Spectrum 2022, 6: pkac035. PMID: 35657341, PMCID: PMC9165550, DOI: 10.1093/jncics/pkac035.
- Griffin J, Jun T, Guin S, Liaw B, Patel V, Tsao C, Rossi M, Chen R, Zhou X, Hantash F, Oh W. MP27-10 CLINICAL UTILITY OF NEXT-GENERATION SEQUENCING FOR PROSTATE CANCER IN THE CONTEXT OF A CHANGING TREATMENT LANDSCAPE. Journal Of Urology 2022, 207: e453. DOI: 10.1097/ju.0000000000002570.10.
- Rettig M, Beltran H, Oh W. Factors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer. Clinical Advances In Hematology And Oncology 2022, 20 Suppl 9: 1-20. PMID: 35579577.
- Oh W. Clinical observations regarding the use of androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer. Clinical Advances In Hematology And Oncology 2022, 20 Suppl 9: 13-16. PMID: 35579580.
- Oh W, Rettig M. Factors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer: Q&A. Clinical Advances In Hematology And Oncology 2022, 20 Suppl 9: 16-17. PMID: 35579581.
- Jun T, Hahn N, Sonpavde G, Albany C, MacVicar G, Hauke R, Fleming M, Gourdin T, Jana B, Oh W, Taik P, Wang H, Varadarajan A, Uzilov A, Galsky M. Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma. The Oncologist 2022, 27: 432-e452. PMID: 35438782, PMCID: PMC9177111, DOI: 10.1093/oncolo/oyab075.
- Gillessen S, Armstrong A, Attard G, Beer T, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow R, Bulbul M, Caffo O, Chi K, Clarke C, Clarke N, Davis I, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke O, Evans C, Fanti S, Feng F, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman M, Hussain M, James N, Jones R, Kanesvaran R, Khauli R, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans A, Morris M, Mottet N, Mrabti H, Murphy D, Murthy V, Oh W, Ost P, O'Sullivan J, Padhani A, Parker C, Poon D, Pritchard C, Rabah D, Rathkopf D, Reiter R, Rubin M, Ryan C, Saad F, Sade J, Sartor O, Scher H, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg C, Suzuki H, Sweeney C, Sydes M, Taplin M, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology 2022, 82: 115-141. PMID: 35450732, DOI: 10.1016/j.eururo.2022.04.002.
- Turco F, Armstrong A, Attard G, Beer T, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow R, Bulbul M, Caffo O, Chi K, Clarke C, Clarke N, Davis I, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Evans C, Fanti S, Feng F, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman M, Hussain M, James N, Jones R, Kanesvaran R, Khauli R, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans A, Morris M, Mottet N, Mrabti H, Murphy D, Murthy V, Oh W, Ekeke O, Ost P, O'Sullivan J, Padhani A, Parker C, Poon D, Pritchard C, Rabah D, Rathkopf D, Reiter R, Rubin M, Ryan C, Saad F, Sade J, Sartor O, Scher H, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg C, Suzuki H, Sweeney C, Sydes M, Taplin M, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Gillessen S, Omlin A. Corrigendum to “What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021” [Eur Urol 82(1):6–11]. European Urology 2022, 82: e18-e19. PMID: 35440417, PMCID: PMC9012951, DOI: 10.1016/j.eururo.2022.04.004.
- Mack P, Klein M, Ayers K, Zhou X, Guin S, Fink M, Rossi M, AI-Kateb H, O’Connell T, Hantash F, Oh W, Newman S, Schadt E, Chen R, Hirsch F. Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma. The Oncologist 2022, 27: 476-486. PMID: 35298662, PMCID: PMC9177106, DOI: 10.1093/oncolo/oyac035.
- Yu H, Tuminello S, Alpert N, van Gerwen M, Yoo S, Mulholland D, Aaronson S, Donovan M, Oh W, Gong Y, Wang L, Zhu J, Taioli E. Global DNA methylation of WTC prostate cancer tissues show signature differences compared to non-exposed cases. Carcinogenesis 2022, 43: 528-537. PMID: 35239955, PMCID: PMC9234756, DOI: 10.1093/carcin/bgac025.
- Li S, Jun T, Tyler J, Schadt E, Kao Y, Wang Z, Konig M, Bettegowda C, Vogelstein J, Papadopoulos N, Parsons R, Chen R, Schadt E, Li L, Oh W. Inpatient Administration of Alpha-1-Adrenergic Receptor Blocking Agents Reduces Mortality in Male COVID-19 Patients. Frontiers In Medicine 2022, 9: 849222. PMID: 35295598, PMCID: PMC8919772, DOI: 10.3389/fmed.2022.849222.
- Welén K, Rosendal E, Freyhult E, Oh W, Gisslén M, Ahlm C, Connolly A, Överby A, Josefsson A. Reply to Carlos G. Wambier and Gerard J. Nau’s Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients Still No Positive Effect of Enzalutamide for Hospitalized COVID-19 Patients. European Urology 2022, 81: e143-e144. PMID: 35248411, PMCID: PMC8864103, DOI: 10.1016/j.eururo.2022.02.016.
- Griffin J, Jun T, Liaw B, Guin S, Tsao C, Patel V, Rossi M, Zhou X, Hantash F, Chen R, Oh W. Clinical utility of next-generation sequencing for prostate cancer in the context of a changing treatment landscape. Journal Of Clinical Oncology 2022, 40: 112-112. DOI: 10.1200/jco.2022.40.6_suppl.112.
- Turco F, Armstrong A, Attard G, Beer T, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow R, Bulbul M, Caffo O, Chi K, Clarke C, Clarke N, Davis I, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Evans C, Fanti S, Feng F, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman M, Hussain M, James N, Jones R, Kanesvaran R, Khauli R, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans A, Morris M, Mottet N, Mrabti H, Murphy D, Murthy V, Oh W, Ekeke Onyeanunam N, Ost P, O'Sullivan J, Padhani A, Parker C, Poon D, Pritchard C, Rabah D, Rathkopf D, Reiter R, Rubin M, Ryan C, Saad F, Pablo Sade J, Sartor O, Scher H, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg C, Suzuki H, Sweeney C, Sydes M, Taplin M, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Gillessen S, Omlin A. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology 2022, 82: 6-11. PMID: 35393158, PMCID: PMC8849852, DOI: 10.1016/j.eururo.2022.02.010.
- Patel R, Li Z, Zimmerman B, Fink M, Wells J, Zhou X, Ayers K, Redfern A, Newman S, Schadt E, Oh W, Chen R, Tiersten A. Impact of body mass index on the efficacy of aromatase inhibitors in patients with metastatic breast cancer. Breast Cancer Research And Treatment 2022, 192: 313-319. PMID: 35006484, DOI: 10.1007/s10549-021-06504-0.
- Mirza H, Garcia J, Bell C, Jones K, Flynn V, Pepe J, Oh W. Fluid Intake in the First Week of Life and the Duration of Hemodynamically Significant Patent Ductus Arteriosus in Extremely Preterm Infants. American Journal Of Perinatology 2021, 40: 1345-1350. PMID: 34384119, DOI: 10.1055/a-1585-6093.
- Evolving Patterns of Metastasis in Renal Cell Carcinoma: Do We Need to Perform Routine Bone Imaging?Lin J, Zhang Y, Hou W, Qin Q, Galsky M, Oh W, Tsao C. Evolving Patterns of Metastasis in Renal Cell Carcinoma: Do We Need to Perform Routine Bone Imaging? Journal Of Kidney Cancer And VHL 2021, 8: 13-19. PMID: 34722126, PMCID: PMC8523177, DOI: 10.15586/jkcvhl.v8i4.202.
- Cirulli G, Martini A, Gandaglia G, Fossati N, Necchi A, Raggi D, Stabile A, Cucchiara V, Leni R, Robesti D, Pellegrino F, Nocera L, Scuderi S, Karakiewicz P, Galsky M, Oh W, Sfakianos J, Parikh A, Tsao C, Montorsi F, Briganti A. SC206 The obesity paradox in metastatic castration resistant prostate cancer. European Urology Open Science 2021, 32: s101. DOI: 10.1016/s2666-1683(21)00897-1.
- Izadmehr S, Lundon D, Mohamed N, Katims A, Patel V, Eilender B, Mehrazin R, Badani K, Sfakianos J, Tsao C, Wiklund P, Oh W, Cordon-Cardo C, Tewari A, Galsky M, Kyprianou N. The Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic. Frontiers In Oncology 2021, 11: 734963. PMID: 34646777, PMCID: PMC8504458, DOI: 10.3389/fonc.2021.734963.
- Mirza H, Garcia J, Bell C, Jones K, Flynn V, Pepe J, Oh W. Fluid Intake in the First Week of Life and the Duration of Hemodynamically Significant Patent Ductus Arteriosus in Extremely Preterm Infants. American Journal Of Perinatology 2021 DOI: 10.1055/s-0041-1735623.
- Martini A, Cirulli G, Gandaglia G, Fossati N, Necchi A, Stabile A, Cucchiara V, Mazzone E, Karakiewicz P, Sfakianos J, Galsky M, Oh W, Gallagher E, Montorsi F, Briganti A. PD05-01 THE OBESITY PARADOX IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER. Journal Of Urology 2021, 206: e55-e55. DOI: 10.1097/ju.0000000000001969.01.
- Martini A, Cirulli G, Parikh A, Sfakianos J, Galsky M, Oh W, Tsao C, Gandaglia G, Fossati N, Stabile A, Necchi A, Cucchiara V, Pellegrino F, Scuderi S, Karakiewicz P, Montorsi F, Briganti A. MP24-09 BALANCING EFFICACY AND TOXICITY OF DOCETAXEL IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER. RESULTS FROM A POOLED ANALYSIS OF THREE PROSPECTIVE RANDOMIZED TRIALS. Journal Of Urology 2021, 206: e415-e415. DOI: 10.1097/ju.0000000000002015.09.
- Mack P, Klein M, Ayers K, Uzilov A, Zhou X, Corrigan D, Dietz M, Fink M, Guin S, Kip N, Rossi M, Oh W, Hantash F, Newman S, Schadt E, Chen R, Hirsch F. 1271P Molecular driver mutations in never-smokers with lung adenocarcinoma. Annals Of Oncology 2021, 32: s993. DOI: 10.1016/j.annonc.2021.08.1873.
- Riddle M, Cefalu W, Evans P, Gerstein H, Nauck M, Oh W, Rothberg A, le Roux C, Rubino F, Schauer P, Taylor R, Twenefour D. Consensus report: definition and interpretation of remission in type 2 diabetes. Diabetologia 2021, 64: 2359-2366. PMID: 34458934, DOI: 10.1007/s00125-021-05542-z.
- Riddle M, Cefalu W, Evans P, Gerstein H, Nauck M, Oh W, Rothberg A, le Roux C, Rubino F, Schauer P, Taylor R, Twenefour D. Consensus report: Definition and interpretation of remission in type 2 diabetes. Diabetic Medicine 2021, 39: e14669. PMID: 34460965, DOI: 10.1111/dme.14669.
- Riddle M, Cefalu W, Evans P, Gerstein H, Nauck M, Oh W, Rothberg A, le Roux C, Rubino F, Schauer P, Taylor R, Twenefour D. Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. The Journal Of Clinical Endocrinology & Metabolism 2021, 107: 1-9. PMID: 34459898, PMCID: PMC8825709, DOI: 10.1210/clinem/dgab585.
- Riddle M, Cefalu W, Evans P, Gerstein H, Nauck M, Oh W, Rothberg A, le Roux C, Rubino F, Schauer P, Taylor R, Twenefour D. Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. Diabetes Care 2021, 44: 2438-2444. PMID: 34462270, PMCID: PMC8929179, DOI: 10.2337/dci21-0034.
- Koshkin V, Patel V, Ali A, Bilen M, Ravindranathan D, Park J, Kellezi O, Cieslik M, Shaya J, Cabal A, Brown L, Labriola M, Graham L, Pritchard C, Tripathi A, Nusrat S, Barata P, Jang A, Chen S, Garje R, Acharya L, Hwang C, Pilling A, Oh W, Jun T, Natesan D, Nguyen C, Kilari D, Pierro M, Thapa B, Cackowski F, Mack A, Heath E, Marshall C, Tagawa S, Halabi S, Schweizer M, Armstrong A, Dorff T, Alva A, McKay R. PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. Prostate Cancer And Prostatic Diseases 2021, 25: 388-396. PMID: 34363009, PMCID: PMC9385488, DOI: 10.1038/s41391-021-00433-1.
- Singh D, Patel V, Oh W, Aguirre-Ghiso J. Prostate Cancer Dormancy and Reactivation in Bone Marrow. Journal Of Clinical Medicine 2021, 10: 2648. PMID: 34208521, PMCID: PMC8234151, DOI: 10.3390/jcm10122648.
- Cirulli G, Martini A, Sfakianos J, Gandaglia G, Fossati N, Stabile A, Cucchiara V, Mazzone E, Necchi A, Karakiewicz P, Briganti A, Montorsi F, Oh W, Gallagher E, Galsky M. P0855 The obesity paradox in metastatic castration resistant prostate cancer. European Urology 2021, 79: s1195-s1196. DOI: 10.1016/s0302-2838(21)01229-x.
- Cirulli G, Martini A, Pellegrino F, Scuderi S, Parikh A, Oh W, Sfakianos J, Karakiewicz P, Galsky M, Tsao C, Cucchiara V, Stabile A, Gandaglia G, Fossati N, Necchi A, Montorsi F, Briganti A. P0860 Balancing efficacy and toxicity of docetaxel in patients with metastatic castration-resistant prostate cancer. Results from a pooled analysis of three prospective randomized trials. European Urology 2021, 79: s1203-s1204. DOI: 10.1016/s0302-2838(21)01234-3.
- A Rapid Guidance Process for the Development of an Anticoagulation Protocol in the COVID-19 PandemicTremblay D, Dunn A, Oh W. A Rapid Guidance Process for the Development of an Anticoagulation Protocol in the COVID-19 Pandemic. Quality Management In Health Care 2021, 30: 276-279. PMID: 34048378, PMCID: PMC8462300, DOI: 10.1097/qmh.0000000000000324.
- Liaw B, Zhong X, Tsao C, Bakst R, Stewart R, Stock R, Galsky M, Oh W. Prostate cancer intensive, non-cross reactive therapy (PRINT) for CRPC: Interim analysis of efficacy endpoints. Journal Of Clinical Oncology 2021, 39: e17027-e17027. DOI: 10.1200/jco.2021.39.15_suppl.e17027.
- Liaw B, Guin S, Jun T, Ayers K, Patel B, O'Connell T, Dietz M, Klein M, Prentice T, Newman S, Fink M, Zhou X, Schadt E, Chen R, Oh W. Comparative efficacy of docetaxel versus novel hormonal agent in de novo metastatic hormone-sensitive prostate cancer: Real-world data curated by deidentified chart abstraction. Journal Of Clinical Oncology 2021, 39: e17047-e17047. DOI: 10.1200/jco.2021.39.15_suppl.e17047.
- Ayers K, Mullaney T, Zhou X, Liu J, Lee K, Ma M, Jones S, Li L, Redfern A, Jappe W, Liu Z, Goldsweig H, Yadav K, Hahner N, Dietz M, Zimmerman M, Prentice T, Newman S, Veluswamy R, Wisnivesky J, Hirsch F, Oh W, Li S, Schadt E, Chen R. Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers. The Oncologist 2021, 26: e1226-e1239. PMID: 33829580, PMCID: PMC8265370, DOI: 10.1002/onco.13780.
- Bikkasani K, Qin Q, Zhong X, Lin J, Galsky M, Oh W, Tsao C. Characterizing Prostate-Specific Antigen Levels at Death in Patients with Metastatic Castration-Resistant Prostate Cancer: Are We Underutilizing Imaging? Clinical Genitourinary Cancer 2021, 19: e346-e351. PMID: 34011488, DOI: 10.1016/j.clgc.2021.04.003.
- Wang L, Sfakianos J, Beaumont K, Akturk G, Horowitz A, Sebra R, Farkas A, Gnjatic S, Hake A, Izadmehr S, Wiklund P, Oh W, Szabo P, Wind-Rotolo M, Unsal-Kacmaz K, Yao X, Schadt E, Sharma P, Bhardwaj N, Zhu J, Galsky M. Myeloid Cell–associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing. Clinical Cancer Research 2021, 27: 4287-4300. PMID: 33837006, PMCID: PMC8338756, DOI: 10.1158/1078-0432.ccr-20-4574.
- Patel V, Zhong X, Shah N, Pina Martina L, Hawley J, Lin E, Gartrell B, Adorno Febles V, Wise D, Qin Q, Mellgard G, Nauseef J, Green D, Vlachostergios P, Kwon D, Huang F, Liaw B, Tagawa S, Morris M, Oh W. The role of androgen deprivation therapy on the clinical course of COVID-19 infection in men with prostate cancer. Journal Of Clinical Oncology 2021, 39: 41-41. DOI: 10.1200/jco.2021.39.6_suppl.41.
- Martini A, Parikh A, Sfakianos J, Montorsi F, Galsky M, Oh W, Tsao C. Predicting toxicity-related docetaxel discontinuation and overall survival in metastatic castration-resistant prostate cancer: a pooled analysis of open phase 3 clinical trial data. Prostate Cancer And Prostatic Diseases 2021, 24: 743-749. PMID: 33531652, DOI: 10.1038/s41391-021-00326-3.
- Parikh A, Zhong X, Mellgard G, Qin Q, Patel V, Wang B, Alerasool P, Garcia P, Leiter A, Gallagher E, Clinton S, Mortazavi A, Monk P, Folefac E, Yin M, Yang Y, Galsky M, Oh W, Tsao C. Risk Factors for Emergency Room and Hospital Care Among Patients With Solid Tumors on Immune Checkpoint Inhibitor Therapy. American Journal Of Clinical Oncology 2021, 44: 114-120. PMID: 33417323, PMCID: PMC7902456, DOI: 10.1097/coc.0000000000000793.
- Mateo J, McKay R, Abida W, Aggarwal R, Alumkal J, Alva A, Feng F, Gao X, Graff J, Hussain M, Karzai F, Montgomery B, Oh W, Patel V, Rathkopf D, Rettig M, Schultz N, Smith M, Solit D, Sternberg C, Van Allen E, VanderWeele D, Vinson J, Soule H, Chinnaiyan A, Small E, Simons J, Dahut W, Miyahira A, Beltran H. Accelerating precision medicine in metastatic prostate cancer. Nature Cancer 2020, 1: 1041-1053. PMID: 34258585, PMCID: PMC8274325, DOI: 10.1038/s43018-020-00141-0.
- Wang Z, Zheutlin A, Kao Y, Ayers K, Gross S, Kovatch P, Nirenberg S, Charney A, Nadkarni G, De Freitas J, O’Reilly P, Just A, Horowitz C, Martin G, Branch A, Glicksberg B, Charney D, Reich D, Oh W, Schadt E, Chen R, Li L. Hospitalised COVID-19 patients of the Mount Sinai Health System: a retrospective observational study using the electronic medical records. BMJ Open 2020, 10: e040441. PMID: 33109676, PMCID: PMC7592304, DOI: 10.1136/bmjopen-2020-040441.
- Martini A, Parikh A, Gandaglia G, Fossati N, Fallara G, Barletta F, Scuderi S, Robesti D, Cannoletta D, Leni R, Cucchiara V, Bravi C, Mazzone E, Rosiello G, Basile G, Nocera L, Necchi A, Moschini M, Sfakianos J, Galsky M, Oh W, Tsao C, Montorsi F, Briganti A. SC241 Predicting toxicity-related Docetaxel discontinuation and survival in metastatic castration-resistant prostate cancer using open phase 3 trial data. European Urology Open Science 2020, 20: s141-s142. DOI: 10.1016/s2666-1683(20)35563-4.
- Cignoli D, Martini A, Sfakianos J, Gandaglia G, Fossati N, Salonia A, Barletta F, Scuderi S, Robesti D, Bravi C, Mazzone E, Rosiello G, Fallara G, Nocera L, Cirulli G, Stabile A, Briganti A, Montorsi F, Oh W, Gallagher E, Galsky M. SC56 The inverse correlation between obesity and mortality in patients with metastatic castration resistant prostate cancer: Results from the control arms of ASCENT2, MAINSAL and VENICE trials. European Urology Open Science 2020, 20: s55-s56. DOI: 10.1016/s2666-1683(20)35378-7.
- Marco B, Martini A, Pfail J, Gandaglia G, Fossati N, Scuderi S, Fallara G, Barletta F, Robesti D, Rizzo A, Basile G, Bravi C, Rosiello G, Nocera L, Stabile A, Gallina A, Salonia A, Montorsi F, Briganti A, Galsky M, Oh W. SC242 Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial. European Urology Open Science 2020, 20: s142. DOI: 10.1016/s2666-1683(20)35564-6.
- Schmid S, Omlin A, Higano C, Sweeney C, Chanza N, Mehra N, Kuppen M, Beltran H, Condeduca V, de Almeida D, Maluf F, Oh W, Tsao C, Sartor O, Ledet E, Di Lorenzo G, Yip S, N. K, Bianchini D, De Giorgi U, Hansen A, Beer T, Pernelle L, Morales-Barrera R, Tucci M, Castro E, Karalis K, Bergman A, Le M, Zürrer-Härdi U, Pezaro C, Suzuki H, Zivi A, Klingbiel D, Schär S, Gillessen S. Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. JAMA Network Open 2020, 3: e2021692. PMID: 33112397, PMCID: PMC7593810, DOI: 10.1001/jamanetworkopen.2020.21692.
- Lowrance W, Breau R, Chou R, Chapin B, Crispino T, Dreicer R, Jarrard D, Kibel A, Morgan T, Morgans A, Oh W, Resnick M, Zietman A, Cookson M. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II. Journal Of Urology 2020, 205: 22-29. PMID: 32960678, DOI: 10.1097/ju.0000000000001376.
- Lowrance W, Breau R, Chou R, Chapin B, Crispino T, Dreicer R, Jarrard D, Kibel A, Morgan T, Morgans A, Oh W, Resnick M, Zietman A, Cookson M. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I. Journal Of Urology 2020, 205: 14-21. PMID: 32960679, DOI: 10.1097/ju.0000000000001375.
- Patel V, Oh W, Galsky M. Treatment of muscle‐invasive and advanced bladder cancer in 2020. CA A Cancer Journal For Clinicians 2020, 70: 404-423. PMID: 32767764, DOI: 10.3322/caac.21631.
- Abramson D, Fallon J, Biran N, Francis J, Jaben K, Oh W. Lacrimal sac adenocarcinoma managed with androgen deprivation. American Journal Of Ophthalmology Case Reports 2020, 19: 100607. PMID: 32760849, PMCID: PMC7393461, DOI: 10.1016/j.ajoc.2020.100607.
- Patel V, Zhong X, Liaw B, Tremblay D, Tsao C, Galsky M, Oh W. Does androgen deprivation therapy protect against severe complications from COVID-19? Annals Of Oncology 2020, 31: 1419-1420. PMID: 32653425, PMCID: PMC7347319, DOI: 10.1016/j.annonc.2020.06.023.
- Tremblay D, van Gerwen M, Alsen M, Thibaud S, Kessler A, Venugopal S, Makki I, Qin Q, Dharmapuri S, Jun T, Bhalla S, Berwick S, Feld J, Mascarenhas J, Troy K, Cromwell C, Dunn A, Oh W, Naymagon L. Impact of anticoagulation prior to COVID-19 infection: a propensity score–matched cohort study. Blood 2020, 136: 144-147. PMID: 32462179, PMCID: PMC7332896, DOI: 10.1182/blood.2020006941.
- Patel V, Qin Q, Wang B, Gogerly-Moragoda M, Mellgard G, Zhong X, Parikh A, Leiter A, Gallagher E, Oh W, Galsky M, Tsao C. Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors. Journal Of Clinical Oncology 2020, 38: e15068-e15068. DOI: 10.1200/jco.2020.38.15_suppl.e15068.
- Jun T, Ganta T, Qin Q, Patel V, Wang B, Mellgard G, Gogerly-Moragoda M, Leiter A, Gallagher E, Oh W, Galsky M, Tsao C. Smoking status and immunotherapy outcomes in smoking-associated cancers. Journal Of Clinical Oncology 2020, 38: e15097-e15097. DOI: 10.1200/jco.2020.38.15_suppl.e15097.
- Ganta T, Jun T, Qin Q, Patel V, Wang B, Mellgard G, Gogerly-Moragoda M, Leiter A, Gallagher E, Oh W, Galsky M, Tsao C. Clinical efficacy of immunotherapy for the treatment of solid tumors in patients with chronic kidney disease. Journal Of Clinical Oncology 2020, 38: e15109-e15109. DOI: 10.1200/jco.2020.38.15_suppl.e15109.
- Parikh A, Mellgard G, Qin Q, Patel V, Wang B, Zhong X, Leiter A, Gallagher E, Galsky M, Oh W, Clinton S, Mortazavi A, Monk P, Folefac E, Yin M, Yang Y, Tsao C. Risk factors for emergency room and hospital care for patients with advanced solid tumors on immune checkpoint inhibitor therapy. Journal Of Clinical Oncology 2020, 38: e15142-e15142. DOI: 10.1200/jco.2020.38.15_suppl.e15142.
- Lin J, Patel V, Qin Q, Wang B, Mellgard G, Gogerly-Moragoda M, Leiter A, Gallagher E, Zhong X, Oh W, Galsky M, Tsao C. What happens at radiographic disease progression in patients with metastatic cancer receiving immune checkpoint inhibitors? A single institution analysis. Journal Of Clinical Oncology 2020, 38: e15157-e15157. DOI: 10.1200/jco.2020.38.15_suppl.e15157.
- Qin Q, Patel V, Wang B, Mellgard G, Gogerly-Moragoda M, Zhong X, Parikh A, Leiter A, Gallagher E, Galsky M, Oh W, Tsao C. Type, timing, and patient characteristics associated with immune-related adverse event development in patients with advanced solid tumors treated with immune checkpoint inhibitors. Journal Of Clinical Oncology 2020, 38: e15160-e15160. DOI: 10.1200/jco.2020.38.15_suppl.e15160.
- Lin J, Zhong X, Galsky M, Oh W, Tsao C. Predictors of successful randomized phase III studies in the treatment metastatic renal cell carcinoma: A meta-analysis. Journal Of Clinical Oncology 2020, 38: e17105-e17105. DOI: 10.1200/jco.2020.38.15_suppl.e17105.
- Liaw B, Tsao C, Galsky M, Bakst R, Stewart R, Stock R, Oh W. PRINT: Prostate cancer intensive, non-cross reactive therapy for CRPC—Early observations of efficacy. Journal Of Clinical Oncology 2020, 38: e17575-e17575. DOI: 10.1200/jco.2020.38.15_suppl.e17575.
- Ayers K, Liu Z, Ma M, Lee K, Newman S, Li L, Zhou X, Mullaney T, Redfern A, Jappe W, Zimmerman M, Prentice T, Oh W, Schadt E, Li D, Chen R. Using real-world data to investigate time-dependent blood count response to PD-1 and PD-L1 inhibitors and its impact on survival in advanced non-small cell lung cancers. Journal Of Clinical Oncology 2020, 38: e21514-e21514. DOI: 10.1200/jco.2020.38.15_suppl.e21514.
- Schweizer M, Ha G, Gulati R, Brown L, McKay R, Dorff T, Hoge A, Reichel J, Vats P, Kilari D, Patel V, Oh W, Chinnaiyan A, Pritchard C, Armstrong A, Montgomery R, Alva A. CDK12-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade. JCO Precision Oncology 2020, 4: 382-392. PMID: 32671317, PMCID: PMC7363399, DOI: 10.1200/po.19.00383.
- Martini A, Pfail J, Montorsi F, Galsky M, Oh W. Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial. Prostate Cancer And Prostatic Diseases 2020, 23: 638-645. PMID: 32313142, DOI: 10.1038/s41391-020-0231-5.
- Martini* A, Sfakianos J, Gandaglia G, Fossati N, Barletta F, Scuderi S, Robesti D, Fallara G, Salonia A, Briganti A, Montorsi F, Oh W, Gallagher E, Galsky M. PD16-05 THE INVERSE CORRELATION BETWEEN OBESITY AND MORTALITY IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER: RESULTS FROM THE CONTROL ARMS OF ASCENT2, MAINSAL AND VENICE TRIALS. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000859.05.
- Martini A, Pfail* J, Fossati N, Gandaglia G, Fallara G, Barletta F, Scuderi S, Robesti D, Salonia A, Briganti A, Montorsi F, Galsky M, Oh W. PD16-06 SURROGATE ENDPOINTS FOR OVERALL SURVIVAL FOR PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER IN THE CHAARTED TRIAL. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000859.06.
- Martini* A, Parikh A, Sfakianos J, Fossati N, Gandaglia G, Scuderi S, Cannoletta D, Fallara G, Mazzone E, Stabile A, Barletta F, Robesti D, Bravi C, Briganti A, Montorsi F, Oh W, Galsky M, Tsao C. PD16-07 PREDICTING TOXICITY-RELATED DOCETAXEL DISCONTINUATION AND SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER USING OPEN PHASE 3 TRIAL DATA. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000859.07.
- Oh W. COVID-19 infection in cancer patients: early observations and unanswered questions. Annals Of Oncology 2020, 31: 838-839. PMID: 32243894, PMCID: PMC7270512, DOI: 10.1016/j.annonc.2020.03.297.
- Liu M, Oxnard G, Klein E, Swanton C, Seiden M, Consortium C, investigators C, Liu M, Oxnard G, Klein E, Smith D, Richards D, Yeatman T, Cohn A, Lapham R, Clement J, Parker A, Tummala M, McIntyre K, Sekeres M, Bryce A, Siegel R, Wang X, Cosgrove D, Abu-Rustum N, Trent J, Thiel D, Becerra C, Agrawal M, Garbo L, Giguere J, Michels R, Harris R, Richey S, McCarthy T, Waterhouse D, Couch F, Wilks S, Krie A, Balaraman R, Restrepo A, Meshad M, Rieger-Christ K, Sullivan T, Lee C, Greenwald D, Oh W, Tsao C, Fleshner N, Kennecke H, Khalil M, Spigel D, Manhas A, Ulrich B, Kovoor P, Stokoe C, Courtright J, Yimer H, Larson T, Swanton C, Seiden M, investigators S, Cummings S, GRAIL I, Absalan F, Alexander G, Allen B, Amini H, Aravanis A, Bagaria S, Bazargan L, Beausang J, Berman J, Betts C, Blocker A, Bredno J, Calef R, Cann G, Carter J, Chang C, Chawla H, Chen X, Chien T, Civello D, Davydov K, Demas V, Desai M, Dong Z, Fayzullina S, Fields A, Filippova D, Freese P, Fung E, Gnerre S, Gross S, Halks-Miller M, Hall M, Hartman A, Hou C, Hubbell E, Hunkapiller N, Jagadeesh K, Jamshidi A, Jiang R, Jung B, Kim T, Klausner R, Kurtzman K, Lee M, Lin W, Lipson J, Liu H, Liu Q, Lopatin M, Maddala T, Maher M, Melton C, Mich A, Nautiyal S, Newman J, Newman J, Nicula V, Nicolaou C, Nikolic O, Pan W, Patel S, Prins S, Rava R, Ronaghi N, Sakarya O, Satya R, Schellenberger J, Scott E, Sehnert A, Shaknovich R, Shanmugam A, Shashidhar K, Shen L, Shenoy A, Shojaee S, Singh P, Steffen K, Tang S, Toung J, Valouev A, Venn O, Williams R, Wu T, Xu H, Yakym C, Yang X, Yecies J, Yip A, Youngren J, Yue J, Zhang J, Zhang L, Zhang L, Zhang N, Advisors, Curtis C, Berry D. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Annals Of Oncology 2020, 31: 745-759. PMID: 33506766, PMCID: PMC8274402, DOI: 10.1016/j.annonc.2020.02.011.
- Schweizer M, Gulati R, Brown L, McKay R, Dorff T, Kilari D, Vats P, Patel V, Oh W, Armstrong A, Montgomery R, Alva A. CDK12 -mutated prostate cancer (PC): Clinical outcomes to standard therapies and immune checkpoint blockade. Journal Of Clinical Oncology 2020, 38: 191-191. DOI: 10.1200/jco.2020.38.6_suppl.191.
- Lin J, Caress A, Ahmed F, Taylor N, Gong Y, Oh W. Elevated circulating CCL2 in prostate cancer patients. Journal Of Clinical Oncology 2020, 38: 201-201. DOI: 10.1200/jco.2020.38.6_suppl.201.
- PRINT: Prostate cancer intensive, non-cross reactive therapy for CRP—Early observations of efficacy.Liaw B, Tsao C, Galsky M, Bakst R, Stewart R, Stock R, Oh W. PRINT: Prostate cancer intensive, non-cross reactive therapy for CRP—Early observations of efficacy. Journal Of Clinical Oncology 2020, 38: 89-89. DOI: 10.1200/jco.2020.38.6_suppl.89.
- Parikh A, Martini A, Sfakianos J, Galsky M, Oh W, Tsao C. Predicting toxicity-related docetaxel discontinuation and survival in metastatic castration-resistant prostate cancer (mCRPC) using open phase III trial data. Journal Of Clinical Oncology 2020, 38: 75-75. DOI: 10.1200/jco.2020.38.6_suppl.75.
- Patel V, Qin Q, Mellgard G, Parikh A, Wang B, Alerasool P, Garcia P, Jaladanki S, Leiter A, Carroll E, Brooks D, Shimol J, Eisenberg E, Gallagher E, Galsky M, Oh W, Tsao C. Characterizing patterns of disease progression in patients with genitourinary cancers treated with immune checkpoint inhibitors. Journal Of Clinical Oncology 2020, 38: 482-482. DOI: 10.1200/jco.2020.38.6_suppl.482.
- Qin Q, Patel V, Mellgard G, Parikh A, Wang B, Alerasool P, Garcia P, Jaladanki S, Leiter A, Carroll E, Brooks D, Shimol J, Eisenberg E, Gallagher E, Galsky M, Oh W, Tsao C. Type, timing, and risk factors associated with immune-related adverse event development in patients with advanced genitourinary cancers treated with immune checkpoint inhibitor. Journal Of Clinical Oncology 2020, 38: 480-480. DOI: 10.1200/jco.2020.38.6_suppl.480.
- Gillessen S, Attard G, Beer T, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow R, Chi K, Clarke N, Davis I, de Bono J, Drake C, Duran I, Eeles R, Efstathiou E, Evans C, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Heinrich D, Higano C, Hofman M, Hussain M, James N, Kanesvaran R, Kantoff P, Khauli R, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans A, Morris M, Mottet N, Mrabti H, Murphy D, Murthy V, Oh W, Ost P, O'Sullivan J, Padhani A, Parker C, Poon D, Pritchard C, Reiter R, Roach M, Rubin M, Ryan C, Saad F, Sade J, Sartor O, Scher H, Shore N, Small E, Smith M, Soule H, Sternberg C, Steuber T, Suzuki H, Sweeney C, Sydes M, Taplin M, Tombal B, Türkeri L, van Oort I, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. European Urology 2020, 77: 508-547. PMID: 32001144, DOI: 10.1016/j.eururo.2020.01.012.
- Fei K, Lin J, Supoyo S, Franco R, Abramson S, Hoke G, Oh W, Stock R, Bickell N. Impact of Age and Life-expectancy on Treatment Receipt in High-risk Prostate Cancer. Journal Of Advances In Medicine And Medical Research 2019, 1-9. DOI: 10.9734/jammr/2019/v30i1130248.
- Mehrazin R, Oh W. Prostate Cancer. 2019, 23-31. DOI: 10.1002/9781119189596.ch2.
- Gong Y, Wang L, Yu H, Alpert N, Cohen M, Prophete C, Horton L, Sisco M, Park S, Lee H, Zelikoff J, Chen L, Hashim D, Suarez-Farinas M, Donovan M, Aaronson S, Galsky M, Zhu J, Taioli E, Oh W. Prostate Cancer in World Trade Center Responders Demonstrates Evidence of an Inflammatory Cascade. Molecular Cancer Research 2019, 17: 1605-1612. PMID: 31221798, PMCID: PMC6684261, DOI: 10.1158/1541-7786.mcr-19-0115.
- Wang L, Gong Y, Saci A, Szabo P, Martini A, Necchi A, Siefker-Radtke A, Pal S, Plimack E, Sfakianos J, Bhardwaj N, Horowitz A, Farkas A, Mulholland D, Fischer B, Oh W, Sharma P, Zhu J, Galsky M. Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer. European Urology 2019, 76: 599-603. PMID: 31272788, PMCID: PMC6801024, DOI: 10.1016/j.eururo.2019.06.025.
- Niglio S, Jia R, Ji J, Ruder S, Patel V, Martini A, Sfakianos J, Marqueen K, Waingankar N, Mehrazin R, Wiklund P, Oh W, Mazumdar M, Ferket B, Galsky M. Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. European Urology 2019, 76: 782-789. PMID: 31200951, DOI: 10.1016/j.eururo.2019.05.037.
- Patel V, Oh W. The evolving landscape of immunotherapy in advanced prostate cancer. Immunotherapy 2019, 11: 903-912. PMID: 31161846, DOI: 10.2217/imt-2019-0019.
- McCafferty J, Grover K, Li L, Li Z, Fink M, Goldsweig H, Ma M, Zhou X, Mullaney T, Redfern A, Jappe W, Zimmerman M, Prentice T, Pan Q, Oh W, Schadt E, Li D, Chen R. A systematic analysis of off-label drug use in real-world data (RWD) across more than 145,000 cancer patients. Journal Of Clinical Oncology 2019, 37: e18031-e18031. DOI: 10.1200/jco.2019.37.15_suppl.e18031.
- Liu Z, Ma M, Grover K, Li L, Goldsweig H, Yadav K, Zhou X, Mullaney T, Redfern A, Jappe W, Zimmerman M, Prentice T, Pan Q, Oh W, Schadt E, Li D, Chen R. Investigating racial differences in treatment responses through analysis of real-world data (RWD). Journal Of Clinical Oncology 2019, 37: e18141-e18141. DOI: 10.1200/jco.2019.37.15_suppl.e18141.
- Ma M, Zhou X, Goldsweig H, Hahner N, Han D, Dietz M, Jones S, Mullaney T, Redfern A, Jappe W, Liu Z, Yadav K, Zimmerman M, Prentice T, Pan Q, Hirsch F, Oh W, Schadt E, Li D, Chen R. Analysis of real-world data (RWD) on treatment (tx) sequencing in patients with advanced non-small cell lung cancer (aNSCLC). Journal Of Clinical Oncology 2019, 37: e20642-e20642. DOI: 10.1200/jco.2019.37.15_suppl.e20642.
- Chong* J, Muhleman M, Say R, Kostakoglu L, Ahmed J, Tewari A, Stock R, Oh W. MP13-01 PET/CT WITH 18 F-FLUCICLOVINE TO PREDICT RECURRENCE IN POST-TREATMENT PROSTATE CANCER AND ITS ROLE IN ALTERING TREATMENT PLANS. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000555214.12968.a4.
- Chong J, Muhleman M, Say R, Kostakoglu L, Ahmed J, Tewari A, Stock R, Oh W. Positron emission tomography with 18F-fluciclovine to predict recurrence in post-treatment recurrent prostate cancer and its role in altering treatment plans. Journal Of Clinical Oncology 2019, 37: 214-214. DOI: 10.1200/jco.2019.37.7_suppl.214.
- Qin Q, Bikkasani K, Oh W, Liaw B, Galsky M, Tsao C. Patients with an extremely high prostate-specific antigen at prostate cancer diagnosis: A single institution analysis. Journal Of Clinical Oncology 2019, 37: 309-309. DOI: 10.1200/jco.2019.37.7_suppl.309.
- Liaw B, Tsao C, Galsky M, Bakst R, Stewart R, Stock R, Oh W. PRINT: Prostate cancer intensive, non-cross reactive therapy for CRPC—Early observations of feasibility and efficacy. Journal Of Clinical Oncology 2019, 37: 310-310. DOI: 10.1200/jco.2019.37.7_suppl.310.
- Patel V, Oh W, Galsky M, Liaw B, Tsao C. Effect of concurrent beta-blocker (BB) use in patients receiving immune checkpoint inhibitors for metastatic urothelial (mUC) and renal cell carcinomas (mRCC). Journal Of Clinical Oncology 2019, 37: 467-467. DOI: 10.1200/jco.2019.37.7_suppl.467.
- Lin J, Oh W, Liaw B, Galsky M, Tsao C. Evolving patterns of metastatic renal cell carcinoma: A meta-analysis. Journal Of Clinical Oncology 2019, 37: 563-563. DOI: 10.1200/jco.2019.37.7_suppl.563.
- Taplin M, Hussain A, Shah S, Shore N, Agrawal M, Clark W, Edenfield W, Nordquist L, Sartor O, Butrynski J, Chatta G, Fleming M, Oh W, Bradley B, Piel J, Nash D, Colak G, Li J, Lebedinsky C, Antonarakis E. ProSTAR: A phase Ib/II study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer (mCRPC). Journal Of Clinical Oncology 2019, 37: tps335-tps335. DOI: 10.1200/jco.2019.37.7_suppl.tps335.
- Bikkasani K, Qin Q, Lin J, Galsky M, Liaw B, Oh W, Tsao C. Characterization of PSA at death in patients with metastatic castration-resistant prostate cancer. Journal Of Clinical Oncology 2019, 37: 184-184. DOI: 10.1200/jco.2019.37.7_suppl.184.
- Ahmed J, Muhleman M, Chong J, Tewari A, Oh W, Kostakoglu L, Stock R. Application of 18-F Fluciclovine PET/CT in Guiding Salvage Radiation Therapy for Recurrent Prostate Cancer. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: e95-e96. DOI: 10.1016/j.ijrobp.2018.07.371.
- Phelps D, Watterberg K, Nolen T, Cole C, Cotten C, Oh W, Poindexter B, Zaterka-Baxter K, Das A, Lacy C, Scorsone A, Walsh M, Bell E, Kennedy K, Schibler K, Sokol G, Laughon M, Lakshminrusimha S, Truog W, Garg M, Carlo W, Laptook A, Van Meurs K, Carlton D, Graf A, DeMauro S, Brion L, Shankaran S, Orge F, Olson R, Mintz-Hittner H, Yang M, Haider K, Wallace D, Chung M, Hug D, Tsui I, Cogen M, Donahue J, Gaynon M, Hutchinson A, Bremer D, Quinn G, He Y, Lucas W, Winter T, Kicklighter S, Kumar K, Chess P, Colaizy T, Hibbs A, Ambalavanan N, Harmon H, McGowan E, Higgins R. Effects of Myo-inositol on Type 1 Retinopathy of Prematurity Among Preterm Infants <28 Weeks' Gestational Age: A Randomized Clinical Trial. JAMA 2018, 320: 1649-1658. PMID: 30357297, DOI: 10.1001/jama.2018.14996.
- Omidele O, Schiff H, Oh W, Tewari A. Multimodal therapy in the treatment of metastatic prostate cancer: A case report. Urology Case Reports 2018, 21: 92-94. PMID: 30258788, PMCID: PMC6154777, DOI: 10.1016/j.eucr.2018.09.010.
- Friedlander P, Wood K, Wassmann K, Christenfeld A, Bhardwaj N, Oh W. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab. Journal For ImmunoTherapy Of Cancer 2018, 6: 90. PMID: 30227886, PMCID: PMC6145108, DOI: 10.1186/s40425-018-0408-9.
- Oh W, Cheng W, Miao R, Vekeman F, Gauthier-Loiselle M, Duh M, Drea E, Szatrowski T. Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting. Urologic Oncology Seminars And Original Investigations 2018, 36: 500.e1-500.e9. PMID: 30201382, DOI: 10.1016/j.urolonc.2018.08.002.
- Wang L, Saci A, Szabo P, Chasalow S, Castillo-Martin M, Domingo-Domenech J, Siefker-Radtke A, Sharma P, Sfakianos J, Gong Y, Dominguez-Andres A, Oh W, Mulholland D, Azrilevich A, Hu L, Cordon-Cardo C, Salmon H, Bhardwaj N, Zhu J, Galsky M. EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nature Communications 2018, 9: 3503. PMID: 30158554, PMCID: PMC6115401, DOI: 10.1038/s41467-018-05992-x.
- Patel V, Liaw B, Oh W. The role of ketoconazole in current prostate cancer care. Nature Reviews Urology 2018, 15: 643-651. PMID: 30154429, DOI: 10.1038/s41585-018-0077-y.
- Lowrance W, Murad M, Oh W, Jarrard D, Resnick M, Cookson M. Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018. Journal Of Urology 2018, 200: 1264-1272. PMID: 30086276, DOI: 10.1016/j.juro.2018.07.090.
- Resende Salgado L, Rhome R, Oh W, Stone N, Stock R. Prostate-specific antigen doubling time is a significant predictor of overall and disease-free survival in patients with prostate adenocarcinoma treated with brachytherapy. Brachytherapy 2018, 17: 874-881. PMID: 30061057, DOI: 10.1016/j.brachy.2018.07.008.
- Lee E, Collazo-Lorduy A, Castillo-Martin M, Gong Y, Wang L, Oh W, Galsky M, Cordon-Cardo C, Zhu J. Identification of microR-106b as a prognostic biomarker of p53-like bladder cancers by ActMiR. Oncogene 2018, 37: 5858-5872. PMID: 29970902, PMCID: PMC6212417, DOI: 10.1038/s41388-018-0367-0.
- Hashim D, Boffetta P, Galsky M, Oh W, Lucchini R, Crane M, Luft B, Moline J, Udasin I, Harrison D, Taioli E. Prostate cancer characteristics in the World Trade Center cohort, 2002–2013. European Journal Of Cancer Prevention 2018, 27: 347-354. PMID: 27898584, PMCID: PMC5443704, DOI: 10.1097/cej.0000000000000315.
- Chong J, Oh W, Liaw B. Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date. OncoTargets And Therapy 2018, 11: 2141-2147. PMID: 29695920, PMCID: PMC5905496, DOI: 10.2147/ott.s147168.
- McClinch K, Avelar R, Callejas D, Izadmehr S, Wiredja D, Perl A, Sangodkar J, Kastrinsky D, Schlatzer D, Cooper M, Kiselar J, Stachnik A, Yao S, Hoon D, McQuaid D, Zaware N, Gong Y, Brautigan D, Plymate S, Sprenger C, Oh W, Levine A, Kirschenbaum A, Sfakianos J, Sears R, DiFeo A, Ioannou Y, Ohlmeyer M, Narla G, Galsky M. Small molecule activators of protein phosphatase 2A for the treatment of castration-resistant prostate cancer. Cancer Research 2018, 78: canres.0123.2017. PMID: 29358171, PMCID: PMC5899650, DOI: 10.1158/0008-5472.can-17-0123.
- Levin R, Given R, Nemeth P, Bosch B, Chapas-Reed J, Oh W. Multicenter extension and switch study evaluating the safety of long-term treatment with abiraterone acetate fine particle formulation (AAFP) in patients with metastatic castration-resistant prostate cancer (mCRPC): The STAAR-E study. Journal Of Clinical Oncology 2018, 36: 181-181. DOI: 10.1200/jco.2018.36.6_suppl.181.
- Liaw B, Oh W. Prostate Cancer. 2018, 344-362. DOI: 10.1002/9781118592168.ch26.
- Tsao C, Oh W. First-Line Treatment of Hormone-Sensitive Metastatic Prostate Cancer: Is There a Single Standard of Care? Journal Of Clinical Oncology 2018, 36: jco.2017.77.431. PMID: 29432079, DOI: 10.1200/jco.2017.77.4315.
- Azad A, Chang P, Devuni D, Bichoupan K, Kesar V, Branch A, Oh W, Galsky M, Ahmad J, Odin J. Real World Experience of Drug Induced Liver Injury in Patients Undergoing Chemotherapy. Journal Of Clinical Gastroenterology And Hepatology 2018, 2 PMID: 30637414, PMCID: PMC6327955, DOI: 10.21767/2575-7733.1000047.
- Galsky M, Wang H, Hahn N, Twardowski P, Pal S, Albany C, Fleming M, Starodub A, Hauke R, Yu M, Zhao Q, Sonpavde G, Donovan M, Patel V, Sfakianos J, Domingo-Domenech J, Oh W, Akers N, Losic B, Gnjatic S, Schadt E, Chen R, Kim-Schulze S, Bhardwaj N, Uzilov A. Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. European Urology 2017, 73: 751-759. PMID: 29248319, DOI: 10.1016/j.eururo.2017.12.001.
- Bickell N, Lin J, Abramson S, Hoke G, Oh W, Hall S, Stock R, Fei K, McAlearney A. Racial Disparities in Clinically Significant Prostate Cancer Treatment: The Potential Health Information Technology Offers. JCO Oncology Practice 2017, 14: jop.2017.025957. PMID: 29194001, PMCID: PMC5765902, DOI: 10.1200/jop.2017.025957.
- Lieberman-Cribbin W, Galsky M, Casey M, Liu B, Oh W, Flores R, Taioli E. Hospital Centralization Impacts High-Risk Lung and Bladder Cancer Surgical Patients. Cancer Investigation 2017, 35: 652-661. PMID: 29243986, DOI: 10.1080/07357907.2017.1406495.
- Galsky M, Shahin M, Jia R, Shaffer D, Gimpel-Tetra K, Tsao C, Baker C, Leiter A, Holland J, Sablinski T, Mehrazin R, Sfakianos J, Acon P, Oh W. Telemedicine-Enabled Clinical Trial of Metformin in Patients With Prostate Cancer. JCO Clinical Cancer Informatics 2017, 1: 1-10. PMID: 30657386, DOI: 10.1200/cci.17.00044.
- Galsky M, Diefenbach M, Mohamed N, Baker C, Pokhriya S, Rogers J, Atreja A, Hu L, Tsao C, Sfakianos J, Mehrazin R, Waingankar N, Oh W, Mazumdar M, Ferket B. Web-Based Tool to Facilitate Shared Decision Making With Regard to Neoadjuvant Chemotherapy Use in Muscle-Invasive Bladder Cancer. JCO Clinical Cancer Informatics 2017, 1: 1-12. PMID: 30657403, PMCID: PMC6874030, DOI: 10.1200/cci.17.00116.
- Drudge-Coates L, Oh W, Tombal B, Delacruz A, Tomlinson B, Ripley A, Mastris K, O'Sullivan J, Shore N. Recognizing Symptom Burden in Advanced Prostate Cancer: A Global Patient and Caregiver Survey. Clinical Genitourinary Cancer 2017, 16: e411-e419. PMID: 29111175, DOI: 10.1016/j.clgc.2017.09.015.
- Galsky M, Diefenbach M, Mohamed N, Baker C, Pokhriya S, Rogers J, Atreja A, Ramireddy K, Hu L, Tsao C, Sfakianos J, Mehrazin R, Hassanzadeh N, Waingankar N, Oh W, Kohli A, Otobo E, Mazumdar M, Ferket B. A Web-Based Tool to Facilitate Shared Decision-Making Regarding Neoadjuvant Chemotherapy Use in Muscle-Invasive Bladder Cancer. Iproceedings 2017, 3: e43. DOI: 10.2196/iproc.8456.
- Friedlander P, Wassmann K, Christenfeld A, Fisher D, Kyi C, Kirkwood J, Bhardwaj N, Oh W. Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab. Journal For ImmunoTherapy Of Cancer 2017, 5: 67. PMID: 28807052, PMCID: PMC5557000, DOI: 10.1186/s40425-017-0272-z.
- Oh W, Miao R, Vekeman F, Sung J, Cheng W, Gauthier-Loiselle M, Dhawan R, Duh M. Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting. Medical Oncology 2017, 34: 160. PMID: 28795333, PMCID: PMC5550521, DOI: 10.1007/s12032-017-1014-2.
- Gillessen S, Attard G, Beer T, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung B, Clarke N, Daugaard G, Davis I, de Bono J, dos Reis R, Drake C, Eeles R, Efstathiou E, Evans C, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano C, James N, Kantoff P, Kellokumpu-Lehtinen P, Khauli R, Kramer G, Logothetis C, Maluf F, Morgans A, Morris M, Mottet N, Murthy V, Oh W, Ost P, Padhani A, Parker C, Pritchard C, Roach M, Rubin M, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg C, Suzuki H, Sweeney C, Sydes M, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. European Urology 2017, 73: 178-211. PMID: 28655541, DOI: 10.1016/j.eururo.2017.06.002.
- Oh W, Miao R, Vekeman F, Sung J, Cheng W, Gauthier-Loiselle M, Dhawan R, Duh M. Real-world Characteristics and Outcomes of Patients With Metastatic Castration-resistant Prostate Cancer Receiving Chemotherapy Versus Androgen Receptor-targeted Therapy After Failure of First-line Androgen Receptor-targeted Therapy in the Community Setting. Clinical Genitourinary Cancer 2017, 16: 50-57. PMID: 28729067, DOI: 10.1016/j.clgc.2017.06.004.
- Pomerantz M, Spisák S, Jia L, Cronin A, Csabai I, Ledet E, Sartor A, Rainville I, O'Connor E, Herbert Z, Szállási Z, Oh W, Kantoff P, Garber J, Schrag D, Kibel A, Freedman M. The association between germline BRCA2 variants and sensitivity to platinum‐based chemotherapy among men with metastatic prostate cancer. Cancer 2017, 123: 3532-3539. PMID: 28608931, PMCID: PMC5802871, DOI: 10.1002/cncr.30808.
- Kyi C, Sabado R, Blazquez A, Posner M, Genden E, Miles B, Khorasani H, Dottino P, Irie H, Port E, Wolf A, Cho H, Parekh S, Mandeli J, Galsky M, Oh W, Gnjatic S, Schadt E, Friedlander P, Bhardwaj N. A phase I study of the safety and immunogenicity of a multipeptide personalized genomic vaccine in the adjuvant treatment of solid cancers. Journal Of Clinical Oncology 2017, 35: tps3114-tps3114. DOI: 10.1200/jco.2017.35.15_suppl.tps3114.
- Oh W, Kandadi H, Sheikh N, Galsky M. Blood-based predictive biomarkers for overall survival (OS) in patients (pts) receiving the immunotherapy sipuleucel-T (sip-T). Journal Of Clinical Oncology 2017, 35: 36-36. DOI: 10.1200/jco.2017.35.7_suppl.36.
- Friedlander P, Wassman K, Kyi C, Oh W, Bhardwaj N. Correlation of consistent blood-based gene expression with change in CTLA4 in two large independent clinical studies of patients with advanced melanoma treated with tremelimumab. Journal Of Clinical Oncology 2017, 35: 6-6. DOI: 10.1200/jco.2017.35.7_suppl.6.
- Oh W, Cheng W, Miao R, Vekeman F, Gauthier-Loiselle M, Duh M, Drea E, Szatrowski T. Real-world outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving second-line (2L) chemotherapy (CT) vs alternative androgen receptor-targeted agents (ARTA) after lack of response to first-line (1L) ARTA in US community oncology practices. Journal Of Clinical Oncology 2017, 35: 214-214. DOI: 10.1200/jco.2017.35.6_suppl.214.
- Galsky M, Shahin M, Olson A, Shaffer D, Gimpel-Tetra K, Tsao C, Baker C, Leiter A, Holland J, Sablinski T, Mehrazin R, Sfakianos J, Acon P, Oh W. Telemedicine-enabled clinical trial of metformin in patients (pts) with biochemically-recurrent prostate cancer (PCa). Journal Of Clinical Oncology 2017, 35: 243-243. DOI: 10.1200/jco.2017.35.6_suppl.243.
- Tsao C, Liaw B, He C, Galsky M, Sfakianos J, Oh W. Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: latest evidence and therapeutic implications. Therapeutic Advances In Medical Oncology 2017, 9: 287-298. PMID: 28491148, PMCID: PMC5405995, DOI: 10.1177/1758834016687261.
- McNeel DG, Bander NH, Beer TM, Drake CG, Fong L, Harrelson S, Kantoff PW, Madan RA, Oh WK, Peace DJ, Petrylak DP, Porterfield H, Sartor O, Shore ND, Slovin SF, Stein MN, Vieweg J, Gulley JL. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. Journal For ImmunoTherapy Of Cancer 2016, 4: 92. PMID: 28031820, PMCID: PMC5170901, DOI: 10.1186/s40425-016-0198-x.
- Roubaud G, Liaw B, Oh W, Mulholland D. Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer. Nature Reviews Clinical Oncology 2016, 14: 269-283. PMID: 27874061, PMCID: PMC5567685, DOI: 10.1038/nrclinonc.2016.181.
- Tsao C, Sfakianos J, Liaw B, Gimpel‐Tetra K, Kemeny M, Bulone L, Shahin M, Oh W, Galsky M. Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer. The Oncologist 2016, 21: 1414-e9. PMID: 27742908, PMCID: PMC5153336, DOI: 10.1634/theoncologist.2016-0026.
- Stock R, Sfakianos J, Oh W, Stone N. Prostate-Specific Antigen Doubling Time Posttreatment Is the Most Significant Predictor of Survival Following the Brachytherapy Management of Localized Prostate Cancer. International Journal Of Radiation Oncology • Biology • Physics 2016, 96: e236. DOI: 10.1016/j.ijrobp.2016.06.1216.
- Gong Y, Wang L, Chippada-Venkata U, Dai X, Oh W, Zhu J. Constructing bayesian networks by integrating gene expression and copy number data identifies NLGN4Y as a novel regulator of prostate cancer progression. Oncotarget 2016, 7: 68688-68707. PMID: 27626693, PMCID: PMC5356583, DOI: 10.18632/oncotarget.11925.
- Wang L, Oh W, Zhu J. Disease-specific classification using deconvoluted whole blood gene expression. Scientific Reports 2016, 6: 32976. PMID: 27596246, PMCID: PMC5011717, DOI: 10.1038/srep32976.
- Casey M, Wisnivesky J, Le V, Sarpel U, Stensland K, Oh W, Galsky M. The Relationship between Centralization of Care and Geographic Barriers to Cystectomy for Bladder Cancer. Bladder Cancer 2016, 2: 319-327. PMID: 27500199, PMCID: PMC4969695, DOI: 10.3233/blc-160058.
- Tsao C, Galsky M, Oh W. Docetaxel for Metastatic Hormone-sensitive Prostate Cancer: Urgent Need to Minimize the Risk of Neutropenic Fever. European Urology 2016, 70: 707-708. PMID: 27417033, DOI: 10.1016/j.eururo.2016.06.041.
- Galsky M, Stensland K, Sfakianos J, Mehrazin R, Diefenbach M, Mohamed N, Tsao C, Boffetta P, Wiklund P, Oh W, Mazumdar M, Ferket B. Comparative Effectiveness of Treatment Strategies for Bladder Cancer With Clinical Evidence of Regional Lymph Node Involvement. Journal Of Clinical Oncology 2016, 34: 2627-2635. PMID: 27269939, PMCID: PMC5012691, DOI: 10.1200/jco.2016.67.5033.
- Oh W, Tombal B, Delacruz A, Tomlinson B, Vella Ripley A, Drudge-Coates L, Mastris K, O'Sullivan J, Shore N. Recognizing symptom burden in advanced prostate cancer: A global patient and caregiver survey. Journal Of Clinical Oncology 2016, 34: 10124-10124. DOI: 10.1200/jco.2016.34.15_suppl.10124.
- Galsky M, Stensland K, Sfakianos J, Mehrazin R, Diefenbach M, Tsao C, Boffetta P, Oh W, Mazumdar M, Ferket B. Comparative effectiveness of treatment strategies for urothelial cancer of the bladder (UCB) with clinical lymph node involvement (cN+). Journal Of Clinical Oncology 2016, 34: 4530-4530. DOI: 10.1200/jco.2016.34.15_suppl.4530.
- McBride R, Patel V, Lorduy A, Castillo-Martin M, Cha E, Berger M, Wang L, Oh W, Zhu J, Cordon-Cardo C, Solit D, Sfakianos J, Galsky M. Prognostic significance of DNA damage repair (DDR) mutations in patients with urothelial carcinoma (UC) and associations with tumor infiltrating lymphocytes (TILs). Journal Of Clinical Oncology 2016, 34: 4538-4538. DOI: 10.1200/jco.2016.34.15_suppl.4538.
- Oh W, Kandadi H, Fan L, Sheikh N, Trager J, Galsky M. Blood-based predictive biomarkers for overall survival (OS) in patients (pts) receiving the immunotherapy sipuleucel-T (sip-T). Journal Of Clinical Oncology 2016, 34: 5026-5026. DOI: 10.1200/jco.2016.34.15_suppl.5026.
- Patel V, McBride R, Lorduy A, Castillo-Martin M, Cha E, Berger M, Wang L, Oh W, Zhu J, Cordon-Cardo C, Solit D, Sfakianos J, Galsky M. Prognostic significance of PIK3CA mutation in patients with muscle-invasive urothelial carcinoma (UC). Journal Of Clinical Oncology 2016, 34: e16002-e16002. DOI: 10.1200/jco.2016.34.15_suppl.e16002.
- Heck M, Thalgott M, Schmid S, Oh W, Gong Y, Wang L, Zhu J, Seitz A, Porst D, Höppner M, Retz M, Gschwend J, Nawroth R. A 2‐Gene Panel Derived From Prostate Cancer‐Enhanced Transcripts in Whole Blood Is Prognostic for Survival and Predicts Treatment Benefit in Metastatic Castration‐Resistant Prostate Cancer. The Prostate 2016, 76: 1160-1168. PMID: 27198487, DOI: 10.1002/pros.23202.
- Collazo-Lorduy A, Castillo-Martin M, Wang L, Patel V, Iyer G, Jordan E, Al-Ahmadie H, Leonard I, Oh W, Zhu J, McBride R, Cordon-Cardo C, Solit D, Sfakianos J, Galsky M. Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition. European Urology 2016, 70: 771-775. PMID: 27178450, PMCID: PMC5489411, DOI: 10.1016/j.eururo.2016.04.037.
- Oh W, Miao R, Duh, Vekeman F, Sung J, Cheng W, Gauthier-Loiselle M, Fortier J, Dhawan R. PCN33 Treatment Sequences, Patient Characteristics, And Overall Survival Of Patients With Post-Docetaxel Metastatic Castration-Resistant Prostate Cancer In The Community Setting. Value In Health 2016, 19: a139. DOI: 10.1016/j.jval.2016.03.1655.
- Shevach J, Marcellino B, Oh W, Tsao C. Enzalutamide in Metastatic Castration Resistant Prostate Cancer. 2016, 157-169. DOI: 10.1007/978-3-319-31341-2_10.
- Leiter A, Doucette J, Krege S, Lin C, Hahn N, Ecke T, Sonpavde G, Bamias A, Oh W, Galsky M. Obesity and Outcomes in Patients with Metastatic Urothelial Carcinoma. Bladder Cancer 2016, 2: 341-349. PMID: 27500201, PMCID: PMC4969712, DOI: 10.3233/blc-160047.
- Kesar V, Devuni D, Azad A, Bichoupan K, Branch A, Oh W, Galsky M, Ahmad J, Odin J. 357 The Clinical Spectrum of Liver Injury in Cancer Patients. Gastroenterology 2016, 150: s1029. DOI: 10.1016/s0016-5085(16)33482-5.
- Kim S, Isola L, Oh W. Severe post-treatment leukopenia associated with the development of encephalopathy following ifosfamide infusion. Anti-Cancer Drugs 2016, 27: 235-238. PMID: 26628483, DOI: 10.1097/cad.0000000000000321.
- Heck M, Thalgott M, Schmid S, Oh W, Gong Y, Wang L, Zhu J, Seitz A, Porst D, Höppner M, Retz M, Gschwend J, Nawroth R. 1072 A 2-gene panel derived from prostate cancer-enhanced transcripts in whole blood is prognostic for survival and predicts treatment benefit in metastatic castration-resistant prostate cancer. European Urology Open Science 2016, 15: e1072. DOI: 10.1016/s1569-9056(16)61073-4.
- Galsky M, Stensland K, Moshier E, Sfakianos J, McBride R, Tsao C, Casey M, Boffetta P, Oh W, Mazumdar M, Wisnivesky J. Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer. Journal Of Clinical Oncology 2016, 34: 825-832. PMID: 26786930, DOI: 10.1200/jco.2015.64.1076.
- Galsky M, Hahn N, Albany C, Fleming M, Starodub A, Twardowski P, Pal S, Hauke R, Sonpavde G, Oh W, Bhardwaj N, Gnjatic S, Kim-Schulze S, Liu Z. Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer. Journal Of Clinical Oncology 2016, 34: 357-357. DOI: 10.1200/jco.2016.34.2_suppl.357.
- Galsky M, Stensland K, Sfakianos J, McBride R, Mehrazin R, Tsao C, Boffetta P, Oh W. Frequency and clinical implications of pathologic complete response (pCR) at cystectomy for muscle-invasive bladder cancer (MIBC) with or without neoadjuvant chemotherapy (NAC). Journal Of Clinical Oncology 2016, 34: 383-383. DOI: 10.1200/jco.2016.34.2_suppl.383.
- Galsky M, Noah H, Starodub A, Hauke R, Twardowski P, Fleming M, Qi J, Sonpavde G, Patel M, Zhu J, Chippada-Venkata U, Albany C, Wang L, Merad M, Oh W, Bhardwaj N, Gnjatic S, Kim-Schulze S. Impact of chemotherapy alone, and chemotherapy plus ipilimumab, on circulating immune cells in patients with metastatic bladder cancer. Journal For ImmunoTherapy Of Cancer 2015, 3: p257. PMCID: PMC4649313, DOI: 10.1186/2051-1426-3-s2-p257.
- Beer T, Vogelzang N, Bartůňková J, Miller K, Oh W, Oudard S, Pandha H, Sartor A, Špíšek R, Toole T, Borgstein N, Gerritsen W. Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer. Journal For ImmunoTherapy Of Cancer 2015, 3: p164. PMCID: PMC4646109, DOI: 10.1186/2051-1426-3-s2-p164.
- Mercer J, Erickson-Owens D, Vohr B, Tucker R, Parker A, Oh W, Padbury J. Effects of Placental Transfusion on Neonatal and 18 Month Outcomes in Preterm Infants: A Randomized Controlled Trial. The Journal Of Pediatrics 2015, 168: 50-55.e1. PMID: 26547399, PMCID: PMC4698069, DOI: 10.1016/j.jpeds.2015.09.068.
- Williams E, Rodriguez-Bravo V, Chippada-Venkata U, De Ia Iglesia-Vicente J, Gong Y, Galsky M, Oh W, Cordon-Cardo C, Domingo-Domenech J. Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells. Journal Of Visualized Experiments 2015 DOI: 10.3791/53182-v.
- Williams E, Rodriguez-Bravo V, Chippada-Venkata U, De Ia Iglesia-Vicente J, Gong Y, Galsky M, Oh W, Cordon-Cardo C, Domingo-Domenech J. Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells. Journal Of Visualized Experiments 2015, 53182. PMID: 26555435, PMCID: PMC4692658, DOI: 10.3791/53182.
- Gartrell B, Small A, Oh W, Galsky M. Renal Cell Carcinoma and Targeted Therapy. 2015, 287-295. DOI: 10.1002/9781118468678.ch29.
- Galsky M, Hahn N, Wong B, Lee K, Argiriadi P, Albany C, Gimpel-Tetra K, Lowe N, Shahin M, Patel V, Tsao C, Oh W. Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma. Cancer Chemotherapy And Pharmacology 2015, 76: 1259-1265. PMID: 26464352, DOI: 10.1007/s00280-015-2884-7.
- Oh W, Miao R, Vekeman F, Sung J, Cheng W, Gauthier-Loiselle M, Fortier J, Dhawan R, Hennessy D, Duh M. 2512 Is there a difference in outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) who receive chemotherapy (CT) vs androgen receptor-targeted therapy (ART) after 1st-line ART in the community setting? European Journal Of Cancer 2015, 51: s478. DOI: 10.1016/s0959-8049(16)31332-6.
- Wang L, Gong Y, Chippada-Venkata U, Heck M, Retz M, Nawroth R, Galsky M, Tsao C, Schadt E, de Bono J, Olmos D, Zhu J, Oh W. A robust blood gene expression-based prognostic model for castration-resistant prostate cancer. BMC Medicine 2015, 13: 201. PMID: 26297150, PMCID: PMC4546313, DOI: 10.1186/s12916-015-0442-0.
- Shevach J, Gallagher E, Kochukoshy T, Gresia V, Brar M, Galsky M, Oh W. Concurrent Diabetes Mellitus may Negatively Influence Clinical Progression and Response to Androgen Deprivation Therapy in Patients with Advanced Prostate Cancer. Frontiers In Oncology 2015, 5: 129. PMID: 26125012, PMCID: PMC4467174, DOI: 10.3389/fonc.2015.00129.
- Gillessen S, Omlin A, Attard G, de Bono J, Efstathiou E, Fizazi K, Halabi S, Nelson P, Sartor O, Smith M, Soule H, Akaza H, Beer T, Beltran H, Chinnaiyan A, Daugaard G, Davis I, De Santis M, Drake C, Eeles R, Fanti S, Gleave M, Heidenreich A, Hussain M, James N, Lecouvet F, Logothetis C, Mastris K, Nilsson S, Oh W, Olmos D, Padhani A, Parker C, Rubin M, Schalken J, Scher H, Sella A, Shore N, Small E, Sternberg C, Suzuki H, Sweeney C, Tannock I, Tombal B. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Annals Of Oncology 2015, 26: 1589-1604. PMID: 26041764, PMCID: PMC4511225, DOI: 10.1093/annonc/mdv257.
- Galsky M, Stensland K, Moshier E, Sfakianos J, McBride R, Tsao C, Casey M, Hall S, Boffetta P, Oh W, Wisnivesky J. Effectiveness of adjuvant chemotherapy (AC) versus observation in patients with ≥ pT3 and/or pN+ bladder cancer (BCa). Journal Of Clinical Oncology 2015, 33: 4517-4517. DOI: 10.1200/jco.2015.33.15_suppl.4517.
- Galsky M, Hahn N, Albany C, Fleming M, Starodub A, Twardowski P, Hauke R, Sonpavde G, Merad M, Gnjatic S, Bhardwaj N, Chippada-Venkata U, Oh W, Kim-Schulze S. Impact of gemcitabine + cisplatin + ipilimumab on circulating immune cells in patients (pts) with metastatic urothelial cancer (mUC). Journal Of Clinical Oncology 2015, 33: 4586-4586. DOI: 10.1200/jco.2015.33.15_suppl.4586.
- Liaw B, Chippada-Venkata U, Gong Y, Wang L, Zhu J, Heck M, Tsao C, Galsky M, Oh W. Influence of prostate cancer disease state and therapeutic selection on peripheral whole-blood RNA signature. Journal Of Clinical Oncology 2015, 33: 5046-5046. DOI: 10.1200/jco.2015.33.15_suppl.5046.
- Oh W, Miao R, Duh M, Vekeman F, Sung J, Cheng W, Hennessy D, Gauthier-Loiselle M, Fortier J, Dhawan R. Clinical features and overall survival (OS) in patients (pts) with post-docetaxel (DTX) metastatic castration-resistant prostate cancer (mCRPC) receiving second-line (2L) therapy in the community setting. Journal Of Clinical Oncology 2015, 33: e16029-e16029. DOI: 10.1200/jco.2015.33.15_suppl.e16029.
- Shevach J, Gallagher E, Kochukoshy T, Gresia V, Brar M, Galsky M, Oh W. Influence of concurrent diabetes mellitus on clinical progression and response to androgen deprivation therapy in patients with advanced prostate cancer. Journal Of Clinical Oncology 2015, 33: e16036-e16036. DOI: 10.1200/jco.2015.33.15_suppl.e16036.
- Vogelzang N, Beer T, Bartunkova J, Kuklík R, Miller K, Oh W, Oudard S, Pandha H, Sartor A, Spisek R, Borgstein N, Gerritsen W. Autologous dendritic cell vaccination (DCVAC/PCa) added to docetaxel chemotherapy in a double-blind, randomized phase III trial (VIABLE) in men with advanced (mCRPC) prostate cancer. Journal Of Clinical Oncology 2015, 33: tps5070-tps5070. DOI: 10.1200/jco.2015.33.15_suppl.tps5070.
- Liaw B, Oh W. Is docetaxel the 'black widow' of mCRPC drugs? Nature Reviews Clinical Oncology 2015, 12: 316-318. PMID: 25917253, DOI: 10.1038/nrclinonc.2015.79.
- Liaw B, Chippada-Venkata U, Gong Y, Wang L, Zhu J, Heck M, Tsao C, Galsky M, Oh W. Influence of prostate cancer disease state and therapeutic selection on peripheral whole-blood RNA signature. Journal Of Clinical Oncology 2015, 33: 166-166. DOI: 10.1200/jco.2015.33.7_suppl.166.
- Galsky M, Stensland K, Moshier E, Sfakianos J, McBride R, Tsao C, Casey M, Hall S, Boffetta P, Oh W, Wisnivesky J. Comparative effectiveness of adjuvant chemotherapy (AC) versus observation in patients with ≥ pT3 and/or pN+ bladder cancer (BCa). Journal Of Clinical Oncology 2015, 33: 292-292. DOI: 10.1200/jco.2015.33.7_suppl.292.
- Leiter A, Doucette J, Krege S, Lin C, Hahn N, Ecke T, Sonpavde G, Bamias A, Oh W, Galsky M. Impact of obesity in patients with metastatic urothelial carcinoma. Journal Of Clinical Oncology 2015, 33: 346-346. DOI: 10.1200/jco.2015.33.7_suppl.346.
- Liaw B, Shevach J, Oh W. Systemic Therapy for the Treatment of Hormone-Sensitive Metastatic Prostate Cancer: from Intermittent Androgen Deprivation Therapy to Chemotherapy. Current Urology Reports 2015, 16: 13. PMID: 25677235, DOI: 10.1007/s11934-015-0486-x.
- Leiter A, Diefenbach M, Doucette J, Oh W, Galsky M. Clinical trial awareness: Changes over time and sociodemographic disparities. Clinical Trials 2015, 12: 215-223. PMID: 25673636, PMCID: PMC4667750, DOI: 10.1177/1740774515571917.
- Galsky M, Stensland K, McBride R, Latif A, Moshier E, Oh W, Wisnivesky J. Geographic Accessibility to Clinical Trials for Advanced Cancer in the United States. JAMA Internal Medicine 2015, 175: 293-295. PMID: 25437434, DOI: 10.1001/jamainternmed.2014.6300.
- Tsao C, Gray K, Nakabayashi M, Evan C, Kantoff P, Huang J, Galsky M, Pomerantz M, Oh W. Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease. Journal Of Urology 2015, 194: 91-97. PMID: 25623747, DOI: 10.1016/j.juro.2015.01.078.
- Casey M, Gross T, Wisnivesky J, Stensland K, Oh W, Galsky M. The Impact of Regionalization of Cystectomy on Racial Disparities in Bladder Cancer Care. Journal Of Urology 2015, 194: 36-41. PMID: 25623748, DOI: 10.1016/j.juro.2015.01.076.
- Gong Y, Chippada‐Venkata U, Galsky M, Huang J, Oh W. Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP‐1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer. The Prostate 2015, 75: 616-627. PMID: 25560638, DOI: 10.1002/pros.22945.
- Petrylak DP, Gandhi JG, Clark WR, Heath E, Lin J, Oh WK, Agus DB, Carthon B, Moran S, Kong N, Suri A, Bargfrede M, Liu G. Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel–prednisone in metastatic castration-resistant prostate cancer. Investigational New Drugs 2015, 33: 397-408. PMID: 25556680, PMCID: PMC4390470, DOI: 10.1007/s10637-014-0199-x.
- Tsao C, Liaw B, Oh W, Galsky M. Muscle invasive bladder cancer: closing the gap between practice and evidence. Minerva Urologica E Nefrologica 2014, 67: 65-73. PMID: 25424386.
- Sonpavde G, Wang C, Galsky M, Oh W, Armstrong A. Cytotoxic chemotherapy in the contemporary management of metastatic castration‐resistant prostate cancer (mCRPC). BJU International 2014, 116: 17-29. PMID: 25046451, DOI: 10.1111/bju.12867.
- Courtney K, Manola J, Elfiky A, Ross R, Oh W, Yap J, Van den Abbeele A, Ryan C, Beer T, Loda M, Priolo C, Kantoff P, Taplin M. A Phase I Study of Everolimus and Docetaxel in Patients With Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer 2014, 13: 113-123. PMID: 25450031, PMCID: PMC4418946, DOI: 10.1016/j.clgc.2014.08.007.
- Leiter A, Sablinski T, Diefenbach M, Foster M, Greenberg A, Holland J, Oh W, Galsky M. Use of Crowdsourcing for Cancer Clinical Trial Development. Journal Of The National Cancer Institute 2014, 106: dju258. PMID: 25217580, DOI: 10.1093/jnci/dju258.
- Stensland K, McBride R, Latif A, Wisnivesky J, Hendricks R, Roper N, Boffetta P, Hall S, Oh W, Galsky M. Adult Cancer Clinical Trials That Fail to Complete: An Epidemic? Journal Of The National Cancer Institute 2014, 106: dju229. PMID: 25190726, DOI: 10.1093/jnci/dju229.
- Agarwal N, Apolo A, Tsao C, Lee K, Godbold J, Soto R, Poole A, Gimpel‐Tetra K, Lowe N, Oh W, Galsky M. Phase Ib/II Trial of Gemcitabine, Cisplatin, and Lenalidomide as First‐Line Therapy in Patients With Metastatic Urothelial Carcinoma. The Oncologist 2014, 19: 915-916. PMID: 25052451, PMCID: PMC4153455, DOI: 10.1634/theoncologist.2014-0153.
- Martin J, Oh W. Evidence-Based Therapeutic Approaches for mCRPC Patients: Rational Sequence of Standard Treatment Options and Design for Future Drug Development. Current Clinical Urology 2014, 321-327. DOI: 10.1007/978-1-4939-1176-9_23.
- Galsky M, Posner M, Holcombe R, Lee K, Misiukiewicz K, Tsao C, Godbold J, Soto R, Gimpel-Tetra K, Lowe N, Oh W. Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors. Cancer Chemotherapy And Pharmacology 2014, 74: 465-471. PMID: 25023489, PMCID: PMC4146643, DOI: 10.1007/s00280-014-2518-5.
- Elfiky A, Pomerantz M, Katz L, Oh W. Genitourinary Cancers. 2014, 118-129. DOI: 10.1093/med/9780199358274.003.0013.
- Gong Y, Chippada-Venkata U, Oh W. Roles of Matrix Metalloproteinases and Their Natural Inhibitors in Prostate Cancer Progression. Cancers 2014, 6: 1298-1327. PMID: 24978435, PMCID: PMC4190542, DOI: 10.3390/cancers6031298.
- Galsky M, Oh W. Mind the gap: Efficacy versus effectiveness and pivotal prostate cancer clinical trial demographics. Cancer 2014, 120: 2944-2945. PMID: 24965362, DOI: 10.1002/cncr.28808.
- Saenger Y, Magidson J, Liaw B, de Moll E, Harcharik S, Fu Y, Wassmann K, Fisher D, Kirkwood J, Oh WK, Friedlander P. Blood mRNA Expression Profiling Predicts Survival in Patients Treated with Tremelimumab. Clinical Cancer Research 2014, 20: 3310-3318. PMID: 24721645, DOI: 10.1158/1078-0432.ccr-13-2906.
- Leiter A, Sablinski T, Diefenbach M, Foster M, Greenberg A, Holland J, Oh W, Galsky M. Use of crowdsourcing for cancer clinical trial development. Journal Of Clinical Oncology 2014, 32: e16019-e16019. DOI: 10.1200/jco.2014.32.15_suppl.e16019.
- Bickell N, Hall S, Stock R, Fei K, Veluswamy R, Franco R, Oh W. Does race affect the quality of treatment for intermediate-risk and high-risk prostate cancer? Journal Of Clinical Oncology 2014, 32: e17678-e17678. DOI: 10.1200/jco.2014.32.15_suppl.e17678.
- The metastatic castration-resistant prostate cancer treatment paradigm: more choices, more questionsYu E, Oh W. The metastatic castration-resistant prostate cancer treatment paradigm: more choices, more questions. Asian Journal Of Andrology 2014, 16: 331-333. PMID: 24759585, PMCID: PMC4023355, DOI: 10.4103/1008-682x.127813.
- Tsao C, Cutting E, Martin J, Oh W. The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer. Therapeutic Advances In Urology 2014, 6: 97-104. PMID: 24883107, PMCID: PMC4003844, DOI: 10.1177/1756287214528557.
- Tsao C, Small A, Hall S, Oh W, Galsky M, Buckstein M, Stock R, Ali G, Morris G. T2 Muscle-Invasive Bladder Cancer. Seminars In Oncology 2014, 41: e11-e18. PMID: 24787300, DOI: 10.1053/j.seminoncol.2014.03.005.
- Sivendran S, Chang R, Pham L, Phelps RG, Harcharik ST, Hall LD, Bernardo SG, Moskalenko MM, Sivendran M, Fu Y, de Moll EH, Pan M, Moon JY, Arora S, Cohain A, DiFeo A, Ferringer TC, Tismenetsky M, Tsui CL, Friedlander PA, Parides MK, Banchereau J, Chaussabel D, Lebwohl MG, Wolchok JD, Bhardwaj N, Burakoff SJ, Oh WK, Palucka K, Merad M, Schadt EE, Saenger YM. Dissection of Immune Gene Networks in Primary Melanoma Tumors Critical for Antitumor Surveillance of Patients with Stage II–III Resectable Disease. Journal Of Investigative Dermatology 2014, 134: 2202-2211. PMID: 24522433, PMCID: PMC4291112, DOI: 10.1038/jid.2014.85.
- Morgan C, Oh W, Naik G, Galsky M, Sonpavde G. Impact of prednisone on toxicities and survival in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of randomized clinical trials. Critical Reviews In Oncology/Hematology 2014, 90: 253-261. PMID: 24500033, DOI: 10.1016/j.critrevonc.2013.12.001.
- Liaw B, Seng S, Galsky M, Tsao C, Febbo P, Oh W. Biomarker development trial of satraplatin in patients with metastatic castrate-resistant prostate cancer. Journal Of Clinical Oncology 2014, 32: 170-170. DOI: 10.1200/jco.2014.32.4_suppl.170.
- Naik G, Morgan C, Galsky M, Oh W, Sonpavde G. Meta-analysis of randomized trials to study the impact of prednisone on toxicities and survival in metastatic castration-resistant prostate cancer. Journal Of Clinical Oncology 2014, 32: 28-28. DOI: 10.1200/jco.2014.32.4_suppl.28.
- Stensland K, McBride R, Wisnivesky J, Latif A, Hendricks R, Roper N, Boffetta P, Hall S, Oh W, Galsky M. Premature termination of genitourinary cancer clinical trials. Journal Of Clinical Oncology 2014, 32: 288-288. DOI: 10.1200/jco.2014.32.4_suppl.288.
- Casey M, Gross T, Stensland K, Oh W, Galsky M. Geographic and racial disparities in the utilization of low-volume cystectomy hospitals for bladder cancer. Journal Of Clinical Oncology 2014, 32: 302-302. DOI: 10.1200/jco.2014.32.4_suppl.302.
- Tsao C, Agarwal N, Apolo A, Lee K, Godbold J, Oh W, Galsky M. Phase Ib/II trial of gemcitabine, cisplatin, plus lenalidomide as first-line therapy for patients with metastatic urothelial carcinoma. Journal Of Clinical Oncology 2014, 32: 321-321. DOI: 10.1200/jco.2014.32.4_suppl.321.
- Oh W, Chippada Venkata U, Wang L, Reese E, Yee T, Kochukoshy T, Tsao C, Galsky M, Zhu J, Gong Y. Validation of a whole-blood RNA prognostic signature in metastatic castration-resistant prostate cancer (mCRPC) patients. Journal Of Clinical Oncology 2014, 32: 36-36. DOI: 10.1200/jco.2014.32.4_suppl.36.
- Galsky M, Latif A, Stensland K, Moshier E, McBride R, Hendricks R, Sonpavde G, Godbold J, Hall S, Oh W, Wisnivesky J. Distribution and geographic accessibility of prostate cancer clinical trials in the United States. Journal Of Clinical Oncology 2014, 32: 59-59. DOI: 10.1200/jco.2014.32.4_suppl.59.
- Tsao C, Galsky M, Oh W. Is Metastatic Prostate Cancer Changing, and How Will We Know It? It's Time for Standard Nomenclature for Nonosseous Metastases in Clinical Trials of Patients with Metastatic Castration Resistant Prostate Cancer. European Urology 2014, 66: 184-185. PMID: 24433812, DOI: 10.1016/j.eururo.2013.12.061.
- Doctor S, Tsao C, Godbold J, Galsky M, Oh W. Is prostate cancer changing?: Evolving patterns of metastatic castration‐resistant prostate cancer. Cancer 2013, 120: 833-839. PMID: 25302607, DOI: 10.1002/cncr.28494.
- Sivendran S, Latif A, McBride R, Stensland K, Wisnivesky J, Haines L, Oh W, Galsky M. Adverse Event Reporting in Cancer Clinical Trial Publications. Journal Of Clinical Oncology 2013, 32: 83-89. PMID: 24323037, DOI: 10.1200/jco.2013.52.2219.
- OH W, McDERMOTT D, PORTA C, LEVY A, ELAIDI R, SCOTTE F, HAWKINS R, CASTELLANO D, BELLMUNT J, RHA S, SUN J, NATHAN P, FEINBERG B, SCOTT J, McDERMOTT R, AHN J, WAGSTAFF J, CHANG Y, OU Y, DONNELLAN P, HUANG C, McCAFFREY J, CHIANG P, CHUANG C, KORVES C, NEARY M, DIAZ J, MEHMUD F, DUH M. Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review. International Journal Of Oncology 2013, 44: 5-16. PMID: 24247547, PMCID: PMC3867384, DOI: 10.3892/ijo.2013.2181.
- Oh W, Venkata U, Wang L, Reese E, Yee T, Kochukoshy T, Tsao C, Galsky M, Zhu J, Gong Y. MC13-0070 Whole blood RNA signature as prognostic and predictive biomarker in genitourinary malignancies. European Journal Of Cancer 2013, 49: s32. DOI: 10.1016/s0959-8049(13)70178-3.
- Gong Y, Scott E, Lu R, Xu Y, Oh W, Yu Q. TIMP-1 Promotes Accumulation of Cancer Associated Fibroblasts and Cancer Progression. PLOS ONE 2013, 8: e77366. PMID: 24143225, PMCID: PMC3797040, DOI: 10.1371/journal.pone.0077366.
- Galsky M, Moshier E, Krege S, Lin C, Hahn N, Ecke T, Sonpavde G, Pond G, Godbold J, Oh W, Bamias A. Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy. Urologic Oncology Seminars And Original Investigations 2013, 32: 48.e1-48.e8. PMID: 24055428, DOI: 10.1016/j.urolonc.2013.07.001.
- Gartrell B, Ying J, Sivendran S, Boucher K, Choueiri T, Sonpavde G, Oh W, Agarwal N, Galsky M. Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. Targeted Oncology 2013, 9: 195-204. PMID: 23852656, PMCID: PMC4744485, DOI: 10.1007/s11523-013-0289-2.
- Galsky M, Oh W. Tumour angiogenesis: an elusive target in castration-resistant prostate cancer. The Lancet Oncology 2013, 14: 681-682. PMID: 23742876, DOI: 10.1016/s1470-2045(13)70239-0.
- Galsky M, Krege S, Lin C, Hahn N, Ecke T, Moshier E, Sonpavde G, Godbold J, Oh W, Bamias A. Relationship between 6‐ and 9‐month progression‐free survival and overall survival in patients with metastatic urothelial cancer treated with first‐line cisplatin‐based chemotherapy. Cancer 2013, 119: 3020-3026. PMID: 23720197, DOI: 10.1002/cncr.28145.
- Galsky M, Moshier E, Krege S, Lin C, Hahn N, Ecke T, Sonpavde G, Godbold J, Oh W, Bamias A. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin‐based chemotherapy. Cancer 2013, 119: 3012-3019. PMID: 23720216, DOI: 10.1002/cncr.28146.
- Galsky M, Xie W, Nakabayashi M, Ross R, Fennessy F, Tempany C, Choueiri T, Khine K, Kantoff P, Taplin M, Oh W. Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer. Prostate Cancer And Prostatic Diseases 2013, 16: 266-270. PMID: 23712318, PMCID: PMC4026061, DOI: 10.1038/pcan.2013.15.
- Sivendran S, Chang R, Harcharik S, Hall L, Bernardo S, Moskalenko M, Phelps R, Sivendran M, Cohain A, DiFeo A, Parides M, Lebwohl M, Friedlander P, Banchereau J, Bhardwaj N, Oh W, Burakoff S, Palucka K, Merad M, Saenger Y. Immune gene expression in primary melanomas to predict lower risk of recurrence and death. Journal Of Clinical Oncology 2013, 31: 3014-3014. DOI: 10.1200/jco.2013.31.15_suppl.3014.
- Doctor S, Tsao C, Godbold J, Galsky M, Oh W. Evolving patterns of metastatic disease in castration-resistant prostate cancer (CRPC) reported in clinical trials from 1990 to 2011. Journal Of Clinical Oncology 2013, 31: 5015-5015. DOI: 10.1200/jco.2013.31.15_suppl.5015.
- Latif A, Stensland K, Hendricks R, Moshier E, Godbold J, Oh W, Galsky M. Cancer clinical trial accessibility in the United States: An analysis of travel distance. Journal Of Clinical Oncology 2013, 31: 6540-6540. DOI: 10.1200/jco.2013.31.15_suppl.6540.
- Stensland K, Latif A, Hendricks R, Roper N, McBride R, Hall S, Oh W, Galsky M. Prevalence and characteristics of prematurely terminated cancer clinical trials. Journal Of Clinical Oncology 2013, 31: 6613-6613. DOI: 10.1200/jco.2013.31.15_suppl.6613.
- Tsao C, Gray K, Nakabayashi M, Evan C, Galsky M, Kantoff P, Oh W, Pomerantz M. Association of Gleason 9-10 prostate cancer with worse outcomes compared to Gleason 8 disease. Journal Of Clinical Oncology 2013, 31: e16032-e16032. DOI: 10.1200/jco.2013.31.15_suppl.e16032.
- Saenger Y, Magidson J, Liaw B, Wassmann K, Barker W, Harcharik S, Fisher D, Oh W, Friedlander P. Blood mRNA signature to predict survival in patients with metastatic melanoma treated with tremelimumab. Journal Of Clinical Oncology 2013, 31: 9080-9080. DOI: 10.1200/jco.2013.31.15_suppl.9080.
- Sivendran S, Agarwal N, Gartrell B, Ying J, Boucher K, Choueiri T, Sonpavde, Oh W, Galsky M. Metabolic complications with the use of mTOR inhibitors for cancer therapy. Cancer Treatment Reviews 2013, 40: 190-196. PMID: 23684373, PMCID: PMC4744486, DOI: 10.1016/j.ctrv.2013.04.005.
- Haines L, Bamias A, Krege S, Lin C, Hahn N, Ecke T, Moshier E, Sonpavde, Godbold J, Oh W, Galsky M. The Impact of Gender on Outcomes in Patients With Metastatic Urothelial Carcinoma. Clinical Genitourinary Cancer 2013, 11: 346-352. PMID: 23673281, DOI: 10.1016/j.clgc.2013.04.010.
- Cookson M, Roth B, Dahm P, Engstrom C, Freedland S, Hussain M, Lin D, Lowrance W, Murad M, Oh W, Penson D, Kibel A. Castration-Resistant Prostate Cancer: AUA Guideline. Journal Of Urology 2013, 190: 429-438. PMID: 23665272, DOI: 10.1016/j.juro.2013.05.005.
- Mistry S, Oh W. New Paradigms in Microtubule-Mediated Endocrine Signaling in Prostate Cancer. Molecular Cancer Therapeutics 2013, 12: 555-566. PMID: 23635655, DOI: 10.1158/1535-7163.mct-12-0871.
- Tsao C, Liaw B, Yee T, Galsky M, Oh W. Metabolic and toxicological considerations of newly approved prostate cancer drugs. Expert Opinion On Drug Metabolism & Toxicology 2013, 9: 835-846. PMID: 23581700, DOI: 10.1517/17425255.2013.789019.
- Pollard M, Moskowitz A, Oh W, Galsky M, Hall S. 128 COST-EFFECTIVE ANALYSIS (CEA) OF THE CURRENT TREATMENT PARADIGM FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC). Journal Of Urology 2013, 189: e51-e52. DOI: 10.1016/j.juro.2013.02.1507.
- Mirza H, Oh W, Laptook, Vohr B, Tucker R, Stonestreet B. Indomethacin Prophylaxis to Prevent Intraventricular Hemorrhage: Association between Incidence and Timing of Drug Administration. The Journal Of Pediatrics 2013, 163: 706-710.e1. PMID: 23522865, PMCID: PMC3939677, DOI: 10.1016/j.jpeds.2013.02.030.
- Sivendran S, Ying J, Gartrell B, Agarwal N, Boucher K, Choueiri T, Sonpavde G, Oh W, Galsky M. Metabolic complications with the use of mTOR inhibitors for cancer therapy: A systematic review and meta-analysis. Journal Of Clinical Oncology 2013, 31: 398-398. DOI: 10.1200/jco.2013.31.6_suppl.398.
- Tsao C, Gray K, Nakabayashi M, Evan C, Galsky M, Kantoff P, Oh W, Pomerantz M. Association of Gleason 9-10 prostate cancer with worse outcomes compared to Gleason 8 disease. Journal Of Clinical Oncology 2013, 31: 157-157. DOI: 10.1200/jco.2013.31.6_suppl.157.
- Gartrell B, Ying J, Sivendran S, Agarwal N, Boucher K, Choueiri T, Sonpavde G, Oh W, Galsky M. Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: A systematic review and meta-analysis. Journal Of Clinical Oncology 2013, 31: 362-362. DOI: 10.1200/jco.2013.31.6_suppl.362.
- Bamias A, Krege S, Lin C, Hahn N, Ecke T, Moshier E, Sonpavde G, Godbold J, Oh W, Koutras A, Pu Y, Galsky M. Cisplatin-based combination chemotherapy in elderly patients with metastatic urothelial cancer. Journal Of Clinical Oncology 2013, 31: 269-269. DOI: 10.1200/jco.2013.31.6_suppl.269.
- Galsky M, Moshier E, Krege S, Lin C, Hahn N, Ecke T, Sonpavde G, Pond G, Godbold J, Oh W, Bamias A. Post-treatment prognostic model for patients (pts) with metastatic urothelial cancer (UC) treated with first-line chemotherapy. Journal Of Clinical Oncology 2013, 31: 256-256. DOI: 10.1200/jco.2013.31.6_suppl.256.
- Galsky M, Krege S, Lin C, Hahn N, Ecke T, Moshier E, Sonpavde G, Godbold J, Oh W, Bamias A. Progression-free survival as an endpoint for clinical trials in first-line metastatic urothelial cancer. Journal Of Clinical Oncology 2013, 31: 251-251. DOI: 10.1200/jco.2013.31.6_suppl.251.
- Galsky M, Xie W, Nakabayashi M, Ross R, Fennessy F, Tempany C, Choueiri T, Khine K, Kantoff P, Taplin M, Oh W. Paradoxical significance of endorectal MRI (erMRI) response to neoadjuvant chemotherapy in patients with high-risk localized prostate cancer (HRLPC). Journal Of Clinical Oncology 2013, 31: 23-23. DOI: 10.1200/jco.2013.31.6_suppl.23.
- Petrylak D, Gandhi J, Clark W, Heath E, Lin J, Oh W, Agus D, Carthon B, Moran S, Kong N, Suri A, Bargfrede M, Liu G. A phase I/II study of safety and efficacy of orteronel (TAK-700), an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC): Updated phase II results. Journal Of Clinical Oncology 2013, 31: 59-59. DOI: 10.1200/jco.2013.31.6_suppl.59.
- Oh W, Doctor S, Godbold J, Galsky M, Tsao C. Evolving patterns of metastatic disease in castration-resistant prostate cancer (CRPC) reported in clinical trials from 1990 to 2011. Journal Of Clinical Oncology 2013, 31: 195-195. DOI: 10.1200/jco.2013.31.6_suppl.195.
- Galsky M, Krege S, Lin C, Hahn N, Ecke T, Moshier E, Sonpavde G, Godbold J, Oh W, Bamias A. Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer. Urologic Oncology Seminars And Original Investigations 2013, 32: 30.e15-30.e21. PMID: 23428534, DOI: 10.1016/j.urolonc.2012.11.001.
- Tsao C, Small A, Kates M, Moshier E, Wisnivesky J, Gartrell B, Sonpavde G, Godbold J, Palese M, Hall S, Oh W, Galsky M. Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis. World Journal Of Urology 2012, 31: 1535-1539. PMID: 23223962, PMCID: PMC4744480, DOI: 10.1007/s00345-012-1001-3.
- Tsao C, Gartrell B, Oh W, Galsky M. Emerging personalized approaches for the management of advanced urothelial carcinoma. Expert Review Of Anticancer Therapy 2012, 12: 1537-1543. PMID: 23253220, PMCID: PMC4744482, DOI: 10.1586/era.12.141.
- Seng S, Tsao C, Oh W. Chemotherapy and Associated Symptoms. 2012, 835-858. DOI: 10.1142/9789814354912_0071.
- Seng S, Liu Z, Chiu S, Proverbs-Singh T, Sonpavde G, Choueiri T, Tsao C, Yu M, Hahn N, Oh W, Galsky M. Risk of Venous Thromboembolism in Patients With Cancer Treated With Cisplatin: A Systematic Review and Meta-Analysis. Journal Of Clinical Oncology 2012, 30: 4416-4426. PMID: 23150697, DOI: 10.1200/jco.2012.42.4358.
- Petrylak D, Gandhi J, Clark W, Heath E, Lin J, Oh W, Agus D, Carthon B, Moran S, Mortimer P, Liu G. P114 Safety and efficacy of orteronel (TAK-700), an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC): Phase 2 results from a phase 1/2 study. European Urology Open Science 2012, 11: 230. DOI: 10.1016/s1569-9056(13)60480-7.
- Proverbs-Singh T, Chiu S, Liu Z, Seng S, Sonpavde G, Choueiri T, Tsao C, Yu M, Hahn N, Oh W, Galsky M. Arterial Thromboembolism in Cancer Patients Treated With Cisplatin: A Systematic Review and Meta-analysis. Journal Of The National Cancer Institute 2012, 104: 1837-1840. PMID: 23093559, DOI: 10.1093/jnci/djs435.
- Tsao C, Oh W. Enzalutamide in metastatic CRPC—old dog, new tricks. Nature Reviews Clinical Oncology 2012, 9: 613-614. PMID: 23044775, DOI: 10.1038/nrclinonc.2012.181.
- Ross R, Galsky M, Scher H, Magidson J, Wassmann K, Lee G, Katz L, Subudhi S, Anand A, Fleisher M, Kantoff P, Oh W. A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. The Lancet Oncology 2012, 13: 1105-1113. PMID: 23059047, DOI: 10.1016/s1470-2045(12)70263-2.
- Lin C, Galsky M, Krege S, Hahn N, Ecke T, Sonpavde G, Oh W, Bamias A. WS14-7 Efficacy of Cisplatin-Based Chemotherapy as First-Line Treatment in Asian Patients with Metastatic Urothelial Carcinoma Results of an Exploratory Subgroup Analysis of a Pool Analysis of Phase II/III Trials. Annals Of Oncology 2012, 23: xi96-xi97. DOI: 10.1016/s0923-7534(20)32244-4.
- Tsao C, Galsky M, Small A, Yee T, Oh W. Targeting the androgen receptor signalling axis in castration‐resistant prostate cancer (CRPC). BJU International 2012, 110: 1580-1588. PMID: 22985411, DOI: 10.1111/j.1464-410x.2012.11445.x.
- Petrylak D, Gandhi J, Clark W, Heath E, Lin J, Oh W, Agus D, Carthon B, Moran S, Liu G. 918P Phase 2 Results from a Phase 1/2 Study of Tak-700 (ORTERONEL), An Oral, Investigational, Nonsteroidal 17,20-Lyase Inhibitor, with Docetaxel and Prednisone (DP) in Metastatic Castration-Resistant Prostate Cancer (MCRPC). Annals Of Oncology 2012, 23: ix302-ix303. DOI: 10.1016/s0923-7534(20)33476-1.
- Nakabayashi M, Werner L, Courtney K, Buckle G, Oh W, Bubley G, Hayes J, Weckstein D, Elfiky A, Sims D, Kantoff P, Taplin M. Phase II trial of RAD001 and bicalutamide for castration‐resistant prostate cancer. BJU International 2012, 110: 1729-1735. PMID: 22928480, DOI: 10.1111/j.1464-410x.2012.11456.x.
- Vinjamoori A, Jagannathan J, Shinagare A, Taplin M, Oh W, Van den Abbeele A, Ramaiya N. Atypical metastases from prostate cancer: 10-year experience at a single institution. American Journal Of Roentgenology 2012, 199: 367-72. PMID: 22826398, DOI: 10.2214/ajr.11.7533.
- Small A, Oh W. Bevacizumab treatment of prostate cancer. Expert Opinion On Biological Therapy 2012, 12: 1241-1249. PMID: 22775507, DOI: 10.1517/14712598.2012.704015.
- Small A, Tsao C, Moshier E, Gartrell B, Wisnivesky J, Godbold J, Smith C, Sonpavde, Oh W, Galsky M. Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy. Cancer 2012, 118: 5947-5954. PMID: 22707387, DOI: 10.1002/cncr.27658.
- Pomerantz M, Elfiky A, Katz L, Oh W. Genitourinary Cancers. 2012, 114-124. DOI: 10.1093/med/9780195366273.003.0013.
- Tsao C, Small A, Moshier E, Gartrell B, Wisnivesky J, Sonpavde, Godbold J, Palese M, Hall S, Oh W, Galsky M. Trends in the Use of Cytoreductive Nephrectomy in the United States. Clinical Genitourinary Cancer 2012, 10: 159-163. PMID: 22651971, PMCID: PMC4744481, DOI: 10.1016/j.clgc.2012.03.008.
- Sivendran S, Liu Z, Portas L, Yu M, Hahn N, Sonpavde, Oh W, Galsky M. Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: A meta-analysis. Cancer Treatment Reviews 2012, 38: 919-925. PMID: 22651902, DOI: 10.1016/j.ctrv.2012.05.001.
- Small A, Tsao C, Moshier E, Gartrell B, Wisnivesky J, Godbold J, Sonpavde G, Palese M, Hall S, Oh W, Galsky M. Trends and variations in utilization of nephron-sparing procedures for stage I kidney cancer in the United States. World Journal Of Urology 2012, 31: 1211-1217. PMID: 22622394, PMCID: PMC4744479, DOI: 10.1007/s00345-012-0873-6.
- Oh W, Kantoff P, Scher H, Magidson J, Wassmann K, Lee G, Katz L, Subudhi S, Anand A, Fleisher M, Galsky M, Ross R. A validated whole-blood RNA transcript-based prognostic model that predicts survival in men with castration-resistant prostate cancer. Journal Of Clinical Oncology 2012, 30: 4516-4516. DOI: 10.1200/jco.2012.30.15_suppl.4516.
- Galsky M, Krege S, Lin C, Hahn N, Ecke T, Moshier E, Sonpavde G, Godbold J, Oh W, Bamias A. Prognostic model for overall survival in patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. Journal Of Clinical Oncology 2012, 30: 4524-4524. DOI: 10.1200/jco.2012.30.15_suppl.4524.
- Tsao C, Small A, Kates M, Gartrell B, Wisnivesky J, Sonpavde G, Palese M, Hall S, Oh W, Galsky M. Trends in the use of cytoreductive nephrectomy for metastatic renal cell carcinoma in the VEGFR tyrosine kinase inhibitor era. Journal Of Clinical Oncology 2012, 30: 4623-4623. DOI: 10.1200/jco.2012.30.15_suppl.4623.
- Petrylak D, Gandhi J, Clark W, Heath E, Lin J, Oh W, Agus D, Kucuk O, Moran S, Wang J, Bargfrede M, Liu G. Phase I results from a phase I/II study of orteronel, an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC). Journal Of Clinical Oncology 2012, 30: 4656-4656. DOI: 10.1200/jco.2012.30.15_suppl.4656.
- Small A, Tsao C, Moshier E, Gartrell B, Wisnivesky J, Godbold J, Smith C, Sonpavde G, Oh W, Galsky M. Prevalence and characteristics of patients with stage IV solid tumors who receive no anticancer therapy. Journal Of Clinical Oncology 2012, 30: 6065-6065. DOI: 10.1200/jco.2012.30.15_suppl.6065.
- Seng S, Liu Z, Chiu S, Proverbs-Singh T, Sonpavde G, Choueiri T, Tsao C, Yu M, Hahn N, Oh W, Galsky M. Risk of venous thromboembolism in cancer patients treated with cisplatin: A systematic review and meta-analysis. Journal Of Clinical Oncology 2012, 30: e21016-e21016. DOI: 10.1200/jco.2012.30.15_suppl.e21016.
- Latif A, Small A, Moshier E, Adelson K, Raptis G, Godbold J, Oh W, Galsky M. Practice patterns in the use of adjuvant therapy for post-menopausal early-stage breast cancer in the pre- and post-Onco type DX era. Journal Of Clinical Oncology 2012, 30: e21032-e21032. DOI: 10.1200/jco.2012.30.15_suppl.e21032.
- Small A, Gong Y, Oh W, Hall S, van Rijn C, Galsky M. The Emerging Role of Circulating Tumor Cell Detection in Genitourinary Cancer. Journal Of Urology 2012, 188: 21-26. PMID: 22578722, DOI: 10.1016/j.juro.2012.02.2558.
- Tsao C, Small A, Galsky M, Oh W. Overcoming castration resistance in prostate cancer. Current Opinion In Urology 2012, 22: 167-174. PMID: 22472508, DOI: 10.1097/mou.0b013e3283523b8b.
- Galsky M, Small A, Tsao C, Oh W. Clinical development of novel therapeutics for castration‐resistant prostate cancer. CA A Cancer Journal For Clinicians 2012, 62: 299-308. PMID: 22535487, DOI: 10.3322/caac.21141.
- Morris B, Tyson J, Stevenson D, Oh W, Phelps D, O'Shea T, McDavid G, Van Meurs K, Vohr B, Grisby C, Yao Q, Kandefer S, Wallace D, Higgins R. Efficacy of phototherapy devices and outcomes among extremely low birth weight infants: multi-center observational study. Journal Of Perinatology 2012, 33: 126-133. PMID: 22499082, PMCID: PMC3570170, DOI: 10.1038/jp.2012.39.
- Small A, Tsao C, Moshier E, Godbold J, Palese M, Hall S, Oh W, Galsky M. 659 RACIAL AND SOCIOECONOMIC DISPARITIES IN THE UTILIZATION OF NEPHRON-SPARING PROCEDURES FOR STAGE I KIDNEY CANCER IN THE UNITED STATES. Journal Of Urology 2012, 187: e269. DOI: 10.1016/j.juro.2012.02.739.
- Lee B, Garcia J, Dreicer R, Tendulkar R, Stephans K, Magi-Galluzzi C, Klein E, Oh W, Stephenson A. 336 ALL HIGH-GRADE PROSTATE CANCERS CREATED EQUALLY? AN ANALYSIS OF CLINICAL FEATURES AND SURVIVAL AMONG PATIENTS WITH BIOPSY GLEASON SCORE 8, 9, AND 10 DISEASE. Journal Of Urology 2012, 187: e137. DOI: 10.1016/j.juro.2012.02.397.
- Small A, Tsao C, Moshier E, Godbold J, Sonpavde G, Oh W, Galsky M. Prevalence and characteristics of patients with metastatic prostate cancer who receive no anticancer therapy. Journal Of Clinical Oncology 2012, 30: 101-101. DOI: 10.1200/jco.2012.30.5_suppl.101.
- Tsao C, Moshier E, Small A, Sonpavde G, Godbold J, Oh W, Galsky M. Cytoreductive nephrectomy in the United States: Patterns of care and patient characteristics. Journal Of Clinical Oncology 2012, 30: 366-366. DOI: 10.1200/jco.2012.30.5_suppl.366.
- Ross R, Galsky M, Febbo P, Barry M, Richie J, Xie W, Fennessy F, Bhatt R, Hayes J, Choueiri T, Tempany C, Kantoff P, Taplin M, Oh W. Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high‐risk localized prostate cancer. Cancer 2012, 118: 4777-4784. PMID: 22282219, PMCID: PMC3791849, DOI: 10.1002/cncr.27416.
- Sun T, Oh W, Jacobus S, Regan M, Pomerantz M, Freedman M, Lee G, Kantoff P. The Impact of Common Genetic Variations in Genes of the Sex Hormone Metabolic Pathways on Steroid Hormone Levels and Prostate Cancer Aggressiveness. Cancer Prevention Research 2011, 4: 2044-2050. PMID: 21900597, PMCID: PMC3773969, DOI: 10.1158/1940-6207.capr-11-0283.
- Tsao C, Moshier E, Seng S, Godbold J, Grossman S, Winston J, Oh W, Galsky M. Impact of the CKD-EPI Equation for Estimating Renal Function on Eligibility for Cisplatin-based Chemotherapy in Patients With Urothelial Cancer. Clinical Genitourinary Cancer 2011, 10: 15-20. PMID: 22130294, DOI: 10.1016/j.clgc.2011.10.004.
- Nakabayashi M, Werner L, Oh W, Regan M, Kantoff P, Taplin M. Secondary Hormonal Therapy in Men With Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer 2011, 9: 95-103. PMID: 21958520, DOI: 10.1016/j.clgc.2011.06.006.
- Galsky M, Camacho L, Chiorean E, Mulkerin D, Hong D, Oh W, Bajorin D. Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors. Annals Of Oncology 2011, 23: 1037-1044. PMID: 21828377, DOI: 10.1093/annonc/mdr358.
- Oh W, Galsky M, Stadler W, Srinivas S, Chu F, Bubley G, Goddard J, Dunbar J, Ross R. Multicenter Phase II Trial of the Heat Shock Protein 90 Inhibitor, Retaspimycin Hydrochloride (IPI-504), in Patients With Castration-resistant Prostate Cancer. Urology 2011, 78: 626-630. PMID: 21762967, PMCID: PMC3166448, DOI: 10.1016/j.urology.2011.04.041.
- Galsky M, Seng S, Camacho L, Chiorean E, Mulkerin D, Hong D, Oh W, Bajorin D. Retrospective Analysis of Satraplatin in Patients with Metastatic Urothelial Cancer Refractory to Standard Platinum-Based Chemotherapy. Clinical Genitourinary Cancer 2011, 9: 27-30. PMID: 21700509, DOI: 10.1016/j.clgc.2011.05.003.
- Yang M, Xie W, Mostaghel E, Nakabayashi M, Werner L, Sun T, Pomerantz M, Freedman M, Ross R, Regan M, Sharifi N, Figg W, Balk S, Brown M, Taplin M, Oh W, Lee G, Kantoff P. SLCO2B1 and SLCO1B3 May Determine Time to Progression for Patients Receiving Androgen Deprivation Therapy for Prostate Cancer. Journal Of Clinical Oncology 2011, 29: 2565-2573. PMID: 21606417, PMCID: PMC3138634, DOI: 10.1200/jco.2010.31.2405.
- Oh W, Galsky M, Barry M, Fennessey F, Richie J, Hayes J, Bhatt R, Taplin M, Febbo P, Ross R. A phase II study of neoadjuvant docetaxel (D) plus bevacizumab (B) in patients (pts) with high-risk localized prostate cancer. Journal Of Clinical Oncology 2011, 29: 4642-4642. DOI: 10.1200/jco.2011.29.15_suppl.4642.
- Galsky M, Chen G, Oh W, Bellmunt J, Roth B, Petrioli R, Dogliotti L, Dreicer R, Sonpavde G. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Journal Of Clinical Oncology 2011, 29: e15027-e15027. DOI: 10.1200/jco.2011.29.15_suppl.e15027.
- Tsao C, Seng S, Grossman S, Oh W, Galsky M. Impact of the chronic kidney disease epidemiology collaboration (CKD-EPI) equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with bladder cancer. Journal Of Clinical Oncology 2011, 29: e15139-e15139. DOI: 10.1200/jco.2011.29.15_suppl.e15139.
- Seng S, Galsky M, Tsao C, Li J, Febbo P, Oh W. Predicting response to platinum chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) using a genomic signature for “BRCAness”: A phase II clinical trial of satraplatin in men with mCRPC who have progressed on docetaxel. Journal Of Clinical Oncology 2011, 29: tps191-tps191. DOI: 10.1200/jco.2011.29.15_suppl.tps191.
- Galsky M, Hahn N, Rosenberg J, Sonpavde G, Hutson T, Oh W, Dreicer R, Vogelzang N, Sternberg C, Bajorin D, Bellmunt J. Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy. Journal Of Clinical Oncology 2011, 29: 2432-2438. PMID: 21555688, DOI: 10.1200/jco.2011.34.8433.
- Galsky M, Chen G, Oh W, Bellmunt J, Roth B, Petrioli R, Dogliotti L, Dreicer R, Sonpavde G. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Annals Of Oncology 2011, 23: 406-410. PMID: 21543626, DOI: 10.1093/annonc/mdr156.
- Pomerantz M, Werner L, Xie W, Regan M, Lee G, Sun T, Evan C, Petrozziello G, Nakabayashi M, Oh W, Kantoff P, Freedman M. Association of Prostate Cancer Risk Loci with Disease Aggressiveness and Prostate Cancer–Specific Mortality. Cancer Prevention Research 2011, 4: 719-728. PMID: 21367958, PMCID: PMC3811002, DOI: 10.1158/1940-6207.capr-10-0292.
- Tsao C, Seng S, Oh W, Galsky M. Endocrine therapy for prostate cancer: review of the latest clinical evidence. Clinical Investigation 2011, 1: 533-541. DOI: 10.4155/cli.11.28.
- Tai S, Sun Y, Squires J, Zhang H, Oh W, Liang C, Huang J. PC3 is a cell line characteristic of prostatic small cell carcinoma. The Prostate 2011, 71: 1668-1679. PMID: 21432867, PMCID: PMC3426349, DOI: 10.1002/pros.21383.
- Misra D, Xie W, Regan M, Ross R, Lee G, Germain D, Kantoff P, Oh W. Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapy. BJU International 2011, 108: 1086-1091. PMID: 21410629, DOI: 10.1111/j.1464-410x.2010.10037.x.
- Sun T, Mary L, Oh W, Freedman M, Pomerantz M, Pienta K, Kantoff P. Inherited Variants in the Chemokine CCL2 Gene and Prostate Cancer Aggressiveness in a Caucasian Cohort. Clinical Cancer Research 2011, 17: 1546-1552. PMID: 21135144, PMCID: PMC3060307, DOI: 10.1158/1078-0432.ccr-10-2015.
- Galsky M, Hahn N, Rosenberg J, Sonpavde G, Oh W, Dreicer R, Vogelzang N, Sternberg C, Bajorin D, Bellmunt J. Defining “cisplatin ineligible” patients with metastatic bladder cancer. Journal Of Clinical Oncology 2011, 29: 238-238. DOI: 10.1200/jco.2011.29.7_suppl.238.
- Sonpavde G, Galsky M, Chen G, Bellmunt J, Roth B, Petrioli R, Hutson T, Dogliotti L, Dreicer R, Oh W. Meta-analysis of randomized trials comparing cisplatin versus carboplatin-based regimens for the first-line therapy of metastatic transitional cell carcinoma of the urothelium (TCCU). Journal Of Clinical Oncology 2011, 29: 247-247. DOI: 10.1200/jco.2011.29.7_suppl.247.
- Galsky M, Hahn N, Rosenberg J, Sonpavde, Hutson T, Oh W, Dreicer R, Vogelzang N, Sternberg C, Bajorin D, Bellmunt J. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. The Lancet Oncology 2011, 12: 211-214. PMID: 21376284, DOI: 10.1016/s1470-2045(10)70275-8.
- Tsao C, Seng S, Oh W, Galsky M. Clinical Development of Cabazitaxel for the Treatment of Castration-Resistant Prostate Cancer. Clinical Medicine Insights Oncology 2011, 5: cmo.s6566. PMID: 21695098, PMCID: PMC3117627, DOI: 10.4137/cmo.s6566.
- Abe M, Xie W, Regan M, King I, Stampfer M, Kantoff P, Oh W, Chan J. Single‐nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer. BJU International 2010, 107: 126-134. PMID: 20477822, PMCID: PMC3010266, DOI: 10.1111/j.1464-410x.2010.09344.x.
- Drzymalski D, Oh W, Werner L, Regan M, Kantoff P, Tuli S. Predictors of survival in patients with prostate cancer and spinal metastasis. Presented at the 2009 Joint Spine Section Meeting. Clinical article. Journal Of Neurosurgery Spine 2010, 13: 789-94. PMID: 21121759, DOI: 10.3171/2010.6.spine10167.
- Oh W, Burakoff S. Cancer Therapy from Bench to Bedside. Annals Of Global Health 2010, 77: 571-572. PMID: 21105120, DOI: 10.1002/msj.20221.
- Tsao C, Oh W. Selective cell death mediated by small conditional RNAs: a novel therapeutic approach to cancer therapy. Asian Journal Of Andrology 2010, 13: 181-2. PMID: 21076441, PMCID: PMC3739191, DOI: 10.1038/aja.2010.148.
- Pomerantz M, Shrestha Y, Flavin R, Regan M, Penney K, Mucci L, Stampfer M, Hunter D, Chanock S, Schafer E, Chan J, Tabernero J, Baselga J, Richardson A, Loda M, Oh W, Kantoff P, Hahn W, Freedman M. Analysis of the 10q11 Cancer Risk Locus Implicates MSMB and NCOA4 in Human Prostate Tumorigenesis. PLOS Genetics 2010, 6: e1001204. PMID: 21085629, PMCID: PMC2978684, DOI: 10.1371/journal.pgen.1001204.
- Anees M, Horak P, El‐Gazzar A, Susani M, Heinze G, Perco P, Loda M, Lis R, Krainer M, Oh W. Recurrence‐free survival in prostate cancer is related to increased stromal TRAIL expression. Cancer 2010, 117: 1172-1182. PMID: 21381010, DOI: 10.1002/cncr.25504.
- Penney K, Pyne S, Schumacher F, Sinnott J, Mucci L, Kraft P, Ma J, Oh W, Kurth T, Kantoff P, Giovannucci E, Stampfer M, Hunter D, Freedman M. Genome-wide Association Study of Prostate Cancer Mortality. Cancer Epidemiology Biomarkers & Prevention 2010, 19: 2869-2876. PMID: 20978177, PMCID: PMC3197738, DOI: 10.1158/1055-9965.epi-10-0601.
- Gansler T, Ganz P, Grant M, Greene F, Johnstone P, Mahoney M, Newman L, Oh W, Thomas C, Thun M, Vickers A, Wender R, Brawley O. Sixty Years of CA: A Cancer Journal for Clinicians. CA A Cancer Journal For Clinicians 2010, 60: 345-350. PMID: 21075954, DOI: 10.3322/caac.20088.
- Sun T, Lee G, Oh W, Pomerantz M, Yang M, Xie W, Freedman M, Kantoff P. Single-Nucleotide Polymorphisms in p53 Pathway and Aggressiveness of Prostate Cancer in a Caucasian Population. Clinical Cancer Research 2010, 16: 5244-5251. PMID: 20855462, PMCID: PMC2970725, DOI: 10.1158/1078-0432.ccr-10-1261.
- Choueiri T, McDermott D, Duh M, Sarda S, Neary M, Oh W. Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: Results from a medical chart review study. Urologic Oncology Seminars And Original Investigations 2010, 30: 848-855. PMID: 20926319, DOI: 10.1016/j.urolonc.2010.07.009.
- Oh W, Vargas R, Jacobus S, Leitzel K, Regan M, Hamer P, Pierce K, Brown‐Shimer S, Carney W, Ali S, Kantoff P, Lipton A. Elevated plasma tissue inhibitor of metalloproteinase‐1 levels predict decreased survival in castration‐resistant prostate cancer patients. Cancer 2010, 117: 517-525. PMID: 20862742, DOI: 10.1002/cncr.25394.
- Galsky M, Dritselis A, Kirkpatrick P, Oh W. Cabazitaxel. Nature Reviews Drug Discovery 2010, 9: 677-678. PMID: 20811375, DOI: 10.1038/nrd3254.
- Choueiri T, Regan M, Rosenberg J, Oh W, Clement J, Amato A, McDermott D, Cho D, Atkins M, Signoretti S. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear‐cell renal cell carcinoma receiving vascular endothelial growth factor‐targeted therapy. BJU International 2010, 106: 772-778. PMID: 20230385, DOI: 10.1111/j.1464-410x.2010.09218.x.
- Brick A, Niu J, Huang J, Oh W. Platinum Agents in Prostate Cancer. 2010, 153-161. DOI: 10.1007/978-1-60327-829-4_14.
- Sun T, Lee G, Werner L, Pomerantz M, Oh W, Kantoff P, Freedman M. Inherited Variations in AR, ESR1, and ESR2 Genes Are Not Associated With Prostate Cancer Aggressiveness or With Efficacy of Androgen Deprivation Therapy. Cancer Epidemiology Biomarkers & Prevention 2010, 19: 1871-1878. PMID: 20615892, PMCID: PMC3755451, DOI: 10.1158/1055-9965.epi-10-0216.
- Seng S, Tsao C, Galsky M, Oh W. Cytotoxic chemotherapy for castration resistant prostate cancer: 2010 and beyond. Drug Discovery Today Therapeutic Strategies 2010, 7: 17-22. DOI: 10.1016/j.ddstr.2011.02.001.
- Harrison M, Hahn N, Pili R, Oh W, Hammers H, Sweeney C, Kim K, Perlman S, Arnott J, Sidor C, Wilding G, Liu G. A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). Investigational New Drugs 2010, 29: 1465-1474. PMID: 20499131, PMCID: PMC3042040, DOI: 10.1007/s10637-010-9455-x.
- Buckle G, Werner L, Oh W, Bubley G, Hayes J, Weckstein D, Elfiky A, Sims D, Kantoff P, Taplin M. Phase II trial of RAD001 (R) and bicalutamide (B) for castration-resistant prostrate cancer (CPRC). Journal Of Clinical Oncology 2010, 28: 4660-4660. DOI: 10.1200/jco.2010.28.15_suppl.4660.
- Elfiky A, Cho D, McDermott D, Rosenberg J, Fortner B, Antràs L, Chen K, Duh M, Jayawant S, Oh W, Atkins M, Choueiri T. Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma. Urologic Oncology Seminars And Original Investigations 2010, 29: 756-763. PMID: 20451414, DOI: 10.1016/j.urolonc.2010.01.008.
- Oh W, McDermott D, Duh, Antràs L, Chen K, Sarda S, Luka A, Whittemore S, Ramamurthy P, Neary M, Choueiri T. PCN50 COSTS OF TREATMENT WITH ANGIOGENESIS INHIBITORS (AIS) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC): RESULTS FROM A MEDICAL CHART REVIEW STUDY. Value In Health 2010, 13: a32. DOI: 10.1016/s1098-3015(10)72139-2.
- Dial E, Duh, Antras L, Rodermund D, Neary M, Choueiri T, Oh W. PUK1 INCIDENCE AND COST OF ADVERSE EVENTS (AES) IN PATIENTS WITH RENAL CELL CARCINOMA (RCC) TREATED WITH ANGIOGENESIS INHIBITORS (AIS). Value In Health 2010, 13: a76. DOI: 10.1016/s1098-3015(10)72356-1.
- Choueiri T, Duh M, Clement J, Brick A, Rogers M, Kwabi C, Shah K, Percy A, Antràs L, Jayawant S, Chen K, Wang S, Luka A, Neary M, McDermott D, Oh W. Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice‐based on medical chart review. BJU International 2010, 105: 1247-1254. PMID: 19863525, DOI: 10.1111/j.1464-410x.2009.08972.x.
- Weinberg A, Alemozaffar M, Soukup J, Kacker R, Choi W, Oh W, Hu J. 587 THE EFFECT OF NEO-ADJUVANT CHEMOTHERAPY ON RADICAL PROSTATECTOMY OUTCOMES IN INTERMEDIATE AND HIGH-RISK PROSTATE CANCER. Journal Of Urology 2010, 183: e230-e231. DOI: 10.1016/j.juro.2010.02.859.
- Bellmunt J, Oh W. Review: Castration-resistant prostate cancer: new science and therapeutic prospects. Therapeutic Advances In Medical Oncology 2010, 2: 189-207. PMID: 21789134, PMCID: PMC3126017, DOI: 10.1177/1758834009359769.
- Oh W, Hu J. Preface. Urologic Clinics Of North America 2010, 37: xiii. PMID: 20152513, DOI: 10.1016/j.ucl.2009.12.001.
- Schutz F, Oh W. Neoadjuvant and Adjuvant Therapies in Prostate Cancer. Urologic Clinics Of North America 2010, 37: 97-104. PMID: 20152523, DOI: 10.1016/j.ucl.2009.11.012.
- Oh W, Ross R, Choueiri T, Kantoff P, Corless C. 8 Cancer of the Genitourinary Tract. 2010, 233-277. DOI: 10.1016/b978-0-323-05905-3.00008-x.
- Oh W, Landrum M, Lamont E, McNeil B, Keating N. Does Oral Antiandrogen Use Before Leuteinizing Hormone-releasing Hormone Therapy in Patients With Metastatic Prostate Cancer Prevent Clinical Consequences of a Testosterone Flare? Urology 2009, 75: 642-647. PMID: 19962733, DOI: 10.1016/j.urology.2009.08.008.
- Taplin M, Regan M, Ko Y, Bubley G, Duggan S, Werner L, Beer T, Ryan C, Mathew P, Tu S, Denmeade S, Oh W, Sartor O, Mantzoros C, Rittmaster R, Kantoff P, Balk S. Phase II Study of Androgen Synthesis Inhibition with Ketoconazole, Hydrocortisone, and Dutasteride in Asymptomatic Castration-Resistant Prostate Cancer. Clinical Cancer Research 2009, 15: 7099-7105. PMID: 19887483, PMCID: PMC3644858, DOI: 10.1158/1078-0432.ccr-09-1722.
- Nakabayashi M, Oh W, Jacobus S, Regan M, Taplin M, Kantoff P, Rosenberg J. Activity of ketoconazole after taxane‐based chemotherapy in castration‐resistant prostate cancer. BJU International 2009, 105: 1392-1396. PMID: 19863532, DOI: 10.1111/j.1464-410x.2009.08971.x.
- Mercer J, Vohr B, Erickson-Owens D, Padbury J, Oh W. Seven-month developmental outcomes of very low birth weight infants enrolled in a randomized controlled trial of delayed versus immediate cord clamping. Journal Of Perinatology 2009, 30: 11-16. PMID: 19847185, PMCID: PMC2799542, DOI: 10.1038/jp.2009.170.
- Heng D, Xie W, Regan M, Warren M, Golshayan A, Sahi C, Eigl B, Ruether J, Cheng T, North S, Venner P, Knox J, N. K, Kollmannsberger C, McDermott D, Oh W, Atkins M, Bukowski R, Rini B, Choueiri T. Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study. Journal Of Clinical Oncology 2009, 27: 5794-5799. PMID: 19826129, DOI: 10.1200/jco.2008.21.4809.
- Aggarwal R, Weinberg V, Small E, Oh W, Rushakoff R, Ryan C. The Mechanism of Action of Estrogen in Castration-Resistant Prostate Cancer: Clues From Hormone Levels. Clinical Genitourinary Cancer 2009, 7: e71-e76. PMID: 19815485, DOI: 10.3816/cgc.2009.n.027.
- Oh W, Magidson J, Bankaitis-Davis D, Siconolfi L, Schurko B, Cantu R, Braitsch S, Wassman K, Kantoff P, Ross R. PP138 A whole blood RNA transcript-based model to predict biopsy Gleason score in newly diagnosed prostate cancer patients. European Journal Of Cancer Supplements 2009, 7: 27. DOI: 10.1016/s1359-6349(09)72197-4.
- Sartor O, Nakabayashi M, Taplin M, Ross R, Kantoff P, Balk S, Oh W. Activity of Dutasteride Plus Ketoconazole in Castration-Refractory Prostate Cancer After Progression on Ketoconazole Alone. Clinical Genitourinary Cancer 2009, 7: e90-e92. PMID: 19815488, DOI: 10.3816/cgc.2009.n.030.
- Jacobsen E, Chen J, Schurko B, Benson C, Oh W. Metastatic seminoma and grade 1 follicular lymphoma presenting concurrently in a supraclavicular lymph node: a case report. Cases Journal 2009, 2: 7273. PMID: 19918516, PMCID: PMC2769346, DOI: 10.4076/1757-1626-2-7273.
- Jia L, Landan G, Pomerantz M, Jaschek R, Herman P, Reich D, Yan C, Khalid O, Kantoff P, Oh W, Manak J, Berman B, Henderson B, Frenkel B, Haiman C, Freedman M, Tanay A, Coetzee G. Functional Enhancers at the Gene-Poor 8q24 Cancer-Linked Locus. PLOS Genetics 2009, 5: e1000597. PMID: 19680443, PMCID: PMC2717370, DOI: 10.1371/journal.pgen.1000597.
- Regan M, O'Donnell E, Kelly W, Halabi S, Berry W, Urakami S, Kikuno N, Oh W. Efficacy of carboplatin–taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials. Annals Of Oncology 2009, 21: 312-318. PMID: 19633053, PMCID: PMC2852201, DOI: 10.1093/annonc/mdp308.
- Duh M, Dial E, Choueiri T, Fournier A, Antras L, Rodermund D, Neary M, Oh W. Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis*. Current Medical Research And Opinion 2009, 25: 2081-2090. PMID: 19586325, DOI: 10.1185/03007990903084800.
- Pomerantz M, Beckwith C, Regan M, Wyman S, Petrovics G, Chen Y, Hawksworth D, Schumacher F, Mucci L, Penney K, Stampfer M, Chan J, Ardlie K, Fritz B, Parkin R, Lin D, Dyke M, Herman P, Lee S, Oh W, Kantoff P, Tewari M, McLeod D, Srivastava S, Freedman M. Evaluation of the 8q24 Prostate Cancer Risk Locus and MYC Expression. Cancer Research 2009, 69: 5568-5574. PMID: 19549893, PMCID: PMC2884104, DOI: 10.1158/0008-5472.can-09-0387.
- Chan J, Oh W, Xie W, Regan M, Stampfer M, King I, Abe M, Kantoff P. Plasma Selenium, Manganese Superoxide Dismutase, and Intermediate- or High-Risk Prostate Cancer. Journal Of Clinical Oncology 2009, 27: 3577-3583. PMID: 19528373, PMCID: PMC2720077, DOI: 10.1200/jco.2008.18.8938.
- Ross R, Bankaitis-Davis D, Siconolfi L, Katz L, Storm K, Magidson J, Wassmann K, Oh W. Sensitivity and specificity of a whole-blood RNA transcript-based diagnostic test for the diagnosis of prostate cancer (CaP) compared with prostate-specific antigen (PSA) alone. Journal Of Clinical Oncology 2009, 27: 5052-5052. DOI: 10.1200/jco.2009.27.15_suppl.5052.
- Oh W, Febbo P, Richie J, Fennessy F, Scibelli G, Hayes J, Choueiri T, Tempany C, Taplin M, Ross R. A phase II study of neoadjuvant chemotherapy with docetaxel and bevacizumab in patients (pts) with high-risk localized prostate cancer: A Prostate Cancer Clinical Trials Consortium trial. Journal Of Clinical Oncology 2009, 27: 5060-5060. DOI: 10.1200/jco.2009.27.15_suppl.5060.
- Dial E, Duh M, Fournier A, Antras L, Rodermund D, Neary M, Oh W. Cost implications of intravenous bevacizumab treatment in patients with renal cell carcinoma (RCC): A retrospective claims database analysis. Journal Of Clinical Oncology 2009, 27: 5112-5112. DOI: 10.1200/jco.2009.27.15_suppl.5112.
- Vinson J, Mathew P, Beer T, Carducci M, Oh W, Small E, Wilding G, Higano C, Hussain M, Scher H. Prostate cancer clinical trials consortium: A multicenter mechanism for the rapid design, development, and implementation of early phase clinical trials. Journal Of Clinical Oncology 2009, 27: e16065-e16065. DOI: 10.1200/jco.2009.27.15_suppl.e16065.
- Choueiri T, Regan M, Oh W, Clement J, Amato A, McDermott D, Cho D, Atkins M, Signoretti S. Prognostic and predictive values of carbonic anhydrase IX (CAIX) and pathologic features in patients with metastatic clear cell renal cell carcinoma receiving targeted therapy. Journal Of Clinical Oncology 2009, 27: e16067-e16067. DOI: 10.1200/jco.2009.27.15_suppl.e16067.
- Michaelson M, Regan M, Oh W, Kaufman D, Olivier K, Michaelson S, Spicer B, Gurski C, Kantoff P, Smith M. Phase II study of sunitinib in men with advanced prostate cancer. Annals Of Oncology 2009, 20: 913-920. PMID: 19403935, PMCID: PMC2674960, DOI: 10.1093/annonc/mdp111.
- Penney K, Salinas C, Pomerantz M, Schumacher F, Beckwith C, Lee G, Oh W, Sartor O, Ostrander E, Kurth T, Ma J, Mucci L, Stanford J, Kantoff P, Hunter D, Stampfer M, Freedman M. Evaluation of 8q24 and 17q Risk Loci and Prostate Cancer Mortality. Clinical Cancer Research 2009, 15: 3223-3230. PMID: 19366828, PMCID: PMC2878092, DOI: 10.1158/1078-0432.ccr-08-2733.
- Priolo C, Oh W, Loda M. Novel therapeutic strategies in prostate cancer: establishing a stratification system for patient selection in targeted trials. IDrugs 2009, 12: 165-8. PMID: 19333896.
- Sher D, Oh W. Reply. Urology 2009, 73: 362. DOI: 10.1016/j.urology.2008.09.016.
- Choueiri T, Xie W, D'Amico A, Ross R, Hu J, Pomerantz M, Regan M, Taplin M, Kantoff P, Sartor O, Oh W. Time to prostate‐specific antigen nadir independently predicts overall survival in patients who have metastatic hormone‐sensitive prostate cancer treated with androgen‐deprivation therapy. Cancer 2009, 115: 981-987. PMID: 19152438, PMCID: PMC2931827, DOI: 10.1002/cncr.24064.
- Morris M, Basch E, Wilding G, Hussain M, Carducci M, Higano C, Kantoff P, Oh W, Small E, George D, Mathew P, Beer T, Slovin S, Ryan C, Logothetis C, Scher H. Department of Defense Prostate Cancer Clinical Trials Consortium: A New Instrument for Prostate Cancer Clinical Research. Clinical Genitourinary Cancer 2009, 7: 51-57. PMID: 19213669, PMCID: PMC3394090, DOI: 10.3816/cgc.2009.n.009.
- Sher D, Mantzoros C, Jacobus S, Regan M, Lee G, Oh W. Absence of Relationship Between Steroid Hormone Levels and Prostate Cancer Tumor Grade. Urology 2008, 73: 356-361. PMID: 19036418, DOI: 10.1016/j.urology.2008.07.068.
- Romanus D, Oh W, Cook F, Weeks J. PCN86 SYMPTOM PREVALENCE IN HORMONE REFRACTORY PROSTATE CANCER (HRPC). Value In Health 2008, 11: a487. DOI: 10.1016/s1098-3015(10)66623-5.
- Rosenberg J, Oh W. What is the current status of second-line chemotherapy for castration-resistant prostate cancer? Nature Reviews Urology 2008, 5: 650-651. PMID: 18936787, DOI: 10.1038/ncpuro1232.
- Mathew P, Thall P, Wen S, Bucana C, Jones D, Horne E, Oh W, Morris M, Lee Y, Logothetis C, Lin S, Fidler I. Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer. British Journal Of Cancer 2008, 99: 1426-1432. PMID: 18841158, PMCID: PMC2579696, DOI: 10.1038/sj.bjc.6604706.
- Simon R, di Sant'Agnese P, Huang L, Xu H, Yao J, Yang Q, Liang S, Liu J, Yu R, Cheng L, Oh W, Palapattu G, Wei J, Huang J. CD44 expression is a feature of prostatic small cell Carcinoma and Distinguishes it from its Mimickers. Human Pathology 2008, 40: 252-258. PMID: 18835619, DOI: 10.1016/j.humpath.2008.07.014.
- Schurko B, Oh W. Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer. Nature Reviews Clinical Oncology 2008, 5: 506-507. PMID: 18648352, DOI: 10.1038/ncponc1201.
- Sher D, Oh W, Jacobus S, Regan M, Lee G, Mantzoros C. Relationship between serum adiponectin and prostate cancer grade. The Prostate 2008, 68: 1592-1598. PMID: 18646046, DOI: 10.1002/pros.20823.
- Clement J, McDermott D, Choueiri T, Brick A, Kwabi C, Shah K, Weiner J, Duh M, Neary M, Oh W. Patients with metastatic renal cell carcinoma (mRCC) receiving sunitinib in “real-world” clinical practice: Baseline characteristics and treatment efficacy. Journal Of Clinical Oncology 2008, 26: 16071-16071. DOI: 10.1200/jco.2008.26.15_suppl.16071.
- Oh W, Leitzel K, Jacobus S, Vargas R, Regan M, Hamer P, Carney W, Ali S, Kantoff P, Lipton A. Elevated plasma TIMP-1 and survival in metastatic castration-resistant prostate cancer patients. Journal Of Clinical Oncology 2008, 26: 11077-11077. DOI: 10.1200/jco.2008.26.15_suppl.11077.
- Duh M, Fournier A, Moyneur E, Dial E, Neary M, Oh W. Dosing and switching patterns for renal cell carcinoma (RCC) patients receiving selected angiogenesis inhibitor therapies. Journal Of Clinical Oncology 2008, 26: 5111-5111. DOI: 10.1200/jco.2008.26.15_suppl.5111.
- Jacobus S, Sher D, Regan M, Chamberland J, Oh W, Mantzoros C. Association between serum adiponectin and prostate cancer risk. Journal Of Clinical Oncology 2008, 26: 5147-5147. DOI: 10.1200/jco.2008.26.15_suppl.5147.
- Harrison M, Hahn N, Pili R, Oh W, Kim K, Wilding G, Sweeney C, Sidor C, Arnott J, Liu G. Phase II study of 2-methoxyestradiol (2ME2) NanoCrystal Dispersion (NCD) in patients with taxane-refractory, metastatic hormone-refractory prostate cancer (HRPC). Journal Of Clinical Oncology 2008, 26: 5173-5173. DOI: 10.1200/jco.2008.26.15_suppl.5173.
- Taplin M, Ko Y, Regan M, Beer T, Carducci M, Mathew P, Bubley G, Oh W, Kantoff P, Balk S. Phase II trial of ketoconazole, hydrocortisone, and dutasteride (KHAD) for castration resistant prostate cancer (CRPC). Journal Of Clinical Oncology 2008, 26: 5068-5068. DOI: 10.1200/jco.2008.26.15_suppl.5068.
- Ross R, Manola J, Oh W, Ryan C, Kim J, Rastarhuyeva I, Yap J, Van Den Abbeele A, Kantoff P, Taplin M. Phase I trial of RAD001 (R) and docetaxel (D) in castration resistant prostate cancer (CRPC) with FDG-PET assessment of RAD001 activity. Journal Of Clinical Oncology 2008, 26: 5069-5069. DOI: 10.1200/jco.2008.26.15_suppl.5069.
- Pomerantz M, Beckwith C, Regan M, Xie W, Herman P, Chan J, Ardlie K, Oh W, Kantoff P, Freedman M. Quantitative gene expression at the 8q24 prostate cancer risk locus. Journal Of Clinical Oncology 2008, 26: 5055-5055. DOI: 10.1200/jco.2008.26.15_suppl.5055.
- Dial E, Fournier A, Moyneur E, Neary M, Duh M, Oh W. Frequency and cost of adverse events in renal cell carcinoma (RCC) patients receiving angiogenesis inhibitor therapies. Journal Of Clinical Oncology 2008, 26: 14609-14609. DOI: 10.1200/jco.2008.26.15_suppl.14609.
- Brick A, McDermott D, Clement J, Kwabi C, Shah K, Weiner J, Duh M, Neary M, Oh W, Choueiri T. Treatment discontinuations, dose reductions, and interruptions for angiogenesis inhibitor therapies in patients with metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2008, 26: 14636-14636. DOI: 10.1200/jco.2008.26.15_suppl.14636.
- Fournier A, Duh, Moyneur É, Dial E, Neary M, Oh W. PUK15 COST IMPLICATIONS OF INTRAVENOUS (IV) BEVACIZUMAB TREATMENT IN PATIENTS WITH RENAL CELL CARCINOMA (RCC). Value In Health 2008, 11: a304-a305. DOI: 10.1016/s1098-3015(10)70960-8.
- Taplin M, Manola J, Oh W, Kantoff P, Bubley G, Smith M, Barb D, Mantzoros C, Gelmann E, Balk S. A phase II study of mifepristone (RU‐486) in castration‐resistant prostate cancer, with a correlative assessment of androgen‐related hormones. BJU International 2008, 101: 1084-1089. PMID: 18399827, DOI: 10.1111/j.1464-410x.2008.07509.x.
- Ross R, Oh W, Xie W, Pomerantz M, Nakabayashi M, Sartor O, Taplin M, Regan M, Kantoff P, Freedman M. Inherited Variation in the Androgen Pathway Is Associated With the Efficacy of Androgen-Deprivation Therapy in Men With Prostate Cancer. Journal Of Clinical Oncology 2008, 26: 842-847. PMID: 18281655, DOI: 10.1200/jco.2007.13.6804.
- Ross R, Xie W, Regan M, Pomerantz M, Nakabayashi M, Daskivich T, Sartor O, Taplin M, Kantoff P, Oh W. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer. Cancer 2008, 112: 1247-1253. PMID: 18293426, DOI: 10.1002/cncr.23304.
- Keating N, O’Malley A, McNaughton‐Collins M, Oh W, Smith M. Use of androgen deprivation therapy for metastatic prostate cancer in older men. BJU International 2008, 101: 1077-1083. PMID: 18190632, PMCID: PMC2900629, DOI: 10.1111/j.1464-410x.2007.07405.x.
- Nakabayashi M, Sartor O, Jacobus S, Regan M, McKearn D, Ross R, Kantoff P, Taplin M, Oh W. Response to docetaxel/carboplatin‐based chemotherapy as first‐ and second‐line therapy in patients with metastatic hormone‐refractory prostate cancer. BJU International 2008, 101: 308-312. PMID: 18184327, DOI: 10.1111/j.1464-410x.2007.07331.x.
- Ross R, Beer T, Jacobus S, Bubley G, Taplin M, Ryan C, Huang J, Oh W. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone‐refractory prostate cancer who are refractory to docetaxel. Cancer 2007, 112: 521-526. PMID: 18085595, DOI: 10.1002/cncr.23195.
- Xie W, Nakabayashi M, Regan M, Oh W. Higher prostate‐specific antigen levels predict improved survival in patients with hormone‐refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase. Cancer 2007, 110: 2709-2715. PMID: 17960608, DOI: 10.1002/cncr.23111.
- Avigan D, Vasir B, George D, Oh W, Atkins M, McDermott D, Kantoff P, Figlin R, Vasconcelles M, Xu Y, Kufe D, Bukowski R. Phase I/II Study of Vaccination With Electrofused Allogeneic Dendritic Cells/Autologous Tumor-derived Cells in Patients With Stage IV Renal Cell Carcinoma. Journal Of Immunotherapy 2007, 30: 749-761. PMID: 17893567, DOI: 10.1097/cji.0b013e3180de4ce8.
- Mathew P, Thall P, Bucana C, Oh W, Morris M, Jones D, Johnson M, Wen S, Pagliaro L, Tannir N, Tu S, Meluch A, Smith L, Cohen L, Kim S, Troncoso P, Fidler I, Logothetis C. Platelet-Derived Growth Factor Receptor Inhibition and Chemotherapy for Castration-Resistant Prostate Cancer with Bone Metastases. Clinical Cancer Research 2007, 13: 5816-5824. PMID: 17908974, DOI: 10.1158/1078-0432.ccr-07-1269.
- Daskivich T, Regan M, Oh W. Distinct Prognostic Role of Prostate-Specific Antigen Doubling Time and Velocity at Emergence of Androgen Independence in Patients Treated with Chemotherapy. Urology 2007, 70: 527-531. PMID: 17905110, DOI: 10.1016/j.urology.2007.04.035.
- Samnotra V, Vassilopoulou-Sellin R, Fojo A, Oh W, LaRocca R, Ernstoff M, Memoli V, Cole B, Quinn D, Simmons P, Tretter C. A phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC). Journal Of Clinical Oncology 2007, 25: 15527-15527. DOI: 10.1200/jco.2007.25.18_suppl.15527.
- Oh W, Leitzel K, Kantoff P, Regan M, Hamer P, Pierce K, Brown-Shimer S, Carney W, Ali S, Lipton A. Elevated plasma TIMP-1 levels predict reduced survival in metastatic hormone-refractory prostate cancer patients. Journal Of Clinical Oncology 2007, 25: 5143-5143. DOI: 10.1200/jco.2007.25.18_suppl.5143.
- Nakabayashi M, Sartor O, Jacobus S, Regan M, McKearn D, Ross R, Kantoff P, Taplin M, Oh W. Response to docetaxel (D)/carboplatin (C)-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer (HRPC). Journal Of Clinical Oncology 2007, 25: 5156-5156. DOI: 10.1200/jco.2007.25.18_suppl.5156.
- Pomerantz M, Manola J, Taplin M, Bubley G, Inman M, Lowell J, Beard C, Kantoff P, Oh W. Phase II Study of Low Dose and High Dose Conjugated Estrogen for Androgen Independent Prostate Cancer. Journal Of Urology 2007, 177: 2146-2150. PMID: 17509304, DOI: 10.1016/j.juro.2007.01.119.
- Oh W. Editorial Comment. Journal Of Urology 2007, 177: 2145. DOI: 10.1016/j.juro.2007.01.265.
- Nakabayashi M, Ling J, Xie W, Regan M, Oh W. Response to Vinorelbine With or Without Estramustine as Second-Line Chemotherapy in Patients with Hormone-Refractory Prostate Cancer. The Cancer Journal 2007, 13: 125-129. PMID: 17476141, DOI: 10.1097/ppo.0b013e3180465940.
- Oh W, Proctor K, Nakabayashi M, Evan C, Tormey L, Daskivich T, Antràs L, Smith M, Neary M, Duh M. The risk of renal impairment in hormone‐refractory prostate cancer patients with bone metastases treated with zoledronic acid. Cancer 2007, 109: 1090-1096. PMID: 17311345, DOI: 10.1002/cncr.22504.
- Oh W, Tay M, Huang J. Is there a role for platinum chemotherapy in the treatment of patients with hormone‐refractory prostate cancer? Cancer 2006, 109: 477-486. PMID: 17186531, DOI: 10.1002/cncr.22439.
- STERNBERG C, KRAINER M, OH W, BRACARDA S, BELLMUNT J, OZEN H, ZLOTTA A, BEER T, OUDARD S, RAUCHENWALD M, SKONECZNA I, BORNER M, FITZPATRICK J. The medical management of prostate cancer: a multidisciplinary team approach. BJU International 2006, 99: 22-27. PMID: 16956362, DOI: 10.1111/j.1464-410x.2006.06477.x.
- Mathew P, Thall P, Wen S, Horne E, Johnson M, Oh W, Morris M, Logothetis C, Fidler I, Bucana C. 79 POSTER Correlative results of in-vivo monitoring of platelet-derived growth factor receptor (PDGFR) activation status in a randomized placebocontrolled trial of docetaxel +/− imatinib in castration-resistant prostate cancer (CRPC) and bone metastases (BM). European Journal Of Cancer Supplements 2006, 4: 28. DOI: 10.1016/s1359-6349(06)70085-4.
- Daskivich T, Regan M, Oh W. Prostate Specific Antigen Doubling Time Calculation: Not as Easy as 1, 2, 4. Journal Of Urology 2006, 176: 1927-1937. PMID: 17070213, DOI: 10.1016/j.juro.2006.07.002.
- Nakabayashi M, Beard C, Kelly S, Carr-Locke D, Oh W. Treatment of a radiation-induced rectal ulcer with hyperbaric oxygen therapy in a man with prostate cancer. Urologic Oncology Seminars And Original Investigations 2006, 24: 503-508. PMID: 17138131, DOI: 10.1016/j.urolonc.2006.02.002.
- Oh W. Preface. Hematology/Oncology Clinics Of North America 2006, 20: xiii-xiv. DOI: 10.1016/j.hoc.2006.07.001.
- Nakabayashi M, Xie W, Regan M, Jackman D, Kantoff P, Oh W. Response to low‐dose ketoconazole and subsequent dose escalation to high‐dose ketoconazole in patients with androgen‐independent prostate cancer. Cancer 2006, 107: 975-981. PMID: 16862573, DOI: 10.1002/cncr.22085.
- Michaelson M, Kaufman D, Kantoff P, Oh W, Smith M. Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer 2006, 107: 530-535. PMID: 16804927, DOI: 10.1002/cncr.22043.
- Hayes J, Oh W, Kantoff P, Manola J, Smith M, Gelmann E, Bubley G, Balk S, Taplin M. Mifepristone (RU-486) in androgen independent prostate cancer. Journal Of Clinical Oncology 2006, 24: 14508-14508. DOI: 10.1200/jco.2006.24.18_suppl.14508.
- Oh W, Manola J, Ross R, Berkowitz A, Ryan C, Eilers K, Beer T. A phase II trial of docetaxel plus carboplatin in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel chemotherapy: Preliminary results. Journal Of Clinical Oncology 2006, 24: 14533-14533. DOI: 10.1200/jco.2006.24.18_suppl.14533.
- Pomerantz M, Manola J, Taplin M, Bubley G, Inman M, Lowell J, Kantoff P, Oh W. Phase II study of low dose (LD) and high dose (HD) premarin in androgen independent prostate cancer (AIPC). Journal Of Clinical Oncology 2006, 24: 4560-4560. DOI: 10.1200/jco.2006.24.18_suppl.4560.
- Mathew P, Thall P, Johnson M, Oh W, Meluch A, Morris M, Troncoso P, Bucana C, Fidler I, Logothetis C. Preliminary results of a randomized placebo-controlled double-blind trial of weekly docetaxel combined with imatinib in men with metastatic androgen-independent prostate cancer (AIPC) and bone metastases (BM). Journal Of Clinical Oncology 2006, 24: 4562-4562. DOI: 10.1200/jco.2006.24.18_suppl.4562.
- Daskivich T, Regan M, Kantoff P, Oh W. Prostate specific antigen doubling time (PSA-DT) and velocity (PSA-V) provide independent prognostic information in androgen independent prostate cancer (AIPC) patients receiving chemotherapy. Journal Of Clinical Oncology 2006, 24: 4616-4616. DOI: 10.1200/jco.2006.24.18_suppl.4616.
- Regan M, Daskivich T, Kantoff P, Oh W. Utility of prostate specific antigen doubling time (PSA-DT) at the start of androgen independent prostate cancer (AIPC) and immediately before chemotherapy in predicting efficacy of taxane chemotherapy. Journal Of Clinical Oncology 2006, 24: 4640-4640. DOI: 10.1200/jco.2006.24.18_suppl.4640.
- Nakabayashi M, Xie W, Regan M, Jackman D, Kantoff P, Oh W. Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer. Journal Of Clinical Oncology 2006, 24: 4646-4646. DOI: 10.1200/jco.2006.24.18_suppl.4646.
- Nakabayashi M, Bartlett R, Oh W. Treatment of Bicalutamide-Induced Gynecomastia With Breast-Reduction Surgery in Prostate Cancer. Journal Of Clinical Oncology 2006, 24: 2958-2959. PMID: 16782932, DOI: 10.1200/jco.2005.03.8505.
- Smith M, Manola J, Kaufman D, Oh W, Bubley G, Kantoff P. Celecoxib Versus Placebo for Men With Prostate Cancer and a Rising Serum Prostate-Specific Antigen After Radical Prostatectomy and/or Radiation Therapy. Journal Of Clinical Oncology 2006, 24: 2723-2728. PMID: 16782912, DOI: 10.1200/jco.2005.03.7804.
- Gilligan T, Oh W, Kantoff P. Carboplatin for Stage I Seminoma. Journal Of Clinical Oncology 2006, 24: 2971-2972. PMID: 16782940, DOI: 10.1200/jco.2005.05.3231.
- Oh W, Hayes J, Evan C, Manola J, George D, Waldron H, Donovan M, Varner J, Orechia J, Katcher B, Lu D, Nevins A, Wright R, Tormey L, Talcott J, Rubin M, Loda M, Sellers W, Richie J, Kantoff P, Weeks J. Development of an Integrated Prostate Cancer Research Information System. Clinical Genitourinary Cancer 2006, 5: 61-66. PMID: 16859581, DOI: 10.3816/cgc.2006.n.019.
- Oh W, Manola J, Babcic V, Harnam N, Kantoff P. Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. Urology 2006, 67: 1235-1240. PMID: 16765185, DOI: 10.1016/j.urology.2006.01.006.
- Daskivich T, Oh W. Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: Insight into mechanisms? Urology 2006, 67: 1084.e15-1084.e17. PMID: 16698377, DOI: 10.1016/j.urology.2005.11.015.
- Daskivich T, Oh W. Recent progress in hormonal therapy for advanced prostate cancer. Current Opinion In Urology 2006, 16: 173-178. PMID: 16679855, DOI: 10.1097/01.mou.0000193392.77469.e2.
- Nakabayashi M, Oh W. Chemotherapy for high‐risk localized prostate cancer. BJU International 2006, 97: 679-683. PMID: 16536752, DOI: 10.1111/j.1464-410x.2006.06092.x.
- Febbo P, Thorner A, Rubin M, Loda M, Kantoff P, Oh W, Golub T, George D. Application of Oligonucleotide Microarrays to Assess the Biological Effects of Neoadjuvant Imatinib Mesylate Treatment for Localized Prostate Cancer. Clinical Cancer Research 2006, 12: 152-158. PMID: 16397037, DOI: 10.1158/1078-0432.ccr-05-1652.
- Rosenberg J, Galsky M, Rohs N, Weinberg V, Oh W, Kelly W, Small E. A retrospective evaluation of second‐line chemotherapy response in hormone‐refractory prostate carcinoma. Cancer 2005, 106: 58-62. PMID: 16329138, DOI: 10.1002/cncr.21559.
- Oh W, Proctor K, Nakabayashi M, Evan C, Tormey L, Breierova L, Smith M, Neary M, Duh. CO4 A COMPARISON OF LOGISTIC REGRESSION AND COX PROPORTIONAL HAZARDS MODELS FOR IDENTIFICATION OF RISK FACTORS FOR RENAL IMPAIRMENT IN HORMONE REFRACTORY PROSTATE CANCER (HRPC) PATIENTS WITH BONE METASTASES (BM) TREATED WITH ZOLEDRONIC ACID (ZA). Value In Health 2005, 8: a16-a17. DOI: 10.1016/s1098-3015(10)67190-2.
- Oh W. Docetaxel in Hormone-Refractory Metastatic Prostate Cancer. Drugs 2005, 65: 2295-2297. DOI: 10.2165/00003495-200565160-00006.
- Oh W. High-Risk Localized Prostate Cancer: Integrating Chemotherapy. The Oncologist 2005, 10: 18-22. PMID: 16272455, DOI: 10.1634/theoncologist.10-90002-18.
- Nakabayashi M, Regan M, Lifsey D, Kantoff P, Taplin M, Sartor O, Oh W. Efficacy of nilutamide as secondary hormonal therapy in androgen‐independent prostate cancer. BJU International 2005, 96: 783-786. PMID: 16153200, DOI: 10.1111/j.1464-410x.2005.05714.x.
- Febbo P, Richie J, George D, Loda M, Manola J, Shankar S, Barnes A, Tempany C, Catalona W, Kantoff P, Oh W. Neoadjuvant Docetaxel before Radical Prostatectomy in Patients with High-Risk Localized Prostate Cancer. Clinical Cancer Research 2005, 11: 5233-5240. PMID: 16033841, DOI: 10.1158/1078-0432.ccr-05-0299.
- Nakabayashi M, Regan M, Lifsey D, Evan C, Kantoff P, Taplin M, Sartor O, Oh W. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer (AIPC). Journal Of Clinical Oncology 2005, 23: 4683-4683. DOI: 10.1200/jco.2005.23.16_suppl.4683.
- Oh W, Manola J, Babcic V, Harnam N, Kantoff P. Response to second-line chemotherapy in patients with hormone refractory prostate cancer (HRPC) receiving two sequences of mitoxantrone (M) and taxanes (T). Journal Of Clinical Oncology 2005, 23: 4616-4616. DOI: 10.1200/jco.2005.23.16_suppl.4616.
- Oh W, George D, Tay M. Response to Docetaxel/Carboplatin in Patients with Hormone-Refractory Prostate Cancer Not Responding to Taxane-Based Chemotherapy. Clinical Genitourinary Cancer 2005, 4: 61-64. PMID: 15992464, DOI: 10.3816/cgc.2005.n.014.
- Michaelson M, Gilligan T, Oh W, Kantoff P, Taplin M, Izquierdo M, Flores L, Smith M. Phase II study of three hour, weekly infusion of trabectedin (ET-743) in men with metastatic, androgen-independent prostate carcinoma (AIPC). Journal Of Clinical Oncology 2005, 23: 4517-4517. DOI: 10.1200/jco.2005.23.16_suppl.4517.
- Galsky M, Small E, Oh W, Chen I, Smith D, Colevas A, Martone L, Curley T, DeLaCruz A, Scher H, Kelly W. Multi-Institutional Randomized Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) With or Without Estramustine Phosphate in Patients With Progressive Castrate Metastatic Prostate Cancer. Journal Of Clinical Oncology 2005, 23: 1439-1446. PMID: 15735119, DOI: 10.1200/jco.2005.09.042.
- Oh W, Hagmann E, Manola J, George D, Gilligan T, Jacobson J, Smith M, Kaufman D, Kantoff P. A Phase I Study of Estramustine, Weekly Docetaxel, and Carboplatin Chemotherapy in Patients with Hormone-Refractory Prostate Cancer. Clinical Cancer Research 2005, 11: 284-289. PMID: 15671557, DOI: 10.1158/1078-0432.284.11.1.
- Tay M, Oh W. Chapter 28 Metastatic Adenocarcinoma of the Prostate. 2005, 505-513. DOI: 10.1016/b978-0-7216-0003-1.50032-0.
- Oh W. AN OVERVIEW OF CHEMOTHERAPY TRIALS IN LOCALIZED AND RECURRENT NONMETASTATIC PROSTATE CANCER. Journal Of Urology 2004, 172: s34-s37. PMID: 15535440, DOI: 10.1097/01.ju.0000141674.92253.fe.
- CARROLL P, CHAN J, D’AMICO A, GELMANN E, IVERSEN P, KLOTZ L, NELSON J, NELSON P, NELSON W, OH W, ROSEN N, RUBIN M, SANDLER H, SELLERS W, SMITH M, XU J, McMANN M, KANTOFF P. FOURTH INTERNATIONAL CONFERENCE ON INNOVATIONS AND CHALLENGES IN PROSTATE CANCER. Journal Of Urology 2004, 172: s3-s5. PMID: 15535434, DOI: 10.1097/01.ju.0000142276.19511.ac.
- Nakabayashi M, Oh W. Neoadjuvant and adjuvant chemotherapy for high-risk localized prostate cancer. Current Treatment Options In Oncology 2004, 5: 349-355. PMID: 15341673, DOI: 10.1007/s11864-004-0025-3.
- Smith M, Manola J, Kaufman D, George D, Oh W, Mueller E, Slovin S, Spiegelman B, Small E, Kantoff P. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate‐specific antigen level after radical prostatectomy and/or radiation therapy. Cancer 2004, 101: 1569-1574. PMID: 15468186, DOI: 10.1002/cncr.20493.
- Kaufman D, Carducci M, Kuzel T, Todd M, Oh W, Smith M, Ye Z, Nicol S, Stadler W. A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urologic Oncology Seminars And Original Investigations 2004, 22: 393-397. PMID: 15464919, DOI: 10.1016/j.urolonc.2004.01.002.
- Oh W, Kantoff P, Weinberg V, Jones G, Rini B, Derynck M, Bok R, Smith M, Bubley G, Rosen R, DiPaola R, Small E. Prospective, Multicenter, Randomized Phase II Trial of the Herbal Supplement, PC-SPES, and Diethylstilbestrol in Patients With Androgen-Independent Prostate Cancer. Journal Of Clinical Oncology 2004, 22: 3705-3712. PMID: 15289492, DOI: 10.1200/jco.2004.10.195.
- Kelly W, Galsky M, Small E, Oh W, Chen I, Smith D, Martone L, Curley T, Delacruz A, Scher H. Multi-institutional trial of the epothilone B analogue BMS-247550 with or without estramustine phosphate (EMP) in patients with progressive castrate-metastatic prostate cancer (PCMPC): Updated results. Journal Of Clinical Oncology 2004, 22: 4509-4509. DOI: 10.1200/jco.2004.22.14_suppl.4509.
- Oh W, Hagmann E, Manola J, George D, Gilligan T, Smith M, Kaufman D, Kantoff P. A phase I study of estramustine, weekly docetaxel and carboplatin (EDC) chemotherapy in patients with hormone refractory prostate cancer (HRPC). Journal Of Clinical Oncology 2004, 22: 4656-4656. DOI: 10.1200/jco.2004.22.14_suppl.4656.
- Tay M, George D, Gilligan T, Kelly S, Appleby L, Taplin M, Febbo P, Kantoff P, Oh W. Docetaxel plus carboplatin (DC) may have significant activity in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel-based chemotherapy. Journal Of Clinical Oncology 2004, 22: 4679-4679. DOI: 10.1200/jco.2004.22.14_suppl.4679.
- George D, Oh W, Gilligan T, Masson E, Souppart C, Wang Y, Ho Y, Lebwohl D, Laurent D, Kantoff P. Phase I study of the novel, oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK): Evaluating the pharmacokinetic effect of a high-fat meal in patients with hormone-refractory prostate cancer (HRPC). Journal Of Clinical Oncology 2004, 22: 4689-4689. DOI: 10.1200/jco.2004.22.14_suppl.4689.
- Kelly W, Galsky M, Small E, Oh W, Chen I, Smith D, Martone L, Curley T, Delacruz A, Scher H. Multi-institutional trial of the epothilone B analogue BMS-247550 with or without estramustine phosphate (EMP) in patients with progressive castrate-metastatic prostate cancer (PCMPC): Updated results. Journal Of Clinical Oncology 2004, 22: 4509-4509. DOI: 10.1200/jco.2004.22.90140.4509.
- Oh W, Hagmann E, Manola J, George D, Gilligan T, Smith M, Kaufman D, Kantoff P. A phase I study of estramustine, weekly docetaxel and carboplatin (EDC) chemotherapy in patients with hormone refractory prostate cancer (HRPC). Journal Of Clinical Oncology 2004, 22: 4656-4656. DOI: 10.1200/jco.2004.22.90140.4656.
- Tay M, George D, Gilligan T, Kelly S, Appleby L, Taplin M, Febbo P, Kantoff P, Oh W. Docetaxel plus carboplatin (DC) may have significant activity in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel-based chemotherapy. Journal Of Clinical Oncology 2004, 22: 4679-4679. DOI: 10.1200/jco.2004.22.90140.4679.
- George D, Oh W, Gilligan T, Masson E, Souppart C, Wang Y, Ho Y, Lebwohl D, Laurent D, Kantoff P. Phase I study of the novel, oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK): Evaluating the pharmacokinetic effect of a high-fat meal in patients with hormone-refractory prostate cancer (HRPC). Journal Of Clinical Oncology 2004, 22: 4689-4689. DOI: 10.1200/jco.2004.22.90140.4689.
- Tay M, Kaufman D, Regan M, Leibowitz S, George D, Febbo P, Manola J, Smith M, Kaplan I, Kantoff P, Oh W. Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate. Annals Of Oncology 2004, 15: 974-978. PMID: 15151957, DOI: 10.1093/annonc/mdh221.
- Abe M, Manola J, Oh W, Parslow D, George D, Austin C, Kantoff P. Plasma Levels of Heat Shock Protein 70 in Patients with Prostate Cancer: A Potential Biomarker for Prostate Cancer. Clinical Genitourinary Cancer 2004, 3: 49-53. PMID: 15279691, DOI: 10.3816/cgc.2004.n.013.
- Liu G, Gandara D, Lara P, Raghavan D, Doroshow J, Twardowski P, Kantoff P, Oh W, Kim K, Wilding G. A Phase II Trial of Flavopiridol (NSC #649890) in Patients with Previously Untreated Metastatic Androgen-Independent Prostate Cancer. Clinical Cancer Research 2004, 10: 924-928. PMID: 14871968, DOI: 10.1158/1078-0432.ccr-03-0050.
- George D, Regan M, Oh W, Tay M, Manola J, Decalo N, Duggan S, Dewolf W, Kantoff P, Bubley G. Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer. Urology 2004, 63: 327-332. PMID: 14972483, DOI: 10.1016/j.urology.2003.09.059.
- Oh W, Halabi S, Kelly W, Werner C, Godley P, Vogelzang N, Small E, B F. A Phase II study of estramustine, docetaxel, and carboplatin with granulocyte–colony‐stimulating factor support in patients with hormone‐refractory prostate carcinoma. Cancer 2003, 98: 2592-2598. PMID: 14669278, DOI: 10.1002/cncr.11829.
- CARROLL P, BENARON D, BLACKLEDGE G, COAKLEY F, D’AMICO A, HIGANO C, IVERSEN P, KATTAN M, NANUS D, NELSON J, OH W, ROACH M, SELLERS W, SMITH M, MCMANN M, KANTOFF P. Third International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment. Journal Of Urology 2003, 170: s3-s5. PMID: 14610403, DOI: 10.1097/01.ju.0000095101.18470.a0.
- Oh W. The Evolving Role of Chemotherapy and Other Systemic Therapies for Managing Localized Prostate Cancer. Journal Of Urology 2003, 170: s28-s34. PMID: 14610407, DOI: 10.1097/01.ju.0000095356.02647.64.
- LEIBOWITZ S, OH W. Overtreatment of a Patient With Presumed Recurrent Prostate Cancer Based on False-Positive Prostate Specific Antigen Results. Journal Of Urology 2003, 170: 1305. PMID: 14501750, DOI: 10.1097/01.ju.0000084670.47887.a5.
- Bhayani S, Ong A, Oh W, Kantoff P, Kavoussi L. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer: a long-term update. Urology 2003, 62: 324-327. PMID: 12893344, DOI: 10.1016/s0090-4295(03)00324-8.
- Oh W, Manola J, Bittmann L, Brufsky A, Kaplan I, Smith M, Kaufman D, Kantoff P. Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up. Urology 2003, 62: 99-104. PMID: 12837431, DOI: 10.1016/s0090-4295(03)00145-6.
- Oh W, Kaplan I, Febbo P, Prisby J, Manola J, Kaufman D, Kantoff P. Neoadjuvant Doxil Chemotherapy Prior to Androgen Ablation Plus Radiotherapy for High-Risk Localized Prostate Cancer: Feasibility and Toxicity. American Journal Of Clinical Oncology 2003, 26: 312. DOI: 10.1097/00000421-200306000-00021.
- Oh W, Kaplan I, Febbo P, Prisby J, Manola J, Kaufman D, Kantoff P. Neoadjuvant Doxil Chemotherapy Prior to Androgen Ablation Plus Radiotherapy for High-Risk Localized Prostate Cancer. American Journal Of Clinical Oncology 2003, 26: 312-316. PMID: 12796607, DOI: 10.1097/01.coc.0000020921.08768.1f.
- Yu E, Oh W. Neoadjuvant therapy for high-risk localized prostate cancer. Current Oncology Reports 2003, 5: 250-257. PMID: 12667424, DOI: 10.1007/s11912-003-0118-3.
- Leibowitz S, Garber J, Fox E, Loda M, Kaufman D, Kantoff P, Oh W. Male Patients with Diagnoses of Both Breast Cancer and Prostate Cancer. The Breast Journal 2003, 9: 208-212. PMID: 12752629, DOI: 10.1046/j.1524-4741.2003.09312.x.
- Oh W. Neoadjuvant therapy before radical prostatectomy in high-risk localized prostate cancer: defining appropriate endpoints. Urologic Oncology Seminars And Original Investigations 2003, 21: 229-234. PMID: 12810211, DOI: 10.1016/s1078-1439(03)00019-x.
- Oh W, Tully P, Kantoff P, Regan M. Physician attitudes toward cytotoxic chemotherapy use in patients with advanced prostate carcinoma. Cancer 2003, 97: 2171-2179. PMID: 12712468, DOI: 10.1002/cncr.11344.
- Lee D, Sartor O, Kosty M, Oh W. Highlights from the Third Annual Meeting of the Society of Urologic Oncology; Bethesda, Maryland, December 13-14, 2002. Clinical Genitourinary Cancer 2003, 1: 203-206. PMID: 15040876, DOI: 10.1016/s1540-0352(11)70002-6.
- Michaelson M, Kaufman D, Oh W. Transitional cell carcinoma of the upper uroepithelial tract. Clinical Advances In Hematology And Oncology 2003, 1: 102-4; discussion 105. PMID: 16224387.
- Oh W. Predicting Outcome in Localized Prostate Cancer: How Far Have We Come? Cancer Investigation 2003, 21: 487-488. PMID: 12901296, DOI: 10.1081/cnv-120018656.
- Oh W, Small E. Complementary and alternative therapies in prostate cancer. Seminars In Oncology 2002, 29: 575-584. PMID: 12516040, DOI: 10.1053/sonc.2002.50007.
- Smith M, Kaufman D, George D, Oh W, Kazanis M, Manola J, Kantoff P. Selective aromatase inhibition for patients with androgen‐independent prostate carcinoma. Cancer 2002, 95: 1864-1868. PMID: 12404279, DOI: 10.1002/cncr.10844.
- OH W. Secondary hormonal therapies in the treatment of prostate cancer. Urology 2002, 60: 87-92. PMID: 12231058, DOI: 10.1016/s0090-4295(02)01581-9.
- Carroll P, Kantoff P, Balk S, Brown M, D’amico A, George D, Grossfeld G, Johnson C, Kelly W, Klotz L, Lee W, Lubeck D, Mcleod D, Oh W, Pollack A, Sartor O, Smith M, Hart C. Overview consensus statement. Urology 2002, 60: 1-6. PMID: 12231036, DOI: 10.1016/s0090-4295(02)01559-5.
- Carlo W, Stark A, Wright L, Tyson J, Papile L, Shankaran S, Donovan E, Oh W, Bauer C, Saha S, Poole W, Stoll B, Network* F. Minimal ventilation to prevent bronchopulmonary dysplasia in extremely-low-birth-weight infants. The Journal Of Pediatrics 2002, 141: 370-375. PMID: 12219057, DOI: 10.1067/mpd.2002.127507.
- Oh W. The Evolving Role of Estrogen Therapy in Prostate Cancer. Clinical Genitourinary Cancer 2002, 1: 81-89. PMID: 15046698, DOI: 10.3816/cgc.2002.n.009.
- D'Amico A, Saegaert T, Chen M, Renshaw A, George D, Oh W, Kantoff P. Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high‐risk prostate cancer. Cancer 2002, 95: 275-280. PMID: 12124826, DOI: 10.1002/cncr.10673.
- Harafuji N, Keys DN, Levine M. Genome-wide identification of tissue-specific enhancers in the Ciona tadpole. Proc Natl Acad Sci U S A 2002, 99: 6802-5. PMID: 12011440, DOI: 10.1073/pnas.052024999.
- OH W, LODA M, KANTOFF P, JANICEK M. PROGRESSIVE SCLEROSIS OF ISOLATED FOOT METASTASIS OF PROSTATE CANCER. Journal Of Urology 2002, 167: 1392. PMID: 11832744, DOI: 10.1016/s0022-5347(05)65312-8.
- OH W, LODA M, KANTOFF P, JANICEK M. PROGRESSIVE SCLEROSIS OF ISOLATED FOOT METASTASIS OF PROSTATE CANCER. Journal Of Urology 2002, 167: 1392. DOI: 10.1097/00005392-200203000-00047.
- Oh W, Small E. PC-SPES and prostate cancer. Urologic Clinics Of North America 2002, 29: 59-66. PMID: 12109356, DOI: 10.1016/s0094-0143(02)00017-4.
- Oh W, George D, Kantoff P. Rapid rise of serum prostate specific antigen levels after discontinuation of the herbal therapy PC‐SPES in patients with advanced prostate carcinoma. Cancer 2002, 94: 686-689. PMID: 11857300, DOI: 10.1002/cncr.10269.
- Oh W, Manola J, George D, Fierman A, Fontaine-Rothe P, Morrissey S, Prisby J, Kaufman D, Shapiro C, Kantoff P, Smith M. A Phase II Trial of Interferon-Alpha and Toremifene in Advanced Renal Cell Cancer Patients. Cancer Investigation 2002, 20: 186-191. PMID: 11901538, DOI: 10.1081/cnv-120001145.
- DAmico A, Saegart T, Chen M, Renshaw A, George D, Oh W, Kantoff P. The impact of anemia on psa outcome following radiation and androgen suppression therapy in patients with high-risk prostate cancer. International Journal Of Radiation Oncology • Biology • Physics 2001, 51: 113. DOI: 10.1016/s0360-3016(01)02031-4.
- Oh W, George D, Kaufman D, Moss K, Smith M, Richie J, Kantoff P. Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: A preliminary report. Seminars In Oncology 2001, 28: 40-44. PMID: 11685727, DOI: 10.1016/s0093-7754(01)90153-8.
- Oh W, George D, Kaufman D, Moss K, Smith M, Richie J, Kantoff P. Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: A preliminary report. Seminars In Oncology 2001, 28: 40-44. DOI: 10.1053/sonc.2001.26899.
- Gilligan T, Oh W. Overall Survival after Prostate‐Specific‐Antigen‐Detected Recurrence Following Conformal Radiation Therapy. The Prostate Journal 2001, 3: 43-44. DOI: 10.1046/j.1525-1411.2001.31007-2.x.
- Gilligan T, Oh W. Bicalutamide Monotherapy Compared with Castration in Patients with Nonmetastatic Locally Advanced Prostate Cancer: 6.3 Years of Follow‐up. The Prostate Journal 2001, 3: 42-43. DOI: 10.1046/j.1525-1411.2001.003001042.x.
- Oh W. Anemia Related to Hormonal Ablation Therapy for Prostate Cancer. The Prostate Journal 2001, 3: 14-17. DOI: 10.1046/j.1525-1411.2001.003001014.x.
- Oh W, George D, Hackmann K, Manola J, Kantoff P. Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer. Urology 2001, 57: 122-126. PMID: 11164156, DOI: 10.1016/s0090-4295(00)00986-9.
- Gilligan T, Oh W. Biochemical Outcome Following External Beam Radiation Therapy With or Without Androgen Suppression Therapy for Clinically Localized Prostate Cancer. The Prostate Journal 2001, 3: 45-46. DOI: 10.1046/j.1525-1411.2001.31007-4.x.
- Kelly W, Curley T, Slovin S, Heller G, McCaffrey J, Bajorin D, Ciolino A, Regan K, Schwartz M, Kantoff P, George D, Oh W, Smith M, Kaufman D, Small E, Schwartz L, Larson S, Tong W, Scher H. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. Journal Of Clinical Oncology 2001, 19: 44-53. PMID: 11134194, DOI: 10.1200/jco.2001.19.1.44.
- Gilligan T, Oh W. Prospective Trial of the Herbal Supplement PC‐SPEC in Patients with Progressive Prostate Cancer. The Prostate Journal 2001, 3: 44-45. DOI: 10.1046/j.1525-1411.2001.31007-3.x.
- Smith M, Kaufman D, Oh W, Guerin K, Seiden M, Makatsoris T, Manola J, Kantoff P. Vinorelbine and estramustine in androgen‐independent metastatic prostate cancer. Cancer 2000, 89: 1824-1828. PMID: 11042579, DOI: 10.1002/1097-0142(20001015)89:8<1824::aid-cncr24>3.0.co;2-r.
- Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman D, Oh W, Demetri G, Figg W, Zhou X, Eng C, Spiegelman B, Kantoff P. Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer. Proceedings Of The National Academy Of Sciences Of The United States Of America 2000, 97: 10990-10995. PMID: 10984506, PMCID: PMC27136, DOI: 10.1073/pnas.180329197.
- George D, Paz‐Ares L, Oh W. Article Reviews. The Prostate Journal 2000, 2: 163-167. DOI: 10.1046/j.1525-1411.2000.23006.x.
- Oh W. Chemotherapy for patients with advanced prostate carcinoma. Cancer 2000, 88: 3015-3021. PMID: 10898346, DOI: 10.1002/1097-0142(20000615)88:12+<3015::aid-cncr18>3.0.co;2-m.
- Kaufman D, Raghavan D, Carducci M, Levine E, Murphy B, Aisner J, Kuzel T, Nicol S, Oh W, Stadler W. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. Journal Of Clinical Oncology 2000, 18: 1921-7. PMID: 10784633, DOI: 10.1200/jco.2000.18.9.1921.
- Eder J, Kantoff P, Roper K, Xu G, Bubley G, Boyden J, Gritz L, Mazzara G, Oh W, Arlen P, Tsang K, Panicali D, Schlom J, Kufe D. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clinical Cancer Research 2000, 6: 1632-8. PMID: 10815880.
- Reid P, Oh W. Article Reviews. The Prostate Journal 2000, 2: 102-105. DOI: 10.1046/j.1525-1411.2000.22008.x.
- Oh W, Manola J, Renshaw A, Brodkin D, Loughlin K, Richie J, Shapiro C, Kantoff P. Smoking and alcohol use may be risk factors for poorer outcome in patients with clear cell renal carcinoma. Urology 2000, 55: 31-35. PMID: 10654890, DOI: 10.1016/s0090-4295(99)00408-2.
- Nelson J, Chen R, Bishoff J, Oh W, Kantoff P, Donehower R, Kavoussi L. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumors. Urology 1999, 54: 1064-1067. PMID: 10604709, DOI: 10.1016/s0090-4295(99)00289-7.
- Bubley G, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg W, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak D, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small E, Smith M, Trump D, Vollmer R, Wilding G. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. Journal Of Clinical Oncology 1999, 17: 3461-7. PMID: 10550143, DOI: 10.1200/jco.1999.17.11.3461.
- Oh W, Kantoff P. Treatment of locally advanced prostate cancer: is chemotherapy the next step? Journal Of Clinical Oncology 1999, 17: 3664-75. PMID: 10550165, DOI: 10.1200/jco.1999.17.11.3664.
- Oh W, Manola J, Richie J, Loughlin K, Kantoff P. A phase II trial of methotrexate, cisplatin, 5‐fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma. Cancer 1999, 86: 1329-1334. PMID: 10506721, DOI: 10.1002/(sici)1097-0142(19991001)86:7<1329::aid-cncr31>3.0.co;2-r.
- Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer.Oh W, Kantoff P. Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer. Seminars In Oncology 1999, 26: 49-54. PMID: 10604270.
- Reid P, Kantoff P, Oh W. Antiandrogens in Prostate Cancer. Investigational New Drugs 1999, 17: 271-284. PMID: 10665479, DOI: 10.1023/a:1006344807086.
- Oh W. Article Reviews. The Prostate Journal 1999, 1: 203-207. DOI: 10.1046/j.1525-1411.1999.14006.x.
- Smith M, Kantoff P, Oh W, Elson G, Manola J, McMullin M, Jacobsen J, Brufsky A, Kaufman D. Phase II Trial of the Antiestrogen Toremifene for Androgen‐Independent Prostate Cancer. The Prostate Journal 1999, 1: 185-189. DOI: 10.1046/j.1525-1411.1999.14003.x.
- Kavoussi L, Nelson J, Chen R, Bishoff J, Donehower R, Oh W, Kantoff P. LAPAROSCOPIC RETROPERITONEAL LYMPH NODE DISSECTION (RPLND) FOR CLINICAL STAGE I NONSEMINOMATOUS GERM CELL TESTICULAR TUMORS (NSGCT). Journal Of Urology 1999, 161: 4.. DOI: 10.1097/00005392-199904010-00018.
- Kelly K, Gaudin P, Slovin S, Curley T, McCaffrey J, Ciolino A, Dalbagni G, Donat S, Scardino P, Scher H, Kantoff P, Smith M, Oh W, Smith D, Small E. PACLITAXEL(T), ESTRAMUSTINE(E) AND CARBOPLATIN(C) IN PATIENTS (Pts) WITH ADVANCED PROSTATE CANCER(PC). Journal Of Urology 1999, 161: 177.. DOI: 10.1097/00005392-199904010-00711.
- Oh W. Article Reviews. The Prostate Journal 1999, 1: 103-108. DOI: 10.1046/j.1525-1411.1999.09916.x.
- Stevenson D, Wright L, Lemons J, Oh W, Korones S, Papile L, Bauer C, Stoll B, Tyson J, Shankaran S, Fanaroff A, Donovan E, Ehrenkranz R, Verter J. Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, January 1993 through December 1994. American Journal Of Obstetrics And Gynecology 1998, 179: 1632-1639. PMID: 9855609, DOI: 10.1016/s0002-9378(98)70037-7.
- OH W, KANTOFF P. MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS. Journal Of Urology 1998, 160: 1220-1229. PMID: 9751323, DOI: 10.1016/s0022-5347(01)62501-1.
- OH W, KANTOFF P. MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER. Journal Of Urology 1998, 160: 1220-1229.. DOI: 10.1097/00005392-199810000-00003.
- Smilow Cancer Hospital at Greenwich77 Lafayette PlaceGreenwich, CT 06830
- Smilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
- Smilow Cancer Hospital at Greenwich77 Lafayette PlaceGreenwich, CT 06830
- Smilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511